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A B STR A C T
Despite the recent advances in the detection, treatment and management o f breast 
cancer, with an increasing range o f hormonal, cytotoxic and more recently MAb 
targeted drug regimes available in the clinic, between 40% and 50% o f patients 
diagnosed will eventually die from this disease. Identification o f biological factors 
which can function as reliable markers o f both prognosis and chemoresponsiveness 
will allow for more precise targeting o f treatment for individual breast cancer 
patients. During the course o f this thesis the expression o f a panel o f MDR associated 
proteins was correlated with patient and tumour characteristics and relapse and 
overall survival in a series of invasive breast carcinomas. In order to address the 
multifactorial nature o f this disease, expression of individual proteins was analysed 
in relation to other markers. The results presented show that MRP-1 protein at 
diagnosis is an independent prognostic factor for overall survival in node positive 
breast cancer patients treated with CMF based chemotherapy, absence o f MRP-1 
expression at diagnosis was significantly associated with increased overall survival. 
Results also indicated that this prognostic role o f M RP-1 is likely to be stronger in 
patients with high grade i.e. grade III tumours. It also appeared that expression of 
cerbB-2 may be associated with reduced relapse and overall survival times in node 
positive patients treated with a CMF based chemotherapeutic regime. On preliminary 
analysis it appeared that the co-expression o f M RP-1 with cerbB-2 in these patients 
may be a stronger prognostic tool than either cerbB-2 or MDR-1 alone. MDR-1 and 
survivin expression levels appeared to correlate in 71% o f patients. There was no 
correlation observed between the other markers studied.
Investigation of MDR-3 Pgp (which has recently been shown to transport several 
cytotoxic drugs) expression was also investigated in these breast cancer patients 
using a novel monoclonal antibody (MAb), 6/1G, which was produced during the 
course o f this research; this MAb specifically recognises the MDR-3 encoded gene 
product. Preliminary results indicate that MDR-3 Pgp was expressed in a high 
proportion (73.3%) o f invasive breast carcinomas studied. The exact significance of 
this expression and the contribution, if  any, o f MDR-3 Pgp in the resistance o f breast 
cancer or other solid cancers further investigation. Immunocytochemical studies with
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antibody 6/1G on a panel of B cell malignancies suggest that MDR-3 Pgp may 
possibly be associated with a more malignant phenotype in B-CLL and that its 
expression may be associated with certain stages o f B cell development.
In an attempt to identify new breast cancer drug resistance associated antigens, MAb 
5C3 was generated using paraffin wax embedded formalin fixed archival breast 
tumour tissue from a biopsy showing no P-170 or MRP-1 expression, as an 
immunogen. Immunohistochemical analysis with this novel MAb of pre  and post 
treatment tumours however, did not reveal any apparent association with resistance 
for the antigen recognised by antibody 5C3. Extensive immunocytochemical and 
Western blot analysis o f both cell lines and tissues with antibody 5C3 suggested that 
the reactive antigen did not appear to be tumour specific and was more likely to be 
an unidentified breast antigen also expressed in the normal breast. Results o f internal 
sequencing analysis o f a 175Kda band which was obtained from 
immunoprécipitation o f the ductal breast carcinoma cell line, ZR-75-1 revealed that 
MAb 5C3 is recognising a heteropolymer o f cytokeratin 6 and cytokeratin 9. The 
expression o f this novel complex in human breast cancer should be further 
investigated to address any possible prognostic implications.
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1.Introduction
l
1.1. Monoclonal antibodies (MAbs)
1.1.1. General introduction
One of the pioneers o f Immunology at the beginning o f the last century, Paul Ehrlich 
proposed the concept o f “receptors” (which we now know as antibodies) secreted by 
cells of the immune system in response to foreign antigens. He foresaw their use as 
“magic bullets” to specifically attack a wide variety o f diseases (Ehrlich 1900).
Antibodies are proteins produced by an individual against the presence o f a foreign 
molecule known as “the antigen”. The antibody will then bind to the antigen and 
elicit a range o f effector mechanisms to destroy this foreign molecule. Since the 
discovery o f these “magic bullets” pioneering researchers have looked on them as 
potential therapeutic agents in a wide range o f diseases. As early as 1895 cancer cells 
were injected into animals, and the resultant antiserum administered to patients 
suffering from various forms of advanced cancer. Although none o f these patients 
were cured, significant improvements in symptoms were observed. During the 
following decades, these trials were repeated by many researchers, however results 
proved inconsistent and contradictory. Antisera being used contained mixtures of 
different antibodies each being directed against a different antigen on cancer cells, in 
addition many o f these antigens were also present on normal cells, thus use o f these 
antibodies could result in harmful side effects.
A major milestone in antibody development was arrived at in 1975 when Kohler and 
Milstein received the Nobel prize for their work which reported for the first time the 
production o f virtually unlimited quantities o f antibody molecules derived from a 
single antibody producing cell in which all antibodies were identical and o f the same 
precise specificity for a given epitope. During the last 25 years immunology research 
has exploded with the availability of thousands of MAbs generated to a vast array of 
antigens which have been exploited in virtually every branch of biomedical science.
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1.1.2. H ybridom a Technology
Murine Chimeric “Humanized” 100% Human
100% mouse protein 33% mouse protein ~ 10% mouse protein 
Figure 1.1. : Evolution of antibodies
All hybridoma technology is based on the fundamental Nobel prize winning work of 
Kohler and Milstein (1975). The evolution o f MAbs from 1975 to the present day is 
represented in Figure 1.1. In 1984 genetic engineering enabled existing murine 
MAbs to be converted into chimeric MAbs, murine constant regions were replaced 
with human constant (C) regions (Boulianne et al., 1984, Riechmann et a l, 1988, 
Issacs 1990). These chimeric antibodies however, vary considerably in their 
immunogenicity when used therapeutically, thus limiting their application in a 
variety o f diseases (Issacs 1990, Kuus-Reichel et al., 1994). Despite this several 
FDA approved therapeutic MAbs are o f this design.
Following on from this, between 1988 and 1991, techniques to successfully 
humanise murine MAbs were developed where the antigen binding complementarity 
determining regions (CDRs) are grafted into human V region framework regions 
(FRs) (reviewed in detail by Clarke, 2000). Framework CDR grafted antibodies are 
more than 90% human. In addition rodent IgG with human constant regions will 
have a longer in vivo half life. An alternative approach for the generation o f fully 
human MAbs is that o f phage display technology. In 1994 Winter et al. showed for
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the first time this technique could be used to select antigen specific antibodies from 
libraries made from the spleen cells of immunised mice, thus bypassing the 
requirement to immortalise the antigen specific B cells as in hybridoma technology 
(reviewed by Hoogenboom & Chames, 2000).
Another alternative approach to the generation o f human MAbs is the genetic 
manipulation o f mice to disable the production o f mouse immunoglobulin and to 
functionally replace them with human antibody producing genes. These transgenic 
mice like the “Xenomouse” developed by Abgenix (CA, US) can then produce 
MAbs in response to immunisation to a variety o f diverse antigens. A lot o f success 
has been achieved with such technology, several high affinity antibodies have been 
generated (Fishwild et al., 1996, Mendez et al., 1997, Tomizuka et a l, 1997, Yang et 
al, 1999, Tomizuka et al., 2000). Thus using this Xenomouse ™ technology it 
should be possible to generate high affinity, fully human MAbs.
A human myeloma cell line suitable for the generation o f human monoclonal 
antibodies as a suitable partner for the derivation o f human-human hybridomas has 
recently been described by Karpas et al., (2001). Such a development will ultimately 
facilitate the isolation of human antibodies which can be used for immunotherapy. 
The first version of the Human Combinational Antibody library (HuCAL) has also 
been described, this will allow the rapid and high through-put development o f human 
antibodies (Krebs et al., 2001).
4
TmdlUonnl mAb Phqgadlsphy
Imnjrtnjlnn 
wlh IsgelAg
Hem I tftaoo, 
gcfiOTBtB tybridomos
Q ii  uiliB lm
Huiran antibody m ouia
ItmuilEstion 
■Mtfi tsrgit Ag
Harvest spteon, 
generals hytmctamac
PtiagB At Ifcnry •  • •
+ * £ « • » ■ ■ *  sour^
Bated bealphaga 
raooniinid VH end VL Human irrib
CHmsrisintt) H um rtad m U H uron mAb Cuari QpMtn H OMrrtori BWqgy
Figure 1.2. Generation of therapeutic human MAbs by obtaining mouse,
chimeric and humanised MAbs, via phage display and with the aid of 
genetically engineered “human antibody” (Ag=antigen, VL=variable light 
chain)
(Taken from “Next generation therapeutics”, Current Opinion in Chemical Biology, 
2001; 5:368-374. Authors, MA van Dijk, JA van de Winkel)
1.1.3. The current state of therapeutic MAbs
As mentioned earlier looking at MAbs as “magic bullets” which potentially can 
combat tumours and other diseases has challenged scientists for the past 25 years. 
The first therapeutic MAb used with success was in 1982 when a complete response 
was observed in a lymphoma patient following administration o f a “tailormade”
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mouse anti-idiotype (anti-D) MAb (Miller 1982). Despite both academic and 
commercial interest sparked by this important development, subsequent work has 
failed to live up to this early success. However the past 5 years have seen a 
turnaround again thanks to the developments in technologies as has been outlined. 
MAbs are now emerging as useful adjuncts for cancer therapy.
Antibodies and their derivatives constitute twenty five percent o f therapeutics 
currently in development. Recent developments have helped to reduce or eliminate 
murine components and fully human MAbs will hopefully become the norm. It is 
still not fully established exactly how antibodies kill tumour cells; the term antibody 
dependent cell mediated cytotoxicity (ADCC) is applied widely to describe this 
process; the recruitment o f killer, natural killer and cytotoxic T lymphocytes is also 
thought to be involved in this process.
The use o f MAbs to interfere with cellular processes inside the cell i.e. intracellular 
signalling is another area o f MAb technology which is being exploited for both 
research and therapeutic purposes. This technology allows antibody genes to be 
introduced into a cell and expressed to produce intracellular antibody which can then 
be used to modify cellular processes etc.
Researchers are also looking at a new type o f anti-cancer MAb that operates not via a 
direct effect on the tumour cell but as a result o f agonistic interaction with key 
receptors on cells o f the immune system; antigen presenting cells (APCs) or 
lymphocytes (anti CD-40 and anti CD-137) (Leach et ah, 1996, French et al., 1999). 
Alternatively such antibodies could act in an antagonistic fashion by blocking 
inhibiting signals delivered by certain receptors (Melero et ah, 1997). As a result 
rapid powerful T cell responses can be stimulated by unknown tumour antigens. The 
great potential o f such reagents lies not only in their ability to augment existing 
ineffectual responses but in their ability to leave the tumour rechallenged (Glennie & 
Johnson, 2000). However only data from animal experiments is available yet, it 
remains to be seen whether this immune stimulation can be achieved in patients.
Another aspect o f antibody based therapy for cancer is the use of antibodies to direct 
cytotoxic agents. Radionucleotides, toxins and pro-drug converting enzymes have all
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been conjugated to MAbs and are at various stages o f clinical trials. The most 
promising results have been reported using radioimmunotherapy for lymphoma, 
where a synergy has been observed between the signalling induced by the anti CD-20 
MAb, Ritoxumab and the delivery of (3 radiation. High response rates were observed 
in both newly diagnosed patients (Kaminski et al., 1998) and in those patients treated 
extensively with chemotherapeutic drugs (Press et al., 1995, Kaminski et al., 1996). 
Preliminary evidence from a trial suggests that this approach is superior to the use of 
Ritoxumab alone (unconjugated MAb) (Witzag et al., 1999). Enzymes that convert 
drugs to their active metabolites can be targeted to tumour cells by MAbs; this is 
known as antibody directed enzyme pro-drug therapy (ADEPT). ADEPT and also 
immunotoxin therapy are still in the early stages o f development so results from 
patient trials are not available yet.
Earlier therapeutic MAbs were primarily directed to target antigens that were not 
involved in the regulation of growth of tumour cells. More recently research has 
revealed that tumour growth may be influenced by the function of discrete oncogene- 
determined cell surface receptors. The cerbB-2 gene (also known as HER-2/neu or 
neu) is a proto-oncogene which encodes a transmembrane growth factor receptor (p- 
185 HER2), which is overexpressed in 25-30% of breast cancer patients. An MAb 
directed to the oncogene product, Neu, was found to reverse the tumour phenotype in 
vitro and exert antitumour effects in vivo (Drebin et a l, 1986, 1988). Trastuzumab 
(Genentech SF, US) is a recombinant DNA derived humanised antibody to HER- 
2/neu. The exact mechanism of action o f this MAb has not been fully elucidated, but 
this antibody does induce a clear down regulation o f the growth factor receptor 
which may reverse the malignant phenotype. This antibody is known to be capable of 
activating o f a signal transduction pathway that leads to inhibition o f tumour cell 
proliferation and possibly cell death (Goldenberg 1999). Trastuzumab has been 
shown to be an efficacious adjuvant therapeutic agent for patients with breast cancer 
who overexpress the Her-2/ neu gene (Baselga et al., 1998, Slamon el al., 1998). 
Recent results have shown that Trastuzumab increases the clinical benefit o f first 
line chemotherapy in metastatic breast cancer in patients whose tumours overexpress 
HER-2/ neu (Slamon et al., 2001).
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Along with trastuzumab, Rituximab (anti CD-20) is one o f the most successful 
therapeutic MAbs. Rituximab (or Rituxan) (IDEC Pharmaceuticals Inc, San Diego, 
CA, US) was discovered in 1990 and was the first MAb approved for the treatment 
o f cancer and the first single agent approved specifically for therapy o f lymphoma. 
Rituximab is a chimeric MAb and is directed against the CD-20 antigen found on the 
surface o f pre-B and mature lymphocytes. This antigen is found on more than 90% 
of B-cells in non-Hodgkins Lymphoma (NHL), but it is not found on stem cells, pre 
B cells, normal plasma cells or in other normal tissues. CD-20 is important in cell 
cycle initiation and differentiation, free CD-20 is not found in the circulation. On 
binding to its target CD-20, lysis o f the B cell takes place, effects on signalling in the 
cell also take place. Little or no binding has been observed in non-lymphoid tissues. 
Despite being a chimeric MAb, in a large study of patients treated with a second 
course o f this antibody, none of the 60 patients developed anti-chimeric antibody 
(HACA) (Davis et al., 1999). Ritoxumab has recently been found to be an active 
agent for the treatment o f follicular cell lymphoma and to be modestly effective in 
mantle cell lymphoma (Ghielmini et al., 2000). The evidence available to date from 
clinical trials with these and other FDA approved antibodies suggests these MAbs 
may have a role in low volume residual disease e.g. when used as adjuvant therapy 
following surgery to remove primary tumour. It is less likely that they will have a 
beneficial role in advanced disease.
As well as their role as drugs antibodies can also act as useful tools for molecular 
characterisation particularly in this “post genomic” era, where more than 40,000 
genes have been revealed via the genome map. Antibodies will play a key role in 
identifying these targets. Estimates from industry suggest that antibody sales will 
approach $5 billion by 2005. 110 new MAb products are in the developmental stage 
spanning 50 disease areas from cancer to inflammatory disease. Antibodies represent 
16% of drugs in development. The recent clinical success o f MAbs is attributable to 
a number o f developments; the identification o f specific cell surface markers and 
molecular targets, the developments in therapeutic MAbs such as CDR grafting to 
improve therapeutic stability and also in improvements in the methods o f production 
of MAbs. Whether this success will continue with therapeutic and diagnostic MAbs 
resulting in improvements in the diagnosis and mortality rates of the common 
diseases remains to be seen.
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1.1.4. MAbs as Diagnostics Tools
MAbs directed to a vast array o f antigens serve as diagnostic tools in virtually every 
area o f biomedical science. Antibody based immunoassays such as ELISA, 
radioimmunoassay etc are the most commonly used diagnostic bioassay. Bioassays 
based on whole cells, receptors and enzymes do not for the most part offer the same 
unlimited applicability and specificity. Advances in technology have resulted in 
improved sensitivity, specificity and detection of immunoassays.
Conjugated antibodies may allow recognition of small number o f tumour cells in 
bone marrow or biopsies o f tissues that would not be recognised by conventional 
histological techniques. Specific properties of tumour cells (also other disease 
conditions) can be identified and quantified using specific MAbs directed to these 
particular cellular components and thus these MAbs can serve as prognostic/ 
predictive markers in the diagnosis and management o f these diseases. MAbs that 
recognise antigens that are associated with various cancers or other disease 
conditions such as autoimmune disorders can be used to detect (and quantify in some 
cases) the antigen in serum, pleural effusions or tissue biopsies either usually by 
ELISA or immunocytochemical analysis.
MAbs can therefore play a pivotal role both in routine classification o f tumours and 
also in the diagnosis o f tumours of uncertain origin. This area o f MAb application is 
continuously expanding as more and more tumour (and non-tumourogenic) 
associated antigens are being identified by researchers. MAbs are readily available 
now for both research and diagnosis that recognise proliferation related antigens, 
tumour specific markers, apoptosis associated markers, drug resistance pumps 
(discussed in detail in section 1.6.) and various oncoproteins.
1.1.5. MAbs as immunohistochemical markers
Immunocytochemistry is a well established and widely used technique (in research 
and routine settings) which enables the localisation o f the antigen of interest in 
cytological as well as histological material at both the light and electron microscope 
level. Immunocytochemistry plays a vital role in diagnostic tumour pathology when
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morphology alone cannot reliably be used to infer the tissue o f origin. In addition 
immunocytochemistry plays a fundamental role in the understanding o f the biology 
of neoplastic growth and has been applied to every aspect o f cellular behaviour. This 
technique involves the use o f labelled antibodies as specific reagents for the 
localisation of tissue components (antigens) in situ and can be performed on either 
frozen sections (fresh tissue that has been cut using a cryostat) or routinely processed 
formalin fixed paraffin wax embedded archival material.
Formaldehyde is the most widely used fixative in routine histopathology and has 
become the gold standard for morphological tissue preservation; although other 
fixatives are sometimes used including Bouins fixative and para-formaldehyde (Merz 
et al., 1995). Immunostaining o f cryostat sections results in a great loss in tissue 
morphology compared to routinely fixed material where resulting morphology is a 
lot superior. In addition the availability o f fresh frozen tissue can be a problem. 
However although archival material should be the most useful option; many 
routinely used antibody markers cannot be detected in routinely processed archival 
sections. The reason for this is because the determinants recognised by these 
antibodies may be masked or denatured by the fixation and processing. The 
molecular mechanisms underlying tissue fixation are not fully understood, it is clear 
that available immunoreactive sites are progressively lost during the fixation process. 
Loss o f antigen expression when using certain antibodies e.g. in the assessment o f P- 
glycoprotein expression levels using the C219 MAb, has been observed in formalin 
fixed paraffin embedded tissue sections when compared to frozen tissue sections 
from the same cell lines and origins (Cordon Cardo et al., 1990).
Researchers have attempted to achieve signal amplification with an acceptable signal 
to noise ratio in an attempt to address this problem (Merz et al., 1995). More 
successful results have been achieved using various antigen retrival methods in an 
attempt to reveal these cross linked proteins. Initially enzyme treatments with trypsin 
or pronase treatment were investigated, however such methods proved difficult to 
standardise even within individual laboratories and reproducibility was poor (Huang 
et al., 1976).
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Microwave or pressure cooker based heat treating methods have been applied with 
some success although several modifications o f the basic method may have to be 
employed to ensure optimum antigen retrival (Cattoretti et al., 1993). In general 
microwave based heat treatment o f MAbs does appear to enhance tissue antigenicity 
while preserving tissue morphology, although positive staining should be interpreted 
carefully particularly in the case o f new or previously untested MAbs (Cuevas et al., 
1994). A new generation of immunohistochemical markers (e.g. Ki-67, Bcl-2, p53, 
PCNA) are now available for clinical studies o f archival tumours thanks to these 
retrieval methods. However it has been reported that such aggressive techniques may 
influence immunolocalisation o f antigens or in some cases cause detachment of 
tissue (Cuevas et a l, 1994, Szekeres et a l, 1994). In addition there is considerable 
scope for intralaboratory variation.
With these constraints in mind researchers have attempted where possible to develop 
MAbs that perform well on routinely processed archival tissue i.e. detect "formalin 
resistant" antigen thus avoiding the use o f often aggressive and sometimes 
inconsistant antigen retrival techniques.
1.2. Tumour specific antigens
Presentation o f a certain antigen can be indicative o f the histogenesis (i.e. 
histological origin) of a tumour. Expression of particular antigens can also be helpful 
in the identification o f poorly differentiated tumours o f unknown origin and 
invaluable in the determination o f the correct origin of poorly differentiated tumours. 
A wide range o f both polyclonal and monoclonal antibodies are commercially 
available that react with antigens which are products o f embyronic and adult tissue 
differentiation. Markers o f tumour cell differentiation that are commonly used in the 
diagnosis o f tumours include tissue specific proteins such as S-100 (gliomas, 
melanomas and schwaanomas), prostate specific antigen (PSA), prostatic acid 
phosphatase (prostate tumours), carcinoembryonic antigen (CEA) (distinquishes 
adenocarcinomas from mesothelioma), alpha feto protein (hepatocellular carcinoma, 
ovarian and testicular germ cell tumours), leucocyte common antigen (distinquishes 
haematopoietic malignancies from non-haematopoietic tumours) and myoglobin
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(striated muscle tumours). Intermediate filaments that function as routine markers 
include cytokeratin (carcinomas, mesotheliomas), vimentin (tumours of 
mesenchymal origin/ lymphomas/ poorly differentiated carcinomas) and glial 
fibrillary acidic protein (gliomas, distinguishes glioma from other brain tumours 
including metastatic ones). Antigenic markers o f hormones and related products can 
also be used, e.g. hormones related to pancreatic islet cells and thyroglobulin are 
used in the characterisation of islet cell tumours and the diagnosis o f neoplasms of 
thyroid origin respectively, see True (1990) for more detail. (Breast cancer associated 
antigenic markers will be discussed in section 1.4.2. and 1.4.3)
1.3. Identification of novel antigens/ proteins
Identification o f novel/ new tumour specific antigens that may have a role as 
potential predictive or prognostic markers is a constant challenge for researchers, 
which has been made easier with the advent o f the new MAb technologies outlined 
above. Various sources of cancer antigens (lymphocytes from metastatic lymph 
nodes, solublised solid tumour, tumour cell lines etc.) have been used to generate 
MAbs directed to these components. Many antigens that have been associated with 
tumours originating from specific organs have been detected with such MAbs, 
however the isolation o f antigens with absolute specificity for a particular type o f 
tumour has proved much more difficult. The first tumour specific antigen was 
reported by Thierry Boon and his colleagues who described the MAGE-1 antigen in 
malignant melanoma; this antigen in conjunction with other more recently described 
melanoma specific antigens has proved useful in the classification o f specific 
melanocytic lesions (van der Bruggen et ah, 1991, Xu et ah, 2002). Using T cell 
lines several human tumour antigens have been defined at the molecular level (the 
majority being malignant melanoma specific antigens) (Boon et ah, 1994, 
Rosenberg, 1997, Xu et ah, 2002). Newer strategies such as SEREX (serological 
identification o f antigens by recombinant expression cloning) have been developed 
that can identify tumour antigens from antibody repertoires of cancer patients. These 
antibody repertoires are comprised o f cDNA libraries constructed from fresh tumour 
samples, packaged into lambda phage vectors and expressed recombinantly in e.coli 
(Sahin et ah, 1997). Tumour antigens identified using this technique include glioma
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associated antigens in astrocytoma patients and cancer-testis antigens in 
gastrointestinal/ breast cancer patients (Mashino et al., 2001, Schmits et al., 2002).
The identification o f novel antigens has been facilitated by a number o f new 
technologies availability for the identification and characterisation o f proteins in cells 
and tissues. The term “proteomics” which denotes all o f the proteins expressed by a 
genome was first coined in late 1994 at the Siena 2D Electrophoresis meeting. 
“Proteomics” is proclaimed as the next step after genomics, the ultimate goal will be 
to assemble a complete library o f proteins. Several new technologies are facilitating 
this high throughput protein identification and discovery. Tissue cell populations can 
be isolated using either Affinity Cell Sorting o f disaggregated cells from pieces of 
fresh tissue (Page et al., 1999) or alternatively by Laser Capture Microdissection 
(LCM) which procures specific tissue cell populations under direct microscopic 
visualisation o f a standard frozen or fixed tissue section (Banks et al., 1999). Isolated 
cells using both o f these methods can then be used for high sensitivity protein 
analysis using 2-D gels. “Proteomes” from a range o f tissues (normal epithelium, 
benign and dysplastic states, in situ cancer, malignant and invasive cancers) can then 
be used to select antibodies from phage display libraries. These antibodies can then 
be spotted onto chips and characterised by SELDI mass spectrophotometry. These 
technologies have enabled for the first time researchers to analyse proteins from 
every stage o f the cancer process (Borrebaeck 2000, Le Naour et al., 2001).
1.4. Breast Cancer
Despite the ever increasing efforts to fully understand the disease process, the 
incidence o f cancer in the population is rising. As a cause o f mortality overall in the 
Western World cancer is second only to cardiovascular disease. Statistics from a 
recently published joint publication by the Irish Cancer Registry and the Northern 
Ireland Cancer Registry reveal that breast cancer was after skin cancer, the 
commonest form of cancer in women and the most common cause o f cancer deaths 
in females. On average each year 2368 new cases o f malignant breast cancer are 
diagnosed in Ireland. (All Ireland Cancer Statistics 1994-1996).
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The management o f breast carcinoma has changed considerably over the past twenty 
years. The number o f available therapeutic options has widened considerably and 
there are an increasing range o f hormonal, cytotoxic and more recently MAb targeted 
drug regimes available which can be used in both the adjuvant and «eo-adjuvant 
settings. However despite the advances both in the detection and in the treatment of 
the disease between 40 to 50% of patients diagnosed will eventually die o f the 
disease. It is vital thus to determine the optimal treatment modality for each 
individual patient and identify sub groups o f women for various treatment strategies. 
Identification o f biologic markers that can predict clinical outcome o f the disease 
(prognostic markers) and the likelihood o f a response to a particular type o f adjuvant 
therapy {predictive markers) will facilitate this. There is a constant search for new 
markers o f both prognosis and chemoresponsiveness.
1.4.1. Classification of Breast Cancers
1.4.1.1. non-invasive breast cancers
The majority o f breast cancers are adenocarcinomas arising from the epithelium of 
either the mammary lobules (lobular cancer) or the mammary ducts (ductal cancer). 
Often invasive breast cancers may be preceded by cancer in situ. In some cases the 
development o f invasive disease may be preceded by cancer in situ in which the 
malignant cells proliferate within the ducts or lobules but do not breach the basement 
membrane (intra ductal cancer or intralobular cancer). Intraductal cancers tend to be 
more common than intralobular ones.
Ductal carcinoma in situ (DCIS) is defined as a proliferation o f epithelial cells with 
cytological features o f malignancy within parenchymal structures o f the breast and is 
distinguished from invasive carcinoma by the absence of stromal invasion across the 
basement membrane. DCIS varies in cell type, growth pattern and extent o f disease 
and may thus represent a group or spectrum of related in situ neoplastic processes. 
Despite the name, most DCIS is thought to arise from the terminal lobular units. 
Previous classifications o f these tumours were based on growth patterns, however 
evidence has emerged that lesions composed of cells of high nuclear grade are more
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aggressive (Lagois 1990, Bellamy et al., 1993). Thus, the classification system 
currently used is based on the nuclear grading of DCIS, tumours are classified as 
high, intermediate and low grade (Holland et al., 1994). High nuclear grade DCIS 
may exhibit several growth patterns, it may be solid with central comedo type 
necrosis or may exhibit micropapillary or cribriform patterns again often with central 
comedo like necrosis (refer to “Pathology Reporting in Breast Cancer Screening”, 
National Coordinating Group for Breast Screening Pathology. NHSBSP 
Publications, Second edition, 1997).
In low grade DCIS  the cells are generally arranged in micropapillary and cribriform 
patterns which are frequently present within the same lesion. Less frequently a solid 
growth pattern is seen. Intermediate nuclear grade DCIS may exhibit a solid, 
cribriform or micropapillary growth pattern. Comedo type and high nuclear grade in 
general have a more aggressive clinical course than other DCIS lesions.
Lesions are also classified according to the Van Nuys Prognostic Index (VNPI), the 
histological type, width o f the excision margins and tumour size are each assigned a 
score o f 1, 2 or 3. These scores are then added to produce the VNPI which represents 
a cumulative score ranging from 3-9.
Lobular carcinoma in situ (LCIS) lesions arise when the entire cell population o f the 
lobular units consist of characteristic small, rounded cells with granular or 
hyperchromatic nuclei, inconspicuous nucleoli and high nucleo-cytoplasmic ratio. 
Unlike DCIS variability of growth pattern is not observed in LCIS
1.4.1.2. invasive breast cancers
‘D uctal’ no specific type (Ductal -  NST)
Invasive tumours originating in the ductal system which exhibit great variation in 
appearance represent approx. 75% of invasive breast tumours. Pure examples o f the 
following variants constitute only a small percentage of the total number; certain 
features of each are seen within the main portion o f commonly presented invasive/ 
infiltrating ductal carcinomas.
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Infiltrating Lobular Carcinoma
These carcinomas are composed of small regular cells identical to those seen in the 
in situ variant. In its classical form, the cells are dissociated from each other or form 
single files or targetoid patterns around uninvolved ducts. Other variants include 
alveolar, solid, tubulo-lobular, pleomorphic and mixed type.
Tubular Carcinoma
These carcinomas are composed of round, ovoid, or angulated single layered tubules 
in a cellular fibrous or fibro-elastotic stroma.
Invasive Cribriform Carcinoma
These carcinomas are composed of masses o f small regular cells similar to those seen 
in tubular carcinoma. The invasive islands, however exhibit a cribriform rather than a 
tubular appearance.
Medullary Carcinoma
These rare tumours are composed of syncytical interconnecting masses o f large 
pleomorphic cells with vesicular nuclei and prominent nucleoli. The border o f the 
tumour is well defined and surrounded by a dense chronic inflammatory cell 
infiltrate, in situ components are uncommon.
M ucinous Carcinoma
These tumours are also known as mucoid, gelatinous or colloid carcinoma. They 
comprise o f uniform small cells in lakes o f extracellular mucin, in situ components 
are uncommon.
M ixed tumours of the above can also arise.
(Refer to “Pathology Reporting in Breast Cancer Screening”, National Coordinating 
Group for Breast Screening Pathology. NHSBSP Publications, Second edition, 
1997).
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1 . 4 . L 3 . Grading o f invasive Breast cancers
The Nottingham method of tumour grading is now widely used both in the UK and 
the US. This system is based on the evaluation of the following histological features: 
glandular (tubule) formation, nuclear pleomorphism and mitotic count. Following 
scoring tumours are graded into well differentiated tumours (grade I), moderately 
differentiated (grade II) and poorly differentiated ones (grade III).
The most commonly used staging system for breast cancers is the TNM system 
recommended by the International Union against Cancer (UICC) which is based on 
tumour size (T1 -  T4), nodal status (NO -N 3) and the presence or absence o f distant 
metastasis (M0-M1).
1.4.2. Established prognostic/ predictive markers in Breast Cancer
Diagnostic histopathology provides for a substantial amount of useful prognostic 
information from routine analysis of breast tumour samples (Galea et al., 1992). 
Tumour size is considered to be the most valuable prognostic factor in breast 
carcinoma and is an important factor in breast cancer screening programmes, lymph 
node status is also very important (Elston et al., 1999). A recent review o f the value 
o f the various prognostic factors in node negative breast cancer concluded that only 
tumour grade and tumour size remain the only markers which may be clinically 
useful for these patients; lack of standardisation in measurement techniques for many 
of the other breast cancer markers limited their current clinical usefulness (Mirza et 
al., 2002). Generally patients with smaller tumours have a better long term survival 
than those with larger tumours. Tubular, mucinous, invasive cribriform, medullary 
and tubular lobular tumour types have all been reported to have a more favourable 
outcome than invasive carcinoma o f no special type (ductal NST). Unusual tumour 
types such as adenoid cystic carcinoma, adenomyoepithelioma and low grade 
adenosquamous carcinoma also have been reported to show a more favourable 
outcome (Elston et al., 1999).
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Even though assessment of histological subtype provides a certain amount of 
prognostic information the effect is shown to be relatively small when evaluated in 
multivariate analysis (Pereira et al., 1995). Histological grade is considered to be a 
more powerful prognostic factor. Several studies have confirmed the strong 
correlation between histological grade and long term survival (reviewed by Henson 
et al., 1991, Elston et al., 1998). Lymphovascular invasion has shown to be a marker 
o f local recurrence (Elston et al., 1998).
Several studies have shown that patients who have histologically confirmed lymph 
node involvement have a significantly poorer prognosis than those without nodal 
metastases (Carter et al., 1989, Galea et al., 1992, Veronesi et al., 1993). The greater 
the number o f nodes involved the worse the prognosis is; in addition metastasis to 
"higher" level nodes in the axilla or apex is associated with a worse outcome 
(Veronesi et al., 1993). A newer method for the classification/ staging o f axillary 
lymph nodes in breast cancer is now being employed which is a minimally invasive 
diagnostic procedure; sentinel node mapping or sentinal lymphonodectomy (the 
sentinel node is the first lymph node encountered by lymphatics draining from 
tissues around a tumour). Methods for identifying the sentinel node include 
radiotracer and blue dye mapping have been advocated by some researchers (Elston 
et al., 1999, Hill et al., 1999, Linehan et al., 1999).
The significance o f the presence o f metastatic carcinoma in the adipose tissue 
surrounding axillary lymph node known as the extra nodal spread or extracapsular 
metastasis (ECM) is still not clear, studies have shown conflicting results regarding 
its prognostic significance however it is generally considered a worse prognostic 
factor in some tumour types (Cascinelli el al., 1987, Donegan et al., 1993, 
Hetelekidis et al., 2000).
Assessment o f vascular invasion (i.e. the presence o f tumour emboli in vascular 
spaces) using immunohistochemical endothelial markers such as CD31 and CD34 
has also been used as a potential prognostic marker in breast carcinoma. Vascular 
invasion has been shown to be a predictor o f early recurrence, however its most 
important prognostic role is thought to be in the prediction o f local recurrence 
(Pinder et al., 1984, Sapino et al., 2001).
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Other morphological characteristics of breast carcinoma that may be prognostically 
significant include the presence of tumour necrosis, stromal fibrosis and stromal 
elastosis. However although there is some published data regarding a possible 
prognostic role for these factors, available results are conflicting and larger studies 
are required to make any conclusion (reviewed by Elston et al., 1999).
It is well established that the presence of estrogen receptor (ER) (ER alpha) can be 
used to predict response to endocrine therapy in patients with invasive breast cancer. 
Receptor negative patients do not respond as well to endocrine therapy (tamoxifen) 
as those patients which are found to be receptor positive. Recent studies have 
focused on the possible predictive role o f ER beta in breast cancer (Jensen et al. 
2001). Presence of ER is not an independent prognostic factor due to its close 
relationship with histological grade (Galea et al., 1992). The combination o f the 
assessment of progesterone receptor (PgR) status as well improves the predictiveness 
(reviewed by Allred et al., 1998).
1.4.3. MAbs raised to breast associated antigens
Over the years several MAbs, both human and murine have been generated using 
various types of immunisation schedules (use o f live cells, membrane preparations, 
purified molecules) against several breast cancer associated antigens in an attempt to 
isolate MAbs which would recognise breast tumour specific antigens. Such 
antibodies could have important clinical diagnostic applications. Although the 
overall goal has always been to identify antigens that are expressed exclusively by 
breast tumour cells, in practise this has not tended to be the case; most o f these breast 
associated antigens have been found to be expressed to a varying degree by normal 
non tumourogenic breast cells and by other tumour cell types. This was the case with 
most of the earlier work in this area with the generation o f several murine MAbs 
which did not prove to recognise breast cancer specific antigens. However some 
MAbs were successfully shown to be reactive with specific breast cancer associated 
antigens, and in addition a small number o f these MAbs have been to have potential 
prognostic significance when screened on patient material. Breast cancer associated
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antigens identified in this way include the tumour marker CA15-3 which is 
recognised by the MAb, DF3 which has shown to have prognostic significance for 
disease free interval and the nmt55 nuclear protein. Loss o f expression o f this antigen 
has been shown in estrogen receptor negative human breast cancer (Traish et al., 
1997, Dimas et ah, 2000). Many o f the MAbs raised to breast cancer associated 
antigens have been shown to recognise high molecular weight glycoproteins (300- 
400 to over 1000 KDa). Members o f this family include the MAbs B72.3 and CC49 
which recognise the tumour associated glycoprotein, TAG-72, which is a 220-400 
KDa glycoprotein and MAb 83D4, which was generated against a cell suspension 
from a paraffin block o f human breast carcinoma tissue, and detects a large group of 
heterogenous o f 300- 1000 KDa proteins (Colcher et al., 1981, Pancino et ah, 1990, 
Charpin el ah, 1992). A second generation MAb LU-BCRU-G7 which was raised 
against a 230 KDa novel glycoprotein has been shown to have significant association 
with early stage breast carcinoma (Rye & Walker 1994). A more recently described 
novel circulating tumour antigen in breast cancer which was identified using 
proteomics based approaches is RS/DJ-1, a novel oncogenic protein which regulates 
RNA protein interaction (Le Naour et ah, 2001).
With the advent o f human MAb technologies it was hoped that more specific 
antibodies could be generated and that the reactivity o f such antibodies would more 
closely mimic the in vivo response o f the malignant cell. However problems 
associated with the production o f human MAbs such as the lack o f stable clones and 
the isolation o f IgM isotypes have meant that very few human breast cancer specific 
antibodies have been produced to date. Hopefully this has started to change with the 
improvements in the generation of human antibodies as previously discussed. Again 
there has been some success in the area, antibody JDB1 was generated by fusion of a 
human lymphoma cell line and peripheral blood lymphocytes from a breast cancer 
patient (Strelkauskas et ah, 1994). This MAb has been shown to identify metastatic 
infiltrating ductal carcinoma in both axiliary nodes and skin and normal breast. Other 
malignancies did not show any reactivity with this antibody.
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1.4.4. Novel prognostic/ predictive markers in Breast Cancer
1.4.4.1. Miscellaneous cellular markers
Over the years in an attempt to identify possible markers for both the prognosis and 
chemoresponsiveness of breast cancer; a wide variety o f novel variables have been 
proposed as possible prognostic factors. The majority o f these are associated with 
mechanisms o f differentiation, invasion, metastasis or growth rate o f the tumour 
(Elston et al., 1999).
There are several antigenic markers that provide useful diagnostic information in 
breast cancer but do not appear to be prognostically important. Metallthionein is a 
protein which is involved in cellular repair, growth and differentiation. Its expression 
is associated with early phase breast cancer (Iochim et al., 1999). Gelsolin is an actin 
filament regulatory protein; altered gelsolin expression appears to be involved in 
progression from normal epithelium to DCIS to invasive breast cancer (Asch et al., 
1999). Expression of CD24, a small mucin like glycosylphosphatidylinositol-linked 
cell surface marker has been suggested as a possible useful marker for breast 
carcinoma, the intensity o f CD24 positivity has been shown to increase with the 
histological grade o f the tumour (Fogel et al., 1999). Recent work suggests that 
frizzled related protein (Frp) may have a possible prognostic role in invasive breast 
cancer (Wong et al., 2002).
T l-S , an oncogene inducible, secreted glycoprotein o f the immunoglobulin family 
has been shown to be a novel and independent tumour biological factor possibly 
associated with reduced progression o f lymph node negative breast cancer (Prechtel 
et a l, 2001). Sialyl-Tn (STn), a carbohydrate antigen formed by the premature 2-6 
sialylation o f N-acetylgalactosamine has been shown to be a marker for short term 
prediction o f breast cancer (Leivonen et a l, 2001). Expression o f Fas protein has 
been associated with aggressive tumour behaviour in locally advanced breast 
carcinomas (Pemick et a l, 2000).
Complete loss of the breast cancer susceptibility gene, BRCA1 nuclear protein 
expression (mutation of this gene has been reported in 80% of familial breast cancer)
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and its correlation with other poor prognostic markers suggest that its expression 
may play an important role in the pathogenesis and prognosis o f sporadic breast 
cancer (Lee et al., 1999). Expression of epithelial mucins including MUC1 are 
thought to be related to the progression of malignant disease (Devine et al., 1992, 
Croce et al., 1997) and proteases such as Cathepsin D may have prognostic 
significance in this malignancy (Tetu et al., 2001).
The matrix metalloproteinases (MMPs) are a family o f zinc dependant 
endopeptidases. It is thought that MMPs are involved in breast cancer initiation, 
invasion and metastasis. MMP-9 overexpression may be an independent prognostic 
factor in node negative breast cancer (Scorilas et al., 2001). MMP-2 has been shown 
to offer prognostic value in certain node negative post menopausal patients 
(Talvensaari-Mattila et al., 2001). Stromelysin-3 has been shown to be a strong 
independent prognostic factor in node negative patients (Ahmad et al., 1998).
Numerous studies have looked at the expression of another protease, urokinase 
plasminogen activator (uPA) which can promote tumour invasion, tissue type PA 
(tPA) and antiproteases including PAI-1 and PAI-2 (Bouchet et al., 1994). Reduced 
tPA mediated plasmin production has been shown to be an independent adverse 
prognostic factor in breast cancer (Chappuis et al., 2001). Studies have revealed that 
evaluation o f uPAR the cellular receptor of uPA may serve as predictor o f overall 
survival in breast cancer and as an indicator o f recurrence in DCIS (Guyton et al., 
2000, Pacheco et al., 2001). In a recent report, uPA and PAI-1 have been shown to 
have independent prognostic value in lymph node negative breast cancer (Look et al., 
2002).
Immunohistochemical expression of cell adhesion molecules such as E-cadherin and
a .2 and Pi integrins (Gonzalez et al., 1999) has also been evaluated. It has been 
reported that cytokeratin 18 expression indicates a favourable prognosis in breast 
cancer patients (Schaller et al., 1996). More recently it has been observed that the 
presence o f cytokeratin positive cells in the bone marrow increases the risk o f relapse 
in patients with breast cancer (Braun et al., 2000). The expression o f luminal 
epithelial antigen (LEA-13 5) has been shown to be an independent and favourable
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prognostic marker in invasive primary breast cancer; its expression appears to 
override the adverse effects o f certain oncogenic and cell proliferation associated 
markers (Liu et al., 2000). CEA immunoreactivity was not shown to be 
prognostically relevant in a large series o f infiltrating breast cancers (Mauri el al.,
1998).
1.4.4.2. Proliferation markers
Cell proliferation constitutes a major determinant in the biological behaviour o f a 
tumour. DNA content and proliferative activity of breast tumours have been 
investigated extensively using various methods including measurement o f mitotic 
index, S phase fraction (SPF) (by flow cytometry) and expression of various 
proliferation associated markers such as Ki-67 (MIB-1), PCNA and Topo II a , in an 
attempt to address the possible prognostic and predictive significance o f these 
paramétrés. It is well recognised that the proliferative activity o f a given tumour is 
an important prognostic factor in primary breast cancer; various markers of 
proliferation have shown that high proliferative activity is directly related to poor 
clinical outcome (Clarke et al., 1996).
The most widely investigated proliferation associated marker is the Ki-67 antigen 
which is expressed during the G l, S, G2 and M phases o f the cell cycle and not by 
non-cycling cells in GO (Gerdes et al., 1984). Expression o f the Ki-67 antigen is 
considered to be a more accurate marker of proliferation than PCNA which has a 
longer half life, in addition there are currently Ki-67 MAbs available that recognise 
formalin resistant epitopes and thus can be used to screen formalin fixed paraffin 
embedded archival material. Several studies have correlated poor clinical outcome 
with expression of Ki-67 (Veronese et al., 1996, Ruldoph el al., 1999a, 1999b).
Measurement o f proliferative activity using Topo II a  specific MAbs such as 
antibody Ki-S4 has shown to be a useful indicator o f prognosis in breast carcinoma 
(Ruldoph et al., 1999b, 1999c). Increased Topo II am R N A  expression has been 
shown to accompany tumour progression in breast cancer, in the same study there 
was no difference in expression o f this protein in relapsed and non-relapsed patients 
(Ito et al., 1998). Recent studies have revealed that increased Topo II a  protein
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expression has been shown to be associated with an aggressive form of breast cancer 
and cellular dedifferentiation and also predicted disease related death, lymph node 
metastasis and advanced tumour stage (Depowski et a l, 2000, Nakopoulou et a l, 
2000).
Mitosin is a recently described 350kDa nuclear phosphoprotein that is expressed in 
the late G l, G2 and M phases o f the cell cycle and is not expressed in GO. 
Preliminary immunohistochemical data suggest that the value o f mitosin expression 
may be superior to that o f SPF in its prognostic value (Clarke et al., 1997).
Caspase-3 is a prominent member o f the CED-3 family o f cysteine proteases which 
act as intracellular effectors o f apoptosis. Increased Caspase-3 positive staining has 
been observed in both in situ and infiltrating breast tumours compared to normal 
mammary epithelium; the prognostic significance of caspase-3 expression in breast 
tumours has not been addressed (Krajewski et al., 1999).
Many studies have suggested that investigation of proliferation markers and certain 
oncogenes such as c-erbB-2 or p53 or other prognostic markers (e.g. receptor status) 
may provide more prognostic information than proliferative activity alone 
(Niewiadomska et al., 1998, Wiesener et al. 1998, Ruldoph el al., 1999c).
I.4.4.3. Oncogenic markers
Overexpression / activation o f genes that promote cellular transformation, tumour 
growth and/ or dissemination i.e. oncogenes have been detected in a significant 
proportion o f breast tumours (Berns et al., 1992).
Dysregulation of programmed cell death i.e. apoptosis mechanisms plays an 
important role in the pathogenesis and progression of breast cancer as well as in the 
responses o f tumours to therapeutic intervention and the overall survival o f breast 
cancer patients. Increased apoptotic index has been associated with high tumour 
grade, large tumour size, DNA aneuploidy, high S phase, high mitotic rate, lack of 
ER and shorter disease interval and overall survival. It is well established that
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increased apoptosis is associated with a worse prognosis in breast carcinoma 
(Vakkala et ah, 1999). Recently apoptosis has also shown to be induced by neo 
adjuvant chemotherapy (also referred to as primary chemotherapy or pre  operative 
chemotherapy). Post chemotherapy apoptotic index has shown to be correlated with 
clinical response and increased relapse free and overall survival o f patients treated in 
this fashion (Shao et ah, 1999). Interestingly, medullary carcinoma o f the breast 
(which exhibits a high mitotic rate and shows an anaplastic histology) in general 
shows a better prognosis than ordinary ductal carcinoma, a high frequency of 
apoptosis in such tumours may be related to a favourable prognosis in these patients 
(Kajiwara et ah, 1999).
Apoptosis is controlled/ regulated positively and negatively by the products of 
different genes. Overexpression o f genes that inhibit apoptosis may play not only in 
the etiology o f various tumours including those o f mammary origin, but also in 
tumour progression. One of the first of these anti-apoptotic/ survival genes to be 
identified was the bcl-2 gene. At least 17 bcl-2 family members have been identified 
(in mammalian cells and viruses) which show sequence homology with bcl-2 but 
possess different functions in the regulation o f apoptosis (reviewed in Reed 1998). 
Interestingly, expression o f bcl-2 is generally associated with favourable prognostic 
indices and thus with a favourable outcome in breast cancer. However there have 
also been reports demonstrating that expression of bcl-2 does not always predict a 
favourable clinical outcome (Silvestrini et ah, 1994). Bcl-2 immunostaining has been 
correlated with ER and PgR in several studies (Leek el al., 1994, Silvestrini et ah, 
1994, Jalava et ah, 2000). Such Bcl-2 negative patient groups may therefore benefit 
from additional treatment with anti estrogen therapy. Bcl-2 positive patients (node 
positive and negative) have shown a better prognosis and an overall better survival 
rate compared to Bcl-2 negative patients, these studies have included uniformly 
treated patients with node negative, node positive or metastatic disease (Joensuu et 
al., 1994, Silvestrini et ah, 1996, Zhang et ah, 1998). Lack o f Bcl-2 expression was 
independently associated with a poor prognosis in patients with higher grade tumours 
who were treated with primary chemotherapy, in the same study p53 expression was 
a independent prognostic marker o f relapse free survival (Bottini et ah, 2000). Bcl-2 
appears to be associated with good prognostic markers both in invasive breast cancer 
and DCIS tumours (Rehman et ah, 2000).
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The exact reason o f how Bcl-2 expression is associated with a favourable outcome is 
not clear but the anti-proliferative effect o f Bcl-2 maybe involved. Alternatively the 
presence o f Bcl-2 may represent a marker o f tumours that have arisen by a less 
aggressive genetic pathway involving a dependence on steroid hormones (Krajewski 
et al., 1999). It appears that Bcl-2 immunopositivity may represent a more treatable 
form of breast cancer, and is therefore associated with longer survival in patients 
with node negative, node negative and metastatic disease.
There are other genes that promote apoptosis such as wild type p53  and c-myc, 
Mutant p53  suppresses apoptosis. It has been reported that the bcl-2 and c-myc 
oncogenes may act in a synergistic fashion in the promotion o f the metastasis process 
in breast tumours (linked to loss of apoptosis) (Sierra et al., 1999). Expression 
patterns o f the tumour suppressor gene, p53  have been widely studied in breast 
cancer. p53 is a transcription factor that participates in cell cycle checkpoint 
processes and apoptosis. Positive p53 (mutated) immunostaining appears to correlate 
with larger tumour size, higher proliferation rate, oncogenic amplification and in 
some studies the absence o f hormone receptors (reviewed by Dhingra and Hortobagl
1996). The overall prognostic role of mutated p53  in breast cancer is still not clear; 
largely due to discrepancies between p53 immunostaining and single strand 
confirmation polymorphism (SSCP)/ DNA sequencing methods. A recent study has 
revealed that increased expression of Bcl-2 as well as p53 is associated with a 
decreased risk of local recurrence, an increased risk was associated with increased 
expression of MIB-1 (Jager et al., 2000). p53 immunostaining in primary breast 
tumours was found to an independent prognostic factor associated with relapse free 
survival. There appears to be an inverse relationship between Bcl-2 and p53 positive 
staining in breast cancer (Krajewski et al., 1997). Co-expression o f c-erbB-2 and p53 
has been shown to be o f independent prognostic value (Beenken et al., 2001).
It has been observed that low levels o f p27Kipl and apoptotic index strongly 
correlated with presence of lymph node metastasis and decreased patient survival; in 
node negative patients p27Kipl also had prognostic value for relapse free and overall 
survival as well as having predictive value for chemotherapy (Wu et al., 1999).
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Less is known regarding the role o f the other members o f the bcl-2 family in breast 
cancer. The ratio between the pro  apoptotic gene Bax and bcl-2 appears to be an 
important determinant o f cellular sensitivity to induction o f apoptosis in breast 
carcinoma. Indeed the exact interaction of all o f these regulatory apoptosis remains 
has not been elucidated to date. However it appears that the ratios o f survival versus 
death related proteins in cells are important as these ratios then function as 
determinants o f either the induction of apoptosis or the promotion o f cell survival in 
response to various insults including that of cytotoxic drugs. Studies o f Bax 
expression in breast cancer have revealed that loss o f Bax immunostaining represents 
a prognostic indicator o f poor response to therapy as well as reduced survival in 
women with metastatic disease who are treated with combination chemotherapy 
(probably due to its role in promoting apoptosis in response to genotoxic injury 
induced by anti cancer drugs) (Krajewski el al, 1995a, Kapranos el al., 1997). The 
prognostic role o f Bax in breast cancer appears to be limited to chemotherapy treated 
patients although it has been observed that Bax (also Bcl-xl ) immunostaining 
predominates in higher histological grades o f ductal carcinomas (grade 111) 
compared to grade 1/11 where Bcl-2 and Bak were predominantly expressed (Sierra 
el al., 1998). There appears to be no correlation between Bax and p53 
immunostaining (Veronese et al., 1996, Yang et al., 1999).
It has been reported that expression o f the pro  apoptotic protein, Bak was associated 
with high apoptotic rate, high tumour grade, overexpression o f p53, expression o f ER 
and low expression of Bcl-2, however no correlation between Bak expression and 
clinical outcome has been reported (Krajewski et al., 1994, 1995b, Rochaix et al.,
1999).
Bcl-xl and Mcl-1 are anti-apoptotic members of the Bcl-2 family which have been 
implicated in cancer chemoresistance (Reed 1997). No correlation o f Mcl-1 
expression with either tumour progression or clinical outcome has been reported 
(Krajewski et al., 1994, Krajewski et al., 1995b). In contrast expression of Bcl-xl is 
commonly reported in breast cancer where intense Bcl-xl positivity has been 
observed in malignant cells compared to normal epithelia, suggesting a possible 
prognostic role. Like Bax the prognostic role of Bcl-xl does not apply to early stage 
disease which is treated with surgery or radiation, the expression o f Bcl-xl in
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metastatic patients treated with chemotherapy has not been investigated (Krajewski 
etal., 1994, 1999, Olopade et al., 1997).
The heat shock protein, Bag-1 (not homologous to bcl-2) has an anti-apoptotic 
function and interacts with several other proteins including Bcl-2 (which it enhances 
the anti-apoptotic function of), the mechanism whereby it interacts with bcl-2 to 
suppress apoptosis is not fully understood (Takayama et al., 1995). Bag-1 appears to 
be expressed in a majority of breast cancers; this expression varies among patients. 
Preliminary results indicate that Bag-1 immunostaining, particularly nuclear staining 
may provide prognostic information in early stage breast cancer; higher levels of 
Bag-1 appear to be associated with a shorter disease free interval, and shorter overall 
survival in these patients (Tang et al., 1999). Immunohistochemical expression of 
Bag-1 was not shown to correlate with either bcl-2 or bcl-xl expression. Breast 
tumours showed high expression of two isoforms o f Bag-1, p46 and p33 in the same 
study (Yang et al., 1999). As there appears to be no correlation between Bag-1 
expression and conventional prognostic indices (except the degree o f differentiation), 
it may constitute an independent predictive factor in breast cancer independent of 
bcl-2 and bcl-xl. Preliminary results published recently suggest that Bag-1 represents 
a potential marker o f improved survival in early stage breast cancer patients 
independent o f the status o f axillary lymph nodes (Turner et al., 2001).
c-myc amplification is detectable in approximately 20% of breast tumours; its 
expression has been shown to correlate with poor tumour differentiation, 
inflammatory carcinoma and loss o f PR, and its overexpression has in some studies 
been associated with an adverse prognosis (Bems et a l, 1992, Chrzon et al., 2001, 
Naidu et al., 2002).
Survivin is a recently discovered gene which encodes a structurally unique IAP 
apoptosis inhibitor (reviewed by Altieri et al., 2001). Survivin is expressed during 
foetal development and is undetectable in terminally differentiated non-neoplastic 
adult human tissues, however the expression appears to be switched on again in most 
common human cancers (and transformed cell lines) (Ambrosini et al., 1997). It has 
been reported that apoptosis inhibition by survivin alone or in co-operation with bcl- 
2 may be a significant prognostic factor of worse outcome in breast carcinoma
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(Tanaka et a l, 2000). Expression of survivin protein was not correlated with p53 in 
this study but did correlate with bcl-2 protein levels and reduced apoptotic index.
The AP-1 family o f transcription factors (which includes c-jun, junB, junD, c-fos, 
fosB, fr a l  and fr a l)  show a differential pattern o f expression in breast cancers, 
expression o f fosB was found to correlate significantly with positive steroid hormone 
receptor status and a more differentiated phenotype (Bamberger et a l, 1999).
The proto oncogene HER-2/ neu (also known as cerb-B-2) is a member o f the 
epidermal growth factor family and its amplification is one o f the most common 
genetic alterations associated with human breast cancer occuring in approximately 
30% of breast carcinomas (Slamon et al., 1987). The HER family plays an important 
role in the regulation of cell growth, survival and differentiation. HER-2/ neu 
amplification and protein overexpression have been implicated both in the 
pathogenesis and clinical behaviour o f human breast cancer. Higher expression of 
HER-2/ neu has been reported in intraductal carcinomas compared to infiltrating 
tumours; and it may be useful in the determining the invasive potential o f DCIS 
patients (Allred et a l, 1992). This oncogene has proved to be one of the most 
promising markers currently under study in breast cancer both as a marker of poor 
prognosis and as a predictor o f chemoresistance. Preclinical studies suggest that 
HER-2/ neu overexpression enhances the metastatic potential o f breast cancer cells 
(Sahin 2000). As already mentioned the growth of breast tumours (in vitro and in 
vivo) overexpressing HER-2 is inhibited by anti-HER-2 MAbs (Drebin et al., 1986, 
1988). With the successful clinical trials o f trastuzumab, the establishment o f  HER-2 
tumour status is obviously a prerequisite for therapeutic use o f this MAb (Baselga et 
a l, 1998, Slamon et a l, 1998, Slamon et a l, 2001). Herceptest (Dako Corporation, 
CA) has been approved by the US Food and Drugs Administration to be used to 
screen tumours by immunohistochemistry for HER-2 status. However there is still 
ongoing controversy as regards whether the establishment o f HER-2 status of 
tumours should be done by immunohistochemistry or by fluoresence in situ 
hybridisation (FISH) (measurement o f gene amplification). It is generally agreed that 
the best approach is to combine both immunohistochemistry and FISH (Wang et al,
2000).
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The HER-2/ neu oncogene has been extensively studied as a prognostic marker 
although this role remains controversial. The first report o f its prognostic role was in 
1987 by Denis Slamon and his colleagues which revealed that HER-2 gene 
amplification independently predicted overall survival and disease free survival in a 
multivariate analysis o f node positive patients (Slamon et al., 1987). Since this, 
several studies have confirmed a significant correlation between HER-2/ neu 
overexpression and poor prognostic markers in node positive disease i.e. a poor 
degree o f differentiation, high nuclear grade, lack o f steroid receptors, high 
proliferative activity and DNA aneuploidy (reviewed by Sahin 2000). Assessment of 
HER-2/ neu status now constitutes one o f the most important prognostic factors in 
node positive breast cancer patients.
The significance o f HER-2/ neu overexpression in node negative patients is 
conflicting, some studies as is the case with node positive patients show a poorer 
prognosis in either certain or all cases while other studies did not find such a 
correlation. These conflicting results may be explained by the small patient numbers 
evaluated, the low event rate and the diversity o f methods used, presently the 
assessment o f HER-2/ neu in node negative cannot be used as a prognostic factor 
routinely (reviewed by Mirza et a l, 2002). It has also been suggested that 
overexpression o f other members o f the HER family, c-erbB-3 and c-erbB-4 
oncoproteins may play a role in the prognosis o f breast carcinoma; increased 
expression o f both o f these oncoproteins has been associated with a prognostically 
favourable ER positive phenotype (Bodey et al., 1997). Higher levels of cerbB-4 
expression have been associated with a more differentiated phenotype (Kew et al.,
2000).
It has been shown that increased Topo II a  expression is associated with an 
aggressive form o f breast cancer featuring erbB-2/ neu amplification and predicts 
disease related death, lymph node metastasis and advanced tumour stage (Depowski 
et al., 2000). In DCIS HER-2/ neu and Topo II a  expression is associated with 
poorly differentiated lesions (Shpitz et al., 2000).
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I.4.4.4. Markers o f Chemosensitivity
Breast cancer is moderately sensitive to multiple chemotherapeutic agents; however 
the duration of this response is usually short and the majority o f these patients will 
eventually relapse and the tumour will fail to respond to chemotherapy. 
Chemotherapy resistance constitutes a major problem in the management o f breast 
carcinoma. To date the exact mechanisms of this resistance have not been fully 
elucidated, it is well recognised that drug resistance in breast cancer is multifactorial 
and heterogeneous. A better understanding of the underlying mechanisms may result 
in the expansion of the use o f MDR modulators and antibody therapy within the 
clinic. Identification o f paramétrés that can accurately predict the response of 
individual patients to chemotherapeutic agents will allow for more precise targeting 
o f these chemotherapeutic drugs in the clinic for breast cancer patients. However 
predictive markers for chemosensitivity for breast cancer are less well established 
than prognostic markers in this disease. There appears a lot o f conflicting data 
regarding the contribution of various markers to the prediction o f response in the 
treatment o f breast cancer, results from evaluation o f HER-2/ neu tumour status and 
its prediction o f response to various chemotherapeutic drugs is probably the most 
convincing to date.
Expression of the mismatch repair protein (MLH1) has recently been shown to be an 
independent predictive factor for poor disease free survival in patients treated with 
neo-adjuvant therapy (MacKay et a l, 2000).
It is well recognised that high tumour proliferation in addition to being a marker of 
poor prognosis has a role in the prediction of response to chemotherapy. 
Retrospective studies have demonstrated that breast cancer tissues with high 
proliferation indices and low grades o f tumour differentiation respond better to 
chemotherapy (Silvestrini & Daidone 1993). Tumour grade, SPF, Bax expression 
independently predicted response to treatment (5-FU, epirubicin and cyclophosmide) 
in metastatic breast cancer patients (Sjostron el al„ 1998). Another study reported 
that Ki-67, DNA ploidy, SPF, and p53 did not predict response to neo adjuvant 
therapy (mitoxantrone, methotrexate +/- mitomycin C and tamoxifen) in primary 
breast cancer patients (Makris et al., 1997). A later study o f SPF and Ki-67
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expression has shown that these markers may have a predictive role in the response 
of patients to neo adjuvant chemotherapy (Makris 1999). Breast tumours with a high 
growth activity by assessment with Ki-67 have been shown to have low 
chemosensitivity (Itaya et ah, 1999). Expression of Ki-67, MDR-1, MRP-1, LRP, 
DNA Topoisomerases or p53 proteins did predict response to neo adjuvant 
chemotherapy in a study by Linn et ah, (1997). It has been suggested that expression 
o f MIB-1, cerbB-2 and p53 may offer possible predictive value in patients who 
received primary chemotherapy (Colleoni et ah, 1999).
Conclusions from studies looking at evaluation of p53  as a possible marker o f 
chemosensitivity vary. p53 overexpressing tumours have been shown to predict 
response to chemotherapy in a number o f studies; lower chemosensitivity has been 
observed in such tumours (Burke et al., 1998, Itaya et ah, 1999, Mottolese et ah, 
2000, Geisler et ah, 2001). In patients treated with neo adjuvant therapy high 
response rates were observed in patients whose pre treatment tumours were p53 
negative/ Pgp negative (Daidone et al., 1999). Other studies however do not support 
a predictive role for p53 (Rein et ah, 2000, Sjostrom et al., 2000, Yang et ah, 2000).
Again the possible predictive role o f Bcl-2 in breast cancer remains controversial. It 
has been suggested that Bcl-2 may predict response to chemotherapy in a number of 
studies (Chang et ah, 2000, Mottolese et ah, 2000, Yang et al., 2000, Geisler et al., 
2001). One study has shown that expression o f Bcl-2 and Bax proteins and apoptotic 
index (Al) may be predictive of response to chemotherapy (Wu et al., 2000). Other 
studies however have shown that Bcl-2 did not predict for response to 
chemotherapeutic drugs (Takei et al., 1999, Poelman et ah, 2000). Investigation of 
survivin expression levels and response to therapy has not been reported to date.
MIB-1, the protein products of the mdm-2 (a gene which plays a central role in the 
regulation o f p53) and p21 (or WAF1, the wild type p53 activated fragment) genes 
were found to have a predictive role in the response to docetaxel and methotrexate/ 
5-FU (Sjostrom et al., 2000). Recent work suggests that mRNA levels o f the breast 
cancer susceptibility gene, BRCA2, may predict response to docetaxel (Egawa et ah,
2001).
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Again there have been several studies directed at the possible predictive role o f HER- 
2/ neu in breast cancer. However results to date have proved conflicting. Early 
studies looking at the possible predictive role o f HER-2/ neu in the response o f breast 
cancer patients treated with CMF therapy suggested that this chemotherapeutic 
regime is o f less benefit to patients with HER-2/ neu overexpressing tumours (Allred 
et ah, 1992, Gusterson et ah, 1992, Tetu & Brisson, 1994, Stal et al., 1995). It was 
reported by Slamon et al. (1987) that HER-2 gene amplification could independently 
predict overall survival and disease free survival in node positive breast cancer using 
multivariate analysis. This observation has been confirmed by several investigators 
(reviewed by Sahin et ah, 1999, Simon et ah, 2001).
However opinions on whether HER-2/ neu status should be used to routinely 
determine which patients might not get benefit from CMF are still mixed, some 
researchers are waiting for more validation or results before recommending such a 
predictor in the clinic (Ravidin 1999). Association of HER-2/ neu with response to 
doxorubicin containing regimes has also been studied; results have suggested that 
HER-2/ neu overexpression may determine which patients have tumours which may 
be particularly sensitive to such drug regimes (Paik et ah, 1998, Thor et ah, 1998). 
Furthermore preliminary results suggest that it may also play a predictive role in 
response to pacitaxel (taxol) (Baselga et ah, 1998).
Amplification o f the cerbB-2 oncogene is thought to be followed by a complex 
sequence o f genetic aberrations which leads to the amplification of the Topo II 
a  gene (Muss et ah, 1994, Jarviven et ah, 1999). Topo II a  amplification and 
deletion are thus common in cerbB-2 amplified breast cancers, which may explain 
the altered chemosensitivity to Topo II inhibitors reported in cerbB-2 amplified 
breast cancers (Jarvinen et ah, 2000).
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1.5. Classification of Haematological malignancies
1.5.1. Acute Leukaemias
Acute leukaemias are neoplastic disorders marked by uncontrolled proliferation of 
haematopoietic cells with a predominence o f immature lymphoid or myeloid cells 
(more than 30% ) in the bone marrow and peripheral blood. Acute leukaemias may 
be designated as lymphoblastic (ALL) or nonlymphoblastic (myleoblastic/ 
monocytic) (ANLL or AML). The incidence o f these malignancies increases with 
age. ALL is the most common childhood malignant neoplasm, 80% o f adults with 
leukaemia have ANLL.
AML is characterised by both the proliferation and the accumulation o f leukaemic 
blast cells o f myeloid origin that cannot enter normal granulo-monocytic 
differentiation. AML consists o f hierarchical subpopulations including a minority of 
proliferarting progenitors. This malignancy is classified according to the French- 
American-British (FAB) study by morphological and histochemical criteria.
FAB Classification of AML
MO myeloblastic, without maturation, mainly differentiated
M l myeloblastic, without maturation
M2 myeloblastic, with maturation
M3 pro-myelocytic
M4 myelomonocytic
M5A monoblastic
M5B pro-monocytic
M6 erthroleukaemia
M7 megakaryoblastic
Table 1.1. : FAB Classification of AML
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1.5.2. Chronic Leukaemias
Chronic Lymphocytic Leukaemia (CLL)
CLL is a malignant haematological disorder characterised by a persistant absolute 
increase in “mature” appearing lymphocytes in the peripheral blood and bone 
marrow. The vast majority of cases are o f B cell (B-CLL) origin, the T cell variant is 
only seen in about 5-10% of patients diagnosed with CLL. B-CLL is the most 
common type o f haematological malignancy in the Western world, particularly 
affecting older age groups. Prolymphocytic leukaemia (PLL) is a variant o f CLL 
which usually occurs in elderly patients. The T cell variant o f PLL is rarely seen and 
follows a less predictable prognosis.
LGL Leukaemia
Clonal diseases o f large granular lymphocytes can be either T cell (T-LGL) of 
natural killer cell origin NK-LGL.
Hairy Cell Leukaemia (HCL)
This is a rare malignancy which is also known as leukaemic reticuloendotheliosis. 
The characteristic cells which are lymphoid appearing with “hairy” cytoplasmic 
projections are always o f B cell origin and the disease is therefore, considered a 
variant o f CLL.
Chronic Myelogenous leukaemia (CML)
CML also referred to as chronic granulocytic leukaemia is a clonal 
myeloproliferative disorder arising from neoplastic proliferation at the level o f the 
pleuripotent stem cell. This malignancy is rare in childhood and peaks in the mid 
fifth decade.
1.5.3. Non Hodgkins Lymphoma (NHL)
NHLs are a diverse group of malignancies o f the lymphoreticular system that have 
heterogenous histopathologic, immunologic, cytogenetic and clinical characteristics. 
The median age for this disease is 50 years, the incidence increases with age. NHL
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are graded histologically as low, intermediate, high and miscellaneous grade. Mantle 
cell lymphoma (MCL) and follicle centre lymphoma (FCL) which belong to the 
NHL group o f malignancies are also classified as sub groups o f B-cell chronic 
lymphoproliferative disorders (B-CLPD).
1.5.4. Multiple Myeloma (MM)
MM and related disorders (plasma cell dyscarias) comprise a spectrum o f diseases 
that are characterised by autonomous proliferation o f differentiated lymphoid cells 
and plasma cells whose physiological function is to secrete immunoglobulins. MM is 
the most common of these diseases representing 75% o f dyscarias, is an incurable 
cancer that accounts for 1% of all cancers and 10% of haematological malignancies. 
Waldenstrom’s macroglobulinemia represents 20% o f dyscarias, the remainder 
consisting of other types of heavy chain disease.
1.6. Multiple Drug Resistance (MDR)
Human malignancies including breast cancer are routinely treated with 
chemotheraptic drugs and/ or hormone therapy, usually following surgery. Radiation 
therapy is given to some patients. However although chemotherapy has the potential 
to cure certain malignancies, in approximately 84% of patients who receive 
chemotherapy, drug resistance will develop. Resistance to these chemotherapeutic 
agents remains the major obstacle in the successful therapy o f many human cancers. 
Certain malignancies do not respond to chemotherapy; these tumours display 
intrinsic resistance. Alternatively other malignancies can be initially sensitive to a 
chemotherapeutic regime, leading to a partial or complete response o f the tumour 
(generally resulting in a decrease in tumour size). Unfortunately these tumours can 
then recur (if a small number o f tumour cells has become resistant to the 
chemotherapeutic agent) and then display resistance not only to the initial 
chemotherapeutic agent but also to other drugs to which the tumour has not
36
previously been exposed. This is termed acquired or secondary resistance (Gerlach et 
al., 1986).
MDR refers to a phenomenon whereby tumour cells acquire resistance to a broad 
range o f structurally and functionally diverse chemotherapeutic drugs including 
anthracyclines, vinca alkaloids, epipophyllotoxins and taxol following exposure to a 
single agent. Several mechanisms have been identified that can render tumour cells 
multidrug resistant. The first mechanism to be discovered and the most widely 
studied o f these is the overexpression o f the MDR-1 gene product, P-glycoprotein 
also referred to as P-170/ Pgp (Gros el al., 1986). Other MDR mechanisms include 
altered levels o f multidrug resistance associated protein (MRP), a 190 kDa 
membrane protein (Cole et a l, 1992), the lung resistance related protein (LRP) 
(Scheper et al., 1993), topo II (Hoffmann & Mattem, 1993), glutathione S transferase 
(GST) (Moscow & Dixon, 1993) and possibly the transported associated with 
antigen processing (TAP) (Izquierdo 1996).
1.6.1. P-glycoproteins/ Pgps
P-glycoproteins (Pgps) are members o f the superfamily of ATP binding cassette 
(ABC) transporter proteins (Schinkel el al., 1991). ABC transporters are membrane 
proteins that contain multiple membrane spanning regions and at least 1 ATP binding 
site (Walker et al., 1982). Various Pgp isoforms have been identified; all o f these 
isoforms are encoded by a group of closely related genes. Two Pgp genes have been 
identified in humans, MDR-1 and MDR-3, these two genes show 80% homology 
(Roninson et a l, 1986, Van Der Bliek et al., 1987).
Pgp class Human Mouse Hamster
1 mdr 1 mdr 3 (mdr la) PgP 1
11 mdr 1 (mdr lb) P8P 2
111 mdr 3 mdr 2 PgP 3
Table 1.2.: Mammalian P-glycoprotein isoforms
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1.6.2. MDR-1 P-glycoprotein
The MDR-1 gene product acts as an energy dependent efflux pump that actively 
transports drugs out o f the cell before they can reach cytotoxic concentrations. It is 
thought that this transport o f drugs by MDR-1/ Pgp involves a translocation or 
flippase mechanism (Grottseman & Higgins 1992). Pgp is typically localised to the 
apical surface o f the cells that express it. P-gp is involved in the normal physiological 
functions o f the cell and is thought to have a protective role i.e. the transport and 
excretion o f naturally occurring xenobiotics (Schinkel et al., 1994). The tissue 
distribution pattern o f P -170 reflects this protective role, however the physiological 
functions of MDR-1/ Pgp have been poorly defined. High expression o f Pgp has 
been found in human adrenal cortical cells, the brush border o f renal proximal tubule 
epithelium, the lumenal surface of biliary hepatocytes, small and large intestinal 
mucosal cells and pancreatic ductules. P-glycoprotein is also expressed at lower 
levels in capillary endothelial cells of the brain and testis, the placenta, lung, prostate, 
NK cells and in CD34 positive bone marrow stem cells (reviewed by Bellamy 1996).
1.6.3. MDR-1/ P-glycoprotein in Breast Cancer
Over the last 10 years several researchers have attempted to address the question of 
the precise clinical relevance o f MDR in breast cancer. Most o f this work has 
focused on the role o f MDR-1/ Pgp in this disease; despite huge variability and 
conflicting results it is likely that M DR-1/ Pgp is expressed in a significant 
proportion of breast cancers; higher levels are seen in tumours exposed to MDR 
substrates. An extensive meta analysis o f MDR-1/ Pgp in breast cancer examined 31 
different studies in detail and reports that MDR-1/ Pgp is expressed in 41.2% of 
breast tumours; this expression is associated with treatment and with a poor response 
to chemotherapy. This report has also concluded that MDR-1/ Pgp is not acting as a 
surrogate for another prognostic marker (Trock et al., 1997).
A factor which probably contributes to the huge variability o f results in assessing 
MDR-1/ Pgp in breast cancer and other malignancies is that majority of studies have 
used only one P-170 specific antibody. Trock et al. (1997) report that 67% of studies
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using immunohistochemistry used only one P-170 antibody. It is generally accepted 
now that at least two antibodies directed to different epitopes o f P-170 should be 
employed in any study (reviewed by Beck et a l, 1996). In addition some of the P- 
170 antibodies have been shown to cross-react with other cellular components; JSB-1 
and C294 cross react with pyruvate carboxylase, the C219 MAb cross reacts with the 
c-erbB-2 protein. C219 may therefore yield false positive results in breast tumours 
which overexpress c-erbB-2, careful interpretation and caution must therefore be 
employed when examining such tumours (Liu et a l, 1997, Chan & Ling 1997).
Several studies have showed MDR-1/ Pgp expression associated with either 
recurrence free survival or overall survival. In a group o f 14 patients with non­
metastatic locally advanced breast carcinoma; strong P-170 positive staining was 
significantly correlated with no initial response to chemotherapy and with a shorter 
progression free survival (Verrelle et al., 1991). Evaluation o f mdr-1 RNA was not 
found to predict response to therapy in primary breast cancers; but expression was 
associated with a metastatic phenotype (Hennequin et al., 1993). Another study of 
locally advanced breast cancers found high Pgp expression was related to a poor 
response to chemotherapy and a short disease-free survival (Botti et al., 1993).
However the debate still goes on as to whether there is enough evidence to support a 
contributory role for MDR-11 Pgp in the MDR of some breast tumours and if so what 
is this exact role. Some researchers feel that MDR-11 Pgp may be just a marker of a 
more aggressive phenotype, high levels o f this protein and indeed other MDR 
markers may be part of the initial phenotype of the malignant cells (Buser et al.
1997).
This relationship between P-170/ Pgp positivity and survival in a range o f tumour 
types is discussed in relation to breast cancer in an editorial by Kaye (1997) where it 
is suggested that P170 expression may be a marker of cell behaviour and metastasis 
(Pinedo et al., 1995). Giaccone et al. (I 995) have suggested that Pgp expression in 
tumour and in desmoplastic stroma cells may identify a subgroup o f very aggressive 
tumours; Pgp was also more often associated with metastatic than primary tumours. 
This group also showed a correlation between Pgp expression in primary tumour and 
development of axillary lymph node metastasis. Buser et al. (1997) found that Pgp
39
was expressed in a higher number of metastatic than early breast cancer tumours. 
Pgp expression in tumour cells and especially when accompanied by Pgp expression 
in fibroblasts in desmoplastic stroma has been shown to be likely to be a marker o f a 
more malignant phenotype (Linn etal., 1996).
Recent studies suggest that protein kinase C (PKC) may be involved in the 
expression status o f the MDR associated genes, MDR-1, MRP and LRP (Beck el al., 
1998). Expression o f Ki-67 has been found to correlate with Pgp expression; in the 
same study estrogen receptor expression was associated with low levels of Pgp 
(Seymour et al., 1995). Linn et al. (1996) showed that co-expression o f p53 and Pgp 
was predictive o f shorter survival time in locally advanced disease. Mutant p53 has 
been shown to regulate MDR-1 gene expression (Chin et a l, 1992). Sequential 
assessment o f Pgp and S-phase fraction has been shown to predict response to 
neoadjuvant chemotherapy (Chevillard et al., 1997). A high PCNA score was not 
found to be predictive o f poor response to chemotherapy and a short disease free 
interval (Botti etal., 1993).
Using flow cytometry expression o f Pgp was found to be positively correlated with 
expression of c-erbB-2, c-myc and c-jun but not ER or EGF-R; GST n was positively 
associated with c-erbB-2 and c-myc but not c-jun, ER or EGF-R (Brotherick et al., 
1996). The majority o f work to date points to the multifactorial nature o f MDR in the 
breast cancer clinic as indeed in all malignancies; it is imperative therefore that 
several MDR associated parameters are investigated in breast cancer patients.
1.6.4. Non Pgp mediated MDR in Breast Cancer
Lower levels of topo II a  are associated with drug resistance (Hoffmann & Mattem
1993). Topo II enzymes represent the key target for a number o f anticancer drugs 
including those used in the treatment of breast cancer such as doxorubicin, 
mitoxantrone and VP-16 thus expression patterns may relate to the sensitivity/ 
resistance o f the tumour in particular chemotherapeutic regimes. In general however 
there have been limited reports o f topo II a  levels correlating with chemosensitivity 
patterns. This may be in part due to the heterogeneous expression o f the protein and
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the high proportion o f non-cycling cells; such observations have been reported by 
Doyle (1994) and Kaufmann et al. (1994).
The chromosome location o f topo II  a  is similar to that of c-erbB-2 (Muss et a l,
1994). Recently it has been reported that topo II a  gene amplification and deletion 
are common in erbB-2 amplified breast cancers and are associated with increased or 
decreased sensitivity to topo II inhibitors in vitro, respectively (Jarvinen et al., 2000). 
An earlier study by the same group did not show topo II a  to be predictive in the 
response to topoisomerase II inhibitors in advanced breast cancer (Jarvinen et al., 
1998).
High topoisomerase II a  levels are usually found in tumours with a high proliferation 
index and aggressive clinical behaviour, topoisomerase II a  expression has been 
associated with poor prognostic markers namely, high tumour grade/ large tumour 
size/ nodal status and the distant metastases at the time o f diagnosis (Hellemans el 
al., 1995). Topoisomerase II a  expression levels have been correlated with tumour 
proliferation rates and with c-erb-2 expression (Lynch et al., 1997, Jarvinen et al., 
1996). High levels o f topoisomerase II a  (and cyclin A) gene expression were 
observed in high grade (G3) tumours which are less well differentiated, show 
enhanced proliferation activity and exhibit a better response to chemotherapy 
compared to intermediate grade (G2) tumours (Beck et al., 1998). Thus it appears 
that elevated topoisomerase II a  expression represents a marker o f proliferation in 
breast cancer and furthermore may play a predictive role in breast cancer i.e. high 
levels o f expression appear to identify those tumours which are most chemosensitive 
to certain chemotherapeutic protocols.
Some researchers suggest a weak correlation between GST n and Pgp expression in 
untreated breast cancer (Keith et al., 1990). High levels of GSH, GST and 
glutathione peroxidase (GPx) were associated with favourable clinical characteristics 
and good prognosis in untreated breast cancer patients; low GSH and GST activity 
were associated with more aggressive/ advanced disease (Buser et al., 1997). 
Immunohistochemical staining o f GST n  has been shown to inversely correlate with 
disease free interval and overall survival rates in node negative patients (Gilbert et
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a l, 1993, Sochacki et a l, 1994). Several other groups have failed to show such 
correlations (Kim et al., 1991, Wright et al., 1992, Peters et a l, 1993).
1.6.5. The MRP family of drug transporters
MRP is also a member o f the ABC family of transporters which has been shown to 
confer resistance. MRP is 1531 amino acid Mr 190,000 glycosylated integral 
membrane protein that is overexpressed in several MDR cell lines (Cole et a l, 1992). 
Like P-glycoprotein MRP1 transports drugs out o f the cell, reducing the 
concentration at the intracellular target.
MRP-1 has been detected in several normal tissues with high levels o f the protein 
being detected in adrenal gland, lung, heart and skeletal muscle and lower 
expressions detected in liver, spleen, kidney and erythrocyte membranes (Flens et a l,
1996). MRP-1 protein expression has also been detected in several human cancers 
and has been implicated in the clinical resistance in a number o f solid malignancies 
and in certain haematological malignancies (see section 1.6.7).
Since the initial discovery o f M RP-1 and the recognition o f the importance o f MRP 
in MDR, seven additional members o f the MRP family have been described, MRP2- 
8 (Kool et a l, 1997, 1999, Bera et al., 2001, Hopper et al., 2001,).
High levels o f M RP-1 gene expression have been associated with poor prognosis in 
childhood neuroblastoma (Bordow et a l, 1994, Peaston et a l, 2001). In adult 
patients with soft tissue sarcomas, expression o f MRP-1 has been associated with 
high histological grade and poor porgnosis (Oda et a l, 1996). It is thought that 
expression o f MRP-1 may play a part in the clinical resistance o f malignant 
melanoma (Ichihashi et a l, 2001). One recent study has suggested that expression of 
this protein along with that of Topo II alpha may have a possible predictive role in 
the chemosensitivity of ovarian and endrometrial carcinomas (Koshiyama et a l, 
2001), however another study of ovarian carcinomas did not show that MRP-1 was 
predictive for chemosensitivity (Goff et al, 2001). Again MRP-1 expression is 
thought to be an important factor for chemotherapy failure in bladder cancer (Chen et
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al., 2001). It has been suggested that MRP-1 expression may be related to the 
intrinisic resistance in human gliomas, recent studies have suggested that MRP-3 
may modulate drug sensitivity to certain anti cancer agents in human gliomas (Mohri 
et al., 2000, Haga et al., 2001). In addition MRP-1 expression may be involved in the 
clinical resistance of oral small cell squamous carcinomas (OSCCs) (Cho & Kim,
2001).
The functions and their role, if  any, in clinical drug resistance o f the newly 
discovered MRP family members have not been fully elucidated to date. Several 
studies investigating such roles for these proteins are currently underway. MRP1, 
MRP2 and MRP3 have all been shown to cause resistance to neutral organic drugs 
and MRP4 overexpression has been associated with resistance to nucleoside 
analogues used in immunodeficiency virus drugs (reviewed by Borst et a l, 2000). 
Recently MRP2 has been implicated in the resistance to cisplatin treatment in 
colorectal cancer (Hinoshita et a l, 2000). A recent report has shown that expression 
of MRP-2 and MRP-3, but not that of M RP-1 can contribute to the MDR phenotype 
o f human hepatocellular carcinomas (Nies et al., 2001). It has been suggested that 
MRP5 may play a role in some cases o f unexplained resistance to thiopurines in 
acute lymphoblastic leukemia (Wijinholds et a l, 2000). Recent work has also 
suggested that MRP-3 may contribute to the intrinsic resistance o f NSCLC cells 
(Young et a l, 2001). Previous studies have suggested that expression o f MRP-1 may 
be significant in non small cell lung cancer, with moderate to high levels o f 
expression being associated with a poor prognosis (Ota et a l, 1995, Chuman et al., 
1996, Giaccone et a l, 1996).
1.6.6. MRP1 protein expression in breast cancer
It is known that MRP-1 is expressed by most breast carcinomas. It has been reported 
in one study that pre chemo Pgp and pre  and post chemo MRP-1 staining predicted 
tumour recurrence and patient death (Mechetner et a l, 1997). A study by Nooter et 
al., (1997a) has concluded that MRP-1 expression is an important predictor o f poor 
prognosis in patients with recurrent breast cancer who were treated with 
chemotherapy. MRP-1 expression was more positive in non-responding tumours than
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in responding ones; these MRP-1 positive patients also showed shorter time to 
disease progression than MRP-1 negative tumours. In a large series o f primary breast 
cancers, the same group showed that MRP expression might be associated with 
shorter relapse free survival in patients with small tumours and in node negative 
tumours; expression was also shown to be predictive o f overall survival in patients 
who received adjuvant systemic chemotherapy with CMF. This work suggests that 
MRP-1 expression in primary breast cancer might be related to a more aggressive 
phenotype (Nooter et al., 1997b). In an earlier study o f MRP-1 and MDR-1 gene 
and protein expression in a large series of primary breast cancer patients, no 
correlation was found between these 2 markers. MDR-1 RNA was detected in 60% 
of patients whereas MRP RNA was detected in 100%; protein levels showed a 
similar pattern although the overall level o f expression was reduced compared to 
RNA levels. Strong M RP-1 positive staining was observed more frequently in the 
primary tumours o f patients with metastatic disease and in locally advanced tumours 
(Filipits et a l, 1996). An earlier study on MRP-1 in various cancers showed 
relatively low levels o f M RP-1 RNA in a series of 32 breast cancers; protein was also 
detected in a small percentage of patients (levels similar to Filipits et a l, 1996) 
(Nooter et a l  1995). No significant difference in MRP protein expression was found 
between advanced local breast cancers and primary operable cancers in a study 
carried out by Linn et al. 1997; whereas significantly higher protein levels o f Pgp, 
Ki-67 and P53 were observed in locally advanced cancers. MRP-1 negative tumour 
status was associated with an excellent prognosis in another immunohistochemical 
study, suggesting again that MRP-1 is of important prognostic value in breast cancer 
(Filipits et a l, 1999a). MRP-1 protein expression was more pronounced in lymph 
node metastasis than in corresponding primary tumour in a recent report by 
Zochbauer-Muller et al. (2001). Increased MRP-1 expression has previously been 
reported in primary tumours with distant metastases (Filipits et al., 1996).
A correlation has been observed between protein kinase C (PKC) and MDR-1, LRP 
and MRP gene expression, furthermore higher levels o f MRP and LRP expression 
were observed in grade I compared to grade II tumours. These results (also 
associated higher levels o f topo II a  in G3 tumours) may explain the better response 
o f grade III tumours to chemotherapeutic regimes (Beck et al. 1998). Using RT-PCR
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a clear relationship has been suggested between GSTtt and MRP (i.e. the glutathione 
conjugate carrier function of MRP) gene expression in breast tumours (Lacave et al.,
1998).
Again as with M D R -ll Pgp there appear to be conflicting results regarding MRP 
expression in breast cancer; however it does appear to be expressed in significant 
number o f tumours and recent work suggests a predictive role for MRP in breast 
cancers. Suggestions that MRP may be associated with advanced disease and/or may 
be a marker o f biological tumour behaviour need to be investigated further. 
Interestingly, MRP-8 the newest member o f the MRP superfamily has been shown to 
be highly expressed in breast cancer, thus this gene may also possibly constitute a 
potential marker in this malignancy (Bera et al., 2001). Low expression o f the breast 
cancer resistance protein (BCRP) compared to other MDR genes was observed in 
breast cancer patients, suggesting that BCRP does not have a significant role in 
breast carcinoma (Kanzaki el al., 2001).
1.6.7. MRP family expression in haematological malignancies
In some studies the expression of MRP 1 and not Pgp has been found to be higher at 
relapse than at diagnosis in AML patients. However in general MRP1 expression at 
diagnosis is not associated with clinical response to induction chemotherapy and 
survival in most studies. It has been reported that intermediate or high MRP1 
expression may be associated with shorter overall survival compared to patients with 
low MRP-1 expression (Filipits et al., 1999b, Han el al., 2000). AML (subtype 
M4E0) patients with an inversion of chromosome 16 (inv[16]) leading to the deletion 
of the MRP1 gene, have a relatively favourable outcome which suggests that MRP1 
may play a role in determining clinical outcome in these patients (Kuss et al., 1996). 
In CLL MRP1 mRNA expression has been detected in both chemotherapy treated 
and untreated CLL (Burger et al., 1994, Beck el al., 1994). There has been one report 
that MRP-1 is involved in the drug resistance o f chronic B-cell lymphoproliferative 
disorders (CLL and NHL) in patients treated with Pgp transportable drugs (Webb et 
al., 1998). A small number o f studies investigating the expression of MRP 1 in ALL
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have reported that MRP1 expression at diagnosis is not associated with response and 
long term survival (reviewed by Sonneveld 2000). MRP1 expression does not appear 
to be of prognostic value in mylelodysplastic syndromes (MDS) (Poulain et ah, 
2000).
The expression/ clinical significance o f the other members o f the MRP family 
members in various haematological malignancies has not been reported. Relatively 
high expression o f another recently discovered ABC transporter, breast cancer 
resistance protein (BCRP) has been observed in 30% o f AML cases investigated, 
suggesting a possible role for this protein in the drug resistance o f certain leukaemias 
(Ross 2000, Sargent et ah, 2000).
1.6.8. LRP/mvp
LRP also known as the major vault protein was first described in non Pgp drug 
resistant cell lines (Scheper et ah, 1993). Like Pgp and MRP, LRP is widely 
expressed in both normal tissues and various tumour types (Izquierdo et ah, 1996).
1.6.9. LRP/mvp expression in breast cancer
Although LRP is frequently expressed in breast cancers, it is not thought to play a 
role in the resistance o f these tumours. LRP is neither associated with known 
prognostic factors nor is it a prognostic factor itself in breast carcinomas, expression 
o f this protein does not appear to prcdict response to CMF or CAF therapy (Pohl et 
ah, 1999, Schneider et al., 2000, 2001). However it has been reported that over 
expression o f LRP prior to neo adjuvant therapy (and associated MDR-1 positivity 
following chemotherapy) appears to be associated with axillary nodal metastasis 
after chemotherapy (Schneider et ah, 2001).
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1.6.10. LRP/mvp expression in haematological malignancies
Expression o f LRP has been shown to be of significance in certain haematological 
malignancies. MM is a clonal plasma cell neoplasm characterised by the proliferation 
o f plasma cells in the bone marrow. This disease has a high initial response however 
drug resistance usually occurs. Both Pgp and LRP have been implicated in drug 
resistance in MM, MRP is not thought to play a role in this resistance (Rimza et a l,
1999). LRP expression is considered to be an important marker for clinical drug 
resistance in MM (Filipits et a l, 1999c, Rimsza el a l, 1999). It is frequently 
expressed in this disease and has been shown to be an independent poor prognostic 
marker for response and survival in patients treated with melphalan combined with 
prednisone (MP) (Raaijmakers et al., 1998). LRP predicts for a poor outcome in 
AML patients (Filipits et a l, 1998, Pirker et a l, 1999). In a recent univariate analysis 
of several drug resistance factors in AML LRP was the only factor with independent 
predictive and prognostic significance (Filipits et a l, 2000a). It is also thought that 
LRP may contribute to drug resistance in certain childhood leukaemias such as 
childhood AML (den Boer et a l, 1998). In diffuse large B cell lymphomas (a 
subtype o f NHL) LRP expression was associated with a worse outcome in previously 
untreated patients (Filipits et a l, 2000b). In the same study MRP1 expression had no 
impact on the outcome of chemotherapy or survival of the patients. In a recent report 
the co expression o f LRP and  Pgp was associated with a shorter overall survival in 
ALL patients (Tsuji et a l, 2000). In patients with adult T cell leukaemia LRP was 
shown to independently predict for a poorer outcome (Ohno et al, 2001).
1.7. MDR-3 P-glycoprotein
MDR-3 is thought to be the most highly conserved Pgp gene amongst various 
mammalian species and human MDR-3 is closely related to murine mdr-2 (91% 
identity, 95% similarity) (Gros et a l, 1988). Classical Multiple Drug Resistance 
(MDR) is associated with overexpression of P-170. Specific information regarding 
the exact role of MDR-3 in normal or resistant cells and in various tissues is limited.
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1.7.1. The function of MDR-3 P-glycoprotein
Like the closely related MDR-1 gene a physiological role as a transport pump has 
been ascribed to MDR-3. By generating mice with a disruption o f the mdr-2 gene, 
this gene has been shown to encode a Pgp located in the canalicular membrane of 
hepatocytes where it functions as a transporter o f phosphatidylcholine into bile (Smit 
et al., 1993, Ruetz & Gros, 1994, 1995). On analysis these mice showed a defect in 
the transport of phospholipids (mainly phosphatidylcholine) into bile. It is thought 
that the MDR-3 and mdr-2 genes may encode a phosphatidylcholine flippase (Ruetz 
& Gros, 1994, Smith et al., 1994, Crawford et al., 1997), MDR-3 and mdr-2 Pgps 
have been identified as specific translocators o f phosphatidylcholine (van Helvoort 
et al., 1996). Given the high conservation o f amino acid sequence between these two 
genes and their respective tissue distribution patterns it is likely that human MDR-3 
fulfils a similar function to murine mdr-2. It has been confirmed that human MDR-3 
Pgp is functionally homologous to murine mdr-2 Pgp (Smith 1998, PhD Thesis). 
Kino et al., (1996) reported that a yeast strain transformed with the MDR-3 gene 
developed low level resistance to the fungicide aureobasidin A. Preliminary results 
using polarised cell systems suggested that MDR-3 may act as a transporter of 
certain cytostatic drugs (Smith 1998, PhD Thesis). Confirmation o f this earlier work 
again using polarized membranes o f MDR-3 transfected cells has now been 
demonstrated indicating that MDR-3 can transport a sub-set o f MDR-1 P- 
glycoprotein substrates including digoxin, paclitaxel and vinblastine (Smith et al.,
2000). Direct interaction o f MDR-3 with these drugs was shown by interference with 
nucleotide trapping. The rate o f this MDR3 mediated transport was low, this may 
explain why MDR3 has not been shown to be previously involved in MDR.
1.7.2. Tissue Distribution of MDR-3 P-glycoprotein
Excluding the liver, a physiological role for MDR-3/ mdr-2 has not been established 
although gene expression studies using PCR and the RNase protection assay have 
revealed details regarding the distribution of these genes in various normal tissues. 
MDR-3 RNA has been detected at high levels in liver and to a lesser extent in kidney, 
spleen, bone marrow, tonsil, striated muscle and adrenal gland which showed very
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low levels (Chin et ah, 1989, Smit et ah, 1994). Murine mdr-2 mRNA and rat mdr-2 
mRNA have both been shown to have a similar distribution pattern to that o f human 
MDR-3; mdr-2 has also been detected in mouse lung and rat mammary tissue 
(Croop et ah, 1989, Teeter et ah, 1990, Brown et ah, 1993, Smit et ah, 1994, Zhang 
et ah, 1996). Using mice transgenic for an MDR-3 mini gene, Smit et ah (1996) 
found that MDR-3 overexpression in Schwaan cells resulted in dysmyelination o f the 
peripheral nervous system.
1.7.3. The role of MDR-3 P-glycoprotein in liver disease
Progressive familial intrahepatic cholestasis (PFIC) is a heterogenous group of 
autosomal recessive liver disorders characterised by early onset o f choleostasis that 
progresses to cirrhosis and liver failure before adulthood (Alonso et al., 1994, 
Whitington et ah, 1994). There are three types o f PFIC, type 1 which is caused by 
defects in bile synthesis, type 2 is caused by defective bile secretion and is known as 
Byler disease; patients with these conditions have normal levels o f gamma- 
glutamyltransferase (GGT). A third subtype of PFIC presents later in life, carries a 
greater risk of portal hypertension and gastrointestinal bleeding and ends in liver 
failure at a later age. This subtype shows elevated levels o f GGT activity, with 
ductular proliferation and portal inflammation observed in the liver o f these patients. 
This condition shares histological, biochemical and genetic features with mice 
lacking mdr-2 (-/-) gene expression. Absence o f MDR-3 mRNA in the liver was 
observed in patients with PFIC (high GGT serum activity) (Deleuze et ah, 1996). It 
has been reported that mutations in the MDR-3 gene lead to this subtype o f PFIC, 
negative canalicular staining for MDR-3 P-glycoprotein (using a polyclonal 
antibody) has been observed in two patients with this subtype of PFIC (de Vree et 
ah, 1998). Larger studies have since showed defects in MDR-3 present in at least one 
third o f patients (neonatal period to early adulthood) with PFIC, and in 1 out o f 47 
Taiwanese infants with PFIC- high GGT (Chen et ah, 2001, Jacquemin et ah, 2001).
Intrahepatic cholestasis o f pregnancy (ICP) is a liver disease o f pregnancy with series 
consequences for the mother and fetus. Recently MDR-3 gene mutations have been
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shown to be responsible for an additional phenotype o f ICP in women with raised 
GGT but no family history o f PFIC (Dixon et al., 2000). It now appears that 
mutations in the MDR-3 gene are involved in a number o f liver diseases, recently 
MDR-3 gene defects have been reported in adults with symptomatic intrahepatic and 
gallbladder cholesterol cholelithiasis (Rosmorduc et al., 2001).
Intrahepatic Mdr-3 mRNA levels were shown to be unaffected in various liver 
diseases including primary biliary cirrhosis, chronic viral hepatitis and non- 
choleostatic liver cirrhosis, MDR-3 Pgp levels were not investigated (Dumoulin et 
al., 1997). Decreased MDR-3 Pgp staining has been reported in liver specimens 
from patients with intrahepatic calculi, which is characterised clinically by chronic 
proliferative cholangitis with frequent stone recurrences (Shoda et al., 2001).
1.7.4. The role of MDR-3 and MDR-1 P-glycoproteins in
haematological malignancies
It is well established that MDR-1 P-glycoprotein is expressed in several 
haematological malignancies and that it may play a diagnostic and/ or predictive role 
in certain malignancies (reviewed by Sonneveld 2000). Data on MDR-3 in the 
various haematological malignancies is more limited.
There is a possibility that MDR-3 may encode a functional drug pump in certain B- 
cell lymphocytic leukaemias. MDR-3 expression appears to be limited to leukaemias 
o f B-cell origin. In addition it has been suggested that MDR-3 expression may be 
further restricted to certain B-cell developmental stages; no MDR-3 expression has 
been found in MM which presents with end stage B-cells (Herweijer et al., 1990). 
MM remains uncurable despite the initial chemosensitivity o f most bone marrow 
plasma cells. The basis o f this resistance is unclear (Pilarski et al., 1999). On analysis 
o f various B-cell malignancies Nooter and Sonneveld (1993) found that malignancies 
representing early B-cell development and also very mature B-cell tumours 
(Waldenstrom and MM) had no MDR-3 expression, whereas B-PLL, CLL and HCL 
representing the intermediate and mature B-cells have been shown to express 
intermediate to high levels o f MDR-3.
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1.7.4.1. CLL
CLL has a highly variable clinical course and presents great difficulty in prognosis 
and therapy. Previous studies have shown that in general B-CLL cases express 
MDR-1 and MDR-3. MDR-1/ P-glycoprotein over expression appears to be intrinisic 
rather than acquired in this disease. PLL (pro-lymphocytic leukaemia) is a variant of 
CLL which is usually refractory to chemotherapy effective in CLL. Sometimes 
patients have a T-cell variant o f this disease which has a less predictable prognosis 
than B-PLL. High levels of MDR-3 gene expression have been observed in cases of 
B-PLL with no detectable MDR-1 expression (Nooter et al., 1990, Herweijer et 
al., 1990). MDR-1 has not been detected in B-PLL. In vitro drug uptake studies have 
shown that in PLL and B-CLL cells expressing MDR-3, drug accumulation can be 
significantly increased upon addition of cyclosporine and to a lesser extent verapamil 
(Herweijer et a l, 1990). However Ludescher et al. (1993) found no evidence that 
overexpression of MDR-3 was related to rhodamine efflux in B-CLL. Increases in 
intracellular rhodamine levels upon addition of cyclosporin A were observed in 
MDR-1 Pgp negative/ MDR-3 Pgp positive acute leukaemia patients (Arai el al.,
1997). Prior treatment has been associated with higher MDR-3 levels (no influence 
on MDR-1 levels) in one study (Herweijer et al., 1990). Later work did not show 
such a correlation (Sonneveld et a l, 1992, Ludescher et al., 1993). In patients with 
advanced B-CLL, MDR-3 mRNA expression (not MDR-1 expression) was 
significantly higher than in early stage disease (Sonneveld 1992). Ludscher el al. 
(1993) also found a tendency towards higher MDR-3 mRNA expression in patients 
with advanced stages o f CLL. In another study MDR-3 (or MDR-1) gene expression 
did not predict for clinical response (el Rouby et al., 1993).
1.7.4.2. A M L
There has only been one study reporting MDR-3 expression in AML. MDR-3 mRNA 
was detected in 11 cases of AML, stage M2, 9 o f these cases had the t(8;21) 
chromosomal abnormality which is one of the most common chromosomal 
abnormalities in AML particularly in subtype M2 (Mizutani et a l, 1997). It is 
thought that expression of MDR-3 may be restricted to certain B cell lineages, AML
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has been classified into subtypes representing various stages o f B cell development 
(French American British, FAB classification) therefore it is likely that MDR-3 may 
show a differential pattern o f expression within these various subtypes. There 
appears to be a high correlation between MDR-1/ P-glycoprotein overexpression and 
clinical drug resistance in AML (Marie et a l, 1996). The MDR-1 gene product has 
been shown to be frequently expressed in AML at diagnosis (i.e. prior to treatment) 
and at relapse. Reports vary regarding the levels o f MDR-1 expression within the 
various French American British (FAB) subclasses o f AML. One study carried out 
over 6 years showed that Pgp overexpression was detected more frequently in FAB 
classes M4, M5A and M5B and less frequently in class M3 (Nussler et a l, 
1996).This M3 promyelocytic sub-type is particularly sensitive to chemotherapy 
(efficacy o f anthracycline treatment) (lack o f Pgp may explain this).
1.7.4.3. N H L
The role, if  any, o f MDR-3 P-glycoprotein in NHL has not been investigated with the 
exception o f a small study which reported MDR-3 expression in B-NHL (9/21 
patients showed MDR-3 expression) (Nooter & Sonneveld 1993). In contrast several 
studies have addressed the role o f MDR-1 P-glycoprotein in NHL. Most o f this work 
on MDR-1 encoded Pgp in NHL has been performed on frozen lymph node sections. 
In general more MDR-1/ Pgp expression is seen in treated than untreated patients. 
There appears to be no difference in Pgp expression between high and low grade 
lymphomas and between B and T sub-types (Marie et al., 1996). Adult T-cell 
lymphoma (ATL) has been shown to frequently express MDR-1/ Pgp at presentation 
(Kuwezuru el a l, 1990). As to whether MDR-1/ Pgp is an indicator of better clinical 
response; three studies have shown a correlation (Pileri et a l, 1991, Cheng et al., 
1993, Rodriguez et al., 1993). A larger study did not show such a correlation 
(Niehans et al., 1992).
1.7.5. D etection of M DR-3 P-glycoprotein
In the majority o f the haematological and tissue studies performed to date, the 
assessment o f MDR-3 status was by MDR-3 gene expression using RT-PCR and the
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RNase protection assay; MDR-3 encoded Pgp levels have not been investigated 
extensively, with the exception of a report by Arai et al., (1997). Some work has 
been performed using polyclonal antibodies generated to the murine mdr-2 and 
human MDR-3 gene products where mdr-2 and MDR-3 Pgps have been observed in 
the canalicular membranes o f liver (Devault and Gros 1990, Buschman et al., 1992, 
Smit et al., 1994, de Vree et al., 1998). Excluding this work however, for the most 
part detection o f the MDR-3 encoded gene product has relied on comparison studies 
with the C219 monoclonal antibody which recognises both the MDR-1 and the 
MDR-3/ mdr-2 encoded gene products (Georges et al., 1990) and MDR-1 specific 
monoclonal antibodies such as JSB-1 and MRK16. At the time o f commencement of 
this thesis no MDR-3 specific MAbs were commercially available, however another 
MAb which specifically recognises the MDR-3 encoded gene product has since been 
described by Scheffer et al. (2000).
In summary, despite the recent advances in the detection, treatment and management 
o f breast cancer, with an increasing range of hormonal, cytotoxic and more recently 
MAb targeted drug regimes available in the clinic, between 40% and 50% of patients 
diagnosed will eventually die from this disease. As has been previously outlined 
identification o f biological factors which can function as reliable markers o f both 
prognosis and chemoresponsiveness will allow for more precise targeting of 
modalities for individual breast cancer patients. Results presented in this thesis, 
attempt to address the possible prognostic and predictive significance o f a number of 
MDR proteins namely, MRP-1, P-170, LRP and MDR-3 which has recently been 
shown to transport cytotoxic drugs, and associated apoptosis and oncogenes in 
invasive breast cancers. Specific information regarding the exact role o f the MDR-3 
gene product and its contribution, if  any, in breast cancer as indeed in other solid 
malignancies is limited. Results presented here, attempt to address the role o f MDR- 
3 in breast cancer and also further address the role o f MDR-3 in certain B-cell 
malignancies. In an attempt to identify a possible novel breast cancer associated 
antigen characterisation of the antigen recognised by a new MAb directed against 
dewaxed formalin fixed paraffin embedded archival ductal breast tumour tissue is 
also presented.
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1 .8 . Aims o f this thesis
1. Carry out an immunohistochemical study o f MDR associated proteins in a panel 
of formalin fixed paraffin embedded invasive breast tumours. In order to identify 
if  any of these proteins have possible prognostic/ predictive value in invasive 
breast cancer, correlate the expression of these proteins with patient and tumour 
characteristics and with Relapse Free Survival and Overall Survival. In addition 
analyse individual expression of these proteins in relation to the other protein 
markers being studied in order to address the multifactorial nature o f this 
malignancy.
2. Generate and characterise a MAb which successfully recognises the MDR-3 
encoded gene product. Attempt to address further the role, if  any, o f the MDR-3 
encoded Pgp in human cancers with particular emphasis on breast and 
haematological malignancies.
3. Using novel production methodology developed in this laboratory (Moran et al.,
1998) generate and characterise a MAb directed against dewaxed formalin fixed 
paraffin embedded archival ductal breast tumour tissue in an attempt to identify a 
possible novel breast cancer associated antigen.
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2. Materials & Methods
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2.1. Cell Culture
2.1.1. Cell cu ltu re  p rocedures
All cell culture work was carried out in a class II down-flow re-circulating laminar 
air-flow cabinet (Nuaire Biological Cabinet). Strict aseptic technique was adhered to 
at all times. The laminar flow cabinet was swabbed with 70% industrial methylated 
spirits (IMS) before and after use, as were all items brought into the cabinet. Each 
cell line was assigned specific media and waste bottles. At any time, only one cell 
line was used in the laminar air-flow cabinet, and upon completion of work with any 
given cell line the laminar air-flow cabinet was allowed to clear for at least 15 
minutes. This was to eliminate any possibilities of cross contamination between the 
various cell lines. The cabinet itself was cleaned weekly with industrial disinfectants 
(Virkon, Antec International or TEGO, TH Goldschmidt) as were all incubators used 
in the culture o f cell lines and hybridomas. These detergents were alternated every 
month.
2.1.2. S ubcu ltu ring  cell lines
During routine subculturing or harvesting o f adherent cell lines, cells were removed 
from their flasks by enzymatic detachment. Waste medium was removed from the 
cells which were then rinsed with pre-warmed trypsin-versene/EDTA (TV) solution 
(0.25% (w/v) trypsin (Gibco 043-05090), 0.01% (w/v) EDTA (Sigma) solution in 
PBS (Oxoid BR14A). This ensured that any naturally occurring trypsin inhibitor in 
residual serum was deactivated. Fresh TV was then placed in the flask and incubated 
until the cells were seen to have detached (2-10 minutes). The TV solution was 
deactivated by the addition of pre-warmed basal medium containing serum. The 
entire solution was then transferred to a 30ml sterile universal tube (Sterilin 128a) 
and centrifuged at 1000 rpm (Allegra™ 6KR Centrifuge, Beckman, USA) for 5 
minutes. The resulting pellet was then re-suspended in pre-warmed growth medium, 
cells counted and tissue culture flasks re-seeded at the required density.
• Addresses o f suppliers are provided in Appendix II.
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Hybridoma and SP/2/0-Ag cells are loosely adherent. Cells were passaged by tapping 
the flask lightly and/or gentle pipetting with a 10ml sterile pipette (Elkay, Ireland). 
Cell suspensions were pooled and centrifuged at 1000 rpm for 5 minutes. The cell 
pellet was then re-suspended in culture medium and a cell count performed (section
2.1.3.) and the cells re-suspended at the desired density. Cells were grown in 5% 
C 0 2.
2.1.3. Cell counting
Cells were trypsinised, pelleted and re-suspended in media as described in section
2.1.2. Cell counting and viability were carried out by using trypan blue (Gibco, 
15250) dye exclusion technique. An aliquot o f Trypan blue was added to a single cell 
suspension at a ratio o f 1:2. After 3 minutes incubation at room temperature, a 
sample o f the mixture was applied to the chamber o f a Neubauer haemocytometer 
over which a glass cover slip had been placed. Cells in the 4 outer comer grids o f the 
chamber were counted microscopically, an average per comer grid was calculated 
with the dilution factor taken into account and the final number multiplied by 104 to 
determine the number o f cells per ml. Non-viable cells were those which stained blue 
while viable cells excluded the trypan blue dye and remained unstained.
2.1.4. Cell freezing
Cells o f various passage numbers were frozen and cryo-preserved to serve as master 
stocks. Vials could then be thawed and cultured for study. Cells to be frozen were 
harvested in the log phase o f growth and counted as described in Section 2.1.3. The 
pellets were re-suspended in foetal calf serum (pre-cooled to 4°C) and an equal 
volume of freezing medium (DMSO (Sigma D-5879)/serum 1:9 (v/v)) was added 
drop-wise to the cell suspension to give a final concentration o f at least 5x106 cells 
per ml. 1.5ml o f the cell suspension was quickly placed in a cryovial (Greiner 
122278) which was placed in the vapour phase o f liquid nitrogen container for 2.5- 
3.5 hr. After this, the cryovials were stored in liquid nitrogen until required.
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2.1.5. Cell thawing
The cryopreserved cells were removed from the liquid nitrogen and thawed at 37°C. 
Immediately prior to removal of a cryovial from the liquid nitrogen, a sterile 
universal tube containing growth medium was prepared for the rapid transfer and 
dilution o f thawed cells (thus reducing the exposure time to DMSO, which is toxic at 
room temperature). Following the addition o f the thawed cell suspension to the 
growth medium, the suspension was centrifuged at 1,000 rpm for 3 minutes, after 
which the pellet was re-suspended in fresh growth medium. A viability count was 
carried out (Section 2.2.3.) and the thawed cells were placed in tissue culture flasks 
and allowed to attach over night, The following day the cultures were re-fed with 
growth medium to remove any residual DMSO.
2.1.6. Mycoplasma analysis an d  sterility  checking o f cell lines
Mycoplasma analysis and sterility checks were carried out routinely on all 
hybridomas and cell lines used during the course of this work (Appendix III).
2.2. Cell lines
Details pertaining to the cell lines used for the experiments detailed in this thesis are 
provided in T ab le  2.1. Cell lines were maintained in 25 cm2 (Costar 3035), 75 cm2 
(Costar 3075) or 175 cm2 (Nunclon, NUNC) tissue culture flasks at 37°C and fed 
every 2-3 days. Cell lines were cultured through 7-10 passages before they were 
discarded and new cultures grown from frozen stocks. Confluent hybridoma cell 
lines were grown for at least 7 days with no change o f growth media when antibody 
was being harvested.
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TABLE 2.1. Cell lines used during the course of this thesis
CELL LINE HISTOLOGY BASAL
MEDIA
SOURCE/ REFERENCE
A2780 human ovarian 
carcinoma
ATC* Prof. RJ Scheper, Free University 
Hospital, Amsterdam, The 
Netherlands.
BRL-3A Buffalo rat liver ATC* ATCC
BSC-1 African green monkey 
kidney
ATC* ATCC
BT-20 human ductal breast 
carcinoma
MEM ATCC
COR-L-26-S human large cell lung 
cancer
RPMI-1640
(Gibco)
Dr. P. Twentyman, Cambridge 
UK.
Twentyman et al., 1986.
COR-L-26-R human large cell lung 
cancer MDR variant
RPMI-1640
(Gibco)
Dr. P. Twentymans, Cambridge 
UK.
Twentyman et al., 1986.
DLKP non-small cell lung 
cancer
ATC* NCTCC Laweiai., 1992
DLKP-SQ non-small cell lung 
cancer
ATC* NCTCC Me Bride et al., 1998
DLKP-Taxotere non-small cell lung 
cancer MDR variant
ATC* NCTCC
DLKPA non-small cell lung 
cancer adriamycin 
resistant
ATC* NCTCC Clyneseia/., 1992
DLKPA-5F clone of above ATC* NCTCC Heenan et a l, 1995
DLKPA-2B clone of above ATC* NCTCC Heenan et al., 1995
FVB #C transgenic mouse 
fibroblast parental
DMEM Prof. Piet Borst, Dept of 
Molecular Biology, Netherlands 
Cancer Institute, Amsterdam, The 
Netherlands.
HL60-S human leukaemia 
promyelocyte
RPMI-1640
(Gibco)
Marsh et al., 1986.
MDA-MB-231 human ductal breast 
carcinoma
ATC* ATCC
MDA-MB-435-S human ductal breast 
carcinoma
ATC*# ECACC
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OAW42-S human ovarian 
adenocarcinoma
ATC* ECACC
OAW42-SR human ovarian 
adenocarcinoma 
spontaneously resistant
ATC* # ECACC
OAW42-A human ovarian 
adenocarcinoma 
adriamycin resistant
ATC* # ECACC
OAW42-A1 human ovarian 
adenocarcinoma 
adriamycin resistant 
(higher)
ATC*# ECACC
RPMI human nasal squamous 
carcinoma
MEM ** ATCC
RPMI-Taxol human nasal squamous 
carcinoma MDR 
variant
MEM** NCTCC Liang et al., 2001
RPMI-Melphalan human nasal squamous 
carcinoma MDR 
variant
MEM** NCTCC Liang et al., 2001
SP-2/0-AG14 myeloma mouse DMEM 
(Glutamax 1 
Gibco, 61965- 
026)
Shulman et al., 1978
T24 Human bladder 
carcinoma
ATC* # ATTCC
VIM# 1 MDR-3 transgenic 
mouse fibroblast
DMEM Prof. Piet Borst, Dept of 
Molecular Biology, Netherlands 
Cancer Institute, Amsterdam, The 
Netherlands.
VOI-VOI MDR-3 transgenic 
mouse fibroblast
DMEM Prof. Piet Borst, Dept of 
Molecular Biology, Netherlands 
Cancer Institute, Amsterdam, The 
Netherlands.
ZR-75-1 human ductal breast 
carcinoma
RPMI-1640 
(Gibco)
ECACC
Engel et al., 1978.
* ATC basal media consists of a 1:1 mixture of DMEM and HAMS F12
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* #  ATC basal media consists of a 1:1 mixture of DMEM and HAMS FI 2 supplemented 
with 1% sodium pyruvate
** MEM supplemented with 1% (vol/vol) non-essential amino acids (NEAA) (Gibco, 043- 
001140)
RPMI 1640 media supplied as a IX stock (Gibco, 52400-025).
DMEM media supplied as a IX stock (Gibco, 61965-026).
ECACC, European Collection of Animal Cell Cultures, Salisbury, Wiltshire, SIM OJG.
ATCC American Type Culture Culture Collection, Rockville, MD, USA.
NCTCC : National Cell and Tissue Culture Centre, Dublin City University, Glasnevin, 
Dublin 9, Ireland.
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2.3. Tissue samples
Formalin fixed paraffin wax embedded tissue was kindly provided by the 
Histopathology Departments o f St. Vincents Hospital, Dublin and The National 
Maternity Hospital, Holies St., Dublin. 5(am sections o f  tissue blocks were cut using 
a microtome, mounted onto poly-l-lysine coated slides (section 2.7.1.) and dried 
overnight at 37° C. Slides were stored at room temperature until required.
2.4. H aem ato lg ical sam ples
Cytospin preparations of peripheral blood, bone marrow and pleural fluid were 
kindly provided by the Department o f Haematology, Belfast City Hospital, Belfast. 
Samples were stored at -20° C until required.
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T ab le  2 .2 .:  M A bs used  d u rin g  th e  course o f th is w o rk
2.5. Monoclonal antibodies
MAb Specificity Reference
Anti Cytokeratin 6 Keratin 6 Wetzels el al., 1991
Anti Cytokeratin 9 (multiepitope 
cocktail)
Keratin 9 Langbein etal., 1994
BR1 anti MDR-1 (6/1C) #
P-170/ Pgp Moran et al., 1997
MRK-16 ** P-170/Pgp Sugawara et al., 1988
MRP-R1 * MRP-1 Flense/ al., 1994
LRP-56 * LRP Scheper et al., 1993
cerbB-2 oncoprotein, 
clone CB11 
(Novacastra, UK.)
CerbB-2 Corbett el al, 1990
Anti human Bcl-2 
oncoprotein (Dako)
Bcl-2 Zutter e ta l, 1991
BRI anti Survivin (1C5)# Survivin Personal communication 
Dr. Irene Cleary
# obtained from Bioresearch Ireland, Dublin.
* kindly provided by Prof. RJ. Scheper, Free University Hospital, 
Amsterdam, The Netherlands.
** kindly provided by Prof. T. Tsuruo, Department of Pathology,
University of Tokoyo, Japan.
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2.6. Monoclonal antibody production
• All experiments on animals were carried out under license and in compliance 
with the rules o f The Cruelty to Animals Act, 1876, E.C. Directive 86/609/EC.
2.6.1. Im m unogen  fo r genera tion  o f a rch iva l b re a s t tu m o u r M A b, 5C3
The procedure for generation of this archival breast tumour MAb was based on 
methodology developed in this laboratory previously (Moran et al., 1998). A  pre  
treatment intraductal breast tumour was chosen as an immunogen. Five lots o f 10 
x 10|im sections were cut on a microtome, placed in 1ml eppendorf tubes and stored 
at R.T until required for immunisation. For screening o f hybridomas and 
characterisation studies 2 x 5  pm sections were mounted onto poly-l-lysine slides, 
dried at 37° C overnight and stored at R.T. until required.
2.6.2. Im m unogen  fo r genera tion  of the  M DR-3  specific M A b, 6/1G
The peptide used for the production of antibody 6/1G was selected after alignment 
searches o f the EMBL Swiss-Prot protein sequence database using the Mail-FASTA 
program. The entire amino acid sequence o f the MDR-3 encoded Pgp (deduced from 
the known cDNA sequence (Van Der Bliek et al. 1988)) was obtained from the data 
bank above using the NETSERV program. From this deduced sequence a 12 amino 
acid peptide was chosen corresponding to the intracellularly located amino acids 13- 
24 (RPTSAEGDFELG) of MDR-3 encoded Pgp which resides in the N-terminal part 
of the protein. This peptide was chosen because of its insignificant homology with 
the MDR-1 encoded Pgp. The peptide was synthesised by BioSyn Ltd. (10, Malone 
Rd, Belfast BT9 5BN, Northern Ireland) and was purchased in both the free form and 
conjugated to bovine serum albumin (BSA) for immunisation and screening 
purposes.
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2.6.3. In  vivo im m unisation  fo r genera tion  o f a rch iv a l b rea s t tu m o u r 
M A b, 5C3
Prior to immunisation o f two Balb/c mice, one 1 0 x 1 0  pm  section was dewaxed as 
follows: 0.5ml of xylene (BDH) was added to sections in the eppendorf tube and 
allowed to stand for 3-4 mins before being centrifuged at 13,000 rpm in a microfuge 
(Hereaus Instruments, Hanau, Germany) for 4 mins. This procedure was repeated 
one more time with fresh xylene and then with 100%, 90% and 70% ethanol, each 
twice. Finally the sections were washed twice in d.F^O and PBS, before being 
resuspended in 0.5 ml o f PBS and an equal volume of Freunds Complete Adjuvant 
(Sigma, F-5881) for immunisation. Using the BCA method (section 2.9.1.) the 
protein content o f each 1 0 x 1 0  pm section was determined to be 600 pg/ ml which 
was divided equally between 2 mice. Each mouse received an intraperitoneal 
injection comprising 0.5 ml o f combined dewaxed protein/ adjuvant. Following 
primary immunisation o f two mice with one lot of dewaxed tumour in Freunds 
complete adjuvant (Sigma, F-5506), two booster injections o f the same material in 
Freunds incomplete adjuvant were each administered at 2 weekly intervals. A similar 
final booster injection was administered 3 days prior to fusion of the immunised 
spleen cells with SP/2/0- Ag myeloma cells .
2.6.4. C om bination  in vivo an d  in vitro im m unisation  regim e fo r 
genera tion  o f M D R-3 specific an tibody  6/1G
Two balb/c mice received an intraperitoneal injection of peptide (140 pg 
reconstituted in 250 pi o f PBS plus an equal volume of Freund's Complete Adjuvant 
(Sigma, F-5881) was added. One booster intraperitoneal injection was administered 
at 14 days (same immunogen plus an equal volume of Freund's Incomplete Adjuvant 
(Sigma, F-5506) was added). At 28 days the spleen was removed from one mouse 
and the spleen cells immunised in vitro with 60pg o f conjugated peptide following 
instructions provided with the in vitro immunisation kit, Cell-Prime (supplied by 
Immune Systems Ltd., Paignton, UK). Three days after in vitro immunisation, the 
spleen cells were fused with SP/2/0-Ag myeloma cells.
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2.6.5. Fusion protocol
The fusion procedure used for the production o f monoclonal antibodies, 6/1G and 
5C3 was a modification o f the protocol outlined by Kohler and Milstein (1975). Prior 
to the removal o f the spleen from the sacrificed mouse, SP/2/0-A gl4 myeloma cells 
(Shulman el al. 1978) were prepared for cell fusion by harvesting 2 x 75 cm2 flasks 
and centrifuging at 1,000 rpm for 5 minutes in HEPES-free serum free medium. This 
step was repeated twice. A cell count was then performed (section 2.1.3.) and the 
cells kept at 37°C.
A Balb/C mouse was then sacrificed by cervical dislocation. The animal was 
swabbed with 70% IMS and the spleen removed in a laminar flow cabinet with 
sterile dissection instruments. Single cells were obtained by forcing the spleen 
through a sterile Falcon cell strainer (Becton Dickinson 2360) using the plunger from 
a sterile 10ml syringe into serum free DMEM (the DMEM referred in this section is 
DMEM with Glutamax I (high glucose concentration - 4.5mg Gibco 61965-026) 
containing pyridoxine and without sodium pyruvate or HEPES. This cell suspension 
was placed in a universal and the volume adjusted to lOmls. Large clumps of cells 
were allowed to pellet by standing at room temperature for 2-3 minutes. The 
supernatant was then transferred to a fresh centrifuge tube and centrifuged at 1,000 
rpm for 5 minutes. A cell count was performed as before (section 2.1.3.).
Splenocyte and SP/2/O-Ag myeloma cells were mixed in a universal at a ratio of 
10:1 (a minimum of lxlO 7 SP/2 are required for this procedure), centrifuged at 
12,000 rpm for 5 minutes and re-suspended in serum free medium. This step was 
repeated twice. Following the final washing step, 1ml o f PEG (polyethylene glycol, 
Roche Diagnostics GmbH, Germany, 783641) (pre-warmed to 37°C) was added to 
the cell pellet with a Pasteur pipette using a gentle swirling and aspirating action for 
30 seconds. After 30 seconds the aspiration was discontinued. 75 seconds after the 
start, 0.5ml o f plating medium (DMEM with Glutamax I, 10% heat inactivated FCS 
(Myoclone Super Plus Foetal Bovine Serum, 16000-044, Gibco BRL Life 
Technologies US), 5% Briclone (Archport Ltd, Ireland) and 1% HAT 
(Hypoxanthine, Aminopterin, Thymidine) (Roche Diagnostics GmbH, 644579) was 
added slowly down the side of the universal while continuing to swirl gently. 5mls of
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plating medium was added over the next 5 minutes (at 1 minute intervals followed by 
the addition o f 5mls). Following this step, the cell suspension was centrifuged at 500 
rpm for 5 minutes. The supernatant was removed and the cells were re-suspended in 
10ml o f plating medium and incubated at room temperature for 15 minutes.
Prior to performing the fusion, 0.5ml o f plating medium was dispensed into each 
well o f 8x48 well plates (Costar, 3548) and the plates were equilibrated in the CO2 
incubator @ 37°C. Following the 15 minute incubation at room temperature one 
drop o f fused cells was added to each well and the plates were incubated for 10-12
days at 37°C, 5% C 0 2.
2.6.6. Screening o f M D R-3 specific M A b, 6/1G
Hybridomas were allowed to form large colonies and grow for at least 10 days 
undisturbed before supernatant was removed to screen for specific antibody 
production. Initially all clones produced were screened by enzyme linked 
immunosorbent assay (ELISA) against the peptide/ BSA complex and against BSA 
alone.
For the peptide ELISA, plates were coated with peptide (lp g  per well in lOOpl 
carbonate buffer and incubated at 4° C overnight (BUFFER 1: 1.68g NaHCOa 
dissolved in 100ml distilled H2O; BUFFER 2: 2.12g Na2 CC>3 dissolved in 100ml 
distilled H20 . 74ml of BUFFER 1 was mixed with 26ml o f BUFFER 2, pH 9.4 - 
9.7). The plates were washed once in PBS and then incubated with blocking buffer 
(1% (w/v) BSA, 0.1% (w/v) Sodium Azide, PBS) for 1.5 hours at room temperature. 
The plates were washed once in PBS again. lOOpl o f test hybridoma supernatant was 
then added to the peptide coated plates and incubated at 37°C for 1 hr. This solution 
was then discarded and the plates washed 3 times with wash buffer (0.1% (v/v) 
Tween 20 (Merck) in PBS). lOOpl o f secondary antibody, alkaline -phosphatase- 
linked rabbit anti-mouse immunoglobulins, IgG, IgM (Dako, diluted 1/10,000 in PBS 
0.1% (v/v) Tween 20) was added to each well and incubated at 37°C for 1 hr. The 
secondary antibody was removed and the plates washed 3 times with wash buffer as 
before. Plates were then incubated with the substrate solution (1 mg/ml p-nitrophenyl
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phosphate (PNPP, Sigma 104-0) in 0.1M glycine, 0.001M M gC^, 0.001 M ZnCh, 
pH 10.4) at 37°C for 0.5-1 hr or until a yellow colour appeared in the wells. The 
reaction was stopped by the addition of 1M NaOH which also enhanced colour. 
Absorbencies were read on a Titerex ELISA plate reader at 405nm. Positive 
reactivity was determined by comparing supernatant containing wells with those 
which had been incubated with PBS instead of supernatant. Only clones positive for 
the peptide/ BSA complex and negative for BSA alone were chosen for further 
expansion. Clone 6/1G was cloned by limiting dilution (section 2.6.9.) to ensure its 
monoclonal status. The resultant supernatant was used for characterisation o f the 
antibody by western blotting and immunocytochemical methods.
2.6.7. Screening  o f arch ival b reas t tu m o u r M A b, 5C3
Hybridomas were allowed to form large colonies and grow for at least 10 days 
undisturbed before supernatant was removed to screen for specific antibody 
production. All clones were screened by immunohistochemistry (section 2.7.3.) using
formalin fixed paraffin wax embedded sections o f the ductal breast tumour tissue
which served as an immunogen i.e. positive control tissue block.
2.6.8 S ub cu ltu re  o f hybridom as
Positive clones were further sub-cultured to 6 well plates (Costar) and gradually 
transferred (fed 2x in HAT medium followed by gradual change into HT 
(Hypoxanthine, Thymidine) medium - 50:50 HAT: HT) (Roche Diagnostics GmbH, 
623091). Eventually (within two weeks) hybridoma clones were weaned off HT (by 
decreasing HT gradually in feeds every three days) and fed with DMEM medium 
supplemented with 5% Briclone (Archport Ltd., Ireland) and 10% heat inactivated 
FCS (Myoclone,Gibco).
2.6.9. Single cell cloning by lim iting  d ilu tion
Using a multi-channel pipette (eppendorf) lOOpl o f DMEM growth medium was 
pipetted into each well of a sterile 96 well tissue culture treated plate. lOOpl o f cell
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suspension from rapidly growing hybridomas at a concentration o f lx l0 4 cells was 
added to the top left hand well and mixed by pipetting. 1 in 2 doubling dilutions were 
performed down the left hand row of the plate (8 wells, 7 dilution steps) and mixed 
by pipetting, ensuring to change the pipette tip each time. 1 in 2 dilutions were also 
performed across the plate using a multi-channel pipette. Plates were then incubated 
for 7-10 days at 37°C, 5 CO2 . Wells with a single colony were chosen. Hybridomas 
were cultured in 25 cm2 flasks and the procedure repeated. The selected clones were 
screened by ELISA, Western blotting and immunocytochemistry and frozen stocks 
made o f positive clones.
2.6.10. Isotype analysis
Isotyping was carried out using the The Isostrip Mouse Monoclonal Antibody 
Isotyping Kit (Roche Diagnostics GmbH, 1493027).
2.6.11. Q u an tita tio n  o f IgG / IgM  levels
IgG/ IgM levels were determined using a RID kit (radio immunodiffusion) (The 
Binding Site, UK).
2.6.12. P ropagation  o f hybridom as by ascitic tu m o u r p ro d u c tio n
Prior to introducing the hybridoma cells into the peritoneal cavity, Balb/c mice were 
primed with 0.5 mis o f Freunds incomplete adjuvant (Sigma, P5506) which was 
administered into the peritoneum. 24 hours later, 5 x 105 hybridoma cells were 
asceptically resuspended in PBS and injected intraperitoneally. Tumour growth was 
evident 7-10 days post - injection. The mice were sacrificed and the ascitic tumour 
fluid drained under sterile conditions by insertion of a sterile 21-gauge needle into 
the peritoneal cavity. The ascitic fluid was centrifuged at 3,400 rpm for 10 minutes 
and the supernatant carefully removed, aliquoted and stored at -20° C. Hybridoma 
cells harvested from the peritoneal cavity were re-cultured in DMEM growth 
medium.
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2.6.12. Purification of the MDR-3 specific MAb, 6/1G
Monoclonal antibody was purified from ascitic fluid using the ImmunoPure IgM 
purification kit from Pierce (44897). MAb 6/1G ascites was dialysed against two 
changes of 20 mM Tris/ 1.25M NaCl using a slide-A-lyser dialysis cassette (Pierce, 
66425) overnight at R.T. on a stirring platform. The sample was diluted 1:1 with the 
ImmunoPure IgM binding buffer provided and was applied to the ImmunoPure 
immobilised MBP column which had been pre-washed and calibrated with 20 mis of 
binding buffer. All subsequent steps were carried out at 4° C. 1 ml o f sample was 
allowed to completely enter column to which .5 ml o f binding buffer was then added 
and the column allowed to incubate for 30 minutes. Unbound protein was removed 
using binding buffer. Elution buffer was then applied to column and the eluted 
fractions were transferred to quartz cuvettes and absorbencies read at 280 nm on a 
spectrophotometer (Titertek, Multiscan Plus). Those fractions which showed highest 
absorbencies were pooled and concentrated 5.5X and exchanged with two changes of 
150Mm Tris, pH 7.4. using Ultrafree - 15 centrifugal filter devices (Millipore, 
UFV2BGC10). Purified antibody was stored at -20° until required.
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2.7. Immunocytochemical analysis
2.7.1. P rep a ra tio n  o f cytospins
Glass slides were coated with poly-l-lysine prior to all immunocytochemical 
procedures (Huang et al., 1983). Glass slides were washed in 0.5% Tween 20, rinsed 
thoroughly, immersed in 70% IMS (industrial grade alcohol) for 10 minutes and 
dried at 37° C. Approx lOpl o f poly-l-lysine was applied to one end of slides and 
spread into an even film over whole surface o f slides. Coated slides were stored at 
R.T. until required.
Cells from actively growing cultures were trypsinised (Section 2.), washed 3 times in 
10 minutes in PBS and diluted to a final concentration o f  l x l 0 6 cells/ml in PBS. 
1 OOpl o f the cell suspension was then applied to a modified eppendorf component of 
a cytofuge and spun onto poly-l-lysine coated glass slides at 400 rpm for 4 minutes 
Cytospins were allowed to air dry over night. Alternatively lOOpl aliquots o f cell 
suspension were spotted directly onto coated slides, air dried for 20 minutes after 
which excess liquid was tapped off. Again slides were allowed to air dry overnight. 
All slides were foil wrapped and stored at -20° C until required.
2.7.2. Im m unofluoresence studies on live cclls
Viable MDR-3 transgenic cells VIM # 1 and their parental cells, FVB # c were 
tested for reactivity with antibody 6/1G by indirect immunofluoresence studies. 
When immunofluoresence studies are performed on viable cells only cell surface 
antigens are recognised (Schachner el al. 1977). Briefly, test cells were adjusted to a 
concentration of l x l 0 6 cells/ ml in PBS. lOOpl o f the cell suspension was pipetted 
into each of two eppendorf tubes and 100pl of antibody 6/1G added (neat 
supernatant) to one and lOOpl of PBS added to the other. The tubes were mixed and 
incubated for 30 min at room temperature. The primary antibody was removed by 
centrifugation of cells at 1000 rpm for 4 min. Cells were washed 3x with PBS by the 
same procedure. 1 OOpl secondary antibody, fluorescein isothicyanate-linked (FITC) 
sheep anti-mouse IgG (Roche Diagnostics GmbH, Germany) diluted 1/50 in PBS
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was added to the tubes, mixed and incubated for 30 min at room temperature. 
Secondary antibody was removed and cells washed as above. Each cell pellet was 
resuspended in a mimimum amount o f Vectashield (Vector Laboratories, U.K.) 
mounting medium and cells viewed using a Nikon phase contrast microscope fitted 
with an FITC filter.
2.7.3. Im m unocytochem istry
All immunocytochemical studies on cell lines, haematological samples and paraffin 
wax embedded archival material were performed according to the method o f Hsu el 
al. (1981) using an avidin-biotin horseradish peroxidase (HRP) conjugated kit (ABC) 
plus an appropriate secondary antibody.
Briefly, cytospin preparations were fixed for optimal time in ice cold acetone (MDR- 
1: 1 minute, MDR-3: 2 minutes, antibody 5C3: 4 minutes) and allowed to air dry for 
at least 15 mins prior to immunostaining. Tissue sections were dewaxed in xylene (2 
x 5 mins), rehydrated in graded alcohols and placed in Tris Buffered Saline (TBS) / 
0.05% (v/v) Tween 20. Endogenous peroxidase activity was quenched by placing 
cytospins in 0.6% (v/v) H2 O2/ methanol and tissue sections in 3% (v/v) H2 O2/ 
distilled H2 O for 5 mins. Antigen retrival was carried at this point if  required as 
outlined below. All slides were blocked for non-specific staining with 20% (v/v) 
normal rabbit serum for 20 mins. Primary antibodies were applied to each sample 
optimally diluted in TBS/0.1% (v/v) Tween 20 (antibody 6/1G: 1:2 to 1:10 dilution; 
antibody 6/1C: neat supernatant or ascites diluted 1:40; MRK-16 used at 50|ig/ml; 
MRP-R1: 1 in 40 dilution, 6.25jig/ml; LRP-56: 1 in 20 dilution; BCL-2: 1 in 50 
dilution, 6.4(.ig/ml; Ki-67: 1 in 50 dilution (9|j,g/ml), survivin: 1 in 5 dilution). 
Primary antibodies were incubated overnight at 4°C or for 2 hours at R.T. which was 
followed by a 30 minute incubation with biotinylated rabbit anti-mouse IgG (1/300 
dilution in TBS/ 0.1% (v/v) Tween 20) or biotinylated rabbit anti-rat (1/500 dilution 
in TBS/ 0.1% (v/v) Tween 20). Finally Vectastain Elite ABC reagent (HRP 
conjugated) (Vector Laboratories, UK PK-7100) was applied for 25 minutes and the 
peroxidase substrate 3’-3 diaminobenzidine tetrahydrochloride (DAB) peroxidase 
substrate kit (Vector Laboratories, UK SK-4100) was then applied for 5-7 mins. All
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incubations were carried out at room temperature and slides were washed after each 
incubation in 3 changes o f (TBS/0.1% (v/v) Tween 20 over 15 minutes. Tissues 
sections and cells were lightly stained with haematoxylin, differentiated in 1% (v/v) 
acid alcohol and ‘blued’ in Scott’s tap water. Following dehydration in graded 
alcohols slides were cleared in xylene and mounted in DPX (BDH, UK). Negative 
control slides in which primary antibody was replaced by control mouse 
immunoglobulins (1-2000, Vector Laboratories, UK) (used within the manufacturers 
recommended concentration range) were included in all experiments.
2.7.4. A ntigen re triv a l
The epitopes of certain antigens are masked by tissue fixation processes in order to 
enable the antibodies that recognise these antigens to work more successfully an 
antigen retrival technique is necessary prior to immunostaining (Cattoretti et al., 
1993). This technique was employed when detecting the Ki-67 antigen and the BCL- 
2 oncoprotein. Following blocking o f endogenous peroxidase activity slides were 
placed in plastic coplin jars immersed in a freshly prepared lOmM citrate buffer, pH
6.0. and covered in microwave plastic film. Coplain jars were placed at fixed 
positions in microwave sections and treated at med-high power for a pre determind 
number of 4 minute cycles for each individual antibody (BCL-2 (Dako) 3 x 
4minutes, Ki67 (Dako) 4 x 4  minutes). Citrate buffer was topped up following each 
cycle. Sections were allowed to stand in buffer for 15 - 20 minutes after which they 
were rinsed briefly in 1 x TBS/ 0.1% (v/v) Tween 20 before proceeding with 
immunohistochemical staining method.
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2.8. Western Blot analysis
2.8.1. P ro te in  C oncen tra tion  D eterm ination
Protein concentration was determined by the BCA method (Smith et al., 1985) using 
a kit obtained from Pierce (Pierce, 23225). Protein samples (crude cell lysates or 
partially purified membranes) were diluted to a final volume o f lOOpl in PBS. BSA 
protein standards o f known concentration were also prepared from a 2mg/ml stock 
solution in PBS in borosicilliate test tubes. Negative controls consisted o f PBS.
100(0.1 o f the BCA reagent (prepared according to the manufacturers instructions) was 
added to each protein sample, mixed and incubated at 60°C for 30 minutes. 
Following a brief cooling period, samples were transferred to plastic cuvettes (Elkay) 
and the absorbencies read on a spectrophotometer (Titertek, Multiscan Plus) at 562 
run. A standard curve o f absorbance vs. protein concentration o f the BSA standards 
was constructed. The protein concentration o f the test samples was then calculated.
2.8.2. P re p a ra tio n  o f m u rin e  tissues an d  cell lysates
Whole cell lysates o f cell lines were prepared by trypsinisation o f cells from culture 
flasks (1 X 75cm2 flask), washing 3 x in PBS, sonicating cells with a Braun Labsonic 
U sonicator (Braun, US) in 250-500pl PBS containing a cocktail o f protease 
inhibitors (Complete ™, 1697498, Roche Diagnostics, GmbH) until all cells were 
disrupted (when viewed microscopically). Samples were finally resuspended 1:1 in 
2X reducing Laemmli sample buffer (Sigma, S-3401) (1.25M Tris-HCL, ph 6.8, 4% 
SDS, 10% 2-Mercaptoethanol, 20% glycerol and 0.02% bromophenol blue) prior to 
performing sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS- 
PAGE). Alternatively after washing with PBS cell pellets were resuspended in 350 
jj,1 of M-Perm mammalian protein extraction reagent (Pierce, 78501), left to stand at 
R.T. for 15 minutes and then spun at 7,500 rpm for 15 minutes (Biofuge, Heraseus ) 
to remove debris. Before resuspension in 2X Laemmli sample buffer samples o f cell 
lysates and murine tissues in PBS were taken for deteimination o f protein 
concentration as outlined above. Equal concentrations (15-30fj.g), where possible of
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all cell membranes or partially purified tissues were applied to appropriate SDS- 
PAGE gels.
Kidney, liver, heart, spleen and lung were removed from a normal healthy Balb/c 
mouse and snap frozen in liquid N2 until required. The tissues were prepared using a 
modification o f the method of Ronchi et al. (1989). Briefly, the tissue samples were 
allowed to thaw whilst being maintained on crushed ice before being homogenised in 
ice cold PBS containing a cocktail of protease inhibitors (Roche Diagnostics GmbH, 
UK). The homogenate was centrifuged at 7500rpm for 10 min and the resultant 
supernatant centrifuged at 38000rpm for 1 hr in an ultracentrifuge (Beckman Optima, 
model XL-80, Beckman U.K. Ltd). The resultant pellet was resuspended in 0.5 ml 
PBS plus 0.5 ml 2X reducing loading buffer (Sigma, S-3401). Aliquoted samples 
were stored at -20°C until required.
For detection o f the antigen recognised by archival breast tumour MAb, 5C3 all test 
samples (in 2X sample buffer) were boiled at 100° C for 3 minutes, detection o f the 
MDR-3 or MDR-1 specific antigen did not require heat treatment. All test samples 
(in 2X sample buffer) were stored at -20° C for short time periods until required for 
gel electrophoresis.
2.8.3. G el e lectrophoresis
Proteins for Western blotting were separated by SDS-PAGE gel electrophoresis 
(Laemmli el al, 1970). Gels were prepared as outlined in table 2.4.3. and poured into
clean 10cm x 8cm gel casting cassettes (Mighty Small™ SE 245, Hoefer, US) which
• 2 consisted o f one glass plate and one aluminium plate separated by 0.75cm plastic
spacers. The resolving gel was poured first and allowed to set. A layer o f saturated
isobutanol (50 mis isobutanol:5 mis dH20 )  was gently layered over the resolving gel
to prevent drying out. When the resolving gel was set the layer o f  isobutanol was
washed off with several changes of d.H20 . The stacking gel was then poured and a
comb was fitted allowing the formation o f wells for sample loading. Once the gels
had set (at room temperature) they were wrapped in tinfoil and stored at 4°C if not
used immediately. Approx. 15 - 30 pg o f protein was applied to each well of the
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polyacrylamide gel. Pre-stained molecular weight markers (New England Biolabs, 
UK) were also loaded onto the gel for the determination o f the molecular weight o f 
unknown protein samples. Gels were run at 250 volts and 45 milliamps. (Atto power 
pack, Atto Corp., Japan) for 1-1.5 hr. (values were halved if  only one gel was being 
run), with IX  Tris/ Glycine/ SDS running buffer (Biorad, 161-0732). When the 
bromophenol dye front had reached the end o f the gel, electrophoresis was stopped, 
the gel removed and equilibrated in transfer buffer (0.25 M Tris - 1.92M Glycine pH
8.4, 10X, Bio-Rad, US, 161-0734) for 15 minutes.
T ab le  2.3. P rep a ra tio n  o f e lectrophoresis gels
Stock solutions 6% Resolving 7.5% Resolving Stacking
Gel Gel Gel
30% Acrylainide/ bis-Acrylamide (Sigma, 3.04 ml 3.8 ml 0.8 ml
A-3574)
d.H20 9.87 ml 9.1 ml 3.89 ml
8X Tris-HCl pH 8.8 (BDH, 444102T) 1.88 ml 1.88 ml „
16X Tris-HCl pH 6.8 (BDH, 444092L) _ _ 0.31 ml
10% SDS (Biorad, 1610416) 150p 150 pi 50 pi
10% Ammonium persulphate 60 pi 60 pi 17 pi
TEMED (Sigma, T-9281) 10 pi 10 pi 5 pi
2.8.4. W este rn  b lo tting
Between 8 to 10 sheets o f filter paper (Whatman, UK, 1001824) were soaked in 
transfer buffer (0.25 M Tris - 1.92M Glycine, 10X (Sigma T-4904), diluted 1 in 10 in 
d.H20) and placed on the anode o f a semi-dry blotting apparatus (Trans-Blot SD 
Semi-Dry Transfer Cell, Bio-Rad, US) taking care to remove all bubbles by rolling a 
glass pasteur pipette across the sheets. PVDF membrane (Roche Diagnostics GmbH, 
972206) or Sequi-blot ™ PVDF (Bio-Rad, US 162-0180) (used for transfer of 
immunoprecipitated proteins) both pre-soaked according to the manufacturers 
instructions were placed over the filter paper and the gel layered on top o f this. A
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further 8-10 sheets of pre-soaked filter paper were paced over the gel and any air 
bubbles removed. The cathode was carefully laid on top o f the stack and the proteins 
transferred from gel to PVDF membrane at 15 volts and 34 milliamps for 25 minutes.
2.8.5. D evelopm ent of W este rn  blots by enhanced  chem ilum inescence
(EC L)
ECL Western blotting detection is a highly sensitive, rapid, quantifiable, non-isotopic 
method for detecting proteins immobilised on membranes. The primary antibody is 
located with the Horseradish-Peroxidase (HRP)-labelled species specific secondary 
antibody. The HRP-labelled molecule catalyses the oxidation o f luminol, resulting in 
the emission o f light - chemiluminescence. Enhanced chemiluminescence (ECL) is 
the sustained emission of light provided by the inclusion o f chemical enhancers in 
the HRP catalysed oxidation of luminol, and gives approximately 1000 fold more 
light that the oxidation o f luminol alone.
Following Western blotting, the filter paper was removed and the membrane blocked 
for non-specific binding by incubating for 1- 4 hours on a rocking platform with non­
fat milk (Marvel, Cadbury). After the blocking step was complete, the blot was 
rinsed once in TBS, and incubated with the primary antibody optimally diluted in 
TBS/0.1% (v/v) Tween 20 overnight at 4°C or 2 hours at R.T. on a rocking platform 
(6/1G supernatant diluted 1/2 or ascites diluted 1:50; 6/1C ascites diluted 1 in 200 to 
1 in 300 and 5C3 supernatant diluted 1 in 10, cytokeratin 6 specific MAb, Ab-1 (MS- 
766-P, Neomarkers, Lab Vision UK) used at a concentration o f 2|a,g/ ml, cytokeratin 
9 specific MAb cocktail supernatant diluted 1 in 100 (651104, Research Diagnostics, 
US). Mouse IgG diluted 1/5,000 (Vector labs, UK) in TBS/0.1% (v/v) Tween 20 or 
irrelevant supernatant served as a negative control. The following day blots were 
washed 3 times within 45 minutes with TBS/ 0.5% (v/v) Tween 20. Blots were then 
incubated with a rabbit anti-mouse HRP-conjugated secondary antibody (Dako, 
P0447) diluted 1/2,000 in TBS/0.1% (v/v) Tween 20 for 1 hour at room temperature 
on a rocking platform. The blots were washed as before, laid out on a glass plate
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covered in parafilm and incubated with ECL reagents (Amersham RPN 2109) for 1 
minute at room temperature. Following this the solution was tapped off, the blot laid 
between two sheets o f cling film and exposed to LUMI film, chemiluminescence 
film (Roche Diagnostics GmbH, 166657) for various time periods and processed 
using standard x-ray developing procedures. Dried film was aligned with pre-stained 
molecular weight markers for molecular weight determination.
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2.9. Immunoprécipitation studies
2.9.1. Im m unopréc ip ita tion
Protein isolated from the ductal carcinoma cell line, ZR-75-1 was directly labelled 
with the antibody 5C3, immunoprecipitated and then detected by Western blot 
analysis using the same antibody to re-probe the blot. Briefly at least 4 x 175 cm2 
flasks o f ZR-75-1 cells were trypsinised and washed 3x with PBS. Cell pellets were 
resuspended in 650 jxl o f M-Perm mammalian protein extraction reagent (Pierce, 
78501), left to stand at R.T. for 15 minutes and then spun at 7,500 rpm for 15 
minutes (Biofuge, Heraseus). (At this point for one experiment with denatured cell 
lysates, the samples were boiled for 3 minutes prior to commencement o f 
immunoprécipitation procedure).
0.5 and 0.25 ml test aliquots o f supernatants were pre-cleared by incubating a 50:50 
mixture o f protein-L (P3351, Sigma, UK) and protein-G agarose (Roche Diagnostics 
GmbH, Germany) (i.e. 50}o.l o f protein-L agarose and 50ffl o f protein - G agarose 
was added to all test samples, 25(0.1 o f each was added to 0.25 ml aliquots for 
negative control IgG samples). All samples were incubated with two changes (2 x 2.5 
hours) o f protein - L/ protein - G agarose beads at 4° C on a rocking platform. Beads 
were removed by spinning at 2,500 rpm for 10 minutes at 4° C. Supernatants were 
removed to clean eppendorf tubes and 100 ja.1 o f antibody 5C3 (concentrated 3X 
supernatant, using Millipore Ultrafree-15 centrifuge filter units, Z-36436-0, Sigma, 
US) was added to 0.5 ml lysate samples; 50 |il o f antibody was added to 0.25 ml 
samples. 50 |o,l o f control mouse IgG (Sigma, 31204) (used at a concentration o f 22 
jjg/ ml) was added to 0.25 ml negative control lysates. Antibody/ lysate mixtures 
were incubated at 4° C overnight on a rocking platform. The following day in order 
to precipitate the antibody-antigen complex, protein - L / protein - G agarose was 
added to the antibody - antigen complex samples as before and incubated at 4° C for 
4 hours on a rocking platform. Beads were removed by spinning at 2,500 rpm for 10 
minutes at 4° C, and the supernatant discarded. To check how much protein was left 
in cell lysate test samples following immunoprécipitation procedure, some o f the 
supernatants were retained and added to 2X laemmili sample buffer (Sigma, 3401)
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and/ or non reducing 3X SDS sample buffer (New England Biolabs, UK), boiled for 
1-3 minutes and stored at -20°C. The beads were then washed for 3 x 15 minute 
periods with buffers as described in Appendix III and pelleted at 2,500 rpm for 10 
minutes. Following final wash and spin as much liquid as possible was removed 
from all samples. 50 jo.1 of 2X laemmili sample buffer (Sigma, 3401) was added to 
original 0.25 ml lysates and control IgG samples, 100 (fl was added to original 0.5 ml 
lysates. In further experiments, non-reducing 3X SDS sample buffer (New England 
Biolabs, UK) was added to test lysates. All samples were boiled for 1 minute and 
stored at -20 0 C until required for SDS-PAGE/ Western blot analysis.
Later experiments employed an optimised 8 hour immunoprécipitation protocol. A 
lysis buffer was prepared (Appendix II) from materials provided in the cellular 
labelling and immunoprécipitation kit supplied by Roche Diagnostics, GmbH. ZR- 
75-1 cell pellets prepared as in earlier experiments were thawed on ice and 
resuspended in lysis buffer (600(4.1 lysis buffer added to each 175 cm2 flask pellet), 
left for 2-3 minutes at R.T. and sonicated briefly (complete cell lysis was confirmed 
by viewing under an inverted microscope). Test and IgG control lysates were 
precleared with two changes ( 2 x 1  hour) o f protein-L/ protein-G agarose (i.e. lOOfil 
o f protein-L and protein-G agarose was added to 200 jal test lysates/ control Ig 
lysate). Beads were removed as previously described. 150pl o f concentrated MAb 
5C3 was added to test lysates and incubated for 1 hour at 4°C , 50|il o f mouse IgG 
was added to negative control lysates (22 pg). Following this lOOpl o f protein-L and 
lOOpl protein-G were added to all lysates and incubated for a further three hours at 
4°C on a rocking platform in order to precipitate the antibody-antigen complex. 
(Some supernatant at this point was placed in 2X loading buffer, boiled for 3 minutes 
and stored at -20°C). Pelleted beads were this time washed for 15 minutes intervals 
with two changes o f wash buffer 1 and 2 and one change of wash buffer 3. Following 
a final wash and spin, as much liquid as possible was removed from all samples. 75 
pi of 2X laemmili sample buffer (Sigma, 3401) was added to test lysates and control 
IgG samples. All samples were boiled for 1 minute and stored at -20 0 C until 
required for SDS-PAGE/ Western blot analysis. Further immunoprecipitated samples 
(in 2X loading buffer) were boiled for 10 mins and stored at -20° C.
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2.9.2. Gel electrophoresis of immunoprecipitated proteins
Immunoprecipitated proteins were separated on 7.5% and 10% SDS-PAGE 
electrophoresis as described in section 2.8.3. Retained supernatants (in reducing and 
non reducing loading buffer) were also separated on 7.5% gels, in addition for some 
experiments combinations o f immunoprecipitated proteins and supernatants were 
also separated on SDS-PAGE. Following SDS-PAGE western blot analysis was 
carried as outlined in section 2.8.4 - 2.8.5.. Immunoprecipitates and whole cell 
lysates o f ZR-75-1 cells were probed with antibody 5C3, anti cytokeratin Ab-1 (MS- 
766-P1, Labvision, UK) or anti cytpkeratin 9 (651104, Research Diagnostics Inc., 
US). Control IgG ZR-75-1 immunoprecipitates were probed with antibody 5C3.
In order to visualise proteins SDS-PAGE gels were stained for 15-30 mins with a 
0.25% (w/v) Coomassie Brilliant Blue R-250 solution (containing 45% methanol 
(v/v) and 45% d.HiO (v/v)) and destained with 45% methanol (v/v)/ 10% acetic acid 
(v/v)/ 45% d. H20.
2.9.3. Preparation of isolated proteins for N-terminal sequencing
ZR-75-1 and control mouse immunoprecipitates were separated on 5 well 7.5% SDS 
PAGE and blotted onto PVDF membrane (Sequiblot ™, Biorad). Following transfer 
the membrane was washed briefly in d.F^O. The blot was then stained for 5 minutes 
with Comassie R-250 (0.25% Comassie Blue R-250 in 40% methanol) and destained 
for 1 hour with 50% (v/v) methanol. The membrane was air-dried for at least 3 hours 
and stored at -20° C. Protein bands were aligned with molecular weight markers and 
ECL films o f immunoprecipitates which had been probed with antibody. The bands 
o f interest were excised and processed for N-terminal sequencing.
2.9.4. Preparation of isolated proteins for internal sequencing
Following immunoprecipitation and separation on 7.5% SDS-PAGE using a 5 well 
spacer ensuring that the maximum amount of protein was loaded, gels were stained 
with Coomassie Brilliant Blue R250 (0.1% (v/v) in methanol, 45% dH20(v/v), 10%
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acetic acid (v/v) and destained with 45% methanol (v/v) /  10% acetic acid (v/v) / 
45% dl-^O (v/v). Staining and destaining protocols were carried out according to 
recommendations from Eurosequence. The band o f interest was excised from gels, 
placed in eppendorf tubes and sent to Eurosequence BV (Gronigen, The 
Netherlands).
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2. Materials & Methods
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2.1. Cell Culture
2.1.1. Cell culture procedures
All cell culture work was carried out in a class II down-flow re-circulating laminar 
air-flow cabinet (Nuaire Biological Cabinet). Strict aseptic technique was adhered to 
at all times. The laminar flow cabinet was swabbed with 70% industrial methylated 
spirits (IMS) before and after use, as were all items brought into the cabinet. Each 
cell line was assigned specific media and waste bottles. At any time, only one cell 
line was used in the laminar air-flow cabinet, and upon completion of work with any 
given cell line the laminar air-flow cabinet was allowed to clear for at least 15 
minutes. This was to eliminate any possibilities o f cross contamination between the 
various cell lines. The cabinet itself was cleaned weekly with industrial disinfectants 
(Virkon, Antec International or TEGO, TH Goldschmidt) as were all incubators used 
in the culture o f cell lines and hybridomas. These detergents were alternated every 
month.
2.1.2. Subculturing cell lines
During routine subculturing or harvesting o f adherent cell lines, cells were removed 
from their flasks by enzymatic detachment. Waste medium was removed from the 
cells which were then rinsed with pre-warmed trypsin-versene/EDTA (TV) solution 
(0.25% (w/v) trypsin (Gibco 043-05090), 0.01% (w/v) EDTA (Sigma) solution in 
PBS (Oxoid BR14A). This ensured that any naturally occurring trypsin inhibitor in 
residual serum was deactivated. Fresh TV was then placed in the flask and incubated 
until the cells were seen to have detached (2-10 minutes). The TV solution was 
deactivated by the addition of pre-warmed basal medium containing serum. The 
entire solution was then transferred to a 30ml sterile universal tube (Sterilin 128a) 
and centrifuged at 1000 rpm (Allegra™ 6KR Centrifuge, Beckman, USA) for 5 
minutes. The resulting pellet was then re-suspended in pre-warmed growth medium, 
cells counted and tissue culture flasks re-seeded at the required density.
• Addresses o f suppliers are provided in Appendix II.
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Hybridoma and SP/2/0-Ag cells are loosely adherent. Cells were passaged by tapping 
the flask lightly and/or gentle pipetting with a 10ml sterile pipette (Elkay, Ireland). 
Cell suspensions were pooled and centrifuged at 1000 rpm for 5 minutes. The cell 
pellet was then re-suspended in culture medium and a cell count performed (section
2.1.3.) and the cells re-suspended at the desired density. Cells were grown in 5% 
C 0 2.
2.1.3. Cell counting
Cells were trypsinised, pelleted and re-suspended in media as described in section
2.1.2. Cell counting and viability were carried out by using trypan blue (Gibco, 
15250) dye exclusion technique. An aliquot o f Trypan blue was added to a single cell 
suspension at a ratio o f 1:2. After 3 minutes incubation at room temperature, a 
sample o f the mixture was applied to the chamber of a Neubauer haemocytometer 
over which a glass cover slip had been placed. Cells in the 4 outer comer grids o f  the 
chamber were counted microscopically, an average per comer grid was calculated 
with the dilution factor taken into account and the final number multiplied by 104 to 
determine the number o f cells per ml. Non-viable cells were those which stained blue 
while viable cells excluded the trypan blue dye and remained unstained.
2.1.4. Cell freezing
Cells o f various passage numbers were frozen and cryo-preserved to serve as master 
stocks. Vials could then be thawed and cultured for study. Cells to be frozen were 
harvested in the log phase o f growth and counted as described in Section 2.1.3. The 
pellets were re-suspended in foetal calf serum (pre-cooled to 4°C) and an equal 
volume o f freezing medium (DMSO (Sigma D-5879)/serum 1:9 (v/v)) was added 
drop-wise to the cell suspension to give a final concentration o f at least 5x106 cells 
per ml. 1.5ml o f the cell suspension was quickly placed in a cryovial (Greiner 
122278) which was placed in the vapour phase o f liquid nitrogen container for 2.5-
3.5 hr. After this, the cryovials were stored in liquid nitrogen until required.
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2.1.5. Cell thawing
The eryopreserved cells were removed from the liquid nitrogen and thawed at 37°C. 
Immediately prior to removal o f a cryovial from the liquid nitrogen, a sterile 
universal tube containing growth medium was prepared for the rapid transfer and 
dilution o f thawed cells (thus reducing the exposure time to DMSO, which is toxic at 
room temperature). Following the addition o f the thawed cell suspension to the 
growth medium, the suspension was centrifuged at 1,000 rpm for 3 minutes, after 
which the pellet was re-suspended in fresh growth medium. A viability count was 
carried out (Section 2.2.3.) and the thawed cells were placed in tissue culture flasks 
and allowed to attach over night, The following day the cultures were re-fed with 
growth medium to remove any residual DMSO.
2.1.6. M ycop lasm a  analysis and sterility checking of cell lines
Mycoplasma analysis and sterility checks were carried out routinely on all 
hybridomas and cell lines used during the course of this work (Appendix III).
2.2. Cell lines
Details pertaining to the cell lines used for the experiments detailed in this thesis are
•y 'y
provided in Table 2.1. Cell lines were maintained in 25 cm (Costar 3035), 75 cm 
(Costar 3075) or 175 cm2 (Nunclon, NUNC) tissue culture flasks at 37°C and fed 
every 2-3 days. Cell lines were cultured through 7-10 passages before they were 
discarded and new cultures grown from frozen stocks. Confluent hybridoma cell 
lines were grown for at least 7 days with no change o f growth media when antibody 
was being harvested.
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TABLE 2.1. Cell lines used during the course of this thesis
CELL LINE HISTOLOGY BASAL
MEDIA
SOURCE/ REFERENCE
A2780 human ovarian 
carcinoma
ATC* Prof. RJ Scheper, Free University 
Hospital, Amsterdam, The 
Netherlands.
BRL-3A Buffalo rat liver ATC* ATCC
BSC-1 African green monkey 
kidney
ATC* ATCC
BT-20 human ductal breast 
carcinoma
MEM ATCC
COR-L-26-S human large cell lung 
cancer
RPMI-1640
(Gibco)
Dr. P. Twentyman, Cambridge 
UK.
Twentyman et al., 1986.
COR-L-26-R human large cell lung 
cancer MDR variant
RPMI-1640
(Gibco)
Dr. P. Twentymans, Cambridge 
UK.
Twentyman et al, 1986.
DLKP non-small cell lung 
cancer
ATC* NCTCC Law et al., 1992
DLKP-SQ non-small cell lung 
cancer
ATC* NCTCC Me Bride et al., 1998
DLKP-Taxotere non-small cell lung 
cancer MDR variant
ATC* NCTCC
DLKPA non-small cell lung 
cancer adriamycin 
resistant
ATC* NCTCC Clynes et a l. 1992
DLKPA-5F clone of above ATC* NCTCC Heenan et al, 1995
DLKPA-2B clone of above ATC* NCTCC Heenan et al., 1995
FVB #C transgenic mouse 
fibroblast parental
D M EM Prof. Piet Borst, Dept of 
Molecular Biology, Netherlands 
Cancer Institute, Amsterdam, The 
Netherlands.
HL60-S human leukaemia 
promyelocyte
RPMI-1640
(Gibco)
Marsh et a l, 1986.
MDA-MB-231 human ductal breast 
carcinoma
ATC* ATCC
MDA-MB-435-S human ductal breast 
carcinoma
ATC* ft ECACC
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OAW42-S human ovarian 
adenocarcinoma
ATC* ECACC
OAW42-SR human ovarian 
adenocarcinoma 
spontaneously resistant
ATC* # ECACC
OAW42-A human ovarian 
adenocarcinoma 
adriamycin resistant
ATC* # ECACC
OAW42-A1 human ovarian 
adenocarcinoma 
adriamycin resistant 
(higher)
ATC * # ECACC
RPMI human nasal squamous 
carcinoma
MEM ** ATCC
RPMI-Taxol human nasal squamous 
carcinoma MDR 
variant
MEM** NCTCC Liang et al, 2001
RPMI-Melphalan human nasal squamous 
carcinoma MDR 
variant
MEM** NCTCC Liang et a l, 2001
SP-2/0-AG14 myeloma mouse DMEM 
(Glutamax 1 
Gibco, 61965- 
026)
Shulman et al., 1978
T24 Human bladder 
carcinoma
ATC*# ATTCC
VIM# 1 MDR-3 transgenic 
mouse fibroblast
DMEM Prof. Piet Borst, Dept of 
Molecular Biology, Netherlands 
Cancer Institute, Amsterdam, The 
Netherlands.
VOI-VOI MDR-3 transgenic 
mouse fibroblast
DMEM Prof. Piet Borst, Dept of 
Molecular Biology, Netherlands 
Cancer Institute, Amsterdam, The 
Netherlands.
ZR-75-1 human ductal breast 
carcinoma
RPMI-1640
(Gibco)
ECACC
Engel et al., 1978.
* ATC basal media consists of a 1:1 mixture of DMEM and HAMS FI 2
60
* # ATC basal media consists of a 1:1 mixture of DMEM and HAMS F12 supplemented 
with 1% sodium pyruvate
** MEM supplemented with 1% (vol/vol) non-essential amino acids (NEAA) (Gibco, 043- 
001140)
RPM I1640 media supplied as a IX stock (Gibco, 52400-025).
DMEM media supplied as a IX stock (Gibco, 61965-026).
ECACC, European Collection of Animal Cell Cultures, S alisbury, Wiltshire, SP4 OJG.
ATCC American Type Culture Culture Collection, Rockville, MD, USA.
NCTCC : National Cell and Tissue Culture Centre, Dublin City University, Glasnevin, 
Dublin 9, Ireland.
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2.3. Tissue samples
Formalin fixed paraffin wax embedded tissue was kindly provided by the 
Histopathology Departments o f  St. Vincents Hospital, Dublin and The National 
Maternity Hospital, Holies St., Dublin. 5(.tm sections o f tissue blocks were cut using 
a microtome, mounted onto poly-l-lysine coated slides (section 2.7.1.) and dried 
overnight at 37° C. Slides were stored at room temperature until required.
2.4. Haematolgical samples
Cytospin preparations o f peripheral blood, bone marrow and pleural fluid were 
kindly provided by the Department o f Haematology, Belfast City Hospital, Belfast. 
Samples were stored at -20° C until required.
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Table 2.2.: MAbs used during the course of this work
2.5. Monoclonal antibodies
MAb Specificity Reference
Anti Cytokeratin 6 Keratin 6 Wetzels et al., 1991
Anti Cytokeratin 9  (muiüepitopc
cocktail)
Keratin 9 Langbeine/«/., 1994
BRI anti MDR-1 (6/1C) #
P-170/Pgp Moran et al., 1997
MRK-16 ** P-170/Pgp Sugawara et ai, 1988
MRP-R1 * MRP-1 Flense/ ai, 1994
LRP-56 * LRP Scheper et al., 1993
cerbB-2 oncoprotein, 
clone CB11 
(Novacastra, UK)
CerbB-2 Corbett et ai, 1990
Anti human Bcl-2 
oncoprotein (Dako)
Bcl-2 Zutter et al., 1991
BRI anti Survivin (1C5) # Survivin Personal communication 
Dr. Irene Cleaiy
# obtained from Bioresearch Ireland, Dublin.
* kindly provided by Prof. R.J. Scheper, Free University Hospital, 
Amsterdam, The Netherlands.
** kindly provided by Prof. T. Tsuruo, Department of Pathology,
University of Tokoyo, Japan.
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2.6. Monoclonal antibody production
• All experiments on animals were carried out under license and in compliance 
with the rules of The Cruelty to Animals Act, 1876, E.C. Directive 86/609/EC.
2.6.1. Immunogen for generation of archival breast tumour MAb, 5C3
The procedure for generation o f this archival breast tumour MAb was based on 
methodology developed in this laboratory previously (Moran et al., 1998). A pre 
treatment intraductal breast tumour was chosen as an immunogen. Five lots o f 10 
x 10(im sections were cut on a microtome, placed in 1ml eppendorf tubes and stored 
at R.T until required for immunisation. For screening of hybridomas and 
characterisation studies 2 x 5  |jm  sections were mounted onto poly-l-lysine slides, 
dried at 37° C overnight and stored at R.T. until required.
2.6.2. Immunogen for generation of the M D R -3  specific MAb, 6/1G
The peptide used for the production o f antibody 6/1G was selected after alignment 
searches o f the EMBL Swiss-Prot protein sequence database using the Mail-FASTA 
program. The entire amino acid sequence o f the MDR-3 encoded Pgp (deduced from 
the known cDNA sequence (Van Der Bliek et al. 1988) ) was obtained from the data 
bank above using the NETSERV program. From this deduced sequence a 12 amino 
acid peptide was chosen corresponding to the intracellularly located amino acids 13- 
24 (RPTSAEGDFELG) of MDR-3 encoded Pgp which resides in the N-terminal part 
o f the protein. This peptide was chosen because o f its insignificant homology with 
the MDR-1 encoded Pgp. The peptide was synthesised by BioSyn Ltd. (10, Malone 
Rd, Belfast BT9 5BN, Northern Ireland) and was purchased in both the free form and 
conjugated to bovine serum albumin (BSA) for immunisation and screening 
purposes.
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2.6.3. I n  vivo  immunisation for generation of archival breast tumour 
MAb, 5C3
Prior to immunisation o f two Balb/c mice, one 1 0 x 1 0  (im section was dewaxed as 
follows: 0,5ml of xylene (BDH) was added to sections in the eppendorf tube and 
allowed to stand for 3-4 mins before being centrifuged at 13,000 rpm in a microfuge 
(Hereaus Instruments, Hanau, Germany) for 4 mins. This procedure was repeated 
one more time with fresh xylene and then with 100%, 90% and 70% ethanol, each 
twice. Finally the sections were washed twice in d.H^O and PBS, before being 
resuspended in 0.5 ml o f PBS and an equal volume of Freunds Complete Adjuvant 
(Sigma, F-5881) for immunisation. Using the BCA method (section 2.9.1.) the 
protein content o f each 10 x 10 pm section was determined to be 600 fig/ ml which 
was divided equally between 2 mice. Each mouse received an intraperitoneal 
injection comprising 0.5 ml o f combined dewaxed protein/ adjuvant. Following 
primary immunisation o f two mice with one lot o f dewaxed tumour in Freunds 
complete adjuvant (Sigma, F-5506), two booster injections o f the same material in 
Freunds incomplete adjuvant were each administered at 2 weekly intervals. A similar 
final booster injection was administered 3 days prior to fusion o f the immunised 
spleen cells with SP/2/0- Ag myeloma cells .
2.6.4. Combination in  vivo and in  vitro  immunisation regime for 
generation of MDR-3 specific antibody 6/1G
Two balb/c mice received an intraperitoneal injection o f peptide (140 jig 
reconstituted in 250 p.1 o f PBS plus an equal volume of Freund's Complete Adjuvant 
(Sigma, F-5881) was added. One booster intraperitoneal injection was administered 
at 14 days (same immunogen plus an equal volume of Freund's Incomplete Adjuvant 
(Sigma, F-5506) was added). At 28 days the spleen was removed from one mouse 
and the spleen cells immunised in vitro with 60|ig o f conjugated peptide following 
instructions provided with the in vitro immunisation kit, Cell-Prime (supplied by 
Immune Systems Ltd., Paignton, UK). Three days after in vitro immunisation, the 
spleen cells were fused with SP/2/0-Ag myeloma cells.
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2.6.5. Fusion protocol
The fusion procedure used for the production o f monoclonal antibodies, 6/1G and 
5C3 was a modification o f the protocol outlined by Kohler and Milstein (1975). Prior 
to the removal o f the spleen from the sacrificed mouse, SP/2/0-A gl4 myeloma cells 
(Shulman et al. 1978) were prepared for cell fusion by harvesting 2 x 75 cm2 flasks 
and centrifuging at 1,000 rpm for 5 minutes in HEPES-free serum free medium. This 
step was repeated twice. A cell count was then performed (section 2.1.3.) and the 
cells kept at 37°C.
A Balb/C mouse was then sacrificed by cervical dislocation. The animal was 
swabbed with 70% IMS and the spleen removed in a laminar flow cabinet with 
sterile dissection instruments. Single cells were obtained by forcing the spleen 
through a sterile Falcon cell strainer (Becton Dickinson 2360) using the plunger from 
a sterile 10ml syringe into serum free DMEM (the DMEM referred in this section is 
DMEM with Glutamax I (high glucose concentration - 4.5mg Gibco 61965-026) 
containing pyridoxine and without sodium pyruvate or HEPES. This cell suspension 
was placed in a universal and the volume adjusted to lOmls. Large clumps o f cells 
were allowed to pellet by standing at room temperature for 2-3 minutes. The 
supernatant was then transferred to a fresh centrifuge tube and centrifuged at 1,000 
rpm for 5 minutes. A cell count was performed as before (section 2.1.3. ).
Splenocyte and SP/2/O-Ag myeloma cells were mixed in a universal at a ratio o f 
10:1 (a minimum of lx l0 7 SP/2 are required for this procedure), centrifuged at 
12,000 rpm for 5 minutes and re-suspended in serum free medium. This step was 
repeated twice. Following the final washing step, 1ml of PEG (polyethylene glycol, 
Roche Diagnostics GmbH, Germany, 783641) (pre-warmed to 37°C) was added to 
the cell pellet with a Pasteur pipette using a gentle swirling and aspirating action for 
30 seconds. After 30 seconds the aspiration was discontinued. 75 seconds after the 
start, 0.5ml o f plating medium (DMEM with Glutamax I, 10% heat inactivated FCS 
(Myoclone Super Plus Foetal Bovine Serum, 16000-044, Gibco BRL Life 
Technologies US), 5% Briclone (Archport Ltd, Ireland) and 1% HAT 
(Hypoxanthine, Aminopterin, Thymidine) (Roche Diagnostics GmbH, 644579) was 
added slowly down the side of the universal while continuing to swirl gently. 5mls of
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plating medium was added over the next 5 minutes (at 1 minute intervals followed by 
the addition o f 5mls). Following this step, the cell suspension was centrifuged at 500 
rpm for 5 minutes. The supernatant was removed and the cells were re-suspended in 
10ml o f plating medium and incubated at room temperature for 15 minutes.
Prior to performing the fusion, 0.5ml of plating medium was dispensed into each 
well o f 8x48 well plates (Costar, 3548) and the plates were equilibrated in the CO2 
incubator @ 37°C. Following the 15 minute incubation at room temperature one 
drop of fused cells was added to each well and the plates were incubated for 10-12 
days at 37°C, 5% C 0 2.
2.6.6. Screening of MDR-3 specific MAb, 6/1G
Hybridomas were allowed to form large colonies and grow for at least 10 days 
undisturbed before supernatant was removed to screen for specific antibody 
production. Initially all clones produced were screened by enzyme linked 
immunosorbent assay (ELISA) against the peptide/ BSA complex and against BSA 
alone.
For the peptide ELISA, plates were coated with peptide ( lpg  per well in 100fil 
carbonate buffer and incubated at 4° C overnight (BUFFER 1: 1.68g NaHCC>3 
dissolved in 100ml distilled H20 ; BUFFER 2: 2.12g Na2C0 3  dissolved in 100ml 
distilled H20 . 74ml o f BUFFER 1 was mixed with 26ml o f BUFFER 2, pH 9.4 - 
9.7). The plates were washed once in PBS and then incubated with blocking buffer 
(1% (w/v) BSA, 0.1% (w/v) Sodium Azide, PBS) for 1.5 hours at room temperature. 
The plates were washed once in PBS again. lOOjal o f test hybridoma supernatant was 
then added to the peptide coated plates and incubated at 37°C for 1 hr. This solution 
was then discarded and the plates washed 3 times with wash buffer (0.1% (v/v) 
Tween 20 (Merck) in PBS). lOOpl of secondary antibody, alkaline -phosphatase- 
linked rabbit anti-mouse immunoglobulins, IgG, IgM (Dako, diluted 1/10,000 in PBS 
0.1% (v/v) Tween 20) was added to each well and incubated at 37°C for 1 hr. The 
secondary antibody was removed and the plates washed 3 times with wash buffer as 
before. Plates were then incubated with the substrate solution (1 mg/ml p-nitrophenyl
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phosphate (PNPP, Sigma 104-0) in 0.1M glycine, 0.001M MgCl2, 0.001 M ZnCl2 , 
pH 10.4) at 37°C for 0.5-1 hr or until a yellow colour appeared in the wells. The 
reaction was stopped by the addition of 1M NaOH which also enhanced colour. 
Absorbencies were read on a Titerex ELISA plate reader at 405nm. Positive 
reactivity was determined by comparing supernatant containing wells with those 
which had been incubated with PBS instead of supernatant. Only clones positive for 
the peptide/ BSA complex and negative for BSA alone were chosen for further 
expansion. Clone 6/1G was cloned by limiting dilution (section 2.6.9.) to ensure its 
monoclonal status. The resultant supernatant was used for characterisation of the 
antibody by western blotting and immunocytochemical methods.
2.6.7. Screening of archival breast tumour MAb, 5C3
Hybridomas were allowed to form large colonies and grow for at least 10 days 
undisturbed before supernatant was removed to screen for specific antibody 
production. All clones were screened by immunohistochemistry (section 2.7.3.) using 
formalin fixed paraffin wax embedded sections o f the ductal breast tumour tissue 
which served as an immunogen i.e. positive control tissue block.
2.6.8 Subculture of hybridomas
Positive clones were further sub-cultured to 6 well plates (Costar) and gradually 
transferred (fed 2x in HAT medium followed by gradual change into HT 
(Hypoxanthine, Thymidine) medium - 50:50 HAT: HT) (Roche Diagnostics GmbH, 
623091). Eventually (within two weeks) hybridoma clones were weaned off HT (by 
decreasing HT gradually in feeds every three days) and fed with DMEM medium 
supplemented with 5% Briclone (Archport Ltd., Ireland) and 10% heat inactivated 
FCS (Myoclone,Gibco).
2.6.9. Single cell cloning by limiting dilution
Using a multi-channel pipette (eppendorf) 100pl o f DMEM growth medium was 
pipetted into each well of a sterile 96 well tissue culture treated plate. 100(4,1 o f cell
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suspension from rapidly growing hybridomas at a concentration o f lx l0 4 cells was 
added to the top left hand well and mixed by pipetting. 1 in 2 doubling dilutions were 
performed down the left hand row of the plate (8 wells, 7 dilution steps) and mixed 
by pipetting, ensuring to change the pipette tip each time. 1 in 2 dilutions were also 
performed across the plate using a multi-channel pipette. Plates were then incubated 
for 7-10 days at 37°C, 5 CO2 . Wells with a single colony were chosen. Hybridomas 
were cultured in 25 cm2 flasks and the procedure repeated. The selected clones were 
screened by ELISA, Western blotting and immunocytochemistry and frozen stocks 
made o f positive clones.
2.6.10. Isotype analysis
Isotyping was carried out using the The Isostrip Mouse Monoclonal Antibody 
Isotyping Kit (Roche Diagnostics GmbH, 1493027).
2.6.11. Quantitation of IgG/ IgM levels
IgG/ IgM levels were determined using a RID kit (radio immunodiffusion) (The 
Binding Site, UK).
2.6.12. Propagation of hybridomas by ascitic tumour production
Prior to introducing the hybridoma cells into the peritoneal cavity, Balb/c mice were 
primed with 0.5 mis of Freunds incomplete adjuvant (Sigma, P5506) which was 
administered into the peritoneum. 24 hours later, 5 x 105 hybridoma cells were 
asceptically resuspended in PBS and injected intraperitoneally. Tumour growth was 
evident 7-10 days post - injection. The mice were sacrificed and the ascitic tumour 
fluid drained under sterile conditions by insertion o f a sterile 21-gauge needle into 
the peritoneal cavity. The ascitic fluid was centrifuged at 3,400 rpm for 10 minutes 
and the supernatant carefully removed, aliquoted and stored at -20° C. Hybridoma 
cells harvested from the peritoneal cavity were re-cultured in DMEM growth 
medium.
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2.6.12. Purification of the MDR-3 specific MAb, 6/1G
Monoclonal antibody was purified from ascitic fluid using the ImmunoPure IgM 
purification kit from Pierce (44897). MAb 6/1G ascites was dialysed against two 
changes o f 20 mM Tris/ 1.25M NaCl using a slide-A-lyser dialysis cassette (Pierce, 
66425) overnight at R.T. on a stirring platform. The sample was diluted 1:1 with the 
ImmunoPure IgM binding buffer provided and was applied to the ImmunoPure 
immobilised MBP column which had been pre-washed and calibrated with 20 mis of 
binding buffer. All subsequent steps were carried out at 4° C. 1 ml o f sample was 
allowed to completely enter column to which .5 ml o f binding buffer was then added 
and the column allowed to incubate for 30 minutes. Unbound protein was removed 
using binding buffer. Elution buffer was then applied to column and the eluted 
fractions were transferred to quartz cuvettes and absorbencies read at 280 nm on a 
spectrophotometer (Titertek, Multiscan Plus). Those fractions which showed highest 
absorbencies were pooled and concentrated 5.5X and exchanged with two changes o f 
150Mm Tris, pH 7.4. using Ultrafree - 15 centrifugal filter devices (Millipore, 
UFV2BGC10). Purified antibody was stored at -20° until required.
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2.7. Immunocytochemical analysis
2.7.1. Preparation of cytospins
Glass slides were coated with poly-l-lysine prior to all immunocytochemical 
procedures (Huang et al., 1983). Glass slides were washed in 0.5% Tween 20, rinsed 
thoroughly, immersed in 70% IMS (industrial grade alcohol) for 10 minutes and 
dried at 37° C. Approx 10^1 of poly-l-lysine was applied to one end o f slides and 
spread into an even film over whole surface of slides. Coated slides were stored at 
R.T. until required.
Cells from actively growing cultures were trypsinised (Section 2.), washed 3 times in 
10 minutes in PBS and diluted to a final concentration o f l x l 0 6 cells/ml in PBS. 
1 OOpl o f the cell suspension was then applied to a modified eppendorf component of 
a cytofuge and spun onto poly-l-lysine coated glass slides at 400 rpm for 4 minutes 
Cytospins were allowed to air dry over night. Alternatively 100|J.l aliquots o f cell 
suspension were spotted directly onto coated slides, air dried for 20 minutes after 
which excess liquid was tapped off. Again slides were allowed to air dry overnight. 
All slides were foil wrapped and stored at -20° C until required.
2.7.2. Immunofluoresence studies on live cells
Viable MDR-3 transgenic cells VIM # 1 and their parental cells, FVB # c were 
tested for reactivity with antibody 6/1G by indirect immunofluoresence studies. 
When immunofluoresence studies are performed on viable cells only cell surface 
antigens are recognised (Schachner et al. 1977). Briefly, test cells were adjusted to a 
concentration o f lxlO6 cells/ ml in PBS. 100(nl o f the cell suspension was pipetted 
into each of two eppendorf tubes and 1 OOjil of antibody 6/1G added (neat 
supernatant) to one and lOOpl o f PBS added to the other. The tubes were mixed and 
incubated for 30 min at room temperature. The primary antibody was removed by 
centrifugation o f cells at 1000 rpm for 4 min. Cells were washed 3x with PBS by the 
same procedure. 1 OOjil secondary antibody, fluorescein isothicyanate-linked (FITC) 
sheep anti-mouse IgG (Roche Diagnostics GmbH, Germany) diluted 1/50 in PBS
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was added to the tubes, mixed and incubated for 30 min at room temperature. 
Secondary antibody was removed and cells washed as above. Each cell pellet was 
resuspended in a mimimum amount o f Vectashield (Vector Laboratories, U.K.) 
mounting medium and cells viewed using a Nikon phase contrast microscope fitted 
with an FITC filter.
2.7.3. Immunocytochemistry
All immunocytochemical studies on cell lines, haematological samples and paraffin 
wax embedded archival material were performed according to the method of Hsu et 
al. (1981) using an avidin-biotin horseradish peroxidase (HRP) conjugated kit (ABC) 
plus an appropriate secondary antibody.
Briefly, cytospin preparations were fixed for optimal time in ice cold acetone (MDR- 
1: 1 minute, MDR-3: 2 minutes, antibody 5C3: 4 minutes) and allowed to air dry for 
at least 15 mins prior to immunostaining. Tissue sections were dewaxed in xylene (2 
x 5 mins), rehydrated in graded alcohols and placed in Tris Buffered Saline (TBS) / 
0.05% (v/v) Tween 20. Endogenous peroxidase activity was quenched by placing 
cytospins in 0.6% (v/v) H 2O2/ methanol and tissue sections in 3% (v/v) H 2 O2 / 
distilled H2 O for 5 mins. Antigen retrival was carried at this point if  required as 
outlined below. All slides were blocked for non-specific staining with 20% (v/v) 
normal rabbit serum for 20 mins. Primary antibodies were applied to each sample 
optimally diluted in TBS/0.1% (v/v) Tween 20 (antibody 6/1G: 1:2 to 1:10 dilution; 
antibody 6/1C: neat supernatant or ascites diluted 1:40; MRK-16 used at 50ug/ml; 
MRP-R1: 1 in 40 dilution, 6.25(ig/ml; LRP-56: 1 in 20 dilution; BCL-2: 1 in 50 
dilution, 6.4(j.g/ml; Ki-67: 1 in 50 dilution (9|j,g/ml), survivin: 1 in 5 dilution). 
Primary antibodies were incubated overnight at 4°C or for 2 hours at R.T. which was 
followed by a 30 minute incubation with biotinylated rabbit anti-mouse IgG (1/300 
dilution in TBS/ 0.1% (v/v) Tween 20) or biotinylated rabbit anti-rat (1/500 dilution 
in TBS/ 0.1% (v/v) Tween 20). Finally Vectastain Elite ABC reagent (HRP 
conjugated) (Vector Laboratories, UK PK-7100) was applied for 25 minutes and the 
peroxidase substrate 3’-3 diaminobenzidine tetrahydrochloride (DAB) peroxidase 
substrate kit (Vector Laboratories, UK SK-4100) was then applied for 5-7 mins. All
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incubations were carried out at room temperature and slides were washed after each 
incubation in 3 changes of (TBS/0.1% (v/v) Tween 20 over 15 minutes. Tissues 
sections and cells were lightly stained with haematoxylin, differentiated in 1% (v/v) 
acid alcohol and ‘blued’ in Scott’s tap water. Following dehydration in graded 
alcohols slides were cleared in xylene and mounted in DPX (BDH, UK). Negative 
control slides in which primary antibody was replaced by control mouse 
immunoglobulins (1-2000, Vector Laboratories, UK) (used within the manufacturers 
recommended concentration range) were included in all experiments.
2.7.4. Antigen retrival
The epitopes of certain antigens are masked by tissue fixation processes in order to 
enable the antibodies that recognise these antigens to work more successfully an 
antigen retrival technique is necessary prior to immunostaining (Cattoretti et al., 
1993). This technique was employed when detecting the Ki-67 antigen and the BCL- 
2 oncoprotein. Following blocking o f endogenous peroxidase activity slides were 
placed in plastic coplin jars immersed in a freshly prepared lOmM citrate buffer, pH 
6.0. and covered in microwave plastic film. Coplain jars were placed at fixed 
positions in microwave sections and treated at med-high power for a pre determind 
number of 4 minute cycles for each individual antibody (BCL-2 (Dako) 3 x 
4minutes, Ki67 (Dako) 4 x 4  minutes). Citrate buffer was topped up following each 
cycle. Sections were allowed to stand in buffer for 15 - 20 minutes after which they 
were rinsed briefly in 1 x TBS/ 0.1% (v/v) Tween 20 before proceeding with 
immunohistochemical staining method.
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2.8. Western Blot analysis
2.8.1. Protein Concentration Determination
Protein concentration was determined by the BCA method (Smith et ah, 1985) using 
a kit obtained from Pierce (Pierce, 23225). Protein samples (crude cell lysates or 
partially purified membranes) were diluted to a final volume o f 100(41 in PBS. BSA 
protein standards o f known concentration were also prepared from a 2mg/ml stock 
solution in PBS in borosicilliate test tubes. Negative controls consisted o f PBS.
100(il o f the BCA reagent (prepared according to the manufacturers instructions) was 
added to each protein sample, mixed and incubated at 60°C for 30 minutes. 
Following a brief cooling period, samples were transferred to plastic cuvettes (Elkay) 
and the absorbencies read on a spectrophotometer (Titertek, Multiscan Plus) at 562 
nm . A standard curve o f absorbance vs. protein concentration o f  the BSA standards 
was constructed. The protein concentration of the test samples was then calculated.
2.8.2. Preparation of murine tissues and cell lysates
Whole cell lysates o f cell lines were prepared by trypsinisation of cells from culture 
flasks (1 X 75cm2 flask), washing 3 x in PBS, sonicating cells with a Braun Labsonic 
U sonicator (Braun, US) in 250-500(0,1 PBS containing a cocktail o f protease 
inhibitors (Complete ™, 1697498, Roche Diagnostics, GmbH) until all cells were 
disrupted (when viewed microscopically). Samples were finally resuspended 1:1 in 
2X reducing Laemmli sample buffer (Sigma, S-3401) (1.25M Tris-HCL, ph 6.8, 4% 
SDS, 10% 2-Mercaptoethanol, 20% glycerol and 0.02% bromophenol blue) prior to 
performing sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS- 
PAGE). Alternatively after washing with PBS cell pellets were resuspended in 350 
pi o f M-Perm mammalian protein extraction reagent (Pierce, 78501), left to stand at 
R.T. for 15 minutes and then spun at 7,500 rpm for 15 minutes (Biofuge, Heraseus ) 
to remove debris. Before resuspension in 2X Laemmli sample buffer samples of cell 
lysates and murine tissues in PBS were taken for determination o f protein 
concentration as outlined above. Equal concentrations (15-30|4,g), where possible of
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all cell membranes or partially purified tissues were applied to appropriate SDS- 
PAGE gels.
Kidney, liver, heart, spleen and lung were removed from a normal healthy Balb/c 
mouse and snap frozen in liquid N 2 until required. The tissues were prepared using a 
modification o f the method of Ronchi et al. (1989). Briefly, the tissue samples were 
allowed to thaw whilst being maintained on crushed ice before being homogenised in 
ice cold PBS containing a cocktail of protease inhibitors (Roche Diagnostics GmbH, 
UK). The homogenate was centrifuged at 7500rpm for 10 min and the resultant 
supernatant centrifuged at 38000rpm for lh r in an ultracentrifuge (Beckman Optima, 
model XL-80, Beckman U.K. Ltd). The resultant pellet was resuspended in 0.5 ml 
PBS plus 0.5 ml 2X reducing loading buffer (Sigma, S-3401). Aliquoted samples 
were stored at -20°C until required.
For detection o f the antigen recognised by archival breast tumour MAb, 5C3 all test 
samples (in 2X sample buffer) were boiled at 100° C for 3 minutes, detection o f the 
MDR-3 or MDR-1 specific antigen did not require heat treatment. All test samples 
(in 2X sample buffer) were stored at -20° C for short time periods until required for 
gel electrophoresis.
2.8.3. Gel electrophoresis
Proteins for Western blotting were separated by SDS-PAGE gel electrophoresis 
(Laemmli et al, 1970). Gels were prepared as outlined in table 2.4.3. and poured into
clean 10cm x 8cm gel casting cassettes (Mighty Small™ SE 245, Hoefer, US) which
•  2 consisted o f one glass plate and one aluminium plate separated by 0.75cm plastic
spacers. The resolving gel was poured first and allowed to set. A layer o f saturated
isobutanol (50 mis isobutanol:5 mis dH20) was gently layered over the resolving gel
to prevent drying out. When the resolving gel was set the layer o f isobutanol was
washed off with several changes o f d.H20. The stacking gel was then poured and a
comb was fitted allowing the formation o f wells for sample loading. Once the gels
had set (at room temperature) they were wrapped in tinfoil and stored at 4°C if  not
used immediately. Approx. 15 - 30 jog o f protein was applied to each well o f the
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polyacrylamide gel. Pre-stained molecular weight markers (New England Biolabs, 
UK) were also loaded onto the gel for the determination o f the molecular weight of 
unknown protein samples. Gels were run at 250 volts and 45 milliamps. (Atto power 
pack, Atto Corp., Japan) for 1-1.5 hr. (values were halved if  only one gel was being 
run), with IX Tris/ Glycine/ SDS running buffer (Biorad, 161-0732). When the 
bromophenol dye front had reached the end o f the gel, electrophoresis was stopped, 
the gel removed and equilibrated in transfer buffer (0.25 M Tris - 1.92M Glycine pH
8.4, 10X, Bio-Rad, US, 161-0734) for 15 minutes.
T ab le  2.3. P rep a ra tio n  o f electrophoresis gels
Stock solutions 6% Resolving 7.5% Resolving Stacking
Gel Gel G el
30% Acrylamide/ bis-Acrylamide (Sigma, 3.04 ml 3.8 ml 0.8 ml
A-3574)
d.H20 9.87 ml 9.1 ml 3.89 ml
8X Tris-HCl pH 8.8 (BDH, 444102T) 1.88 ml 1.88 ml ,_
16X Tris-HCl pH 6.8 (BDH, 444092L) __ 0.31 ml
10% SDS (Biorad, 1610416) 150(x 150 pi 50 pi
10% Ammonium persulphate 60 pi 60 pi 17 pi
TEMED (Sigma, T-9281) 10 pi 10 pi 5 pi
2.8.4. W este rn  b lo tting
Between 8 to 10 sheets o f filter paper (Whatman, UK, 1001824) were soaked in 
transfer buffer (0.25 M Tris - 1.92M Glycine, 10X (Sigma T-4904), diluted 1 in 10 in 
d.H20) and placed on the anode of a semi-dry blotting apparatus (Trans-Blot SD 
Semi-Dry Transfer Cell, Bio-Rad, US) taking care to remove all bubbles by rolling a 
glass pasteur pipette across the sheets. PVDF membrane (Roche Diagnostics GmbH, 
972206) or Sequi-blot ™ PVDF (Bio-Rad, US 162-0180) (used for transfer of 
immunoprecipitated proteins) both pre-soaked according to the manufacturers 
instructions were placed over the filter paper and the gel layered on top of this. A
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further 8-10 sheets o f pre-soaked filter paper were paced over the gel and any air 
bubbles removed. The cathode was carefully laid on top o f the stack and the proteins 
transferred from gel to PVDF membrane at 15 volts and 34 milliamps for 25 minutes.
2.8.5. D evelopm ent o f W este rn  blots by  enhanced  chem ilum inescence
(EC L )
ECL Western blotting detection is a highly sensitive, rapid, quantifiable, non-isotopic 
method for detecting proteins immobilised on membranes. The primary antibody is 
located with the Horseradish-Peroxidase (HRP)-labelled species specific secondary 
antibody. The HRP-labelled molecule catalyses the oxidation o f luminol, resulting in 
the emission of light - chemiluminescence. Enhanced chemiluminescence (ECL) is 
the sustained emission o f light provided by the inclusion of chemical enhancers in 
the HRP catalysed oxidation of luminol, and gives approximately 1000 fold more 
light that the oxidation o f luminol alone.
Following Western blotting, the filter paper was removed and the membrane blocked 
for non-specific binding by incubating for 1 - 4 hours on a rocking platform with non­
fat milk (Marvel, Cadbury). After the blocking step was complete, the blot was 
rinsed once in TBS, and incubated with the primary antibody optimally diluted in 
TBS/0.1% (v/v) Tween 20 overnight at 4°C or 2 hours at R.T. on a rocking platform 
(6/1G supernatant diluted 1/2 or ascites diluted 1:50; 6/1C ascites diluted 1 in 200 to 
1 in 300 and 5C3 supernatant diluted 1 in 10, cytokeratin 6 specific MAb, Ab-1 (MS- 
766-P, Neomarkers, Lab Vision UK) used at a concentration o f 2|jg/ ml, cytokeratin 
9 specific MAb cocktail supernatant diluted 1 in 100 (651104, Research Diagnostics, 
US). Mouse IgG diluted 1/5,000 (Vector labs, UK) in TBS/0.1% (v/v) Tween 20 or 
irrelevant supernatant served as a negative control. The following day blots were 
washed 3 times within 45 minutes with TBS/ 0.5% (v/v) Tween 20. Blots were then 
incubated with a rabbit anti-mouse HRP-conjugated secondary antibody (Dako, 
P0447) diluted 1/2,000 in TBS/0.1% (v/v) Tween 20 for 1 hour at room temperature 
on a rocking platform. The blots were washed as before, laid out on a glass plate
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covered in parafilm and incubated with ECL reagents (Amersham RPN 2109) for 1 
minute at room temperature. Following this the solution was tapped off, the blot laid 
between two sheets o f cling film and exposed to LUMI film, chemiluminescence 
film (Roche Diagnostics GmbH, 166657) for various time periods and processed 
using standard x-ray developing procedures. Dried film was aligned with pre-stained 
molecular weight markers for molecular weight determination.
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2.9. Immunoprécipitation studies
2.9.1. Im m unopréc ip ita tion
Protein isolated from the ductal carcinoma cell line, ZR-75-1 was directly labelled
with the antibody 5C3, immunoprecipitated and then detected by Western blot
• 2analysis using the same antibody to re-probe the blot. Briefly at least 4 x 175 cm 
flasks o f ZR-75-1 cells were trypsinised and washed 3x with PBS. Cell pellets were 
resuspended in 650 p.1 o f M-Perm mammalian protein extraction reagent (Pierce, 
78501), left to stand at R.T. for 15 minutes and then spun at 7,500 rpm for 15 
minutes (Biofuge, Heraseus). (At this point for one experiment with denatured cell 
lysates, the samples were boiled for 3 minutes prior to commencement o f 
immunoprécipitation procedure).
0.5 and 0.25 ml test aliquots o f supernatants were pre-cleared by incubating a 50:50 
mixture of protein-L (P3351, Sigma, UK) and protein-G agarose (Roche Diagnostics 
GmbH, Germany) (i.e. 50}j,l o f protein-L agarose and 50jil o f protein - G agarose 
was added to all test samples, 25|ol of each was added to 0.25 ml aliquots for 
negative control IgG samples). All samples were incubated with two changes (2 x 2.5 
hours) o f protein - L/ protein - G agarose beads at 4° C on a rocking platform. Beads 
were removed by spinning at 2,500 rpm for 10 minutes at 4° C. Supernatants were 
removed to clean eppendorf tubes and 100 ja.1 o f antibody 5C3 (concentrated 3X 
supernatant, using Millipore Ultrafree-15 centrifuge filter units, Z-36436-0, Sigma, 
US) was added to 0.5 ml lysate samples; 50 |ol of antibody was added to 0.25 ml 
samples. 50 jal o f control mouse IgG (Sigma, 31204) (used at a concentration o f 22 
(j.g/ ml) was added to 0.25 ml negative control lysates. Antibody/ lysate mixtures 
were incubated at 4° C overnight on a rocking platform. The following day in order 
to precipitate the antibody-antigen complex, protein - L / protein - G agarose was 
added to the antibody - antigen complex samples as before and incubated at 4° C for 
4 hours on a rocking platform. Beads were removed by spinning at 2,500 rpm for 10 
minutes at 4° C, and the supernatant discarded. To check how much protein was left 
in cell lysate test samples following immunoprécipitation procedure, some o f the 
supernatants were retained and added to 2X laemmili sample buffer (Sigma, 3401)
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and/ or non reducing 3X SDS sample buffer (New England Biolabs, UK), boiled for 
1-3 minutes and stored at -20°C. The beads were then washed for 3 x 15 minute 
periods with buffers as described in Appendix III and pelleted at 2,500 rpm for 10 
minutes. Following final wash and spin as much liquid as possible was removed 
from all samples. 50 pi o f 2X laemmili sample buffer (Sigma, 3401) was added to 
original 0.25 ml lysates and control IgG samples, 100 pi was added to original 0.5 ml 
lysates. In further experiments, non-reducing 3X SDS sample buffer (New England 
Biolabs, UK) was added to test lysates. All samples were boiled for 1 minute and 
stored at -20 0 C until required for SDS-PAGE/ Western blot analysis.
Later experiments employed an optimised 8 hour immunoprécipitation protocol. A 
lysis buffer was prepared (Appendix II) from materials provided in the cellular 
labelling and immunoprécipitation kit supplied by Roche Diagnostics, GmbH. ZR- 
75-1 cell pellets prepared as in earlier experiments were thawed on ice and 
resuspended in lysis buffer (600pl lysis buffer added to each 175 cm flask pellet), 
left for 2-3 minutes at R.T. and sonicated briefly (complete cell lysis was confirmed 
by viewing under an inverted microscope). Test and IgG control lysates were 
precleared with two changes ( 2 x 1  hour) o f protein-L/ protein-G agarose (i.e. lOOpl 
o f protein-L and protein-G agarose was added to 200 pi test lysates/ control Ig 
lysate). Beads were removed as previously described. 150pl o f concentrated MAb 
5C3 was added to test lysates and incubated for 1 hour at 4°C , 50pi o f mouse IgG 
was added to negative control lysates (22 pg). Following this lOOpl of protein-L and 
lOOpl protein-G were added to all lysates and incubated for a further three hours at 
4°C on a rocking platform in order to precipitate the antibody-antigen complex. 
(Some supernatant at this point was placed in 2X loading buffer, boiled for 3 minutes 
and stored at -20°C). Pelleted beads were this time washed for 15 minutes intervals 
with two changes of wash buffer 1 and 2 and one change of wash buffer 3. Following 
a final wash and spin, as much liquid as possible was removed from all samples. 75 
pi of 2X laemmili sample buffer (Sigma, 3401) was added to test lysates and control 
IgG samples. All samples were boiled for 1 minute and stored at -20 0 C until 
required for SDS-PAGE/ Western blot analysis. Further immunoprecipitated samples 
(in 2X loading buffer) were boiled for 10 mins and stored at -20° C.
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2.9.2. Gel electrophoresis of immunoprecipitated proteins
Immunoprecipitated proteins were separated on 7.5% and 10% SDS-PAGE 
electrophoresis as described in section 2.8.3. Retained supernatants (in reducing and 
non reducing loading buffer) were also separated on 7.5% gels, in addition for some 
experiments combinations o f immunoprecipitated proteins and supernatants were 
also separated on SDS-PAGE. Following SDS-PAGE western blot analysis was 
carried as outlined in section 2.8.4 - 2.8.5.. Immunoprecipitates and whole cell 
lysates o f ZR-75-1 cells were probed with antibody 5C3, anti cytokeratin Ab-1 (MS- 
766-P1, Labvision, UK) or anti cytpkeratin 9 (651104, Research Diagnostics Inc., 
US). Control IgG ZR-75-1 immunoprecipitates were probed with antibody 5C3.
In order to visualise proteins SDS-PAGE gels were stained for 15-30 mins with a 
0.25% (w/v) Coomassie Brilliant Blue R-250 solution (containing 45% methanol 
(v/v) and 45% d.FbO (v/v)) and destained with 45% methanol (v/v)/ 10% acetic acid 
(v/v)/ 45% d. H20 .
2.9.3. P re p a ra tio n  o f isolated p ro te ins fo r N -term inal sequencing
ZR-75-1 and control mouse immunoprecipitates were separated on 5 well 7.5% SDS 
PAGE and blotted onto PVDF membrane (Sequiblot ™, Biorad). Following transfer 
the membrane was washed briefly in d.FkO. The blot was then stained for 5 minutes 
with Comassie R-250 (0.25% Comassie Blue R-250 in 40% methanol) and destained 
for 1 hour with 50% (v/v) methanol. The membrane was air-dried for at least 3 hours 
and stored at -20° C. Protein bands were aligned with molecular weight markers and 
ECL films of immunoprecipitates which had been probed with antibody. The bands 
of interest were excised and processed for N-terminal sequencing.
2.9.4. P re p a ra tio n  o f isolated p ro te ins fo r in te rn a l sequencing
Following immunoprecipitation and separation on 7.5% SDS-PAGE using a 5 well 
spacer ensuring that the maximum amount o f protein was loaded, gels were stained 
with Coomassie Brilliant Blue R250 (0.1% (v/v) in methanol, 45% dH20(v/v), 10%
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acetic acid (v/v) and destained with 45% methanol (v/v) /  10% acetic acid (v/v) / 
45% dF^O (v/v). Staining and destaining protocols were carried out according to 
recommendations from Eurosequence. The band of interest was excised from gels, 
placed in eppendorf tubes and sent to Eurosequence BV (Gronigen, The 
Netherlands).
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3. Results
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3. RESULTS
3.1. M D R  associated p ro te in  expression in invasive b re a s t can cer
patien ts.
The emergence of drug resistance is one o f the main obstacles to the successful 
chemotherapy of breast cancer. As previously discussed in section 1.4.2 and 1.4.4., 
identification o f biological factors which can function as reliable prognostic markers 
and more importantly predictive markers will allow for more precise targeting of 
modalities for breast cancer patients. Results presented here attempt to address the 
possible prognostic and predictive significance of MDR associated proteins in breast 
cancer. Immunohistochemical expression o f these proteins have been correlated with 
patient and tumour characteristics, with relapse-free survival and overall survival in 
patients with invasive breast cancer. In addition immunohistochemical expression o f 
individual MDR markers studied is analysed in relation to other MDR associated 
proteins. This study was undertaken in collaboration with Dr. Susan Kennedy o f the 
Department o f Pathology and colleagues in the Department of Surgery at St. 
Vincents Hospital, Dublin 2.
Primary breast specimens from a total o f 204 patients were included in this study. 
Pre and post formalin fixed paraffin embedded archival tumour samples from 46 of 
these patients were analysed by means of immunohistochemistry for expression o f 
MRP-1, cerbB-2, MDR-1, LRP, Bcl-2 and survivin proteins. MRP-1 protein 
expression was also studied in an additional 158 pre treatment archival tumours 
(technical work carried out at Royal Victoria Eye and Ear Hospital, Dublin). All o f 
the patients studied were treated with surgery at St. Vincents Hospital between 1982 
and 1995.
Following surgery all o f these patients received adjuvant chemotherapy or hormonal 
therapy or combination therapy. 103 (50.4%) of the patients studied received 
chemotherapy/ combination therapy. O f this group, 56 patients received standard 
CMF therapy, 26 patients received ACMF, 1 patient received taxol, 1 patient 
received PMF, 1 patient received VMF/ chloroambucil; the exact details o f the 
chemotherapy administered to 17 patients were not known at the time o f compiling
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these results. Chemotherapy treated patients referred to, in the results presented in 
this thesis, represent this group. O f this group o f 103 patients; 45 relapsed during 
follow up and died of disease (status referred to in Tables 3.1.4. and 3.1.5. as dead 
(d)), 46 are currently disease free (status referred in Tables 3.1.4. and 3.1.5 to as alive 
(a)) and 8 have relapsed but are currently alive (status referred to in Tables 3.1.4. and
3.1.5 as recurrence (r)). There was a minimum of 5 years follow up for all patients 
included in this study.
Immunohistochemical analysis o f tumours was carried out using a panel o f MAbs for 
various MDR markers (Table 3.1.1.). Tumours stained with appropriate MAbs were 
scored and presented throughout these results, by the percentage o f  positive tumour 
cells stained with appropriate MAbs.
MDR-1, Mrk-16, LRP-56, MRP-R1, cerbB-2 and Bcl-2 MAbs:
1 = 1-25% of tumour cell stained
2 = 26-50% of tumour cells stained
3 =51:100% of tumour cells stained
Survivin MAb, 1C5: (note : the difference in survivin scoring 
system will be taken into account in any comparative analysis 
with other histochemical markers)
1 = 1-10% of tumour cell stained
2 = 11-49% of tumour cells stained
3 = 50-100% of tumour cells stained
For all MAbs the percentage o f  tumour cells stained is followed by the intensity of 
the staining observed:
Level 1 = weak staining
Level 2 =intermediate level of staining
Level 3 =intense staining.
Unless otherwise stated any positive immunohistochemical score (percentage of 
tumour cells stained and intensity o f staining) was considered positive for analysis of
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results presented here. Immunohistochemical results together with clinico 
pathological details of patients / tumours studied are presented in Tables, 3.1.4. and
3.1.5.
Table 3.1.1.
M A bs used in investigation o fM D R  associated pro tein  expression in breast cancer 
patients.
MAb Specificity Reference
BRI anti MDR-1 (6/1C) # P-170/ Pgp Moran et al., 1997
MRK-16 P-170/Pgp Sugawara et al., 1988
MRP-R1 * MRP-1 F lens etal., 1994
LRP-56 * LRP Scheper et al., 1993
cerbB-2 oncoprotein, clone CB11 
(Novacastra, UK)
CerbB-2 Corbett et a l, 1990
Anti human Bcl-2 oncoprotein 
(Dako)
Bcl-2 Zutter etal., 1991
BRI anti Survivin (1C5) # Survivin Personal communication Dr. Irene Cleary
# obtained from Bioresearch Ireland, Dublin.
* kindly provided by Prof. R.J. Scheper, Free University Hospital, Amsterdam, The 
Netherlands.
** kindly provided by Prof. T. Tsuruo, Department o f  Pathology, University o f
Tokoyo, Japan.
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Table 3.1.2. Patient and tumour characteristics of invasive breast cancers (n=204)
preliminary study 
n=46
follow up study 
n=158
total n=204
Age
< 50 years 12 26% 45 28.5 % 57 28%
> 50 years 34 74% 109 69% 143 70%
unknown 4 2.5% 4 2%
ER status
ER+ 15 33% 87 55% 103 50%
E R - 18 39% 26 16.5% 44 22%
unknown 13 28% 45 28.5% 58 28%
Node status
node positive 40 87% 75 47% 115 56%
node negative 6 13% 80 51% 86 42%
unknown 3 2% 3 2%
Tumour size
< 2cm 13 28% 55 34.8% 68 33%
2-5cm 18 40%% 84 53.7% 102 50%
>5 cm 9 19.5% 9 5.7% 18 9%
unknown 6 13% 8 5% 14 7%
Histological grade
Grade I 4 9% 18 11% 22 10.8%
Grade 11 5 11% 65 41% 72 35.3%
Grade III 25 54% 72 46% 107 49%
unknown 11 24% 3 3% 14 6.8%
Histological classification 28 60.8% 98 62% 126 62%
Infiltrating ductal +/-DCIS 
Infiltrating lobular +/-LCIS 
lobular tubular/alveolar
3 6.5% 22 14% 25 12%
ductal/lobular 1 2.2% 6 4% 7 3%
Infiltrating mucinous 
Nos/ infiltrating
15 32.6% 33 20% 43 23.5%
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Table 3.1.3. Patient and tumour characteristics o f chemotherapy treated invasive
breast cancers (n=103)
n %
Age
< 50 years 18 17.4%
> 50 years 69 67%
ER status
ER+ 48 46.6%
ER- 35 33.98%
unknown 20 19.4%
Node status
node positive 72 69.6%
node negative 29 28.2%
unknown 3 2.9%
Tumour size
< 2cm 22 21.4%
2-5cm 55 53.5%
>5cm 18 17.5%
unknown 8 7.8%
Histological grade
Grade I (low) 9 8.7%
Grade II (intermediate) 29 28.2%
Grade III (high) 52 50.4%
unknown 12 11.6%
Histological subtype
Infiltrating ductal +/-DCIS 72 69.9%
Infiltrating lobular +/-LCIS 
lobular tubular/alveolar 
ductal/lobular
8 7.8%
Infiltrating mucinous 2 1.9%
Nos/ infiltrating 32 31%
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Table 3.1.4.
C linical fea tu res o f  tumours, treatm ent details o f  pa tien ts an d  im m unohistochem ical 
analysis o f  M D R  associated pro teins in p re  and p o st treatm ent archival tum our m aterial 
fro m  invasive breast cancer pa tien ts (n=46).
Key: d =status of these patients: dead of disease, a = status of these patients: alive at date last seen,
r = status of these patients: recurrence of disease, alive at date last seen, os = overall survival, rfs = 
relapse free survival, In du = infiltrating ductal, In lob = infiltrating lobular, DCIS = ductal 
carcinoma in situ (comedo/ cribriform/ solid), In tubular = infiltrating tubular, In municous = 
infiltrating mucinous, LCIS = lobular carcinoma in situ, turn size = tumour size (cm), grade = 
histological grade, ER = estrogen receptor status (pos/neg), Tam = tamoxifen therapy, RT = radiation 
therapy (Y/N), Node = lymph node status (0/1), chemo = adjuvant chemotherapy administered, CMF 
= cyclophosphamide/ methotrexate/5-fluorauacil, ACMF = adriamycin/ cyclophosphamide/ 
methotrexate/ 5-fluorouracil, meg= megace, VMF = vinblastine, methotrexate, 5-fluouracil, chlorb = 
chlorambucil,. MDR protein marker expression (immunhistochemical analysis of MDR-1, Mrk-16, 
LRP, MRP-1, cerbB2, Bcl-2, survivin, all performed pre treatment, immunohistochemical analysis of 
post treatment samples where available indicated in columns directly following each marker).
89
voo
no status os rfs size grade ER Tam RT Node Diagnosis Chemo Mdr-1 post Mrk-1 LRP post MRP-1 post cerbB post Bcl-2 post Burvfvin post Mdr-3
1 d 3 3 5.5 3 neg N Y 1 R In Du, DCIS-com ACMFx12 3+3 3+3 3+3
2 d 5 2 neg Y 1 L In Du, DCIS CMFx9 3+3 DC I 1+2 DCIS neg neg neg 3+2 3+{2-3) 2+3 2+3
3 d 7 6 1.5 3 neg Y Y 1 R In Du DCIS-com neg 1+2 neg neg
4 d 9 4 7 3 neg Y N 1 In Ca ACMFx12 1(1-2) neg
5 d 0 0 9 Y 1 L In Du DCIS PMF neg 3+1 neg 2+3 neg neg 3+3 3+3 neg neg 2+1 3+(1~2)
6 d 3 1 10 Y 1 L In Ca CMF 2+2 neg neg neg neg neg 2+1 neg 3+(2-3) 3+0-2) 2+(1-2) 2+(1-2)
7 d 11 5 2.2 pos Y Y 1 L In Du. DCIS CMFx9 neg 1+1 2+2 neg neg 1+3 3+3 3+(2-3)
8 d 1 0 5 3 Y 1 R In Du DCIS CMFx9 neg 2+1 neg neg 1+1 2+1 neg neg 3+( 1 -2) 3+(2-3) neg 3+(2-3)
9 d 7 1 4 neg Y 1 R In Ca VMFChlorb neg 1+2 neg 1+1 1+3 3+3 (1-2)+ 2+2 neg 3+1 1+0-2) 2+2
10 d 4 2 6 3 pos N N 1 L In Du, DCIS CMFx9 \U2 1+1 neg neg 1+2 neg neg neg 3+3 3+3 3+2 neg
11 d 6 4 2 pos Y Y 1 Lin Du ACMFX12 (2-3)+1 neg 3+3 2+3
12 d 3 3 3 2 Y 1 R In Du CMFx9 neg 2+1 neg neg 1+1 2+1 neg neg neg neg 2+1 3+(1-2)
13 d 3 2 3 3 pos Y 1 Lin Du CMFx9 3+3 2+3 neg neg 3+1 1+1 1+1 neg
14 d 6 1 3.5 3 pos Y Y 1 L In lobular LCIS ACMFX12 neg neg 2+2
15 d 2 2 4 3 1 L In ca 3+3 2+3
16 d 3 3 2 3 neg Y 1 Lin Du CMFx9 1+1 1+1 neg 1+1 3+3 3+3 neg neg neg neg 3+2 3+2
17 d 7 5 6 neg N 1 R In Ca CMFx9 2+2 2+1 neg neg 3+2 3+3 neg 1+1 3+3 3+3 3+2
18 d 2 2 5 3 neg y Y 1 Lin Du, DCIS A4CMFX8 1+2 2+2
19 d 2 2 2 0 L In Du, DCIS CMFx9 2+1 1+2 1+2 neg 3+3 3+3 3+3 3+3 2+2 neg 3+3 2+3
20 d 2 1 2.5 3 neg Y 0 In Du ACMF neg neg
21 d 6 6 neg Y 0 L In Du CMFx9 neg neg 1+2 2+1 3+3 3+3 neg neg 3+2 2+2
22 r 2 2 3 3 pos 1 R In Ca CMFd1d8x6 1+1 1+1 3+3 2+2 2+2
23 r 4 4 2.8/4 1 pos N 1 R In mucinous CMFx9 neg neg neg neg
24 r 2 2 1 1 pos Y Y 0 R In Du ACMF neg 1+2 neg neg
25 a 7 7 0.6 3 neg N N 0 L In Du DCIS-com CMFX6 neg 3+3
28 a 7 7 2.7 3 neg N Y 0 R In Du CMFx6 1+1 neg
27 a 12 12 3 3 neg N N 1 L In Ca, NOS CMFx9 1+2 1+2 neg neg 2+1 neg
28 a 13 13 1.7 neg N Y 1 R In Du CMFx9 3+2 neg 1+2 neg 3+(2-3) 3+3
29 a 8 8 1 3 neg N N 1 R In lobular CMFx9 neg neg
30 a 15 15 2 3 neg 1 L In Ca, NOS CMF 1+2 2+1 neg neg 2+2 2+2
31 a 13 13 1.5 pos Y y 1 Lln Du CMFx9 3+2 neg neg 3+3
32 a 6 6 2 Y Y 1 R In Du, DCIS CMF 2+2 neg
33 a 10 10 2.5 pos 1 R In Du CMFx9 DCIS neg neg neg 1+1 1+1
34 a 8 7 2 2 pos Y Y 1 R In Ca ACMF neg neg
35 a 9 9 3 Y 1 R In Ca ACMF 3+3 2+2 1+2 neg 3+1 3+3
36 a 7 7 1.2 1 Y 1 R In Du CMFx9 meg neg neg
37 a 13 13 8 3 pos 1 R In Du CMFx9 1+1 2+3 neg neg 1+0-2) 3+3
38 a 10 10 3 3 pos Y Y 1 L In Ca, NOS CMFx9 neg neg neg neg neg neg
39 a 14 14 3 Y 1 Lln Ca CMFx9 1+2 2+1 1+1 neg 2+1 neg
Table 3.1.2. MDR associated protein expression in invasive breast carcinomas (n=46).
no status os rfs SiZB grade ER Tam RT Node Diagnosis Chemo Mdr-1 post Mrfc-1 LRP post MRP-1 post certoB post Bcl-2 post survivin post Mdr-3
40 a 9 9 1 3j N Iy 1 |L In Du, DC IS |CMFx9 1+3 neg neg neg neg 2+2
41 d 7 4 3 2 neg N 1 L In Ca, NOS Zoldafex DCIS neg 1+1 neg
42 d 0 0 3 3 Y 0 RlnDu, DCIS Tamoxifen neg neg 3+(1-2) 3+3 3+3 1+1 3+1 1+1 neg
43id 0 0 2 neg Y In 11R In Qu. DCIS I Tamoxifen 3+3 3+3 neg neg 2+2 neg 3+3 3+3 neg 1+1 3+(2-3) 3+(1*2)
44 d 3 1 3.5 3 pos Y Y 1 |R In Du | Tamoxifen 1+2 1+1
45 a 8 8 2 3 pos Y 1 it In Ca, NOS Zoldalex 2+2
46 r 8 3 3 l| 1 iL in crib tub com Zoldalex neg 3+3 neg neg 3+3
Table 3.1.2. MDR associated protein expression in invasive breast carcinomas (n=46).
Table 3.1.5.
Clinical fea tures o f  tumours, treatment details o f  patients and  immunohistochemical 
analysis o f  MRP-1 protein in pre  treatment archival tum our material fro m  invasive 
breast cancer patients (n=158).
Key: d =status of these patients: dead of disease, a = status of these patients: alive at date last seen,
r = status of these patients: recurrence of disease, alive at date last seen, os = overall survival, rfs = 
relapse free survival, In du = infiltrating ductal, In lob = infiltrating lobular, DCIS = ductal 
carcinoma in situ (comedo/ cribriform/ solid), In tubular = infiltrating tubular, In municous = 
infiltrating mucinous, LCIS = lobular carcinoma in situ, turn size = tumour size (cm), grade -  
histological grade, ER = estrogen receptor status (pos/neg), Tam = tamoxifen therapy, RT = radiation 
therapy (Y/N), Node = lymph node status (0/1), chemo = adjuvant chemotherapy administered, CMF 
= cyclophosphamide/ methotrexate/5-fluorauacil, ACMF = adriamycin/ cyclophosphamide/ 
methotrexate/ 5-fluorouracil, meg= megace, VMF = vinblastine, methotrexate, 5-fluouracil, chlorb = 
chlorambucil, All of these archival tumour samples were pre treatment.
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VDU)
no status os rfs size grade ER RT Node Diagnosis chemo MRP-1
1 a 8 8 2.4 2 1 y 0 In Du none 3+3
2 a 8 8 2.5 3 1 n/y? 0 In Du none 3+3
3 a 7 7 0.6 2 1 y 1 In Lo neg
4 a 6 6 2 2 1 0 In Du None 2+2
5 a 7 7 2.5 3 0 y 1 In Du, DCIS-com 2+1
6 a 7 7 2.5 2 1 0 In Du, DCIS neg
7 a 7 7 3.9 1 1 y 0 In Ca, NOS 3+2
8 a 7 7 1.5 1 1 y 0 In Lo 2+2
9 a 7 7 3.5 2 1 y 0 In Du 2+1
10 a 6 6 1 2 1 y 0 In Lo, LCIS none neg
11 a 6 6 2 1 0 y 0 In Du, LCIS none 3+2
12 a 0 0 2.5 2 0 n 0 In Du None +,... 3+1
13 a 7 7 3 3 1 y 1 In Du, DCIS-crib none neg
14 a 6 6 3 3 1 y 1 In Du + DCIS none neg
15 a 7 7 2.5 2 1 Y 1 In Du None 3+2
16 a 7 7 2.5 3 1 y 1 In Du, DCIS-com none 3+2
17 a 5 5 4.2 2 1 y 1 In Du, DCIS-sol+com None 3+3
18 a 7 7 1 2 1 n 0 In Du, DCIS-com None 2+3
19 a 7 7 2 3 1 Y 1 In Du None 3+3
20 a 6 6 2.7 3 1 y 1 In Ca, NOS none 2+3
21 a 0 0 3 2 1 n 0 In Ca None + .... 2+1
22 a 6 6 1.5 2 0 y 0 In Lo-pleomorphic None 2-1+1
23 a 7 7 1 2 0 N 0 In Du, DCIS-com+crib None neg
24 a 9 1 0 Y 0 Mucinous Ca megace 1+2
25 a 7 7 2 2 0 In Du, DCIS sol 1-2+1
26 a 7 7 2 2 y 0 In Ca none 3+1
27 a 7 7 8 3 0 1 In Ca-com 2+2
28 a 6 6 2 3 1 y 0 In Du, NOS None neg
29 a 6 6 2.3 3 0 Y 1 In Du None 3+3
30 a 3 3 2 3 1 y 1 In Du None + .... 3+3
31 a 5 5 2 3 0 y 1 In Du, DCIS neg
32 a 3 3 1 0 In Du 3+3
33 a 7 7 1.9 1 1 0 Intraductal Ca-com + crib None neg
34 a 7 7 2 2 1 y 1 In Lo none neg
35 a 8 S 3 1 1 Y 1 In Lo,DCIS-crib, com none neg
36 a 6 6 2.5 2 0 y 0 In com Ca 2+2
37 a 2 2 2 3 y 0 In Ca neg
38 a 6 6 6 3 1 y 1 In Du none 2+2
Table 3.1.5. MRP-1 protein expression in invasive breast carcinomas (n=158)
no status os rfs size grade ER RT Node Diagnosis chemo MRP-1
39 a 4 4 3 1 1 0 Mucinous Ca neg
40 a 1.5 2 1 1 In Lo 2+1
41 a 8 8 2 2 1 n 1 in Du Zoladex 2+2
42 a 7 7 3 2 1 Y 0 In Ca, NOS none neg
43 a 8 8 2 2 1 Y 0 In Lo none neg
44 a 4.3 2 1 y 0 In Ca, NOS 2+2
45 a 8 8 1.9 1 1 y 0 Mucinous Ca none 3+1
46 a 5 5 2 3 0 n 0 In Lo, LCIS None +... 2+2
47 a 7 7 2.5 2 0 y 0 In Du, DCIS none 2+1
48 a 1.8 2 1 n 0 In Du None 1-2+3
49 a 8 8 1 y neg
50 a 6 6 4.2 3 0 Y 0 In Ca, NOS none neg
51 d 2 2 2.5 3 0 In Du, NOS neg
52 d 1 1 2.3 2 1 y 0 In Du none 2+1
53 d 6 6 1.5 2 1 Y 0 In Du none neg
54 d 6 6 3.5 3 0 y 0 In Du, DCIS-com none 3+3
55 d 3 1 2.3 3 1 n 1 In Du megace 2+1
56 d 7 7 2 2 0 y 0 In Lo None neg
57 d 5 5 1.5 3 1 y 1 In Ca, NOS Arimidex 2+1
58 d 3 3 3.5 3 y 0 In Du None 2-3+1
59 d 0 0 3 3 1 y 1 In Du none neg
60 d 2 1 2.4 3 1 y 1 In Lo None 2+1
61 d 2 1 4 3 1 y 0 In Ca, NOS none 2+3
62 d 2 2 4.5 3 1 n 0 In Du none 2+3
63 d 6 6 1.3 2 1 y 0 In Du 1+1
64 d 1 0 3.2 3 0 y/n ? 0 In Du, DCIS none 3+2
65 d 3 3 2.5 2 1 y 0 In Du NOS, DCIS-crib, com none 3+2
66 d 3 2 4.5 2 1 y 1 In Lo none 1+1-2
67 d 6 6 2 2 1 y 0 In Du none neg
68 d 2 3 1 In Du neg
69 d 3 3 3.5 3 1 In Du 3+3
70 d 7 7 1.5 2 0 n 1 In Lo, LCIS com none 1+1-2
71 d 1 2 4.5 3 n 1 In Du None+ palliative 3+3
72 d 0 0 2 3 0 In Du, DCIS sol, crib neg
73 r 0 1 0.7 3 1 1 In Ca, NOS 3+3
74 r 1.5 3 0 1 In Du neg
75 r 7 8 3.5 3 1 y 1 In Du aredia neg
76 r 1 6 1.5 2 1 y 0 In tubulo-lobular, LCIS none 1+2
Table 3.1.5. MRP-1 protein expression in invasive breast carcinomas (n=158)
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L /ì
no status os rfs size grade ER RT Node Diagnosis chemo MRP-1
77 r 2 4 3 2 1 1 In Lo 2+3
78 r 2.5 3 1 y 0 In Ca None neg
79 r 2 1.8 3 1 y 0 In Du none 2+3
80 r 5 6 5 2 1 n 0 In Du, DCIS crib, com, pap None+ palliative 1+2
81 r 2 6 3 1 1 y 0 Mucinous Ca none 2+2
82 r 1 3 1 n 1 In Du none 3+3
83 r 7 7 3 2 1 y 0 In Du neg
84 r 5 5 2.5 2 1 y 0 In Du 1+1-2
85 ? 4 2 0 In Du, DCIS com, crib neg
86 ? 3 3 1 Y 1 In Du, DCIS-com neg
87 ? 3 Y In Ca neg
88 ? 1.5 2 1 Y 0 In Du, DCIS-crib None 1+2
89 ? 4 1 1 1 In Lo neg
90 ? 2 2 0 In Du, DCIS 2+2
91 ? 1.5 1 0 In Du neg
92 ? 3.5 1 1 0 In Mucinous, DCIS neg
93 ? 2.2 3 0 NOS neg
94 ? 2.2 3 1 1 In Du, DCIS com, crib, pap neg
95 ? 2.5 3 n 0 In Du None 1-2+2
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96 a 7 7 3 3 1 y 0 In Ca, NOS CMFx9 neg
97 a 6 6 2.5 3 0 n 0 In Du, DCIS CMFx9 3+3
98 a 7 7 2.6 1 1 n 1 In Du ACMF 3+
99 a 7 7 4 2 0 n 0 In Ca, NOS CMFX9 2+2
100 a 6 6 1.2 2 1 n 1 In Du A4CMF x 8 3+3
101 a 6 6 2 3 1 y 0 In Ou Yes neg
102 a 7 7 1.5 2 1 y 1 In Lo, DCIS ACMF 2+2
103 a 5 5 3.5 5 1 Y 1 In Ca ACMF 1+1
104 a 6 6 2.5 2 1 Y 1 In Du Yes 3+3
105 a 3 2 In Du, DCIS ACMF neg
106 a 5 5 2.5 3 0 0 In Du CMF x 8 3+3
107 a 7 7 4.3 3 1 n 1 In Lo, In Tubular, crib Yes 3+3
108 a 2 2 1.5 1 1 y 0 In Ca A4CMF x 8 3+3
109 a 5 5 5 2 1 y 0 In Du Yes 3+2
110 a 5 5 4.5 3 0 In Du. DCIS CMFx9 neg
111 a 6 6 3.2 2 1 y 0 In Du, DCIS-crib, com Yes neg
112 a 6 6 1 Y 1 CMFx12 neg
113 a 5 5 3 3 1 y 0 In Lo, DCIS CMF neg
114 a 6 6 2.5 2 1 y 1 In Du CMF x 9 3+3
115 a 1 1 3.8 3 1 y 0 In Du CMF x 9 1+1
116 a 5 5 3 2 1 n 1 In Du Yes 2-3+2
117 a 6 6 2 2 1 y 1 In Du A4CMF x 8 neg
118 a 7 7 3 3 1 y 1 In Du ACMF 1+1
119 a 4 4 2.5 2 n 0 In Du Yes 3+2
120 a 7 7 1.8 1 1 n 0 In Ca, NOS CMF x 7 neg
121 a 6 6 3 2 1 Y 0 In Lo, LCIS CMF X 6 1+2
122 a 7 7 4 2 0 n 0 In Du CMF 1-2+3
123 d 2 2 2.5 3 0 n 1 In Du, DCIS CMF X 9 neg
124 d 3 6 3.5 3 1 Y 1 In Ca, DCIS ACMF 3+2
125 d 2 2 5 2 1 y 0 In Lo ACMF, 1+2
126 d 2 3 2.3 2 0 y 1 In Du CMF.bleomycin.doxirubicin 2+2
127 d 2 2 3 3 0 y 1 In Du CMF x 9 2+3
128 d 1 2 DCIS n In Du, DCIS CMF neg
129 d 1 6 3 2 0 y 0 In Du Yes 3+2
130 d 2 3 3 2 0 Y 1 In Du, DCIS ACMF neg
131 d 6 6 2 1 1 n 1 In Du, DCIS A4CMF X 8 2+1
132 d 3 3 2 2 1 Y 0 In Du Yes neg
133 d 6 7 1.8 3 0 n 0 In Du CMF 1+1-2
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134 d 3 6 3 3 1 Y 1 In Du CMF 2+2
135 d 0 0 3.5 3 1 1 in Du CMFx9 2+3
136 d 1 1 5 3 0 n 1 In Du ACMF, doxorubicin 3+3
137 d 2 2 2 3 0 1 In Ca- undiff, DCIS-solid CAF 3+3
138 d 1 2 5 1 0 y In Lo-alveolar Yes neg
139 d 3 3 4 2 0 n 1 In Du, DCIS ACMF 2+1
140 d 4 4 4.5 3 0 1 In Du, DCIS A4CMF x 8 1+2
141 d 2 2 1.5 3 1 y 1 In Du ACMF, VNB, Mito C 3+3
142 d 1 2 1.3 2 Y In Du CMF, Taxotere 2+1
143 d 3 4 4 3 n 1 In Du, DCIS yes 3+3
144 d 2 2 2.5 3 1 Y 1 In Du CMFX8 3+2
145 d 4 5 3 3 1 Y 1 In Du, NOS CMFx9 neg
146 d 0 3 3 2 1 1 In Du ACMF, zoldalex 2+2
147 d 3 7 2 3 1 y In Lo CMF 2+2
148 d 3 7 5.5 3 1 y 1 In Du A4CMF x 8 3+3
149 d 2 4 2.2 2 1 Y 1 Ca CMFx9, VAT, Taxotere neg
150 r 4 8 5 2 0 1 In mucinous Ca Taxol 3+3
151 r 2 3 2.8 3 0 y 1 In Ca, NOS CMF 1-1+2
152 r 19 21 1.8 2 1 y In Du CMF x 20 neg
153 r 3 5 2 2 1 y 1 In Du CMF neg
154 r 6 7 4 3 1 y 1 In Du Yes 3+1
155 r 1 7 3.5 2 0 1 In Du, In Lo, DCIS-crib CMFx6 neg
156 r 2 2 6 3 0 1 In Du CMF neg
157 r 1 7 1.5 1 n 1 In Du, DCIS com yes 2+1
158 ? 1.5 3 1 yes neg
Table 3.1.5. MRP-1 protein expression in invasive breast carcinomas (n=158)
3.1.1. MRP-1 protein expression
MRP-1 protein expression was studied in pre  treatment tumours from a total o f 204 
patients with invasive breast cancer. 103 patients who received chemotherapy 
following surgery were investigated for MRP-1 protein expression prior  to treatment 
with chemotherapy, MRP-1 expression was studied in 20 post chemotherapy 
treatment tumours from this group of patients. Immunohistochemical analysis results 
are presented in Tables 3.1.4. and 3.1.5. Representative tumours stained with the 
MRP-1 specific MAb, MRP-R1 are presented in Figures 3.2 and 3.3.
MRP-1 protein expression in relation to known clinico-pathological factors i.e. 
treatment status, node status, age (<50 years/ >50 years), ER status, tumour size, and 
histological grade is presented in Tables 3.1.6. For analysis purposes, patients were 
divided into two groups; those who had MRP-1 positive tumours and those who had 
MRP-1 negative tumours. The association o f MRP-1 + tumours and MRP-1 -  
tumours with clinico-pathological factors is presented in Table 3.1.6. and 3.1.8. In 
addition, MRP-1 positive tumours which showed an immunohistochemical score of 
3+3 are correlated with histological grade in Figure 3.3. (Table 3.1.7.).
Correlation o f MRP-1 expression with relapse free survival and overall survival 
times in patients who did not receive chemotherapy and chemotherapy treated 
patients is presented in Tables 3.1.9 -  3.1.12. MRP-1 expression is also correlated 
with relapse free survival and overall survival times in chemotherapy treated patients 
who received CMF alone (Tables 3.1.15.- 3.1.6) and in combination with adriamycin 
(ACMF) (Tables 3.1.13.-3.1.14).
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Figure 3.1.1. Immunohistochemical analysis of MRP-1 protein expression (I)
(a) MRP-1 positive tumour (pre treatment) from a patient with infiltrating ductal 
carcinoma (refer to patient no. 17, Table 3.1.4.) stained with MRP-R1 MAb, 
positive staining (typical granular membranous type staining) can be observed in 
infiltrating tumour cells (original magnification 60x). (b) Following treatment there 
was a slight increase in the level o f MRP-1 positivity observed, intense MRP-1 
positive staining can be observed in infiltrating tumour cells at interface o f stroma 
(original magnification 40x). (c) Infiltrating carcinoma cells (pre treatment) from 
another patient with infiltrating ductal carcinoma (refer to patient no. 16, Table
3.1.4.) showing intense MRP positive staining, this tumour showed weak Pgp 
expression (original magnification 60x). Both o f these patients relapsed and are now 
deceased. (Strep/ HRP method using DAB as chromogen, sections were 
counterstained with haematoxylin).
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Tumour cells from two patients w ith infiltrating ductal carcinoma (pre treatment) 
stained with MRP-R1 M Ab. Both o f  these patients are currently alive and have not 
relapsed (refer to patients no. 26 (a) and 38 (b), Table 3.1.4.). W eak MRP-1 
expression can be observed in tumour (a) (original m agnification 40x) while second 
tumour is negative for MRP-1 expression (b) (original m agnification lOx) and 
(StrepABC/ HRP method using DAB as chromogen, sections were counterstained 
with haematoxylin).
Figure 3.1.2. Immunohistochemical analysis of MRP-1 protein expression (II)
Table 3.1.6.
M RP-1 expression in invasive breast tum ours and  association with chemotherapy 
treatment, node status, E R  status, age, tum our size and histological grade and  
histological subytpe o f  tumour.
Immnnohistochemical analysis of MRP-1 expression (n/%)
Total n=204 %
Total group n =204 126/201 62.6%
Chemotherapy treated group n=103 63/103 61.2%
Node Status
Node positive patients n=l 15 72/115 62.6%
Node negative patients n=86 54/86 62.7%
unknown n = 3
Age
< 50  years 50/79 63.3%
> 50 years 72/119 60.5%
unknown n = 6
ER status
ER+ 69/102 67.6%
E R - 38/55 69.1%
Tuntour size
< 2cm 35/68 51.47%
2-5cm 64/102 62.7%
>5cm 13/18 77.7%
Histological grade
Grade I (low) 12/22 52.6%
Grade II (intermediate) 45/67 67.1%
Grade III (high) 66/102 64.5%
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Table 3.1.7.
M RP-1 positive tum ours with an immunohistochemical score o f  3+3 and  association with 
histological grade
Histological grade
Grade III 19/26 73%
Grade II 6/26 23%
Grade I 1/26 3.8%
% 3+3 MRP-1 positive tumours v’s histological grade
g % 3+3 MRP-1 positive 
tumours
Histological Grade
Figure 3.1.3.
Association of MRP-1 positive tumours with an immunohistochemical score of 
3+3 and histological grade of tumour.
H igh histological grade appeared to be strongly associated with MRP-1 positive 
tumours which had an immunohistochemical score o f  3+3. 73% o f  3+3 MRP-1 
positive tumours were grade III (high grade), this compares to 23% o f  grade II 
(intermediate grade) and only 3.8% o f  grade I (low grade).
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Table 3.1.8.
Association  o fM R P -1  + /M R P -1  -  tum ours with node status, E R  status, tum our size and  
histological grade
MRP-1 + MRP-1 -
Node status (n=204) 
Node positive 
Node negative 
unknown n = 3
72/126
54/126
57%
42.8%
43/75
32/75
57.3%
42.6%
Node status chemotherapy 
treated patients (n=103) 
Node positive 
Node negative
46/63
17/63
73%
26.9%
26/38
12/38
68.4%
31.6%
ER status (n=204)
ER +
ER-
69/107
38/107
64.5%
35.5%
3/50
17/50
66%
34%
Tumour size (n=204) 
<2cm  
2-5 cm 
>5 cm
35/112
64/112
13/112
31.2%
57.1%
11.6%
33/76
38/76
5/76
43.4%
50%
6.8%
Histological grade (n=204)
Grade I 
Grade II 
Grade III
10/116
47/116
60/116
8.6%
40.5%
51.7%
12/67
23/67
33/27
17.9%
34.3%
49.2%
103
Table 3.1.9.
MRP-1 protein expression (+/-) at diagnosis and correlation with R elapse F ree Survival 
in non chem otherapy treated patients
M RP-1  +
relapse free survival % MRP-1 + tumours 
node negative
% MRP-1 + tumours 
node positive total
0-3 years 12/30 40% 9/22 40.9% 21/52 40.3%
4-7 years 16/30 53.3% 9/22 40.9% 27/52 51.9%
8+ years 2/30 6.6% 4/22 18.2% 6/52 11.5%
M RP-1 -
% MRP-1 - tumours
node negative
% MRP-1 - tumours
node positive total
0-3 years 1/14 7% 2/10 20% 3/24 12.5%
4-7 years 11/14 78.9% 8/10 80% 19/24 79.2%
8+ years 2/14 14.2% 2/24 8.3%
Table 3.1.10.
MRP-1 protein expression (+/-) at diagnosis and correlation with O verall S urviva l in 
non chem otherapy treated patients
M R P-1 +
overall survival % MRP-1 + tumours
node negative
% MRP-1 + tumours 
node positive total
0-3 years 9/27 33.3% 7/22 31.8% 16/49 32.6%
4-7 years 16/27 59.2% 11/22 50% 27/49 55.1%
8+ years 2/27 7.4% 4/22 18.2% 6/49 12.2%
M R P -1 -
overall survival % MRP-1 - tumours 
node negative
% MRP-1 - tumours 
node positive total
0-3 years 1/14 7.1% 1/9 11.1% 2/23 8.6%
4-7 years 11/14 78.69% 7/9 77.7% 18/23 78.3%
8+ years 2/14 14.2% 1/9 11.1% 3/23 13%
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Table 3.1.11.
MRP-1 protein expression (+/-) at diagnosis and correlation with Relapse Free Survival 
in chem otherapy treated  patients
M RP-1 +
relapse free survival % MRP-1 + tumours 
node negative
% M RP-I + tumours 
node positive total
0-3 years 5/14 35.5% 23/45 51.1% 28/59 47.5%
4-7 years 9/14 64.3% 17/45 37.8% 27/59 42.4%
8+ years 0/14 0% 7/45 15.6% 7/59 11.8%
M R P -I -
relapse free survival % MRP-1 - tumours 
node negative
% MRP-1 - tumours 
node positive total
0-3 years 3/11 27.3% 7/34 20.5% 10/45 22.2%
4-7 years 7/11 63.7% 10/34 29.4% 17/45 37.8%
8+ years 1/11 9% 17/34 50% 18/45 40%
Table 3.1.12.
MRP-1 protein expression (+/-) at diagnosis and correlation with Overall Survival in 
chem otherapy treated  patients
M RP-1  +
overall survival % MRP-1 + tumours 
node negative
% MRP-1 + tumours 
node positive total
0-3 years 3/14 21.4% 18/45 40% 21/59 35.6%
4-7 years 11/14 78.6% 22/45 48.9% 33/59 56%
8+ years 10/14 0% 5/45 11.1% 5/59 8.5%
M RP-1
% MRP-1 - tumours 
node negative
% MRP-1 - tumours 
node positive total
0-3 years 2/11 18.2% 7/34 20.6% 9/45 20%
4-7 years 8/11 72.8% 10/34 29.4% 18/45 40%
8+ years 1/11 9% 17/34 56.6% 18/45 40%
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Table 3.1.13.
MRP-1 protein expression (+/-) at diagnosis in patients who received adriamycin/taxol 
in combination with C M F therapy and correlation with Relapse Free Survivial (figures in 
brackets = MRP-1 positive tumours with a score of 1+1 were considered negative,).
M RP-1 +
relapse free survival % MRP-1 + tumours 
node negative
% MRP-1 + tumours 
node positive total
0-3 years 1/1 100% 
(1/1 100%)
8/19 42% 
(7/14 50%)
9/20 45% 
(8/15 53.3%)
4-7 years 10/19 52.6% 
(6/14 42.8%)
10/20 50% 
(6/15 40%)
8+ years 1/19 5.3% 
(1/14 7.1%)
1/20 5% 
(1/15 6.6%)
M RP-1 -
% MRP-1 - tumours 
node negative
% MRP-1 - tumours 
node positive total
0-3 years 2/2 100% 
(2/2 100%)
1/4 25%
(2/9 22%)
3/6 50% 
(4/11 36.3%)
4-7 years 3/4 75% 
(7/9 77.7%)
3/6 50% 
(7/11 63.6)
8+ years
Table 3.1.14.
MRP-1 protein expression (+/-) at diagnosis in patients who received adriamycin/taxol 
in combination with C M F therapy and correlation with Overall Survival in 
chemotherapy treated patients
M RP-1  +
overall survival % MRP-1 + tumours 
node negative
% MRP-1 + tumours 
node positive total
0-3 years 1/1 100% 
(1/1 100%)
7/19 36.8% 
(6/14 42.5%)
8/20 40% 
(7/15 46.6%)
4-7 years 10/19 52.6% 
(6/14 42.8%)
10/20 50% 
6/15 40%
8+ years 2/19 10.5% 
(2/14 14.3%)
2/20 10% 
2/15 13.3%
M RP-1 -
% MRP-1 - tumours 
node negative
% MRP-1 - tumours 
node positive total
0-3 years 1/2 50% 
(1/2 50%)
1/4 25%
(2/9 22.2%)
2/6 33.3% 
(3/11 27.3%)
4-7 years 1/2 50% 
(1/2 50%)
3/4 75%
(7/9 77.7%)
4/6 66.6% 
(8/11 72.8%)
8+ years
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Table 3.1.15.
MRP-1 protein expression (+/-) at diagnosis in patients who received C M F therapy and 
correlation with Relapse Free Survivial.
M RP-1 +
relapse free survival % MRP-1 + tumours
node negative
% MRP-1 + tumours 
node positive total
0-3 years 3/12 25% 13/23 56.5% 16/35 45.7%
4-7 years 9/12 75% 7/23 30.4% 16/35 45.7%
8+ years 3/23 13% 3/35 8.6%
M RP-1 -
% MRP-1 - tumours 
node negative
% MRP-1 - tumours 
node positive total
0-3 years 1/9 11.1% 7/20 35% 8/29 27.5%
4-7 years 7/9 77.7% 7/20 35% 14/29 48.2%
8+ years 1/9 11.1% 6/20 30% 7/29 24.1%
Table 3.1.16.
MRP-1 protein expression (+/-) at diagnosis in patients who received C M F therapy and 
correlation with Overall Survival
M RP-1 +
overall survival % MRP-1 + tumours 
node negative
% MRP-1 + tumours 
node positive total
0-3 years 1/12 8.3% 9/22 40.9% 10/34 29.4%
4-7 years 11/12 91.6% 8/22 3.3% 19/34 55.9%
8+ years 5/22 22.7% 5/34 14.7%
M RP-1 -
% MRP-1 - tumours 
node negative
% MRP-1 - tumours 
node positive total
0-3 years 1/9 11.1% 4/20 20% 5/29 17.2%
4-7 years 7/9 77.7% 9/20 45% 16/29 55.1%
8+ years 1/9 11.1% 7/20 35% 8/29 27.5%
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In summary, results presented indicate that MRP-1 protein was expressed at 
diagnosis in 62.6% o f invasive breast tumours studied. Analysis o f these results 
suggest that MRP-1 protein expression in this group o f 204 invasive breast cancer 
patients does not appear to be associated with node status, ER status or age of 
patients at diagnosis (< 50 years/ >50 years) (Table 3.1.6.).
There did however, appear to be a weak association between MRP-1 expression and 
larger tumour size; higher MRP-1 expression levels (77.7%) were observed in larger 
tumours (>5 cm) compared to smaller tumours (< 2 cm), o f which only 51.5% were 
MRP-1 positive. Again, it appeared that MRP-1 expression may be associated 
(weakly) with higher histological grade (Tables 3.1.6. and 3.1.7). Only 8.6% of 
MRP-1 positive tumours were grade I (low grade). There was a strong association 
(statistically significant) between MRP-1 positive tumours with an 
immunohistochemical score o f 3+3 and histological grade III (high grade), this is 
illustrated in Figure 3.1.3. 73% of these MRP-1 positive tumours were grade III, this 
compares to 23% of grade II (intermediate grade) and only 3.8% grade I.
In patients who did not receive chemotherapy, it appeared that MRP-1 expression 
may possibly be associated with a shortened relapse free period in both node positive 
and node negative patients; a higher percentage o f M RP-1 positive patients relapsed 
within 1-3 years (40% of node negative patients, 40.9% of node positive patients) 
compared to MRP-1 negative patients (7% of node negative patients, 20% of node 
positive patients) (Table 3.1.9.). A similar trend was observed for overall survival 
again in both node positive and node negative patients, a higher proportion o f MRP-1 
positive patients survived for less than 3 years than MRP-1 negative patients (Table 
3.1.10).
The MRP-1 expression observed in tumours o f patients who received chemotherapy 
(61.2%) was similar to that observed in tumours from patients who did not receive 
chemotherapy (62.6%) (Table 3.1.6.). In node positive chemotherapy treated 
patients, 61% of patients with MRP-1 positive tumours relapsed and are now 
deceased, compared to only 37.5% of patients with MRP-1 negative tumours. A 
higher percentage o f M RP-1 negative patients compared to MRP-1 positive patients 
are currently disease free.
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On analysis o f actual Relapse Free Survival time (years) more MRP-1 positivity at 
diagnosis appeared to be associated with a shortened relapse free period (1-3 years) 
(51.1% o f MRP-1 positive patients relapsed within the first 3 years, only 20.5% of 
MRP-1 negative patients relapsed within this period) (Table 3.1.11) in chemotherapy 
treated node positive patients (not in node negative patients). Again a markedly 
lower percentage o f MRP-1 positive patients (15.6%) showed more than 8 years 
relapse free survival compared to 50% of MRP-1 negative patients showing 8 or 
more years relapse free survival. A similar trend was observed on analysis o f overall 
survival o f node positive patients (Table 3.1.12). 56.6% of patients with MRP-1 
negative tumours at diagnosis survived for at least 8 years, only 11.1% o f M RP-1 
positive patients survived for this length of time.
When specific chemotherapy treatments were analysed, it appeared that this 
association appeared to stronger in patients who received standard CMF 
chemotherapy compared to those patients who received adriamycin in combination 
with CMF or who received Taxol. Immunohistochemical analysis o f post treatment 
tumours from 20 chemotherapy treated patients revealed that expression o f MRP-1 
was not associated with exposure to chemotherapeutic drugs; MRP-1 expression did 
not appear to increase following treatment.
MRP-1 protein expression values appeared to correlate with MDR-1 protein 
expression in 55% of chemotherapy treated patients studied (8/20 positive for both 
markers, 3/20 negative for both markers). As this figure is very close to 50% this 
can be viewed as no correlation. MRP-1 protein expression appeared, however, to 
correlate weakly with survivin protein expression in 63.2% of patients studied (10/19 
tumours were positive for both markers, 2/19 tumours were negative for both 
markers). There did not appear to be any correlation o f MRP-1 protein with LRP or 
Bcl-2 protein expression. MRP-1 expression values in relation to cerbB-2 expression 
are presented in the following section.
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3.1.1.1. Statistical Analysis of MRP-1 expression
The association o f MRP-1 expression with patient and tumour characteristics 
(tumour size, histological grade o f tumour, ER status, node status and age o f patients 
at diagnosis) was evaluated using the Chi-squared test. Survival analysis (Overall 
survival and Relapse free survival probabilities) was performed using the Kaplan and 
Meier method; differences between survival curves were analysed by means o f  the 
log rank test. These parameters were analysed in both the chemotherapy treated 
patient group and in those patients who did not receive chemotherapy. Multivariate 
analysis using Cox’s proportional hazards models was applied to all patients, patients 
who received chemotherapy, patients who did not receive chemotherapy and node 
positive/ node negative patient groups to evaluate the predictive power o f each 
variable independently o f the others. For all tests a P  value o f below 0.05 was 
considered to be statistically significant.
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Prognostic significance of MRP-1 expression and clinical-pathological 
parameters in all invasive breast cancer patients (regardless of nodal status or 
chemotherapy treatment status)
Multivariate analysis using Cox’s proportional hazards models revealed that tumour 
size (P=.029) and nodal status (P=.026) were independent prognostic factors for 
relapse free survival and that tumour grade (P=.002) was the only clinical- 
pathological parameter which had independent prognostic value as regards overall 
survival (Table 3.1.17.).
MRP-1 expression at diagnosis (P=.094) failed marginally to be a significant 
prognostic factor for overall survival in invasive breast carcinoma patients. It was not 
shown to be an independent prognostic factor for relapse free survival in these 
patients.
Table 3.1.17.
Multivariate Cox regression analysis o f Relapse free survival and Overall Survival as a 
function o f MRP-1 expression and patient and tumour characteristics in all patients with 
invasive breast carcinomas (n=163).
Variable Relapse free survival 
/ ‘-value
Overall survival 
P-value
Tumour size .029 .289
Tumour grade .328 .002
Nodal status .026 .312
ER status .131 .135
MRP-1 .340 .094
Ill
Expression of MRP-1 expression and its correlation with clinical-pathological 
parameters in patients who did not receive chemotherapy
Chi-squared analysis did not reveal any association between MRP-1 expression at 
diagnosis in patients who did not receive chemotherapy and size o f tumour, node 
status, ER status, age o f patients at diagnosis or histological grade.
Prognostic significance of MRP-1 expression and clinicopathological parameters 
in patients who did not receive chemotherapy
Kaplan-Meier analysis did not reveal any association between absence o f MRP-1 at 
diagnosis and either Relapse free Survival time (P=0.7485) or Overall Survival times 
(P=0.7195) in node positive patients who did not receive chemotherapy (n=18) 
(Figure 3.1.4.). Similarly in node negative patients; no associations with regards to 
either Relapse free survival (P=0.1595) or Overall Survival times (P=0.5606) (n=35) 
(Figure 3.1.5.) were shown. Analysis o f node negative patients by histological grade 
also failed to show any associations between MRP-1 expression and either Relapse 
free Survival or Overall Survival times in patients with grade II tumours (n=20) 
(P=0.8602 and P=0.4997, respectively). However in patients with higher grade 
tumours i.e. grade III (n=l l )  MRP-1 expression just failed to reach significance, 
(P=0.1046 and P= 0.1046, respectively, note : these P values were identical). There 
were not enough cases o f grade II and grade III tumours node positive tumours from 
patients who had not received chemotherapy to carry out Kaplan Meier analysis.
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Figure 3.1.4.
Relapse free survival and Overall survival as a function of MRP-1 status i
node positive patients who did not receive chemotherapy (n=18)( MRP-
positive patients (13/18), MRP-1 negative patients (5/18)).
No association is observed in these patients between MRP-1 expression a 
diagnosis and either Relapse free survival (P=0.7485) or Overall free surviva 
(P=0.7195).
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Figure 3.1.5.
Relapse free survival and Overall survival as a function of MRP-1 status i 
node negative patients who did not receive chemotherapy (n=35) (—  MRP-1 
positive patients (24/35), MRP-1 negative patients (11/35)).
No association is observed in these patients between MRP-1 expression a 
diagnosis and either Relapse free survival (P=0.1595) or Overall survival
(P=0.5606).
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Multivariate analysis using Cox’s proportional hazards models showed that in 
patients that were not treated with chemotherapy (Table 3.1.18. (a)) tumour size 
(P=.049) was the only clinicopathological parameter that was an independent 
prognostic factor for relapse free survival, although nodal status (P=. 072) just failed 
marginally to show significance an independent prognostic factor. Tumour grade 
(P=.019) and ER status (P=.007) were identified as prognostic factors for overall 
survival. Again nodal status just failed marginally (P=.079) to have prognostic value. 
MRP-1 expression was not recognised as an independent prognostic for either 
relapse free survival (P=.589) or overall survival (P=.664) in patients who did not 
receive chemotherapy.
Table 3.1.18.
Multivariate Cox regression analysis o f Relapse free survival and Overall Survival as a 
function o f MRP-1 expression and patient and tumour characteristics in patients not treated 
with chemotherapy (n=77).
Variable Relapse free survival 
P-value
Overall survival 
P-value
Tumour size .049 .436
Tumour grade .591 .019
Nodal status .072 .079
ER status .484 .007
MRP-1 .589 .664
Patients stratified according to nodal status were also subjected to Cox regression 
analysis (Table 3.1.19.). In node negative patients neither MRP-1 expression or any 
other clinical-pathological feature analysed was identified to have independent 
prognostic power as regards either relapse free survival or overall survival. Likewise 
in node positive patients MRP-1, tumour grade, tumour size and ER status were not 
identified as independent prognostic factors for either relapse free survival or overall 
survival.
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Table 3.1.19.
Multivariate Cox regression analysis o f Relapse free survival and Overall Survival as a 
function o f MRP-1 expression and patient and tumour characteristics (a) node positive 
patients not treated with chemotherapy and (b) node negative patients who did not receive 
chemotherapy.
(a) node positive patients not treated  with chemotherapy (n=17)
Variable Relapse free survival 
P-value
Overall survival 
P-value
Tumour size .981 .994
Tumour grade .981 .994
ER status .983 .983
MRP-1 .885 .984
(b) node negative patients not treated  with chemotherapy (n=33)
Variable Relapse free survival 
P-value
Overall survival 
P-value
Tumour size .117 .747
Tumour grade .895 .607
ER status .800 .584
MRP-1 .178 .612
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Expression of MRP-1 protein and its correlation with clinical-pathological 
parameters in patients treated with chemotherapy
Using the Chi-squared method a significant association was observed between MRP- 
1 expression and high histological grade in chemotherapy treated patients (P=.035), 
MRP-1 expression was not significantly associated with any of the other 
clinicopathological parameters studied.
Prognostic significance of MRP-1 expression and clinical-pathological 
parameters in patients treated with chemotherapy
Kaplan-Meier analysis demonstrated a significant association between MRP-1 
expression at diagnosis Overall Survival in node positive chemotherapy treated 
patients (n=76). Patients with MRP-1 negative tumours at diagnosis showed 
significantly increased Overall Survival times (P=0.0625) compared to those patients 
with MRP-1 positive tumours (Figure 3.1.4.). No association between MRP-1 
expression and Relapse free Survival (P=0.2050) was observed in these patients 
(Figure 3.1.4.). However in node positive patients with grade III tumours (n=41), a 
significant association was found between MRP-1 expression and both Relapse free 
survival (P=0.0066) and Overall survival (P=0.0111) (Figure 3.1.8.). No association 
with either Relapse free survival (P=0.3214) or Overall survival (P=0.8501) were 
found in patients with grade II tumours (n=19) (Figure 3.1.7.).
In node negative chemotherapy treated patients Kaplan-Meier analysis did not show 
any association between absence of MRP-1 expression at diagnosis and increased 
Relapse free survival times (P=0.8126) or increased Overall survival times 
(P=0.5307) in these patients (n=31). There were not sufficient number o f cases of 
grade II/ grade II node negative chemotherapy tumours to carry out statistical 
analysis for each histological grade.
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Figure 3.1.6.
Relapse free survival and Overall survival as a function of MRP-1 status i 
node positive chemotherapy treated patients (n=76) (—  MRP-1 positive 
patients (51/76), MRP-1 negative patients (25/76).
No association is observed between MRP-1 expression at diagnosis in these 
patients and Relapse free survival (P=0.2050). An association is observed; 
which marginally fails to reach statistical significance, with Overall survival 
(P=0.0625). Patients with MRP-1 negative tumours at diagnosis show increased 
Overall survival compared to those patients with MRP-1 positive tumours.
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Figure 3.1.7.
Relapse free survival and Overall free survival as a function of MRP-1 status in 
chemotherapy treated node positive patients with grade II tumours
(intermediate histological grade) (n=22) ( MRP-1 positive patients (n=17/22)
, ___ MRP-1 negative patients (5/22).
No association is observed between MRP-1 expression at diagnosis in these patients 
with grade II tumours and either Relapse free survival (P=0.3214) or Overall 
Survival (P=0.8501).
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Figure 3.1.8.
Relapse free survival and Overall survival as a function of MRP-1 status i 
chemotherapy treated node positive patients with grade III tumours (high
histological grade) (n=41) (—  MRP-1 positive patients (28/41), MRP-1
negative patients (13/41).
A highly significant association is observed in these patients between MRP- 
expression at diagnosis and both Relapse free survival (P=0.0066) and Overall 
survival (P=0.0111). Patients with grade III tumours that are MRP-1 negative at 
diagnosis show increased Relapse free survival and Overall survival time 
compared to those patients with grade III tumours that are MRP-1 positive at 
diagnosis.
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Figure 3.1.9.
Relapse free survival and Overall survival as a function of MRP-1 status in node 
negative patients who received chemotherapy (n=31) —  MRP-1 positive 
patients (19/31), MRP-1 negative patients (12/31).
No association is observed in these patients between MRP-1 expression at diagnosis 
and either Relapse free survival (P=0.8126) or Overall survival (P=0.5307).
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Multivariate analysis using Cox’s proportional hazards models showed that in 
chemotherapy treated patients (Table 3.1.20), MRP-1 expression at diagnosis was an 
independent prognostic factor for overall survival (P=.048) but not for relapse free 
survival (P=.862). Nodal status (P=.016) ER status (P=.010) were independent 
prognostic factors for relapse free survival. ER status (P=.013) was an independent 
prognostic factor for overall survival; nodal status (P=.088) and histological grade 
(P=.083) failed marginally to show significance as independent prognostic factors.
Table 3.1.20.
Multivariate Cox regression analysis o f Relapse free survival and Overall Survival as a 
function o f MRP-1 expression and patient and tumour characteristics in patients treated 
with chemotherapy.
Variable Relapse free survival 
P-value
Overall survival 
P-value
Tumour size .336 .447
Tumour grade .451 .083
Nodal status .016 .088
ER status .010 .013
MRP-1 .862 .048
Patients stratified according to nodal status were also subjected to Cox regression 
analysis (Table 3.1.21.) In node negative chemotherapy patients MRP-1 was not 
identified as an independent prognostic factor for either relapse free survival 
(P=.670) or overall survival (P=.160). ER status was the only clinicopathological 
parameter that showed independent prognostic significance in these patients, it was 
identified as an independent prognostic factor for overall survival (P=.037). None of 
the other clinicopathological factors showed independent prognostic value regarding 
either relapse free survival or overall survival.
In node positive chemotherapy treated patients, MRP-1 expression at diagnosis was 
identified as a highly significant independent prognostic factor for overall survival
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(P=.002), it failed to show independent prognostic significance as regards relapse 
free survival (P=.213). ER status was an independent prognostic factor for relapse 
free survival (P=.008) and overall survival (P-.006). Histological grade was also 
identified as a highly significant independent prognostic factor for overall survival 
(P=.002), but it marginally failed to achieve significance for relapse free survival 
(P=.071).
Table 3.1.21.
Multivariate Cox regression analysis o f Relapse free survival and Overall Survival as a 
function o f MRP-1 expression and patient and tumour characteristics in (a) node positive 
patients treated with chemotherapy and (b) node negative patients treated with 
chemotherapy
(a) node positive patients treated with chemotherapy
Variable Relapse free survival 
P-value
Overall survival 
P-value
Tumour size .135 .559
Tumour grade .071 .002
ER status .008 .006
MRP-1 .213 .002
(b) node negative patients treated with chemotherapy
Variable Relapse free survival 
P-value
Overall survival 
P-value
Tumour size .382 .134
Tumour grade .623 .688
ER status .240 .037
MRP-1 .670 .160
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3.1.2. cerbB-2 protein expression
cerbB-2 protein expression was studied in pre  treatment tumours from 45 patients 
with invasive breast cancer. 40 of these patients received chemotherapy following 
surgery . cerbB-2 expression was studied in 17 post treatment tumours from this 
group o f patients. Immunohistochemical analysis results are presented in Table 3.1.4. 
Representative tumours stained with the cerbB-2 specific MAb, CB 11, are presented 
in Figures 3.1.10. and 3.1.11.
cerbB-2 protein expression in relation to known clinico-pathological factors i.e. node 
status, ER status, tumour size, and histological grade is presented in Table 3.1.22. 
Correlation of cerbB-2 expression with relapse free survival and overall survival in 
chemotherapy treated patients is presented in Tables 3.1.23 -  3.1.24. Correlation 
between the co-expression o f  cerbB-2 and MRP-1 and disease status o f patients, 
relapse free survival and overall survival times is presented in Tables 3.1.25. -  
3.1.27.
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cFigure 3.1.10. Immunohistochemical analysis of cerbB-2 protein levels (I)
(a) Infiltrating ductal tum our cells from a patient who relapsed and subsequently died 
(refer to patient no. 19, Table 3.1.4.), stained w ith cerbB-2, clone CB11 M Ab 
(Novacastra), intense membranous positivity can be observed in tumour cells at pre 
treatment stage (original magnification 20x). (b) Following treatment there was no 
change in cerbB-2 status, positive staining can be observed in infiltrating tumour 
cells (original magnification lOx). (c) DC1S tumour cells (pre treatment) (refer to 
patient no. 1, Table 3.1.4.) showing intense cerbB-2 m em branous positive staining, 
(original magnification 20x), again this patient relapsed and is now deceased. 
(StrepABC/ HRP method using DAB as chromogen, sections w ere counterstained 
w ith haematoxylin).
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(a) High grade infiltrating carcinoma (refer to patient no. 30, Table 3.1.4.) (pre 
treatment) stained w ith  cerbB-2 M Ab, clone CB11, no cerbB-2 positivity can be 
observed in infiltrating tum our cells (original m agnification 40x). This patient is 
currently alive and has not relapsed, (b) Ductal carcinoma cells (pre treatment) from 
another patient who is currently alive and well (refer to patient no. 34, Table 3.1.4), 
stained w ith cerbB-2 M Ab, clone CB11, again no positivity can be observed in 
tum our cells (original m agnification 40x). (StrepABC/ HRP method using DAB as 
chromogen all sections were counterstained w ith haematoxylin).
Figure 3.1.11. Immunohistochemical analysis of cerbB-2 protein levels (II)
Table 3.1.22.
cerbB-2 protein  expression in  invasive breast tum ours and  association with node status, 
E R  status, tum our size and histological grade
Immunohistochemical analysis of cerbB-2 expression (n/%)
chemotherapy treated 1 1/40 27.5%
patients n -40
non chemotherapy 4/5 80%
treated patients n=5
Node status
node positive 8/34 23.5%
node negative 1/6 16.6%
ER status
ER + 2/12 16.6%
ER- 4/15 26.6%
Tumour size
<2 cm 1/11 9.1%
2-5 cm 3/4 25%
>5cm 3/9 30%
Histological grade
Grade 1 3/3 100%
Grade 11 1/1 100%
Grade III 6/22 27.3%
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Table 3.1.23.
cerbB-2 protein expression (+/-) at diagnosis and correlation with Relapse Free 
Survival in chemotherapy treated patients 
cerbB-2 +
relapse free survival % cerbB-2 + tumours 
node negative
% cerhB-2 + tumours 
node positive total
0-3 years 1/3 33.3% 7/11 63.4% 8/14 57.1%
4-7 years 2/3 66.6% 4/11 36.3% 6/14 42.9%
8+ years 0/11 0% 0/14 0%
cerbB-2 -
relapse free survival % cerbB-2 - tumours 
node negative
% cerbB-2 - tumours 
node positive total
0-3 years 2/3 66.6% 6/23 26% 8/26 30.8%
4-7 years 1/3 33.3% 7/23 30.4% 8/26 30.8%
8+ years 10/23 43.4% 10/26 38.5%
Table 3.1.24.
cerbB-2 protein expression (+/-) at diagnosis and correlation with Overall Survival in 
chemotherapy treated patients
cerbB-2 +
overall survival % cerbB-2 + tumours 
node negative
% cerbB-2 + tumours 
node positive total
0-3 years 1/3 33.3% 6/10 60% 7/13 53.8%
4-7 years 2/3 66.6% 4/10 40% 6/13 46.2%
8+ years 0/3 0% 0/10 0% 0/13 0%
cerbB-2 -
% cerbB-2 - tumours 
node negative
% cerbB-2 - tumours 
node positive total
0-3 years 1/3 33.3% 4/26 15.4% 5/29 17.2%
4-7 years 2/3 66.6% 10/26 38.5% 12/29 41.4%
8+ years 12/26 46.2% 12/29 41.4%
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Table 3.1.25.
cerbB-2 / MRP-1 protein expression in chem otherapy treated  tumours and correlation 
with disease status (n=40).
MRP-1 +/cerbB-2 - MRP-1 - /cerbB-2 + MRP-1 +/ cerbB-2 + MRP-1 -/ cerbB-2 -
dod 8/21 (38%) 2/21 (9.5%) 7/21 (33.3%) 4/21 (19.4%)
a&w 5/17 (29.4%) 1/17 (5.9%) 0/17 (0%) 11/17 (64.7%)
rec “ 1/3 (33.3%) 2/3 (66.6%)
Table 3.1.26.
cerbB-2 and MRP-1 protein expression at diagnosis and correlation with R elapse Free 
Survival in chem otherapy treated patien ts
MRP-1 +/cerbB-2 - MRP-1 - /cerbB-2 + MRP-1 +/ cerbB-2 + MRP-1 -/ cerbB-2 -
0-3 years 5/14 35.7% 2/3 66.6% 6/8 75% 4/15 26.7%
4-7 years 5/14 35.7% 1/3 33.3% 2/8 25% 4/15 26.7%
8+ years 4/14 28.6% 7/15 46.7%
T ab le  3.1.27.
cerbB -2 an d  M RP-1 p ro te in  expression an d  co rre la tion  w ith  Overall Survival in 
chemotherapy treated pa tien ts
MRP-1 +/cerbB-2 - MRP-1 - /cerbB-2 + MRP-1 +/ cerbB-2 + MRP-1 -/ cerbB-2 -
0-3 years 5/14 35.7% 2/3 66.6% 5/8 62.5% 2/15 13.3%
4-7 years 3/14 21.4% 1/3 33.3% 3/8 37.5% 6/15 40%
8+ years 5/14 35.7% 7/15 46.7%
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In summary, results presented indicate that cerbB-2 protein was expressed in 27% of 
invasive breast tumours at diagnosis from chemotherapy treated patients. cerbB-2 
was expressed 80% (4/5) o f tumours from patients who did not receive 
chemotherapy (Table 3.1.22.). Most o f this observed cerb-B-2 positive staining was 
membranous in a nature, although cytoplasmic positivity was observed in some 
tumours. Membranous cerbB-2 positivity is generally considered to be specific for 
HER-2/ neu overexpression and has been shown to correlate with gene amplification. 
In contrast the significance o f cytoplasmic positive staining is still controversial. 
Only tumours which showed membranous positivity (a small number of these did 
have some cytoplasmic reactivity) were considered positive. cerbB-2 expression did 
not appear to be associated with node status, ER status or tumour size (Table 3.1.22). 
It appears from these results that grade III tumours studied exhibited lower 
expression levels o f cerbB-2 protein.
On analysis o f Relapse Free Survival times, results suggest that cerbB-2 expression 
at diagnosis is strongly associated with a shortened relapse free period in node 
positive patients (Table 3.1.23). A higher percentage o f cerbB-2 + tumours relapsed 
within 3 years compared to cerbB-2 -  tumours, 43.4% o f cerB-2 -  tumours had a 
relapse free period o f at least 8 years; all o f the cerbB-2 + tumours studied relapsed 
within 8 year. A similar trend was observed on analysis o f Overall Survival in node 
positive patients. It appeared that cerbB-2 expression was strongly associated with a 
shortened overall survival time in these patients. 60% o f cerbB-2 + patients survived 
less than 3 years following diagnosis compared to 15.4% of cerbB-2 -  patients 
(Table 3.1.24).
When cerbB-2 expression was correlated with expression o f MRP-1, results 
indicated that 75% o f patients with MRP-1 + / cerbB-2 + tumours relapsed within 3 
years, compared to only 26.7% of patients with MRP-1 -/ cerbB-2 -  tumours (Table 
3.1.26.). On analysis of overall survival, again co-expression o f these two markers 
was associated with a shortened overall survival (Table 3.1.27.), however in this case 
MRP-1 -/ cerbB-2 + tumours exhibited similar overall survival times. Tumours 
which were negative for both markers again showed an increased survival time. 
These results suggest that co-expression o f these 2 markers may be more strongly
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associated with a shortened relapse free survival and possibly with a shortened 
overall suivival in node positive patients.
Expression o f cerbB2 did not appear to correlate with any of the other markers 
studied. Post treatment tumours from 17 chemotherapy treated patients were also 
investigated. cerbB-2 expression did not appear to increase following treatment with 
chemotherapeutic drugs, a slight increase in expression was observed in 2 patients.
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3.1.3 MDR-1 Pgp expression
Pgp expression was studied in pre  treatment tumours from 20 chemotherapy treated 
patients with invasive breast cancer. Pgp expression was studied in 17 post treatment 
tumours from this group o f patients. Immunohistochemical analysis results are 
presented in Table 3.1.4. Representative tumours stained with the MDR-1 specific 
MAb, 6/1C, are presented in Figures 3.1.12.
MDR-1 expression in relation to known clinico-pathological factors i.e. node status, 
ER status, tumour size, and histological grade is presented in Tables 3.1.26. 
Correlation o f MDR-1 Pgp expression (i.e. MDR-1 positive/ MDR-1 negative 
tumours) with relapse free survival and overall survival in chemotherapy treated 
patients is presented in Tables 3.1.27 -  3.1.28.
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(a) Pre treatment (original magnification 20x) and (b) post treatment infiltrating 
tumour cells (original magnification 20x) from a ductal carcinoma patient (refer to 
patient no. 17, Table 3.1.4.) stained with BRI anti MDR-1, 6/1C. Intense MDR-1 
positivity can be observed in both the pre  and post tumour samples, the level o f Pgp 
positivity was not altered following treatment, (c) DCIS tumour, comedo type 
(centre o f tumour has undergone necrosis and does not show any MDR-1 reactivity) 
(refer to patient no. 2, Table 3.1.4.) (pre treatment) showing intense MDR-1 positive 
staining, positivity can also be observed in surrounding infiltrating tumour cells. 
Both o f these patients relapsed and are now deceased (original magnification 20x). 
(StrepABC/ HRP method using DAB as chromogen, sections were counterstained 
with haematoxylin).
Figure 3.1.12. Immunohistochemical analysis of Pgp expression
Table 3.1.26.
MDR-1 Pgp expression in invasive breast tumours and association with node status, ER  
status, tumour size and histological grade.
Immunohistochemical analysis o f  MDR-1 (n/%)
n =  20
chemotherapy treated 
patients n=20
14/20 70%
Node status
node positive 13/19 68.4%
node negative 1/1 100%
ER status
ER + 6/7 85.7%
ER- 2/4 50%
Tumour size
<2 cm 7/7 100%
2-5 cm 2/6 33.3%
>5cm 4/6 66.6%
Histological grade
Grade I -
Grade II -
Grade III 7/10 70%
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Table 3.1.27.
MDR-1 Pgp expression (+/-) at diagnosis and correlation with relapse free survival in 
chemotherapy treated patients
M DR-1 +
relapse free survival % MDR-1 + tumours 
node negative
% MDR-1 + tumours 
node positive total
0-3 years
8/13 61.5% 8/16 50%
4-7 years 1/13 7.6% 1/16 6.2%
8+ years 3/3 100% 4/13 30.5% 7/16 43.8%
MDR-1 -
% MDR-1 - tumours 
node negative
% MDR-1 - tumours 
node positive total
0-3 years 1/3 33.3% 1/6 16.66%
4-7 years
8+ years 3/3 100% 2/3 66.6% 5/6 83.3%
Table 3.1.28.
MDR-1 Pgp expression (+/-) at diagnosis and correlation with overall survival in 
chemotherapy treated patients
M D R-1 +
relapse free survival % MDR-1 + tumours 
node negative
% MDR-1 + tumours 
node positive total
0-3 years 5/13 38.5% 5/16 31.3%
4-7 years 4/13 30.7% 4/16 25%
8+ years 3/3 100% 4/13 30.7% 7/16 43.8%
MDR-1 -
% MDR-1 - tumours 
node negative
% MDR-1 - tumours 
node positive total
0-3 years 1/5 20% 1/5 20%
4-7 years 2/5 40% 2/5 40%
8+ years 2/5 40% 2/5 40%
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In summary, MDR-1 was expressed in 70% of tumours at diagnosis in chemotherapy 
treated patients. Results presented indicate that expression o f MDR-1 Pgp does not 
appear to be associated with node status or ER status (very weak association with ER 
+). No conclusion can be drawn as regards association with histological grade as 
MDR-1 Pgp expression was only studied in grade III tumours o f which 70% were 
MDR-1 positive. Again as regards association with tumour size a definite conclusion 
cannot be reached due to small sample size, the results however do suggest that 
MDR-1 appears to be associated more strongly with tumours that are less than 2 cm.
77.7% of pre chemotherapy treatment tumours from patients currently alive (a) who 
have not relapsed were MDR-1 positive, 55.5% of those patients who relapsed and 
are now deceased (d) were MDR-1 positive. Looking at the actual correlation of 
MDR-1 expression in node positive patients with relapse free survival suggests that 
MDR-1 + node positive patients are more likely to relapse within 3 years compared 
to MDR-1 -  patients (Table 3.1.27.). As regards overall survival a similar trend was 
observed, but the association was weaker (Table 3.1.28.). However the numbers of 
patients studied were very small, thus no statistical analysis could be carried out in 
order to verify these results. No conclusion as regards node negative patients can be 
made as there were only 3 patients studied for MDR-1 Pgp expression.
Differences between the 2 Pgp MAbs used in this study were noted both in the 
intensity o f Pgp positive staining observed and in the number o f tumour cells stained 
within individual sections.
4 pre treatment tumours which were MDR-1 negative showed MDR-1 Pgp positivity 
following chemotherapy (all o f these 4 patients relapsed within 3 years). There 
appeared to be no increase in staining in those post treatment that were MDR-1 
positive at diagnosis. It is not possible to conclude that MDR-1 Pgp expression is 
associated with chemotherapy treatment in these patients.
As previously outlined, MDR-1 protein expression appeared to correlate with MRP-1 
protein expression in 55% of chemotherapy treated patients, however this can be 
taken as no correlation. Survivin protein levels appear to correlate with MDR-1 
values in 15/21 (71.4%) of chemotherapy treated patients (2/21 negative for both
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markers, 19/21 positive for both markers). MDR-1 expression did not appear to 
correlate with cerbB-2, Bcl-2 or LRP protein.
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3.1.4. LRP protein expression
LRP protein expression was studied in pre  treatment tumours from 14 patients with 
invasive breast cancer (12 chemotherapy treated). Immunohistochemical results are 
presented in Table 3.1.4.
4 LRP negative pre  treatment tumours showed some degree o f LRP positivity 
following chemotherapy (1 patient alive, 3 patients deceased). Again as sample 
numbers are small it is not possible to conclude that LRP expression is associated 
with exposure to chemotherapeutic drugs. LRP expression values did not appear to 
correlate with expression o f any other o f the markers studied.
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3.1.5. BCL-2 protein expression
BCL-2 expression was studied in pre  treatment tumours from 15 chemotherapy 
treated patients with invasive breast cancer. Immunohistochemical analysis results 
are presented in Table 3.1.4. Representative tumours stained with a BCL-2 specific 
MAb are presented in Figures 3.1.13.
Due to small sample size it was not possible to analyse in detail BCL-2 protein 
expression in relation to known clinico-pathological factors. The association o f BCL- 
2 + tumours and BCL-2 - tumours with relapse free survival and overall survival in 
chemotherapy treated patients is presented in Table 3.1.29.
139
•TV . ' ■ I ?
■
"•i k-- % '  
y  ^
m <c>
t§
1>
»sstei. ^
’  : 1S -  V
_ v  *» i js . v ¡*J *.
\ \ «f A  . c J i .  n
.> *
S  it-V- •. . f f l  ■*>
\ \
\
yr i  ^J
°
*  • t
1» *3 Tl *• •iJM
\
\  - ■ ? 
V ; . v  V  -  ■“
* V  v | *
a
Figure 3.1.13. Immunohistochemical analysis of Bcl-2 protein levels
(a) Bcl-2 positive tumour (pre treatment) stained with Bcl-2 MAb, clone 124 (Dako) 
showing intense Bcl-2 positive staining in DCIS component and in surrounding 
infiltrating tumour cells (original magnification lOx). Bcl-2 status was not altered 
following treatment, (b) Post treatment tumour from same patient showing Bcl-2 
positivity in infiltrating tumour cells (original magnification lOx). This patient 
showed a relatively long relapse free period (5 years) (refer to patient no. 17, Table
3.1.4.). (StrepABC/ HRP method using DAB as substrate, sections were 
counterstained with haematoxylin).
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Table 3.1.29.
Association of BCL-2 +/ BCL-2 -  tum ours with relapse free survival and overall survival 
in chemotherapy treated patients
relapse free survival (years) B C L -2  + B C L -2  -
0 -3 7 /9  7 7 .7 % 3 /3  10 0 %
4 -7 2 /9  2 2 .2 %
8 +
overall survival (years) B C L -2  + B C L - 2 -
0 -3 7 /9  7 7 .7 % 3 /3  100%
4 -7 2 /9  2 2 .2 %
8 +
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Bcl-2 protein was expressed in 61.5% of chemotherapy treated tumours at diagnosis. 
There did not appear to be any increase in BCL-2 expression following treatment, 
suggesting that BCL-2 expression is not associated with exposure to 
chemotherapeutic drugs.
Results suggest that there appeared to be a weak association between BCL-2 
negative tumours and a shortened relapse free period and overall survival times 
(Table 3.1.29.) compared to BCL-1 positive tumours; a higher percentage o f BCL-2 
-  patients relapsed (and died) within 3 years compared to BCL-2 + patients.
Bcl-2 and survivin protein expression values appeared to correlate in 50% of 
chemotherapy treated patients. There did not appear to be a correlation between 
BCL-2 and any o f the other markers studied.
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3.1.1.6. Survivin protein expression
Survivin protein expression was studied in pre treatment tumours from 24 patients 
with invasive breast cancer, 22 o f these patients received chemotherapy. 
Immunohistochemical results are presented in Table 3.1.4. Representative tumours 
stained with survivin specific MAb are presented in Figures 3.1.14.
Due to small sample size it was not possible to analyse in detail survivin protein 
expression in relation to known clinico-pathological factors. The association of 
survivin + tumours and survivin - tumours with relapse free survival and overall 
survival in chemotherapy treated patients is presented in Table 3.1.30.
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(a) Infiltrating tumour cells from a ductal carcinoma (pre treatment) (refer to patient 
no. 16, Table 3.1.4.) showing intense survivin positive cytoplasmic staining with 
supernatant 1C5 (original magnification 40x). This patient relapsed and is now 
deceased, (b) DCIS tumour cells (pre treatment) from a patient who did not relapse 
and is currently alive and well (refer to patient no. 31, Table 3.1.4.), showing 
survivin positivity also (original magnification 20x) (StrepABC/ HRP method using 
DAB as substrate, sections were counterstained with haematoxylin).
Figure 3.1.14. Immunohistochemical analysis of survivin protein levels
Table 3.1.30.
Association of survivin +/ survivin -  tum ours with relapse free survival and overall 
survival in chemotherapy treated patients
node negative patients/ node positive patients
relapse free survival (years) survivin + survivin -
0-3 9/19 47.4% 1/3 33.3%
4-7 1/19 5.2%
8+ 9/19 47.4% 2/3 66.6%
node negative patients/ node positive patients
overall survival (years) s u r v iv in  + s u r v iv in -
0-3 7/21 33.3% 1/7 14.3%
4-7 4/21 19% 4/7 57.1%
8+ 8/21 38% 2/7 28.5%
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In summary, Survivin protein was observed in 86.3% of chemotherapy treated 
patients at diagnosis. An increase in survivin positive staining was only observed in 1 
patient following chemotherapy treatment indicating that survivin expression is not 
associated with exposure to chemotherapeutic drugs.
As survivin protein was observed in the majority of tumours studied it was not 
possible to correlate survivin expression with node status, ER status, tumour size or 
histological grade.
On initial analysis, results suggested that expression o f survivin protein at diagnosis 
(combined node positive and node negative patients) may be possibly associated with 
shortened relapse free survival (i.e. 1-3 years); 47.3% of patients with survivin 
positive tumours relapsed within 3 years compared to 33.3% of patients w ith survivin 
negative tumours). However on analysis o f overall survival times, it appeared 38% 
of patients with survivin positive tumours survived for 8 or more years, compared to 
only 28.5% of survivin negative tumours (Table 3.1.30.) This observation suggested 
that survivin expression at diagnosis is actually associated with a good prognosis i.e. 
longer overall survival in chemotherapy treated patients. The numbers studied were 
small, therefore it was not possible to carry out statistical analysis. Survivin 
positivity was also observed at diagnosis, in 2 Tamoxifen treated patients; both o f 
these patients relapsed within 1 year following treatment.
As previously outlined Survivin protein expression appeared to correlate with MRP- 
1 and MDR-1 protein expression chemotherapy treated patients. Bcl-2 and survivin 
protein expression values appeared to correlate in 50% of chemotherapy treated 
patients. cerbB-2 and survivin protein expression values appeared to correlate in 
36.6% of chemotherapy treated patients studied. There did not appear to be any 
correlation with LRP protein expression observed.
There appeared to be considerable heterogeneity between the intensity o f the staining 
observed and in the number o f tumour cells stained within individual tumours. 
Nuclear survivin positivity was observed in a number o f tumour samples.
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3.1.7. Conclusion
Results from an investigation of the possible prognostic/predictive role o f a panel of 
MDR associated markers in invasive breast cancers have been presented in sections
3.1.1.-3.1.6.
In a large series of invasive breast carcinomas (n=204), larger tumour size and 
positive lymph node status were identified as independent prognostic factors for 
decreased relapse free survival. Higher histological grade was identified as a highly 
significant independent prognostic factor for decreased overall survival in these 
patients. MRP-1 expression at diagnosis just failed to show independent prognostic 
significance for overall survival.
A highly significant association was shown between MRP-1 expression and both 
Overall survival and Relapse free survival in node positive chemotherapy treated 
patients with grade III tumours in patients with grade III tumours. Multivariate 
analysis revealed that MRP-1 expression was an independent prognostic factor for 
overall survival but not relapse free survival in node positive patients treated with 
chemotherapy.
No association was shown between MRP-1 expression and either relapse free 
survival or overall survival in node negative chemotherapy treated patients.
ER status was shown to be an independent prognostic factor for both relapse free 
survival and  overall survival in node positive chemotherapy treated patients, and for 
overall survival only in node negative patients. Histological grade (higher grade 
associated with a worse outcome) and nodal status (lymph node positive status 
associated with a worse out come just failed to show significance as independent 
prognostic factors for overall survival in node positive patients chemotherapy treated 
patients. Small tumour size was not identified as an independent prognostic factor for 
relapse free survival or overall survival.
MRP-1 expression at diagnosis was significantly associated with higher histological 
grade in chemotherapy treated patients, no association with other clinicopathological
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parameters was found. In patients who did not receive chemotherapy, MRP-1 was 
not associated with any of the clinicopathological parameters studied.
In patients who did not receive chemotherapy; no association was shown between 
MRP-1 expression at diagnosis and either Relapse free survival or Overall survival, 
regardless o f the node status of the patients. However in node negative patients with 
grade III tumours, it appeared that there may be a trend towards absence of M RP-1 
expression at diagnosis being associated with decreased relapse free survival and 
overall in these patients. None of the clinical-pathological features studied were 
shown to have any independent prognostic value for either overall survival or relapse 
free survival in these patients.
Preliminary analysis o f results of a smaller group o f patients studied for cerbB-2 
expression (n=46), indicated that cerbB-2 positivity at diagnosis appeared to be 
associated with decreased relapse free survival and overall survival in node positive 
patients treated with CMF based chemotherapy. Results also suggest that perhaps the 
co-expression of MRP-1 and cerbB-2 protein may possibly be more strongly 
associated with shortened Relapse free survival and possibly shortened Overall 
Survival in node positive patients.
MDR-1 Pgp expression did not appear to be associated with any clinicopathological 
features in 46 patients studied. Preliminary analysis did suggest, however, that there 
is an association between MRP-1 Pgp expression at diagnosis and shortened relapse 
free survival and possibly overall survival in chemotherapy treated patients.
Bcl-2 expression at diagnosis appeared to be associated with increased relapse free 
survival time in chemotherapy treated patients. Survivin protein expression at 
diagnosis also appeared to be associated with a better outcome, tumours that were 
survivin positive at diagnosis appeared to show longer overall survival compared to 
survivin negative tumours. Nuclear survivin positivity, the relevance o f which at this 
point could not be explained, was observed in a number o f tumours samples.
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MDR-3 expression did not appear to correlate with known patient and tumour 
characteristics; results suggested that expression o f this protein did not appear to 
have any prognostic value as regards clinical outcome of patients.
Expression o f any of the MDR associated proteins studied did not appear to be 
associated exposure to chemotherapeutic drugs. In addition there not appear to be 
any correlation between expression o f any of these individual proteins and any other 
of the proteins studied.
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3.2. G eneration and  characterisa tion  of an M DR-3 specific M Ab using a
com bined in vitro! in vivo im m unisation system
3.2.1. B ackground
At the time of commencement of this thesis no MDR-3 specific MAbs were 
commercially available. The majority o f haematological and tissue studies that had been 
performed previously had focused on MDR-3 gene expression studies, MDR-3 encoded 
Pgp levels have not been investigated extensively. Excluding a small number o f studies 
(discussed in section 1.7.5.), for the most part most part detection o f the MDR-3 
encoded gene product had relied on comparison studies with the C219 monoclonal 
antibody which recognises both the MDR-1 and the MDR-3/ mdr-2 encoded gene 
products (Georges etal., 1990) and MDR-1 specific monoclonal antibodies such as JSB- 
1 and MRK16.
In order to generate a MAb that would specifically recognise the MDR-3 encoded gene 
product, a suitable immunisation peptide was chosen (section 2.6.2. and 2.6.3.). The 
entire amino acid sequence of the MDR-3 encoded Pgp (deduced from the known cDNA 
sequence (Van Der Bliek et al. 1988)) was obtained from the EMBL Swiss-Prot protein 
sequence data bank above using the NETSERV program. From this deduced sequence, 
using the Mail FASTA programme, a 12 amino acid peptide was chosen which showed 
insignificant homology with the MDR-1 encoded Pgp. This peptide corresponded to the 
intracellularly located amino acids 13-24 (RPTSAEGDFELG) of MDR-3 encoded Pgp, 
which resides in the N-terminal part o f the protein. FASTA similarity searches indicated 
that this peptide did not show homology with any other significant proteins e.g. other 
MDR proteins.
3.2.2. Fusion results
Following fusion using a combined in vitro/ in vivo immunisation regime employing an 
in vitro immunisation kit from Immune Systems, Bristol, UK (section 2.6.4.) a total of 
384 hybridoma supernatants (100% fusion) were screened by ELISA . Supernatants 
from 48 clones which were positive for the peptide/ BSA complex alone were chosen for
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further expansion. 11 of these hybridomas were studied in detail, based on reactivity 
patterns with control cell lines. Supernatant 6/1G was chosen for further study and was 
cloned by limiting dilution prior to further characterisation (section 2.6.9.).
3.2.3. Isotype Analysis o f antibody 6/1G
Isotype was determined to be subclass IgM (section 2.6.10.) ( Isostrip, Roche 
Diagnostics GmbH, 1493027).
3.2.4. W estern B lotting studies o f control cell lines
The MDR-3 transgenic murine ear fibroblast lines , VOl-VOl and VIM #1 which were 
used as positive control cell lines, were derived from primary MDR-3 transgenic FVB 
mice expressing an MDR-3 minigene (Smith et al., 1994). The control (parental) cell 
line, FVB#C was similarly made from wild type mice (Table 2.2) (Smith et al., 1994). 
(These cell lines were obtained courtesy o f Prof. P. Borst, The Netherlands). 
On Western blotting of cell lysates o f Vim # 1 cells, antibody 6/1G reacted with a band 
at 170kDa. This band was only very faintly detected on preparations o f parental FVB # 
c cells. A 170 kDa band was also detected on MDR-3 transgenic VOl-VOl cells (data not 
shown). A faint band was detected on cell lysates of the sensitive DLKP cell line and 
its adriamycin resistant variant, DLKPA. In contrast a distinct band on cell lysate 
preparations from DLKP-A cells which overexpress MDR-1 encoded Pgp can be seen 
with MAb 6/1C, which is specific for the MDR-1 gene product (Figure 3.2.1).
Previous results show lack o f positivity o f the MDR-3 transgenic cell lines, VOl-V O l 
and Vim # 1 with MAb, 6/1C (specific for the MDR-1 encoded gene product) (Moran et 
al., 1997). Taken together these results indicate that 6/1G detects the MDR-3, but not the 
MDR-1 encoded protein.
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Figure 3.2.1. Western blot analysis of antibody 6/1G and the MDR-1 specific 
MAb 6/ 1C on the MDR-3 transgenic cell line Vim # 1, its parental cell line FVB 
# c, the multidrug resistant MDR-1 over expressing DLKPA cell line and its 
sensitive counterpart DLKP.
Immunoblot o f crude cell lysates o f  the above cell lines which were separated on 
7.5% SDS PAGE and probed with antibody 6/ 1G. Antibody 6/1G reacts with a band 
at 170kDa on Vim # 1 cells, a very faint band is detected on FVB # c cells. A  faint 
band can also be observed on both the sensitive DLKP cell line and its adriamycin 
variant DLKPA. In contrast DLKPA cells which overexpress MDR-1 encoded Pgp 
react with a distinct band at 170 kDa when probed with the MDR-1 specific MAb 
6/1C, no band is detected on the sensitive DLKP cell line.
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3.2.5. Immunofluoresence studies on live cells
Immunofluoresence studies on live cells (section 2.7.2. ) revealed no detectable staining 
on the MDR-3 transgenic cell line, Vim # 1 or its parental FVB # c cell line indicating 
that the epitope recognised by antibody 6/1G was not expressed on the cell surface of 
these cells .
3.2.6. Im m unocytochem ical studies o f control cell lines
Immunocytochemical studies on cytospins of both Vim # 1 and VOl-VOl MDR-3 
transgenic cell lines showed consistent cytoplasmic and plasma membranous staining 
with antibody 6/1G ; negligible staining was observed on parental FVB # c cells (Figure 
3.2.2). The C219 MAb which detects both the MDR-1 and the MDR-3 gene products, 
gave a similar pattern o f reactivity on VIM # 1 and VOl-VOl cells (Figure 3.2.3).
Immunocytochemical analysis o f resistant DLKP-A and sensitive DLKP cells showed 
equivalent low level staining with antibody 6/1G (Figure 3.2.3). In contrast previous 
results showed strong staining on DLKP A cells with negligible staining observed on 
DLKP cells with both the MDR-1 specific MAb, 6/1C and the widely used anti MDR-1/ 
MDR-3 gene product MAb, C219 (Heenan et al., 1997, Moran et a l, 1997). Analysis o f 
the ovarian carcinoma cell line, A2780 showed negligible reactivity with antibody 6/1G.
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Figure 3.2.2.: Immunocytochemical analysis of antibody 6/1G on the MDR-3 
transgenic cell line Vim # 1 and its parental cell line FVB # C.
(a) Vim # 1 cells showing intense cytoplasmic and plasma membrane positivity with 
antibody 6/1G (original magnification 60x). (b) FVB # C cells showing negligable 
reactivity with antibody 6/1G (original magnification 60x). (Strep ABC/ HRP 
method using DAB as chromogen, cells were counterstained with haematoxylin)
3.2.7. Im m unohistochem ical analysis of form alin  fixed paraffin  em bedded
tissues
Formalin fixed paraffin embedded normal liver tissue showed 6/1G positive staining in 
hepatocytes throughout the entire liver lobule with specific staining observed on 
canalicular membranes. This MDR-3 positive staining can be observed in Figure 3.2.3.
3.2.8. W estern  Blot analysis o f a sm all panel o f  hum an, sim ian and  ra t  cell
lines of varying histological origin w ith  an tibody 6/1G.
A distinct band at 170kDa was observed with cell lysate preparations o f the Buffalo rat 
liver cell line, BRL-3A and the human transitional carcinoma cell line, T24. A very 
faint band was visible at this molecular weight on the African green monkey kidney cell 
line, BSC-1 (Figure 3.2.4.).
3.2.9. W estern blot analysis o f norm al m urine tissues w ith an tibody 6/1G.
Murine kidney and liver tissues preparations showed a single band at 170kDa on 
Western Blot analysis, when probed with antibody 6/1G (Personal communication, Dr. 
E. Moran).
3.2.10. P ropagation  o f antibody 6/ 1G by ascitic tum our production
Following introduction of hybridoma cells into the peritoneal cavity of Balb/C mice 
which were previously primed with pristane (T 7640, Sigma), ascitic fluid was removed 
and centrifuged and the supernatant tested. Recovered ascites showed consistent 
reactivity on control cell line both by immunocytochemical and Western blot analysis. 
Ascitic fluid produced using hybridoma 6/1G grown in protein free medium showed 
weak immunoreactivity on positive control cell lines.
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Figure 3.2.3. Immunohistochemical analysis of formalin fixed paraffin 
embedded human liver
Normal (post necrospy tissue) stained with antibody 6/1G. Diffuse MDR-3 specific 
staining can be observed throughout the whole liver lobule with intense positive 
staining localised on canalicular membranes (original magnification lOOx) (Strep 
ABC method using DAB as chromogen, tissue was counterstained with methyl 
green).
Figure 3.2.4. Western Blot analysis of a small panel of cell lines of varying 
histological origin with antibody 6/1G.
Immunoblot o f  crude cell lysates o f  the M DR-3 transgenic Vim # 1 cell line, the 
Buffalo rat liver cell line, BRL-3A, the hum an bladder carcinom a cell line, T24, the 
human lung carcinoma cell line, DLKP and the A frican green m onkey cell line, 
BSC-1 seperated on 7.5%  SDS PAGE and probed with antibody 6/1G. A  distinct 
band at 170 kD a can be seen in VIM #1, BRL-2A and T24 cells , a  very faint band 
can be observed in D LK P and BSC-1 cells.
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3.2.11. Purification of 6/ 1G ascites
Following purification of antibody 6/1G ascites using the Immune Pure IgM purification 
kit from Pierce, US (section 2.6.12.) recovered fractions o f antibody when concentrated 
failed to show any immunoreactivity on MDR-3 transgenic Vim # 1 cells. Negligible 
staining was observed of formalin fixed paraffin embedded liver sections. The IgM 
concentration in purified samples was determined by Radial immunodiffusion (The 
Binding Site, UK) (section 2.6.11.) to be approx. 1.66 /ag/ml.
3.2.12. P roduction  and  characteristion  o f an tibody 6/1G in pro tein  free
m edium  (Gibco)
Harvested concentrated supernatants from antibody 6/1G grown in protein free 
hybridoma medium supplemented with glutamax 1 (Gibco) reacted with a distinct band 
at 170kDa on Vim # 1 cells; on parental FVB # C cells a very faint band was detected at 
170 kDa (Figure 3.2.5. ). Similarly consistent cytoplasmic and plasma membranous 
staining was observed on Vim # 1 cells when stained with protein free supernatants. 
Negligible reactivity was observed on parental FVB # C cells (Figure 3.2.6). The IgM 
concentration in these samples as determined by Radial immunodiffusion (The Binding 
Site , UK) (section 2.6.11.) was in the range of 10 -15 |4g/ ml.
158
170 kDa
Figure 3.2.5.: Western blot analysis of antibody 6/1G grown in protein free 
medium (PFHM) (Gibco) on the MDR-3 transgenic cell line Vim # 1
Imunoblot o f  a crude cell lysate preparation o f  V im  # 1 cells which were separated 
on 7.5% SDS PAGE and probed w ith antibody 6/ 1G (concentrated PFHM  
supernatant diluted 1:20 in TBS/ 0.1% (v/v Tw een 20). Antibody 6/1G reacts w ith a 
band at 170kDa on V im #  1 cells.
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Figure 3.2.6.: Immunocytochemical analysis of antibody 6/1G grown in protein 
free medium (PFHM) (Gibco) on the MDR-3 transgenic cell line Vim # 1 and its 
parental cell line FVB # C.
(a) Vim # 1 cells showing intense cytoplasmic and membranous positivity with 
antibody 6/1G (PFHM  supernatant) (original magnification 40x). (b) FVB # C cells 
showing negligible reactivity with antibody 6/1G (PFHM  supernatant) (original 
magnification 40x). (Strep A BC/ HRP m ethod using DAB as chromogen, cells were 
counterstained with methyl green).
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A panel of human tumour cell lines of varying histological origin together with resistant 
variants of a number of these were probed with antibody 6/1C . Representative results 
from this survey can be observed in Figures 3.2.7. and 3.2.8.
3.2.13. Investigation of MDR-3 encoded Pgp expression in a panel of
human tumour cell lines
CELL LINE 6/1G REACTIVITY
DLKP +
DLKPSQ +
DLKP Taxotere selection +
DLKPA +
DLKPA 5F -ve *
DLKPA 2B +
COR-L26-S +
COR-L26-R +
OAW42-S +
OAW42-SR +
A2780 +
BT-20 +
MDA-MB-43 5- S +
RPMI parental +/-
RPMI taxol +/-
RPMI melphalan +
Key: + detectable MDR-3 Pgp expression
+/- very low/ basal level of MDR-3 Pgp expression 
* preliminary result
Table 3.2.1. Western Blot Analysis o f  a panel o f human tumour cell lines with the MDR-3 specific 
MAb, 6/1G.
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Figure 3.2.7. W estern  blot analysis of a selection of human tumour cell lines 
and  th e ir d ru g  selected resistant variants with MDR-3 specific antibody 6/1 G  
(1)
Immunoblot of crude cell lysates o f  the human nasal carcinoma cell line R P M I2650 
and its melphalan and taxol selected variants (lanes 1-3), the large cell lung 
carcinoma cell line COR-L26S and its adriamycin selected variant COR-L26R(lanes 
4-5) and the ductal breast carcinoma cell line, MDA-MB-435-S (lane 6) separated 
on 7.5% SDS PAGE and probed with antibody 6/ 1G (PFHM supernatant).
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Figure 3.2.8. Western blot analysis of a selection of human tumour cell lines 
and their drug selected resistant variants with MDR-3 specific antibody 6/1G 
(2).
Immunoblot o f  crude cell lysates o f  the sm all cell carcinoma cell line DLKP (lane 2) 
and its adriamycin (lane 1) and taxotere (lane 3) selected variants separated on 7.5% 
SDS PAGE and probed with antibody 6/ 1G (PFHM  supernatant).
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A number of invasive breast tumours investigated (11/15) for MDR-3 Pgp expression 
using antibody 6/1G appeared to have detectable MDR-3 Pgp expression (Table 3.2.2.). 
14 of the patients received adjuvant chemotherapy, 1 patient received primary 
chemotherapy. A representative MDR-3 positive tumour can be observed in Figure
3.2.7.
3.2.14. Investigation of MDR-3 encoded Pgp expression in archival breast
tumour samples
Table 3.2.2.
Clinical features o f tumours, treatment details ofpatients and immunohistochemical analysis ofMDR- 
3 Pgp using MAb 6/1G in pre chemotherapy treatment archival tumour material from invasive breast 
cancer patients (n=14).
Key: dod = death of disease, a&w = alive and well, rec = recurrence of disease, In du = infiltrating
ductal, In lob = infdtrating lobular, DCIS = ductal carcinoma in situ (comedo/ cribriform/ solid), In 
tubu lar = infiltrating tubular, In municous = infiltrating mucinous, LCIS = lobular carcinoma in situ, 
turn size = tumour size (cm), grade = histological grade, E R  = estrogen receptor status (pos/neg), Tam  = 
tamoxifen therapy, RT = radiation therapy (Y/N), Node = lymph node status (pos/neg), chemo = adjuvant 
chemotherapy, CM F = cyclophosphamide/ methotrexate/5-fluorauacil, ACM F = adriamycin/ 
cyclophosphamide/ methotrexate/ 5-fluorouracil, meg= megace, VM F = vinblastine, methotrexate, 5- 
fluouracil, chlorb = chlorambucil,.
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Patient Diagnosis turn grade ER Tam RT Node Chemo MDR-3
1 dod R In Du, DCIS-com 5.5 3 neg N Y pos ACMFx12 3+3
2 a&w L In Ca, NOS 2 3 neg pos CMF 2+2
3 a&w Lin Du 1.5 pos Y y pos CMFx9 3+3
4 a&w R In Du 2.5 pos pos CMFx9 1+1
5 a&w R In Ca 3 Y pos ACMF 3+3
6 rec R In Ca 3 3 pos pos CMFd1d8x6 2+2
7 a&w L In Ca, NOS 3 3 neg N N pos CMFx9 neg
8 rec L in crib tub com 3 1 pos Zoldalex 3+3
9 a&w R In Du 8 3 pos pos CMFx9 3+3
0 a&w L In Ca, NOS 3 3 pos Y Y pos CMFx9 neg
11 a&w L Inf Ca 3 Y pos CMFx9 neg
12 a&w L In Du, DCIS 1 3 ? N Y pos CMFx9 2+2
13 dod iL In lobular LCIS 3.5 3 pos Y Y pos ACMFx12 2+2
14 a&w R In Du 1.7 neg N Y pos CMFx9 3+3
15 a&w L infil ca 1 Adr CMFpost* neg
•primary chem
Table 3.2.2. Imm unohistochemical analysis o f  MDR-3 Pgp in a panel o f  archival invasive breast
tum ours
Figure 3.2.9. Immunohistochemical analysis of MDR-3 Pgp in archival breast 
tumours
Invasive tum our cells from an infiltrating breast carcinom a showing MDR-3 positive 
staining {pre treatment) (original m agnification 40x) (Strep ABC m ethod using DAB 
as chromogen, tissue was counterstained w ith haematoxylin).
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3.2.15. Im m unocytochem ical analysis o f MDR-1 and  M DR-3 encoded Pgp
expression in B-cell leukaem ias
A small series of B-cell haematological malignancies were investigated for MDR-3 Pgp 
expression using this antibody; it has been indicated that MDR-3 may be involved in 
drug resistance in certain B-cell lymphocytic leukaemias (Nooter et al., 1990, Herweijer 
et al., 1990). For comparison, we also examined MDR-1 Pgp expression levels using 
BR1 MDR-1 MAb, 6/1C.
3.2.15.1 B-cell chronic lymphocytic leukemia (B-CLL)
Two cases of B-CLL (section 1.5.) studied showed MDR-1 positivity using BRI MAb, 
MDR-1 (6/1C) in normal and malignant cell types. Anti MDR-3 MAb, 6/1G showed a 
differential pattern of staining in both cases of B-CLL with the larger malignant cells 
(more pleiomorphic, possibly associated with higher grade/ more malignant phenotype) 
showing more intense MDR-3 positivity than the smaller malignant cell, this staining
pattern can be seen in Figure 3.2.10. Both these samples were from patients who had
received prior treatment.
3.2.15.2 Acute myleoid leukaemia (AML)
Of three AML (section 1.5) cases included in this study a specimen from a patient 
presenting with AML, French American British (FAB) classification (see Table 1.1), 
MO was negative for MDR-1 and MDR-3 protein expression. An AML, FAB M l sample 
showed MDR-1 positivity but did not show any MDR-3 positivity. The third sample, 
FAB M5a exhibited weak MDR-1 positivity in monoblasts with very intense MDR-3 
positivity (which was very granular in nature) also observed in these monoblasts (Figure
3.2.11.). None o f these patients had received treatment.
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F igu re  3.2.10. : Im m unocytocheniical analysis o f M D R-3 an d  M D R -1 P gp  
levels in B-CLL,
Peripheral blood from a B-CLL patient stained with antibody 6/1G, intense MDR-3 
positive staining can be observed in the larger possibly more malignant cell type, 
smaller malignant cells show less positivity (original magnification lOOx). (Strep 
ABC/HRP method using DAB as chromogen, cells were counterstained with 
haematoxylin).
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Figure 3.2.11. : Immunocytochemical analysis of MDR-3 and MDR-1 Pgp 
levels in AML.
Peripheral blood from  an AML stage M 5a patient stained w ith antibody 6/1G 
showing M DR-3 positive staining in  m onoblasts (original m agnification 40x). (Strep 
ABC/ H RP method using DAB as chromogen, cells w ere counterstained with 
haematoxylin)
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3.2.15.3. B-cell non-Hodgkins Lymphoma (B-NHL)
A series o f B-NHL (section 1.5.) cases investigated showed varying levels o f MDR-3 
and MDR-1 Pgp expression; no obvious trend in expression pattern was observed in this 
preliminary study. However within the particular sub groups of this disease (mantle cell 
lymphoma, follicle centre lymphoma) some differences in MDR-3/ MDR-1 Pgp 
expression were noted.
3.2.15.4. Follicle centre lymphoma:
In 3 out 4 cases o f Follicle centre lymphoma investigated there appears to be co­
expression o f MDR-3 and MDR-1 Pgp. In samples from 2 of these patients the level of 
MDR-3 Pgp expression in malignant cells appeared to be higher than that of MDR-1 
Pgp, this can be observed in Figure 3.2.13. where malignant cells show intense MDR-3 
positive staining, only weak MDR-1 positivity can be observed. One case o f follicle 
centre lymphoma (atypical CD5 +ve type) showed weak positivity for MDR-1 and did 
not show any MDR-3 positivity prior to treatment . At 16 days post treatment MDR-3 
expression was increased significantly this can be observed in Figure 3.2.12. where 
intense MDR-3 positivity can be observed in malignant cells; MDR-1 positive staining 
also increased significantly but not to the same degree as MDR-3 Pgp. Further post 
treatment samples from this patient will need to be investigated.
3.2.15.5. Mantle cell lymphoma:
One case of mantle cell lymphoma showed MDR-3 positivity and was negative for 
MDR-1; a second case however showed a reversal of these results. Both o f these patients 
had not received treatment. Two further cases of mantle cell lymphoma investigated 
showed co-expression of both MDR-1 and MDR-3 Pgp, although more intense positive 
staining was observed with both antibodies in case 1, which also showed very weak 
MRP-1 positivity. Negative MRP-3 and LRP protein expression was observed in case 2.
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3.2,15.6. B-NHL (not further classified):
Peripheral blood samples from 2 B-NHL patients were negative for both MDR-3 and 
MDR-1 Pgp expression. Neither o f these patients had received treatment.
3.2.15.7. T  cell clonal disease o f  large granular lymphocytes (T-LGL):
One case o f  this very aggressive disease o f  clonal proliferation included ¡n this study 
showed weak MDR-3 and MDR-1 expression. This patient had not been treated.
3.2.15.8. Chronic granulamatous leukaemia (CGL):
A bone m arrow  effusion from 1 CGL patient who had not been treated showed intense 
M DR-3 positive staining. MDR-1 Pgp results were inconclusive.
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F ig u re  3.2.12. : Im m unocytochem ical analysis o f M D R-3 and  M DR-1 P gp  
levels in  B -N H L (1)
(a) Peripheral blood from a follicle centre lym phom a (atypical type, CD5 +ve) 
patient stained with antibody 6/1C] showing negligible MDR-3 positivity at pre 
treatment stage (original m agnification 40x). (b) Peripheral blood from  same patient 
at post treatment stage showing intense MDR-3 positive staining (original 
magnification 60x). (Strep ABC/ HRP m ethod using DAB as chromogen, cells were 
counterstained with haematoxylin)
a\
F igure  3.2.13. : Innnunocytochem ical analysis of MDR-1 and  MDR-1 Pgp 
levels in B-N HL (2).
(a) Pleural fluid from a follicle centre lymphoma patient (CD5 -ve) stained with the 
MDR-1 specific antibody, 6/1C, showing very weak MDR-1 positivity in some 
malignant cells (original magnification 60x). (b) Pleural fluid from the same patient 
stained with antibody 6/1G, MDR-3 positive staining can be observed in malignant 
cells (original magnification 60x). (Strep ABC/ HRP method using DAB as 
chromogen, cells were counterstained with haematoxolyin)
173
PATIENT DIAGNOSIS MDR-1 EXPRESSION MDR-3 EXPRESSION
1 B-CLL * PB + +
intense MDR-3 positivity 
associated with larger, possibly 
more malignant cells
2 B-CLL * PB + +
intense MDR-3 positivity 
associated with larger, possibly 
more malignant cells
3 ? mantle cell PB + -
4 ? mantle cell PB - +
5 Follicle centre PB + +
> positive than MDR-1
6 Follicle centre * BM - -
7 Follicle centre PF - / + (v.weak) + (weak - moderate)
8 Follicle centre * PB - /  + -
PB + weak +
PF - -
9 B-NHL PB * -/+
10 B-NHL PB ” “
11 PL/ CGL BM 7 *
12 T-LGL * PB + weak + weak
13 AML MO PB *
14 AML Ml PB + - /  +
15 AML M5 PB - /  + +
Table 3.2.3.: Immunocytochemical analysis o f MDR-3 and MDR-1 protein expression levels in B-
cell leukaemias using antibody 6/1G and the MDR-1 specific MAB, 6/1C.
Key: * patients who received treatment
B-CLL B cell chronic lymphocytic leukaemia
B-NHL B cell non Hodgkins lymphoma
T-LGL clonal disease of large granular lymphocytes (T cell
origin)
CGL Chronic granulamatous leukaemia
PB peripheral blood sample
BM bone marrow sample
PF pleural fluid sample
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3.2.16. Conclusion
Antibody 6/1C which specifically recognises the MDR-3 encoded gene product was 
successfully generated by means of a combination of in vitro and in vivo immunisation 
regimes and characterised by immunocytochemical and western blotting. Expression of 
MDR-3 using this antibody was investigated in a series o f 13 invasive breast cancer 
patients, revealing that MDR-3 Pgp was expressed in 73.3% of tumours studied. There 
did not appear to be any association between this MDR-3 expression at diagnosis and 
patient out come, exposure to chemotherapeutic drugs or any clinical-pathological 
features. Investigation of MDR-3 Pgp expression in a very small number of 
haematological malignancies suggested that this Pgp may possibly be associated with a 
more malignant phenotype in B-CLL and also may possibly be associated with certain B 
cell developmental stages.
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3.3. Generation and characterisation of a novel MAb raised to
formalin fixed paraffin embedded infiltrating breast ductal
tumour
3.3.1. Background to this work
A novel production system to generate monoclonal antibodies has been developed in 
this laboratory using dewaxed formalin fixed paraffin embedded archival material as 
a source o f immunogen. Novel monoclonal antibodies raised to dewaxed formalin 
fixed paraffin embedded normal kidney tissue have been successfully generated and 
one o f these antibodies, 1/11C has been partially characterised (Moran et al., 1998). 
The long term aim in developing such a system was to facilitate the isolation of novel 
antigens which may be overexpressed or indeed underexpressed in breast cancer; this 
malignancy is o f particular interest to this research group. We have access to a large 
archival tumour tissue base at St. Vincents Hospital Dublin which enables analysis 
o f serial samples from individual patients, thus providing us with an extensive range 
o f breast tumours at different stages of treatment to use as possible sources of 
immunogens. It was decided therefore to consider a series o f pre and post treatment 
samples from relapsed breast cancer patients which were being investigated for MDR 
protein levels (discussed in detail in section 3.1.) as possible immunogens for 
generation of novel monoclonal antibodies.
3.3.2. Choice of immunogen
Pgp expression levels and MRP protein expression levels in a small number of 
patients (due to time constraints o f immunisation schedule) were taken into 
consideration. Other parameters were also taken into account in the final choice of 
immunogen such as availability/ number o f tissue blocks. A pre treatment infiltrating 
ductal tumour tissue block was chosen as the immunogen. This patient, like the 
majority in the archival study, was diagnosed with a high grade infiltrating ductal 
carcinoma of the breast extensive DCIS, comedo type. Following treatment this 
patient relapsed. The tumour chosen showed low level Pgp positivity at diagnosis, 
following treatment this expression level was not significantly altered. Small groups 
o f tumour cells in pre treatment block showed weak MRP-R1 positivity, no MRP 
positive staining was observed at post treatment stage. It was likely therefore that
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neither MDR-1/ Pgp or MRP was responsible for the resistance exhibited by this 
particular patient, and that overexpression of some other protein maybe be involved.
By using this tumour as an immunogen and screening against pre  and post archival 
tumour material, it was anticipated that MAbs recognising a novel antigen associated 
with resistance in breast cancer might be generated. Also, by investigating a larger 
tissue base which would include normal breast, benign and other breast tumour types 
the possibility o f the antigens recognised by these monoclonal antibodies being 
associated with a particular cell type in breast cancer could be elucidated.
3.3.3. Fusion results
The protein concentration of the immunogen (i.e. 10 x 10 pm dewaxed sections as 
described in section 2.6.3.) was determined to be 600 pg/ ml, which was divided 
equally between two Balb/c mice. A primary immunisation in Freund’s complete 
adjuvant, FCA and 2 boosters in Freund’s incomplete adjuvant, FIA at 2 weekly 
intervals were carried out using freshly dewaxed tissue in each occasion; a final 
booster in Freunds incomplete adjuvant, FIA was administered 3 days prior to fusion. 
As was observed with generation o f kidney monoclonal antibody (Moran et al., 
1998) following excision from mouse, the spleen did not have a healthy appearance 
as is the case following immunisations with various protein immunogens used 
routinely in this laboratory The spleen had a darkened haemorragic appearance and 
looked atrophied. 8 x 24 well plates were used to plate out fused cells.
Following fusion 375 clones, (97% efficiency) were screened by 
immunohistochemistry on tissue sections from pre  treatment control tumour block. 
36 o f these supernatants (10% of total) were considered positive (i.e. they produced 
specific staining o f tumour cells with minimal background) and were rescreened, 16 
representative clones (the majority o f clones appeared to stain tumour cells in an 
identical fashion) were screened for a third time. Finally based on reactivity patterns 
which can be seen in Figure 3.3.1. (i.e. intense cytoplasmic staining) o f tumour cells 
7 positive clones were chosen for further expansion. Following repeated screening on 
3 different pre  treatment blocks from this patient antibodies 5C3 and 2D5 were
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further characterised. When primary antibody was omitted and replaced with either 
TBS or control mouse IgG, no staining was observed at any stage.
3.3.4. Antibody 5C3 and 2D5 reactivity patterns on controlp r e  
treatment tumour
Intense cytoplasmic staining of tumour cells was observed on all 3 pre  treatment 
tumour blocks with both supernatants. When viewed at lOOx magnification this 
positive staining appeared to be radiating towards the plasma membrane in a 
cytokeratin like fashion. Within tumour ducts some cells were more intensely stained 
than others; in some cases tumour cells at the edge o f the tumour duct appeared to 
have more intense positivity than those in centre o f ducts. In one pre  treatment 
tumour section there was very intense staining o f individual tumour cells which 
appear to be almost in rows (this may represent tumour cells invading lymphatic 
channels i.e. desmoplasmic stromal reaction which is present according to the 
histopathology report); this can be observed in Figure 3.3.2. Some low level staining 
o f normal breast ducts was also observed; endothelial cells and muscle layers of 
some vessels also appear to have some positivity. Preliminary results indicate that 
antibody 5C3 appears to react weakly on post treatment material from this patient.
3.3.5. Isotyping of 5C3 antibody
Isotype was determined to be IgGi subclass, (Isostrip, Isostrip, Roche Diagnostics 
GmbH, 1493027) (section 2.6.10.).
3.3.6. Immunohistochemical analysis of antibody 5C3 on formalin fixed
paraffin embedded p re  and p o s t  treatment breast cancer tumours
Antibody 5C3 reacted with a number o f pre  and post treatment tumours screened. 
There was considerable heterogeneity in the staining pattern observed. In a number 
o f pre and post treatment tumours staining with antibody 5C3 showed very intense 
positivity that was associated with certain infiltrating tumour cells (similar in staining 
intensity to that observed in invading cells in control pre  treatment tumour Figure
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3.3.2); while weaker reactivity was associated in some cases with non invasive 
tumour cells i.e. DCIS tumour cells which are often seen along with invasive ductal 
tumours. An example o f this staining pattern can be seen in Figure 3.3.3. A number 
o f pre  and post tumours showed negative reactivity. In all positive tumours screened 
staining of some normal breast tissue was observed. This antibody also appeared to 
cross-react with some endothelial cells, muscle and some stromal tissue which may 
be due to the unpurified nature o f the supernatant.
3.3.7. Immunohistochemical analysis of formalin fixed paraffin 
embedded non-cancer breast tissue
A number o f non-cancer breast tissues were investigated for antibody 5C3 reactivity. 
There appeared to be some degree o f reactivity with antibody 5C3 on all o f the 
tissues investigated. The staining intensity however, was less than that observed in 
tumour cells from patients with infiltrating breast carcinomas.
3.3.8. Immunohistochemical analysis of formalin fixed paraffin 
embedded normal adult tissues.
A small panel o f available formalin fixed paraffin embedded tissues were 
investigated for antibody 5C3 reactivity.
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Figure 3.3.1. : P re  treatment ductal breast tumour which was used as 
immunogen stained with supernatant 5C3. This staining pattern was 
representative of all 7 positive clones which were expanded following a third 
screening.
(a) Intense cytoplasmic positivity which is granular in nature can be observed in 
infiltrating tumour cells (original magnification lOOx). (b) The DCIS component 
(comedo type) also shows cytoplasmic positivity in tumour cells however this 
staining is not as intense as that observed in infiltrating tumour cells; the centre of 
tumour which has undergone necrosis is negative (original magnification 60x) 
(StrepABC/ HRP method using DAB as chromogen, sections were counterstained 
with hematoxylin).
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Figure 3.3.2. : P re  treatment ductal breast tumour block which was used as 
immunogen stained with antibody 5C3 and negative control section stained with 
TBS.
(a) Intense cytoplasmic staining o f individual infiltrating tumour cells which appear 
to be organised in rows can be observed in this control tumour section stained with 
supernatant 5C3, this may represent tumour cells invading lymphatic channels (i.e. 
desmoplasmic stromal reaction) (original magnification 20x). (b) No staining can be 
observed in negative control section (original magnification 20x).
(strepABC/ HRP method using DAB as chromogen, sections were counterstained 
with haematoxylin).
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Figure 3.3.3.: Immunohistochemical analysis of p r e  and p o s t  treatment breast 
tumours with antibody 5C3 (1).
(a) Post treatment intraductal tumour showing intense 5C3 positive staining in 
infiltrating tumour cells. This tumour showed a differential pattern o f staining with 
antibody 5C3 (original magnification 20x). The 5C3 positivity observed ranged from 
very intense staining of infiltrating tumour cells to low level 5C3 positive staining in 
some DCIS cells, this can be observed in the DCIS (comedo type) tumour in 
photomicrograph (b) (original magnification 20x). StrepABC/ HRP method using 
DAB as chromogen, sections were counterstained with methyl green.
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Figure 3.3.4. : Immunohistochemical analysis p r e  and p o s t  treatment breast 
tumours with antibody 5C3 (2).
(a) Pre treatment infiltrating tumour cells showing intense staining w ith antibody 
5C3, particularly strong reactivity was observed around lipid. W eaker 5C3 positivity 
was observed in DC1S tum our cells (original magnification 40x). (b) Pre treatment 
tumour from another ductal carcinoma patient again showing strong reactivity in 
infiltrating tum our cells w ith antibody 5C3 (original m agnification 20x). Strep ABC/ 
HRP method using DAB as chromogen, sections were counterstained with methyl 
green).
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3.3.9. Immunocytochemical analysis of a panel of cell lines for antibody
5C3 reactivity
A panel o f cell lines as outlined in Table 3.3.1. was investigated using 
immunocytochemistry for 5C3 expression. Representative cells stained with antibody 
5C3 can be observed in Figures 3.3.5. and 3.3.6. In all cases cytoplasmic positivity 
was observed which was similar to the staining observed in individual tumour cells 
in formalin fixed paraffin embedded tissue sections. All o f the ductal breast tumour 
cell lines, ZR-75-1, MDA-MB-231, MDA-MB-435-S and BT-20 exhibited intense 
5C3 positivity, a reduced level o f staining was observed in the non-tumourogenic cell 
line, MCF-10A. Ovarian, lung and leukaemia tumour cell lines also showed varying 
degrees o f 5C3 reactivity, the sensitive non-small cell lung tumour cell line, DLKP 
and the ovarian adenocarcinoma sensitive and spontaneously resistant variants 
OAW42-S and OAW42-SR appeared to show weaker 5C3 reactivity than their MDR 
variants. The MDR nasal carcinoma cell line, RPMI (melphalan selected) did not 
show any 5C3 positivity. Some very weak staining was observed on negative control 
slides (stained with control mouse IgG ) o f some cell lines.
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CELL LINE HISTOPATHOLOGY 5C3 REACTIVITY
ZR-75-1 Breast ductal carcinoma ++
BT-20 Breast ductal carcinoma ++
MDA-MB-231 Breast ductal carcinoma ++
MDA-MB-435-S Breast ductal carcinoma ++
MCF-10A Breast non-tumourogenic -/+
A2780 Ovarian MDR variant ++
OAW42-A1 Ovarian MDR variant ++
OAW42-A Ovarian MDR variant ++
OAW42-SR Ovarian spontaneously resistant 
variant
+
OAW42-S Ovarian sensitive variant +
DLKPA Lung non-small cell MDR variant ++
DLKP Lung non-small cell sensitive +
HL-60 Leukaemia ++
RPMI (melphalan) Nasal carcinoma MDR variant
'
TABLE 3.3.1. : Immunocytochemical analysis o f  a selection o f ductal breast carcinoma cell lines, 
a non-tumourogenic breast cell line and tumour cell lines o f  various histological types fo r  
antibody 5C3 reactivity.
++ intense 5C3 reactivity 
+ low level 5C3 reactivity 
-/+ very low level 5C3 reactivity 
negative 5C3 reactivity
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Figure 3.3.5. :Immunocytochemical analysis of ZR-75-1 ductal carcinoma, 
BT-20 adenocarcinoma, MDA-MB-231 ductal carcinoma and MDA-MB-435-S 
ductal carcinoma breast cell lines with antibody 5C3.
(a) ZR-75-1 (b) BT-20 (c) MDA-MB-231 and (d) M DA-M B-435-S breast cell lines 
all showing cytoplasmic reactivity w ith antibody 5C3. (original magnification o f  all 
photomicrographs 40x). (Strep ABC/HRP method using DAB as chromogen, cells 
w ere counterstained w ith methyl green)
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Figure 3.3.6. : Immunocytochemical analysis of OAW42SR spontaneously 
resistant ovarian carcinoma and resistant variants, OAW42A and OAW42A, 
A2780 ovarian carcinoma, DLKPA non small cell carcinoma resistant variant 
and RPMI melphalan resistant nasal carcinoma cell lines with antibody 5C3.
(a) OAW 42-SR showing 5C3 positivity.(b) OAW 42-A and (c) OAW 42-A1 cells 
showing intense 5C3 positivity. (d) A2780 and (e) DLKPA cells showing intense 
cytoplasmic 5C3 positivity. (f) RPMI (melphalan) cells showing negligible 5C3 
positivity (original magnification o f  all photom icrographs 40x). ( Strep A BC/ HRP 
method using DAB as chromogen, cells were counterstained w ith methyl green).
3.3.10. W este rn  b lo t analysis o f a p anel o f  cell lines fo r an tibody  5C3
reactiv ity
Western blotting analysis was carried out on a selection o f ductal breast carcinoma 
cell lines in order to determine the molecular weight o f the antigen reactive with 
antibody 5C3. In addition, a range of tumour cell lines o f various histological origins 
and MDR status as well as a non-tumourogenic breast cell line were probed with 
antibody 5C3. Immunoblotting with antibody 5C3 o f the ductal breast carcinoma cell 
lines, ZR-75-1, BT-20, MDA-MB-231 and MDA-MB435-S and the breast 
carcinoma cell line, MCF-7 identified a series of bands at approx. 210kDa, 150kDa, 
95kDa, and 50kDa on crude cell lysates o f all o f these tumour cell lines. However the 
relative expression o f each these 5C3 reactive bands appeared to vary among some 
cell lines and individual western blot analysis a representative immunoblot can be 
seen in Figures 3.3.7. A very distinct band at higher than 210kDa was identified on 
the ductal carcinoma cell line ZR-75-1. This band was at a slightly lower molecular 
weight in all other cell lines probed with antibody. In addition this 210kDa band was 
consistantly detected on all immunoblots regardless o f the relative expression o f the 
lower bands.
Immunoblotting o f ovarian and colon tumour cell lines revealed similar bands being 
identified, each with varying relative expression. The 210kDa band was not detected 
as strongly in these cell lines as was observed in some o f the breast tumour cell lines.
3.3.11. W este rn  b lo t analysis o f n o rm a l m urine  tissues fo r an tibody  5C3
reactiv ity
A range of purified normal murine tissues were investigated for antibody 5C3 
reactivity. In contrast to the panel o f cell lines investigated probing o f these tissues 
with antibody 5C3 did not reveal bands o f similar molecular weights to those seen in 
the cells lines. The major band identified in these tissues was at approx. 70kDa 
(specifically spleen and lung), a 50kDa band was identified in all tissues (Figure
3.3.7.). The 70kDa band was not identified in any o f the cell lines investigated to 
date.
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Figure 3.3.7. Western blot analysis of murine spleen, kidney, liver and lung 
tissues, ductal breast carcinoma cel! lines, ZR-75-1, MDA-MB-231 and BT-20, 
the non-tnmourogenic breast cell line, MCF-10A and the colon carcinoma cell 
line HT116 with antibody 5C3.
Imm unoblot o f  partially purified norm al m urine tissues and crude cell lysates o f  the 
above cell lines which were separated on 6% SDS PAGE and probed w ith antibody 
5C3. Antibody 5C3 appears to recognise a  series o f  bands at 21 OkDa, 150kDa, 
95kDa in all cell lines. These bands are only w eakly detected in murine tissues. In 
contrast a distinct band at approx 70kDa can be seen in spleen and to a lesser degree 
in lung; a  very faint band is detected in kidney and liver. A  50kDa band is detected 
in all tissue preparations. (20 |ig  protein per lane loaded * M CF-10 only 10 pg 
protein loaded)
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3.3.12. Immunoprécipitation studies
Due to its consistent reactivity with antibody 5C3, the ductal breast carcinoma cell 
line, ZR-75-1 was thus chosen for immunoprécipitation studies with antibody 5C3. 
Immunoprécipitation was carried out using a cocktail o f  protein L and protein G to 
pull out the 5C3 reactive antigen from crude cell lysates o f ZR-75-1 cells. Following 
separation on 7.5% SDS Page, western blot analysis o f  the ZR-75-1 
immunoprecipitates revealed a band at approx. 175 kDa ( Figure 3.3.8) when probed 
with antibody 5C3 (the predominant band detected by western blotting of ZR-75-1 
lysates was at approx. 210 kDa). No band was detected in immunoprecipitates of 
mouse IgG. Remaining supernatant following incubation o f antibody/ lysate with 
protein L/ protein G was also added to reducing/ non reducing loading buffer and 
separated on SDS-PAGE. Western blot analysis o f reduced supernatants revealed 
again multiple bands that were observed on ZR-75-1 cell lysate probed with antibody 
5C3; the 175kDa band was also detected (Figure 3.3.9). Western Blot analysis o f a 
1:1 mixture o f remaining supernatant and ZR-75-1 immunoprecipitates revealed 
again a series o f bands including the 175kDa (Figure 3.3.9). When non reduced 
samples of ZR-75-1 immunoprecipitates, remaining supernatant and 1: 1 mixtures of 
these were separated on SDS-PAGE and probed with antibody 5C3, no distinct bands 
could be observed (Figure 3.3.9.).
3.3.13. N -T erm inal sequence analysis
Further ZR-75-1 immunoprecipitates were transferred to PYDF (Sequiblot, Biorad) 
and stained with Coomassie Blue R-250, the major band at approx. 175 kDa 
corresponding to that observed on Western blots of immunoprecipitated cells, was 
excised from PVDF membrane and processed for N-terminal sequencing (Dr. Kevin 
Howland, University o f Kent, UK) (section 2.9.2.). However results from sequencing 
revealed that the protein was N-terminally blocked. It was attempted to overcome 
this by the addition o f 0.1% thioglycolic acid to gels, however gels did not resolve 
correctly. Internal sequencing involves sequencing o f amino acid sequences o f a 
protein other that its N or C terminal sequences. This is carried out by N-terminal
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sequence analysis o f a peptide after digestion and purification from a protein digest. 
It was decided to proceed with internal sequencing analysis.
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F igu re  3.3.8. : W estern  b lo t analysis o f im m unoprecip ita tes  o f ZR-75-1 cells 
p robed  w ith  an tibody  5C3.
Immunoprecipitates o f  ZR-75-1 ductal breast carcinoma cells (lane 1: 0.5ml crude 
cell lysate/ 50 fil protein G and protein L, lane 2 : 0.25ml crude cell lysate/ 50 jal 
protein G and protein L) and control mouse IgG (lane 3) separated on 7.5% SDS 
PAGE and probed w ith M Ab, 5C3. A band at approx. 175 kD a is detected in ZR- 
75-1 precipitates, no band is detected in control mouse IgG immunoprecipitate. 
IgG bands only are detected when primary antibody is omitted (lanes 4: ZR-75- 
1 immunoprecipitate, lane 5: IgG immunoprecipitate).
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Figure 3.3.9. : Western blot analysis of immunoprecipitates and
supernatants of ZR-75-1 cells probed with antibody 5C3.
Reduced (lane 1) and non reduced (lane 3) im munoprecipitates o f  ZR-75-1 cells, 
control mouse IgG (lane 2), reduced supernatant retained following 
immunoprécipitation (lane 5) and ZR-75-1 immunoprecipitate/ supernatant 
(50:50) (lane 4) separated on 7.5% SDS-PAGE and probed with antibody 5C3. A 
band at approx. 175 kDa is detected in ZR-75-1 immunoprecipitates, this band is 
also clearly observed in immunoprecipitate/ supernatant sample where the 220 
kDa reactive band can also be observed. All 5C3 reactive bands are identified on 
supernatant sample, no 5C3 reactive bands are detected in non reduced 
immunoprecipitates.
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3.3.14. Internal sequence analysis
Following separation on 7.5% SDS-PAGE, the gel was stained with 0.25% 
Coomassie Blue and destained accordingly (section 2.9.3., protocols as 
recommended by Eurosequence ). The 175kDa band was excised from the gel and 
processed for internal sequencing via an in gel digest (Eurosequence BV, The 
Netherlands). A representative 7.5% SDS-PAGE gel showing the band o f interest 
can be observed in Figure 3.3.10.
An in situ trypsin digest o f protein (i.e.gel) was carried out by Eurosequence 
following which resulting peptides were extracted from gel. These were then 
checked for successful digestion, which in the case of the first sample sent was not 
proved to be the case. However a second sample o f protein was successfully 
digested, revealing that a mixture o f peptides were present. These peptides were then 
subjected to HPLC for purification. This revealed that a mixture o f two peptides 
were present, their sequence levels were determined to be approx. 1:2. (Appendix 
IV).
Data base searching carried out by Eurosequence indicated that these peptides 
corresponded to human cytokeratin 6B (data base analysis subsequently checked at 
NCTCC suggested a better match with cytokeratin 6D) and human cytokeratin 9. The 
sequence results showed that the levels were approx. 1:2 (cytokeratin 6: cytokeratin 
9). These results suggested that the antigen recognised by antibody 5C3 was a 
complex consisting o f two cytokeratin 9 (type I cytokeratin, 62 kDa) proteins and 
one cytokeratin 6 protein (type II cytokeratin, 56 kDa). It was likely that the 175 Kda 
band represented this complex i.e. the sum of these individual cytokeratin m.w.s.
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Figure 3.3.10.: Immunoprecipitates of ZR-75-1 cells separated on 7.5% SDS- 
PAGE and stained Coomassie Blue R-250.
Immunoprecipitates o f  ZR-75-1 cells (lane 3 and 4) separated on 7.5% SDS-PAGE 
and stained 0.25% Coomassie B lue R-250 (lane 1: m olecular weight markers), (lane 
2: no sample loaded, spillover only). A band at approx. 175 kDa is detected on 
immunoprecipitates, IgG bands are also detected. The 175 kDa band was excised 
and sent to Eurosequence BV, The Netherlands for internal sequencing.
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3.3.15. W este rn  b lo t analysis o f ZR-75-1 im m unoprec ip ita tes  and  cell
lysates fo r C y to k era tin  6 and  C y tokera tin  9.
In an attempt to disassociate this proposed complex, further ZR-75-1 
immunoprecipitates were boiled for an increased time i.e. 10 mins following 
immunoprécipitation. These immunoprecipitates were separated on 12.5% SDS- 
PAGE and stained with 0.25% (w/vol) Coomassie Blue. A band at approx. 60 kDa as 
well as the 175 kDa was observed (cytokeratin 9 reacts with a 62 kDa band, 
cytokeratin 6 reacts with a 56 kDa ). When probed with antibody 5C3 only IgG 
bands were detected, no band specific for either cytokeratin 6 or cytokeratin 9 were 
detected. It appeared therefore that antibody 5C3 appears to recognise hetropolymer, 
cytokeratin 6/9 when "complexed", but it does not appear to recognise the 
disassociated complex.
When ZR-75-1 immunoprecipitates were probed with a MAb which specifically 
recognises cytokeratin 9, a cytokeratin 9 reactive band (62 kDa) was identified on 
immunoprecipitates which were boiled for 10 mins, a very faint cytokeratin 9 
reactive band could be observed on immunoprecipitates which were boiled for 1 min 
(Figure 3.3.11.). IgG bands were also detected by the secondary antibody. Following 
probing o f ZR-75-1 immunoprecipitates with a MAb that specifically recognises 
cytokeratin 6, only IgG bands were observed. No cytokeratin 6 reactive bands were 
detected in immunoprecipitated samples boiled for either 1 min or 10 mins (Figure
3.3.12.).
A cytokeratin 6 (56 kDa) reactive band was identified on crude cell lysates o f ZR-75- 
1 cells when probed with the cytokeratin 6 specific MAb (Figure 3.3.13.). A 
cytokeratin 9 (62 kDa) reactive band was not observed on crude cell lysates probed 
with the cytokeratin 9 specific MAb (Figure 3.3.14).
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Figure 3.3.11.: Western Blot analysis of ZR-75-1 immunoprecipitates probed 
with cytokeratin 6 specific MAb.
ZR-75-1 immunoprecipitates boiled for 1 min (lane 2) and in an attempt to 
disassociate the proposed complex, further samples which were boiled for 10 mins 
(lane 1) following immunoprécipitation which were separated on 7.5% SDS-PAGE 
and probed w ith cytokeratin 6. N o cytokeratin reactive band is identified in either 
immunoprecipitate, IgG  (heavy and light chain) bands are only detected .
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Figure 3.3.12.: Western Blot analysis of ZR-75-1 immunoprecipitates probed 
with cytokeratin 9 specific MAb.
ZR-75-1 immunoprecipitates boiled for 1 min (lane 2) and in an attempt to 
disassociate the proposed com plex further samples which were boiled for 10 mitts 
(lane 1) following immunoprécipitation which were separated on 7.5% SDS-PAGE 
and probed with cytokeratin 9. A cytokeratin 9 reactive band is detected at approx. 
62kDa in ZR-75-1 immunoprecipitates which were boiled for 10 mins, a  very  faint 
band can be observed in im munoprecipitates w hich w ere boiled for 1 min. IgG 
bands (heavy and light chain) are also detected.
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F ig u re  3.3.13. : W estern  Blot analysis o f ZR -75 c ru d e  cell lysates an d  ZR-75-1 
im m unoprecip ita tes probed  w ith an ti-cy to k era tin  6 specific M A b.
ZR-75-1 crude cell lysates (lane 1) and ZR-75-1 im munoprecipitates (boiled for 10 
mins following immunoprécipitation) (lane 2) which were separated on 10% SDS- 
PAGE and probed w ith cytokeratin 6 MAb . Cytokeratin 6 reacts w ith a band at 
approx. 56 kDa in crude cell lysates o f  ZR-75-1 cells. N o  cytokeratin 6 reactive band 
is detected in immunoprecipitated samples.
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Figure 3.3.14. : Western Biot analysis of ZR-75 crude cell lysates and ZR-75-1 
immunoprecipltates probed with anti-cytokeratin 9 specific MAb.
ZR-75-1 crude cell lysates (lanes 1) immunoprecipitates (lane 2) (boiled for 10 mins 
following immunoprécipitation) which were separated on 10% SDS-PAGE and 
probed w ith cytokeratin 6 M Ab . A cytokeratin band is identified at approx. 62 kDa 
in immunoprecipitated ZR-75-1 cells, this band is not observed in crude cell lysates 
probed w ith cytokeratin 9 M Ab.
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3.3.16. Conclusion
Antibody 5C3 was generated using paraffin wax em bedded form alin fixed archival 
breast tum our tissue from  a biopsy as an immunogen. There did not appear to be any 
apparent association w ith resistance for the antigen recognised by antibody 5C3. 
Furtherm ore this antigen did not appear to be tum our specific, it was shown to  be 
expressed in  both norm al and malignant breast tissue and was expressed in a  num ber 
o f  other tum our types. Results o f  internal sequencing o f  a 175 K da band w hich was 
obtained from im munoprecipitation o f  a ductal carcinom a cell line revealed the 
reactive antigen o f  antibody 5C3 to be a heteropolym er o f  cytokeratin 6 and 
cytokeratin 9.
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4. Discussion
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4.1. Discussion
In breast cancer, the most frequently used prognostic factors remain those 
determined by clinical or standard pathological approaches namely lymph node 
status, tumour size, histological grade, nuclear grade and tumour histology. To date 
the only valuable predictive factors in this disease are estrogen receptor and 
progesterone receptor which can predict response to hormonal treatments. Despite all 
o f the studies directed at identifying new molecular markers o f both prognosis and 
chemosensitivity, only cerbB-2 appears to hold any promise as a prognostic and 
possibly predictive marker. In an attempt to identify additional molecular markers, a 
panel o f MDR and associated apoptosis/ oncogene markers were investigated during 
the course o f this work in a series o f invasive breast carcinomas. 
Immunohistochemical expression of drug transporters, MRP-1, MDR-1 and LRP, the 
HER-2 neu oncogene and the anti apoptotic proteins, BCL-2 and survivin were 
correlated with patient and tumour characteristics in patients with invasive breast 
cancer. Furthermore, expression of these proteins was correlated with Relapse Free 
Survival and Overall Survival. In order to address further the multifactorial nature of 
the disease, expression of individual protein markers is also analysed in relation to 
other markers.
In patients with invasive carcinoma studied here multivariate analysis revealed that 
in these patients nodal status and tumour size were independent prognostic factors 
for relapse free survival; tumour grade was an independent prognostic factor for 
overall survival. It is well recognised that smaller tumour size, lower histological 
grade and a negative lymph node status (i.e. no spread to the lymph nodes) are 
indicitive o f a better prognosis in invasive breast cancer.
Invasive carcinomas studied were classified into two groups for further analysis; 
namely patients who received chemotherapy following surgery (endocrine therapy 
was also given in some cases), and patients who did not receive chemotherapy 
following surgery (endocrine therapy was given only in the majority o f cases). 
Furthermore patients were also stratified according to node status; namely node 
positive patients and node negative patients.
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Multivariate analysis o f patients who did not receive chemotherapy revealed that 
small tumour size was an independent prognostic factor for relapse free survival; 
nodal status failed marginally to show significance. Histological grade was an 
independent prognostic factor for overall survival, again nodal status failed 
marginally to show significance. In these patients ER status was shown to be an 
independent prognostic factor for overall survival. When these patients were further 
stratified into node positive and node negative patients; none of the 
clinicopathological parameters analysed were identified as independent prognostic 
factors in node negative patients. Tumour size and tumour grade are the only 
features considered to offer any prognostic value in lymph node negative breast 
cancer (Mirza et al., 2002). Tumours from the node negative patients studied here 
tended to be lower grade tumours (histological grade II or grade III), there were less 
grade III tumours which may explain why tumour grade did not have any prognostic 
significance. Again as tumours not treated with chemotherapy would tend to be 
smaller tumours anyway, tumour size thus would not be able to offer prognostic 
value.
In patients treated with chemotherapy multivariate analysis revealed that nodal 
status and ER status were independent prognostic factors for relapse free survival. 
ER status was also identified as an independent prognostic factor for overall survival; 
tumour grade and nodal status failed marginally to show independent prognostic 
value for overall survival.
Again patients were further stratified according to nodal status, revealing ER status 
to be a prognostic factor for both relapse free survival and overall survival in node 
positive patients and for overall survival only in node negative patients. No other 
clinicopathological parameter was identified as an independent prognostic factor in 
node negative patients treated with chemotherapy. Only tumours from 23 node 
negative patients were studied, perhaps this number was too small to reveal any 
independent prognostic factors, in this patient group.
Histological grade was shown to be a highly significant independent prognostic 
factor for Overall survival in node positive chemotherapy treated patients, it 
marginally failed to reach significance for relapse free survival. Tumour size was not
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identified as an independent prognostic factor in node positive chemotherapy treated 
patients.
MRP-1 has been shown to be expressed in several human cancers (section 1.6.5.), in 
addition expression of this ATP drug transporter has been associated with poor 
patient outcome in a number of these malignancies including breast cancer (reviewed 
by Borst, 2000). During the course of this thesis, MRP-1 protein expression was 
studied by means of immunohistochemical analysis in a total o f 204 untreated 
archival tumours from patients with invasive breast cancer. MRP-1 protein was 
expressed to varying degrees at diagnosis in 62.6% of these invasive tumours; this 
observation is in general agreement with previous studies o f MRP-1 in breast 
cancers. The majority o f MRP-1 staining observed was membranous with some 
granular cytoplasmic positivity observed in some tumours; this has been reported 
previously by Flens et a l  (1996). Our results also indicated that for the most part 
when the intensity o f the MRP-1 positive staining increased the percentage o f tumour 
cells stained also increased (Table 3.1.2. and 3.1.3.); this has previously been 
observed by Flens et al., (1996). Previous immunohistochemical studies o f MRP-1 
protein expression in primary breast carcinomas have ranged from 30% to 100% 
MRP-1 positivity (Filipits et a l, 1996, Nooter et al., 1997, Filipits et al., 1999a). 
Likewise RNA expression patterns in primary breast carcinomas have also shown 
variation; mRNA expression levels in untreated tumours o f 70% to 100% have been 
reported (Filipits et al., 1996, Dexter el a l, 1998, Ito et al., 1997, Ferrero et al.,
2000). The results presented here suggest that in agreement with these previous 
studies, MRP-1 is detectable in a large proportion o f human breast carcinomas.
Previous studies have indicated that MRP-1 mRNA expression and MRP-1 protein 
expression values when assessed in the same tumours do not always correlate 
(Filipits et al., 1996, Nooter et al., 1995, Ito et al., 1997). One main contributory 
factor to such differences is the presence o f normal cells as well as tumour cells in 
bulk detection methods such as RT-PCR and RNase protection assay and in addition 
tumour cell heterogeneity may be a factor. Breast cancers are known to be heavily 
infiltrated by normal lymphocytes (Nooter et al., 1995). In parallel with the work 
presented in this thesis, a study on the expression o f MRP-1 mRNA in the same 
series o f breast tumours was also carried out in this laboratory (personnel
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communication, Linehan et al.,). Preliminary analysis suggested that MRP-1 protein 
expression and RNA values did not appear to correlate in these invasive breast 
carcinomas.
Expression o f MRP-1 protein, assessed by immunohistochemistry, was not 
significantly associated with age of patients (<50 years/ >50 years), node status, ER 
status, tumour size or histological subtype in either chemotherapy-treated patients or 
non-chemotherapy-treated patients. MRP-1 expression has been associated with 
estrogen receptor status in only one study; expression was more frequent in estrogen 
and progesterone receptor negative tumours (Filipits et al., 1999). Other studies have 
shown that MRP-1 expression at diagnosis is independent o f the age of patients at 
diagnosis, menopausal status, node status and histological subtype, again in 
agreement with the findings presented here (Filipits et al., 1996, Nooter et al., 
1997b).
Preliminary analysis revealed that there was an association between MRP-1 positive 
tumours and an immunohistochemical score o f 3+3 and high histological grade 
(grade III) 73% of 3+3 MRP-1 positive tumours had a high histological grade 
whereas only 23% and 3.8% were grade II and grade I, respectively. One previous 
study has reported more frequent expression of MRP-1 protein (and LRP protein) 
associated with tumours o f an intermediate histological (moderately differentiated) 
grade (i.e. grade II), compared to those with a high histological grade III (Beck et al.,
1998). Grade III tumours are the most aggressive and show the worse prognosis 
(section 1.4.1.2.). Our results did show that MRP-1 expression was significantly 
associated with higher histological grade in chemotherapy treated patients. Taken 
together these results suggested that MRP-1 is possibly associated with a more 
aggressive tumour phenotype in these patients. This effect was not seen with patients 
who did not receive chemotherapy, reflecting perhaps, the less aggressive nature of 
tumours which are not recommended for chemotherapy.
Our initial observation o f a possible weak association between MRP-1 expression 
and larger tumour size in patients studied was not found to be statistically significant. 
Only one previous study has reported MRP-1 expression being associated with larger 
tumour size (Filipits et al., 1996). In general, previous studies indicate that
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expression o f M RP-1 is independent of tumour size and histological grade (Filipits et 
a l, 1996, Nooter et al., 1997a). Increased MRP-1 expression has however, been 
shown to be associated with primary tumours which have distant metastases and in 
lymph node metastases compared to primary tumours (Filipits et a l, 1996, 
Zochbauer-Muller et al., 2001).
On preliminary analysis o f the data it appeared that a higher proportion o f untreated 
tumours from those chemotherapy treated patients who relapsed following treatment 
and subsequently died were MRP-1 positive at diagnosis, compared to those patients 
who did not relapse following treatment and who are currently alive and well. 
Previous studies have observed both higher MRP-1 gene expression levels and MRP- 
1 protein expression levels in relapsed primary breast cancer patients compared to 
non-relapsed patients (Nooter et a l, 1997, Ito et al., 1998). Our results indicate that a 
higher percentage o f node positive chemotherapy treated patients with MRP-1 
positive tumours at diagnosis (61.7%) relapsed and died compared to those patients 
with MRP-1 negative tumours (37.5%). However as all o f  the patients studied were 
diagnosed at different times, and the follow up period was not similar for individual 
patients, no firm conclusions could be drawn from these observations as regards 
MRP-1 expression and its association, if  any, with clinical outcome in these patients.
MRP-1 expression was then correlated with relapse free survival and overall survival 
times in node positive and in node negative patients. In patients who did not receive 
chemotherapy, it appeared that MRP-1 expression at diagnosis may possibly be 
associated with a shortened relapse free period both in node positive and node 
negative patients (Table 3.1.9.). This trend was observed more strongly in node 
negative patients; 40% of these patients with MRP-1 positive tumours relapsed 
within 3 years following diagnosis compared to only 7% of patients with MRP-1 
negative tumours. In node positive patients with MRP-1 positive tumours a similar 
number o f patients relapsed within 3 years (40.9%), however only 20% of these 
patients with MRP-1 negative tumours relapsed within this time.
On preliminary analysis o f overall survival times in these patients it appeared that 
there may be a similar trend of MRP-1 expression being associated with reduced 
overall survival times in these patients; a shortened overall survival appeared to be
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associated with MRP-1 positive tumours compared to MRP-1 negative tumours. This 
trend was observed in both node negative and node positive patients (Table 3.1.10). 
MRP-1 expression has been associated with increased risk for failure in node 
negative breast cancer patients in two previous immunohistochemical studies (Nooter 
et al., 1997b, Filipits et al., 1999).
However when these results were analysed statistically using Kaplan Meier 
analyses, no association was shown between MRP-1 expression and either Overall 
survival or Relapse free survival, regardless o f nodal status, although values for 
grade III tumours tended to be closer to significance than grade II tumours. This 
observation suggests that perhaps if  more tumours representative o f each histological 
were analysed, MRP-1 expression may hold possible prognostic value in higher 
grade, III tumours. Multivariate analysis did not however reveal MRP-1 expression 
to be an independent prognostic factor for outcome in patients who did not receive 
chemotherapy. In conclusion, in patients who did not receive chemotherapy MRP-1, 
expression at diagnosis did not offer any prognostic value in these patients.
Similar levels o f M RP-1 protein expression were observed in pre treatment biopsies 
from chemotherapy treated patients (61.6%) and in patients who did not receive 
chemotherapy (62.6%). Immunohistochemical analysis o f 20 post chemotherapy 
treated tumour specimens revealed that MRP-1 expression was not markedly 
increased following treatment, indicating that expression of MRP-1 is not associated 
with exposure to chemotherapeutic drugs. It has previously been reported that MRP- 
1 expression was not associated with prior chemotherapy (Nooter et al., 1995).
The majority o f these patients received standard CMF treatment. The drugs used in 
this regime are not in general, considered within the drug profile for MRP-1, 
although methotrexate has been shown to be a substrate for MRP-1 (Hooijberg et al.,
1999). Only one post treatment tumour studied was from a patient who received 
adriamycin in combination with CMF. This patient was negative for MRP-1 at 
diagnosis but did show MRP-1 positivity following chemotherapeutic treatment. 
Adriamycin is a substrate for MRP-1 and also MDR-1 Pgp. As only one patient was 
studied it cannot be concluded that MRP-1 expression is associated with ACMF 
treatment
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On preliminary analysis o f chemotherapy treated patients, it appeared that in node 
positive patients, 61% o f patients with MRP-1 positive tumours who relapsed are 
now deceased (d), compared to only 37.5% of patients with MRP-1 negative 
tumours. This trend was more strongly observed in node negative patients. A higher 
percentage o f M RP-1 negative patients (node negative and node positive) compared 
to MRP-1 positive patients currently alive and showing no recurrence). Again, as all 
o f the patients studied were diagnosed at different times, follow-up times were not 
equal so no firm conclusions could be drawn regarding MRP-1 expression and 
association with clinical outcome by simply comparing “d” with “a” patients 
(although the results did suggest a possible interesting association).
MRP-1 expression was correlated with actual relapse free survival and overall 
survival times in these chemotherapy treated patients. On preliminary analysis o f the 
results presented here, more MRP-1 positivity at diagnosis appeared to be associated 
with a shortened relapse free period (1-3 years) (Table 3.1.11.) in chemotherapy 
treated node positive patients. This analysis did not reveal such an association in 
node negative chemotherapy treated patients. A higher percentage o f node positive 
MRP-1 positive patients (51.1%) compared to MRP-1 negative patients (20.5%) 
relapsed within 3 years o f diagnosis. Again a markedly lower percentage o f M RP-1 
positive patients (15.6%) showed more than 8 years relapse free survival compared 
to 50% of M RP-1 negative patients showing 8 or more years relapse free survival. A 
similar trend was observed on analysis o f overall survival in node positive patients. 
56.6% of patients with MRP-1 negative tumours at diagnosis survived for at least 8 
years whereas, only 11.1% of M RP-1 positive patients survived for this length of 
time (Table 3.1.12). Again from this analysis, MRP-1 did not appear to be associated 
with a shortened overall survival period in node negative chemotherapy treated 
patients.
The possibility cannot be ruled out that expression o f MRP-1 at diagnosis may be 
associated with a poor prognosis regardless of the treatment that follows. However, 
56% of node positive chemotherapy treated patients with MRP-1 negative tumours 
at diagnosis survived for 8 or more years, compared to only 11% of M RP-1 positive 
tumours (Table 3.1.12.). Such an association was not observed in non-chemotherapy
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treated patients (Table 3.1.0). This preliminary analysis suggested that MRP-1 
expression may have predictive value in patients treated with a CMF based regime, 
in relation to overall survival and possibly a weaker association with relapse.
Kaplan Meier survival analysis o f node positive patients, revealed a significant 
association between MRP-1 expression and Overall survival time in these patients, 
but not Relapse free survival. A highly significant association was however, shown 
between absence o f M RP-1 expression at diagnosis and increased overall survival in 
both node negative and node positive chemotherapy treated patients with higher 
grade tumours ( grade III). This effect was not seen in patients with grade II tumours.
Multivariate analysis identified MRP-1 as an independent prognostic factor for 
overall survival but not relapse free survival in chemotherapy treated patients. When 
stratified according to nodal status; MRP-1 expression was revealed to be a highly 
significant independent prognostic factor for overall survival in node positive 
chemotherapy treated patients, but not in node negative patients.
When specific chemotherapy treatments were analysed, it appeared that this 
association between the absence o f MRP-1 expression at diagnosis and increased 
Overall survival and Relapse free survival, may possibly be stronger in patients who 
received standard CMF chemotherapy compared to those patients who received 
adriamycin in combination with CMF (ACMF) or who received Taxol (Table 3.1.13. 
-  3.1.1.16). However as the numbers o f patients studied is small when the 
chemotherapy treated group is sub divided by the type o f treatment (only 26 patients 
received ACMF) no definitive conclusions can be drawn regarding the difference 
between MRP-1 expression and overall and relapse free survival in these two groups. 
Rather, it can be concluded that absence o f M RP-1 protein expression at diagnosis in 
both node positive and node negative primary breast cancer treated with either 
standard CMF or CMF in combination with adriamycin is significantly associated 
with increased survival times in these patients. Nooter et a l, (1997b) have reported 
that in adjuvant chemotherapy treated node positive patients who received CMF, 
MRP-1 was also associated with shortened relapse-free survival and overall survival 
times. Their study did not however show an association in node negative patients.
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It can be concluded that absence of MRP-1 protein expression at diagnosis offers 
independent prognostic value with regard to overall survival in invasive breast cancer 
patients treated with CMF based chemotherapy, its prognostic value is significantly 
stronger in node positive patients. Results presented suggest that the prognostic value 
of M RP-1 expression is likely to yield the most significant prognostic power in node 
positive patients with a high histological grade (i.e. grade III) tumours. Its significant 
association with histological grade suggests that its expression is possibly associated 
with a more aggressive tumour phenotype in invasive breast carcinoma, associated 
with a worse outcome in invasive breast carcinomas
The question as to whether MRP-1 has predictive value in those patients who 
received CMF based chemotherapy is however more difficult to establish. 
Multivariate analysis o f all patients with invasive breast carcinomas showed that 
MRP-1 expression marginally failed to show significance as a prognostic factor for 
overall survival regardless o f chemotherapy status or nodal status. When patients 
were stratified according to chemotherapy status and node status, the prognostic 
value of M RP-1 was shown to be significant in chemotherapy treated patients only, 
suggesting that perhaps MRP-1 expression may have possible predictive value in 
patients treated with CMF based chemotherapy. However as numbers of 
representative tumours in certain subgroups in this study were relatively small, it 
would be necessary to carry out similar analyses on a larger tumour base to establish 
if  MRP-1 expression at diagnosis has possible predictive power.
MRP-1 protein expression values did not appear to correlate with MDR-1 protein 
expression. Previous studies have also failed to find a correlation between these two 
transport pumps (Filipits et al., 1996, Ferrero et al., 2000), although one previous 
study has reported that pre chemo Pgp and pre  and post chemotherapy MRP-1 
expression predicted tumour recurrence and patient death (Mechetner et al., 1997). 
Our results did not, however, suggest any such association between the expression of 
these two proteins. There did appear to be a slight correlation between MRP-1 and 
survivin protein expression in 63.2% o f patients studied, but the small number of 
patients analysed for both markers do not allow us to assess if this association is 
strong enough to be statistically significant. The relationship between these two 
proteins has not previously been investigated in breast cancer. No apparent
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correlation was observed between MRP-1 protein and either LRP or Bcl-2 protein 
expression.
The HER-2 proto-oncogene also referred to as cerbB-2, encodes a transmembrane 
tyrosine growth factor that is overexpressed in 25-30% o f breast carcinomas. As 
discussed in the introduction, expression o f HER-2 in relation to both prognosis and 
the response to cytotoxic and hormonal therapies has been investigated by several 
investigators. Overexpression o f this proto-oncogene has been associated with poor 
clinical outcome in node positive breast carcinomas; the correlation o f HER-2 and 
prognosis in node negative patients has produced more conflicting results (reviewed 
by Sahin 2000, Simon et al., 2001). HER-2 is currently the most promising marker 
under study in breast cancer, both as a marker o f poor prognosis and as an indicator 
o f cerbB-2 specific therapy. 1998 saw the approval o f the use o f trastuzamab 
(Herceptin), a recombinant MAb which targets HER-2 for use in the treatment o f 
breast cancer. It has recently been demonstrated that Trastuzumab increases the 
clinical benefit o f first line chemotherapy in metastatic breast tumours that 
overexpress HER-2 (Slamon et al., 2001).
During the course o f this thesis HER-2 protein expression was studied in a total o f 46 
untreated tumours from patients with invasive breast cancer. cerbB-2 protein was 
expressed in 27% (11/40) o f invasive breast tumours at diagnosis from chemotherapy 
treated patients and was expressed in 80% (4/5) o f tumours from patients who did 
not receive chemotherapy. Membranous cerbB-2 positivity is generally considered to 
be specific for HER-2/ neu overexpression and has been shown to correlate with 
gene amplification although for borderline cases, FISH is considered more definitive 
in predicting responsiveness to Herceptin. In contrast the significance o f cytoplasmic 
positive staining is still controversial. Tumours studied which showed only 
cytoplasmic positivity in this study were not considered positive. There has been a 
lot of controversy regarding cerbB-2 specific MAbs. The MAb CB11 which was 
used for this study was the MAb employed in a study which showed that 
overexpression o f cerbB-2 predicted poor clinical outcome (Keshgegian & Cnaan, 
1997).
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In our study cerbB-2 expression did not appear to be associated with node status, ER 
status, tumour size or histological sub-type (Table 3.1.7). Overexpression has been 
associated with the prognostically favourable ER positive phenotype (Bodey et al.,
1997).
On analysis of results it appeared that a weak association could be observed between 
lower expression levels of cerbB-2 protein and higher grade (grade III) tumours. This 
is an unexpected observation, overexpression o f HER-2 is generally associated with 
poor markers o f prognosis which would include high grade carcinomas (i.e. poorly 
differentiated). As the numbers o f grade I (3) and grade II (1) tumours in this group 
were small i.e. the majority o f the tumours (22) were grade III, this observation can 
probably be discounted.
On preliminary analysis it appeared that a much lower percentage of pre  treatment 
tumours from patients who are currently disease free showed cerbB-2 positivity (1/15 
node positive patients, 0/2 node negative patients) than those patients who relapsed 
and died o f disease. Tumours from 11/ 17 patients currently disease free were 
negative for both MRP-1 and cerbB-2. Again as was the case with MRP-1, where all 
o f the patients were diagnosed at different times, no conclusions can be drawn from 
these observations. On analysis o f actual Relapse Free Survival times, results suggest 
that cerbB-2 expression at diagnosis was strongly associated with a shortened relapse 
free period in node positive patients (Table 3.1.18). A higher percentage of node 
positive patients with cerbB-2 positive tumours at diagnosis relapsed within 3 years 
compared to node positive patients with cerbB-2 negative tumours. 43% of cerB-2 
negative tumours had a relapse free period of at least 8 years; all o f the cerbB-2 
positive tumours studied relapsed within 8 years. This association was not observed 
in node negative patients.
A similar association was observed on analysis o f Overall Survival times in node 
positive patients. It appeared that cerbB-2 expression was strongly associated with a 
shortened overall survival time in these patients. 60% of cerbB-2 positive patients 
survived less than 3 years following diagnosis compared to 15.4% of cerbB-2 
negative patients (Table 3.1.19). Again this was not observed in node negative 
patients.
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The first study revealing that HER-2 gene amplification could independently predict 
overall survival and disease free survival in node positive breast cancer using 
multivariate analysis was published by Slamon et al., (1987). Since then several 
studies have confirmed this association in patients treated with CMF, although a 
small number o f these did not find such an association (reviewed by Sahin 2000, 
Simon et al., 2001). However opinions on whether HER-2/ neu status should be used 
to routinely determine which patients might not get benefit from CMF are still 
mixed, some researchers are waiting for more validation or results before 
recommending such a predictor in the clinic (Ravidin 1999, Hamilton 2000).
cerbB-2 overexpression may also determine which patients have tumours which may 
be particularity sensitive to doxorubicin containing drug regimes (Paik et al., 1998, 
Thor et al., 1998, Yamauchi et al., 2001). Furthermore preliminary results suggest 
that it may also play a predictive role in response to paclitaxel (taxol) (Baselga et al„
1998). Recently it has been reported that topoisomerase II a  deletions and 
amplifications can predict response to epirubicin in cerbB-2 positive tumours 
(Jarvinen et al., 2000).
Thus results of our study are in agreement with overexpression of cerb-B2 in primary 
node positive breast cancer possibly being associated with a poor outcome i.e. 
shortened relapse free survival and overall survival in patients treated with an 
adjuvant CMF based regime.
To our knowledge, although it has been suggested that there may be a possible link 
between expression of M RP-1 and expression o f certain oncogenes such as cerbB-2, 
there does not appear to be any reported analysis of these two markers in relation to 
any possible role for their co-expression (Ito et al., 1998). When the co-expression of 
both cerbB-2 and MRP-1 proteins were analysed, results indicated that 75% of 
patients with MRP-1 positive / cerbB-2 positive tumours relapsed within 3 years. 
Only 26.7% of patients with MRP-1 negative / cerbB-2 negative tumours relapsed 
within this time (Table 3.1.21.). On analysis o f overall survival, again co-expression 
of these two markers was associated with a shortened overall survival only 13.3% of
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MRP-1 negative / cerbB-2 negative tumours survived for less than 3 years (Table 
3.1.22.). However in this case MRP-1 negative / cerbB-2 positive tumours exhibited 
similar overall survival times than those tumours that expressed both proteins.
These results suggest that co-expression of these two markers may be more strongly 
associated with a shortened relapse free survival and possibly with a shortened 
overall survival in breast cancer patients, than expression o f either o f these individual 
proteins. As the number o f node negative tumours studied was very small, it cannot 
be concluded that this observation o f an association between the co-expression o f 
MRP-1 and cerbB-2 patient outcome only applies to node positive patients. In 
addition again as the numbers studied were small, it was not possible to carry out 
statistical analysis on the co-expression o f these two markers and their association 
with relapse free survival and overall survival times. This interesting observation 
should be addressed in a larger tumour base to see if  it is indeed statistically 
significant. In addition this observation should be investigated in node negative 
patients also.
Apart from MRP-1, expression o f cerbB2 did not appear to correlate with any o f the 
other protein markers studied. Post treatment tumours from 17 chemotherapy treated 
patients were also investigated. cerbB-2 expression did not generally appear to 
increase following treatment with chemotherapeutic drugs although a slight increase 
in expression was observed in 2 patients. It can be concluded that cerb2B-2 
expression is not in general associated with exposure to a CMF based 
chemotherapeutic regime.
MDR-1/ Pgp expression in breast cancer has been extensively investigated. A meta 
analysis carried out o f MDR-1/ Pgp in breast cancer by Trock et a l, (1997) reviewed 
in detail all o f the 31 studies which had been published at that point. This review 
concluded that MDR-1/ Pgp is expressed in 27.1% of breast tumours using RNAase 
protection assay methods and 48.5% of tumours using immunohistochemistry 
methods; the latter have proved more sensitive than gene expression analyses in 
published studies to date. Trock et a l, (1997) also concluded that MDR-1/ Pgp 
expression is associated with treatment and with a poor response to chemotherapy in 
breast cancer. Pgp positivity has been associated with poor treatment outcome in
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both primary and advanced cancers; there is limited data regarding any possible 
association with outcome in metastatic disease (Lehart et al., 1996).
In this thesis MDR-1 Pgp expression was studied in 20 untreated tumours from 
patients who subsequently received chemotherapy; 70% of these chemotherapy 
treated patients showed MDR-1 positivity at diagnosis (Table 3.1.23). This 
percentage is higher than the average MDR-1 expression level observed with 
immunohistochemical studies as reviewed by Trock el al., 1997. However this is the 
first study o f MDR-1 in breast carcinomas using MAb 6/1C (Moran et al., 1997). 
Differences were observed between MAb 6/1C and MRK-16 expression in 
individual tumours both in the intensity of the staining and in the percentage of 
tumour cells stained; this is in agreement with previous reports outlining varying 
specificity and staining patterns o f Pgp specific antibodies (Bittl et al., 1993). Ideally 
two antibodies directed to different epitopes o f MDR-1 Pgp should be employed in 
such studies (Beck et al., 1996, Trock et al., 1997).
The results presented in this thesis indicate that expression of MDR-1 Pgp does not 
appear to be associated with ER status, age o f patients at diagnosis or node status in 
these invasive breast carcinomas. There was a very slight association o f MDR-1 
positivity with ER positive tumours, however as the numbers were small this was 
discounted. No conclusion can be drawn as regards association with histological 
grade as all of the tumours studied for MDR-1 Pgp expression were grade III; 70% of 
these tumours were MDR-1 positive. Again as regards association with tumour size a 
definite conclusion cannot be reached due to small sample size, the results however 
do suggest that MDR-1 appears to be associated more strongly with tumours that are 
less than 2 cm. Previous studies indicate that none o f the known prognostic 
attributes i.e. node status, tumour size, tumour histology, histological grade or ER 
status are significantly associated with expression o f MDR-1 Pgp (reviewed by 
Trock et al., 1997).
MDR-1 Pgp expression was studied in post treatment tumours from 17 of these 
patients. 4 pre  treatment tumours which were MDR-1 negative showed MDR-1 Pgp 
positivity following chemotherapy (all o f these 4 patients relapsed within 3 years). 
There appeared to be no increase in staining in those post treatment tumours that
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were MDR-1 positive at diagnosis. As the number o f patients examined was small it 
is not possible to conclude with statistical significance that MDR-1 Pgp expression is 
associated with chemotherapy treatment, but these preliminary results indicate that 
the question warrants further investigation.
In previous studies higher expression of MDR-1/ Pgp has been observed in patients 
who received MDR-1/ Pgp related drugs than that observed in tumours from patients 
treated with non-MDR-1/ Pgp related drugs (reviewed by Trock et ah, 1997). All of 
the patients studied for Pgp expression with the exception o f one who received 
adriamycin, a Pgp substrate, in combination with CMF, received CMF therapy. The 
drugs used in the CMF combination (i.e. cytclophosphamide, methotrexate, 5- 
fluorouracil) are not Pgp substrates.
On preliminary analysis, 77.7% of pre  treatment tumours from patients currently 
alive who have not relapsed were MDR-1 positive, compared to 55.5% o f those 
patients who relapsed and are now deceased. This observation suggests that MDR- 
1/Pgp expression is associated with a good prognosis. Again as with analysis o f other 
markers, as patients were diagnosed at different times no conclusion could be drawn. 
Trock et ah, (1997) reported that tumours with detectable MDR-1 Pgp were three 
times more likely to exhibit an incomplete response to cytotoxic therapy. To further 
explain our unexpected results, MDR-1 expression was correlated with relapse free 
and overall survival times. This analysis suggests that MDR-1 positive node positive 
patients are more likely to relapse within 3 years compared to MDR-1 negative 
patients, as regards overall survival a similar trend was observed, but the association 
was weaker (Tables 3.1.24.- 3.1.25.). Our initial unexpected observation of an 
association o f MDR-1 with a good outcome proved not to be the case, indicating as 
we have discussed that using the current status o f patients does not allow for correct 
interpretation o f markers with clinical outcome. No conclusion as regards node 
negative patients can be made as there were only 3 patients studied for MDR-1 Pgp 
expression. Previous studies addressing the expression of MDR-1 Pgp and any 
possible association with relapse free survival and overall survival times have proved 
conflicting. A number o f studies have associated MDR-1/Pgp expression reduced 
relapse free survival and overall survival times while other studies have failed to 
observe this association (reviewed by Trock et ah, 1997). These preliminary results
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suggest that expression of MDR-1 Pgp may possibly be associated with a shortened 
relapse free period in invasive breast cancer, however as the numbers are small it is 
not possible to carry out statistical analysis on these results.
LRP has been detected previously prior to and following treatment in breast cancer 
but results indicate that it does not play a prognostic/ predictive role in breast cancer, 
(Izquierdo et al., 1996, Linn et ah, 1997, Pohl et ah, 1999, Schneider et al., 2001). 
However a recent report has suggested that the combination o f LRP expression after 
chemotherapy treatment and  MDR-1 positivity before treatment has prognostic value 
in the determination whether axillary nodal invasion will occur (Schneider et ah, 
2001).
LRP protein expression was studied in pre treatment tumours from 14 patients with 
invasive breast cancer (12 chemotherapy treated). 4 LRP negative pre  treatment 
tumours showed some degree of LRP positivity following chemotherapy. Again as 
sample numbers are small it is not possible to conclude that LRP expression is 
associated with exposure to chemotherapeutic drugs. As the level o f expression of 
LRP expression observed in these tumours was low, it was unlikely that LRP was 
playing any significant role in these breast tumours. LRP expression values did not 
appear to correlate with expression o f any other o f the markers studied.
Bcl-2 is another well established prognostic marker in breast cancer being associated 
with a favourable outcome. A number o f studies have shown that Bcl-2 positivity 
correlates with positive hormone receptors and is associated with a well 
differentiated phenotype (Takei et ah, 1999, Nakopoulou et al., 1999, Rochaix et 
ah, 1999).
Bcl-2 protein was studied in tumour material from chemotherapy treated patients 
obtained prior to treatment. Bcl-2 protein was expressed in 61.5% of these tumours at 
diagnosis. The proportion o f patients showing Bcl-2 positive staining is in agreement 
with previous immunohistochemical studies of Bcl-2 protein expression in breast 
cancer (Hellemans et ah, 1995, Tanaka et ah, 2000). There did not appear to be any 
increase in BCL-2 expression following treatment, suggesting that BCL-2 expression 
is not associated with exposure to chemotherapeutic drugs. Due to the small numbers
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studied it could not be concluded if the expression of Bcl-2 was associated with age 
of patients, node status, ER status, tumour size or histological grade
The results suggest that there may be a weak association between BCL-2 negative 
tumours and a shortened relapse free period and overall survival times compared to 
BCL-1 positive tumours; a higher percentage of BCL-2 negative patients relapsed 
and died within 3 years compared to BCL-2 positive patients. As the numbers are 
small statistical analysis cannot be carried out, however it is possible that BCL-2 
may be a good prognostic marker in these patients which is not an unexpected result. 
A collaborative study looking at BCL-2 mRNA expression by RT-PCR in the same 
large series o f invasive tumours as MRP-1, showed that there was a statistically 
significant association between BCL-2 negativity and reduced relapse rate and 
reduced survival rate in these patients (personal communication Cronin et a l, ).
Several studies have reported that Bcl-2 expression is associated with a longer 
disease free/ relapse free period (Binder et al., 1995, Hellemans et a l, 1995, 
Kobayashi et a l, 1997, Jansen el a l, 1998, Itaya et al., 1999). Reports regarding 
BCL-2 as a predictor o f response to adjuvant chemotherapy are conflicting with 
several studies finding that BCL-2 did not predict response to various 
chemotherapeutic regimes including CMF, epidoxorubicin or doxorubicin alone 
while other studies have failed to do so (reviewed by Daidone el a l, 1999). It is 
generally felt that there is not enough evidence to date to support such a predictive 
role for Bcl-2 in breast cancer (Hamilton 2000).
Bcl-2 and survivin protein expression values appeared to correlate in 50% of 
chemotherapy treated patients, i.e. there was no correlation between these two 
proteins. There did not appear to be a correlation between BCL-2 and any o f the 
other markers studied. Again as mentioned previously it is not possible to draw any 
final conclusions regarding comparative studies with survivin immunohistochemistry 
as the scoring system employed was slightly different to that involving other MAb 
markers.
At the time o f this investigation a new MAb to the recently discovered anti apoptotic 
survivin protein was generated in this laboratory (Cleary et a l, personnal
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communication). As the expression of survivin protein had not, then been 
investigated in breast cancer it was decided to look at the expression of antibody 1C5 
in these breast tumours to establish the role, if  any o f survivin protein expression in 
this malignancy. Investigation of survivin as a possible marker o f 
chemoresponsiveness has not been reported to date. Presently survivin protein has 
been associated with a poor prognosis in several human cancers including breast 
cancer, colorectal cancer and ovarian cancers (Tanaka et al., 2000, Sarela et a l, 
2000, Yoshida et al., 2001).
Survivin protein expression was studied in 24 untreated breast tumours; 22 o f these 
patients had received chemotherapy. Survivin protein expression was observed in 
86.3% of chemotherapy treated patients at diagnosis. This proportion o f tumours 
expressing detectable survivin protein is in agreement with a recent study by Tanaka 
et a l, (1999) where survivin protein was detected in 70% o f breast cancer patients 
investigated. There appeared to be considerable heterogeneity between the intensity 
o f the staining observed and in the number of tumour cells stained within individual 
tumours. The number o f positive tumour cells stained within individual tumours 
varied between 20 and 100% in the study by Taneka et al., (2000). However the 
intensity o f the staining was usually homogenous in their study; this difference may 
be accounted by the fact that we were using a MAb recognising a different epitope o f 
survivin protein. Different staining features when using different MAbs have been 
observed frequently (Bittl et a l, 1993)
Nuclear survivin positivity was observed in a number o f tumour samples. Survivin 
positive staining had previously been observed in the cytoplasm of tumour cells, 
however recent studies have reported detection of this protein primarily in the 
nucleus o f hepatocellular carcinoma cells, in the nuclei o f glandular epithelial cells in 
the normal human endometrium and in gastric tumour cells (Ito et a l, 2000, Konno 
et a l, 2000, Okada et al.,2001). It has also been shown that nuclear survivin 
positivity is associated with a shortened disease free survival in ovarian carcinomas 
(Yoshida et al., 2001). The significance o f this nuclear positivity should be addressed 
in any further study in breast carcinomas.
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As previously outlined Survivin protein expression appeared to correlate with MRP- 
1 (62.3%) and MDR-1 protein (71.4%) expression chemotherapy treated patients. 
Bcl-2 and survivin protein expression values appeared to correlate in 50% of 
chemotherapy treated patients, thus it can be concluded that there is no correlation 
between these two proteins. In addition, as the scoring system for 
immunohistochemical analysis o f survivin (section 3.1) differed from that o f the 
other proteins studied, no direct comparative conclusions can be drawn. In contrast 
Tanaka et a l, (2000) reported a close association between these two proteins; a 
positive correlation has been shown between these two in other malignancies 
(Thompson et a l, 1995, Yang et a l, 1996, Kawasaki et a l, 1998, Adida et a l, 1998). 
Perhaps if  a larger number o f tumours were analysed for these two proteins such an 
association would also be shown in these invasive breast cancer patients. There did 
not appear to be any correlation o f survivin protein with either cerbB-2 protein or 
LRP protein expression observed.
As survivin protein was observed in the majority o f tumours studied it was not 
possible to correlate survivin expression with node status, ER status, tumour size or 
histological grade.
On initial analysis, results suggested that expression of survivin protein at diagnosis 
may be possibly associated with shortened relapse free survival (i.e. 1-3 years). 
However on analysis o f overall survival times, it appeared 38% of patients with 
survivin positive tumours survived for 8 or more years, compared to only 28% of 
survivin negative tumours (Table 3.1.26.). This observation suggested that survivin 
expression at diagnosis might be actually associated with a good prognosis i.e. longer 
overall survival in chemotherapy treated patients, but the numbers studied were 
small, therefore it was not possible to carry out statistical analysis. Tanaka et al, 
(1999) found that survivin expression in breast carcinomas, in association with a 
reduced apoptotic index was indicative o f a poor prognosis. In general survivin 
expression has been associated with unfavourable prognostic markers, increased risk 
o f recurrence and increased resistance to chemotherapy (reviewed by Altieri et al.,
2001). However nuclear survivin expression has been associated with a favourable 
prognosis in gastric cancer patients (Okada et a l, 2001). A larger series o f patients
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should be investigated in order to address these observations further and see if  they 
are significant.
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MDR-3 Pgp has now been shown to transport several cytotoxic drugs including 
digoxin, pacitaxel, daunorubicin, vinblastine and invermectin (Smith el al., 2000). 
Previously MDR-3 has been found to be associated with the drug resistance in 
certain B-cell leukaemias (Herweijer et al., 1990, Nooter et al., 1990). This Pgp has 
also been demonstrated to be responsible for the drug resistance in an MDR-3 
transformed yeast strain (Kino et al., 1996). However the role o f  MDR-3, if  any, in 
breast cancer and other solid cancers, and a clearer explanation o f its possible role in 
the drug resistance o f B-cell malignancies remains to be solved. At the time o f 
commencement o f this thesis, there were no MDR-3 specific MAbs available 
commercially, so it was decided to attempt to generate a MAb which was specific 
for the MDR-3 encoded gene product. Such an MAb would be useful in establishing 
further the role, o f MDR-3 outside the liver.
This laboratory had successfully produced specific MAbs to the MDR-1 encoded 
gene product and Topoisomerase I la  using short synthetic peptides as immunogens 
(Moran et al., 1997). In an attempt to produce a MAb which would specifically 
recognise the MDR-3 encoded gene product, a peptide corresponding to the 
intracellularly located amino acids, 13-24 (RPTSAEGDFELG) of MDR-3 encoded 
Pgp which resides in the N-terminal part o f the protein was choosen following 
alignment searches o f the EMBL Swiss-Prot protein sequence database using the 
Mail-FASTA program. The chosen peptide showed insignificant homology with 
MDR-1 encoded Pgp. The fusion protein used by Smit et al. (1994) to generate the 
REG-1 polyclonal antibody consisted of amino acids 2-58 from the N-terminal 
region of MDR-3 Pgp. The AVLCL2 polyclonal also produced by Smit et al. (1994), 
using a 13 amino acid synthetic peptide shared 7 amino acids with the synthetic 
peptide used for the production o f antibody 6/1G. However this antibody appeared to 
work well on Western blotting only and did not appear suitable for 
immunohistochemical studies.
Due to time constraints it was decided to carry out a combination o f in vitro and in 
vivo immunisation with the choosen peptide coupled with the carrier protein BSA in 
an attempt to generate an MDR-3 specific MAb. Following screening by ELISA 
supernatant 6/1G was chosen for further study. This hybridoma was cloned by
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limiting dilution prior to further characterisation. Isotype analysis of antibody 6/1G 
revealed that it to be subclass IgM. This was not an unexpected result considering 
that an in vitro immunisation had been used and the number o f boosts administered 
to mouse was small, an effective secondary response may not have been elicited in 
the animal. Thus there was an increased likelihood of isolating an IgM antibody 
(section 1.2.).
Preliminary characterisation of antibody 6/ 1G was carried out using the MDR-3 
transgenic cell lines, V O l-V O l and VIM # 1 and FVB # C, their parental cell line. 
Immunofluoresence studies with antibody 6/ 1G on live cell preparations o f these 
control cell lines revealed no detectable staining indicating that the epitope 
recognised by antibody 6/ 1G was not expressed on the cell surface. So it appeared 
that antibody 6/ 1G was recognising an internal epitope which would have been 
expected given that the peptide chosen corresponded to amino acids which are 
believed to be intracellularly located in MDR-3 Pgp. Western blotting studies with 
antibody 6/1G identified a single band at 170kDa on cell lysate preparations o f the 
MDR-3 transgenic cell lines, V O l-V O l and Vim # 1. In their successful attempt to 
produce MDR-3 specific polyclonal antibodies Smit el al. (1994) observed that the 
apparent molecular weight o f MDR-3 Pgp in V O l-V O l cells was approximately the 
same as for MDR-1 encoded Pgp. By comparison with MAb C219 this group 
showed that V O l-V O l cells do not express MDR-1 Pgp. Previous work in this 
laboratory has shown by both immunocytochemistry and Western blotting methods 
using BRI MAb MDR-1, 6/1C that both the V O l- V O l and the Vim # 1 cell lines do 
not express MDR-1 Pgp (Moran et al., 1997). It appeared, therefore, that antibody 
6/1G was specifically recognising the MDR-3 gene product. These Western blotting 
results were confirmed by immunocytochemical studies on fixed cells which 
revealed consistent cytoplasmic/ plasma membranous staining on both V O l-V O l 
and Vim # 1 cells (section 3.3.5). Negligible staining was observed on preparations 
of FVB # c cells. The C219 MAb, which recognises the MDR-1 and MDR-3 
encoded gene products, gave a similar pattern o f reactivity on the MDR-3 cell lines. 
Two of the three polyclonal antibodies; anti-REG 1 and anti-REG 2 produced by 
Smit et al. (1994) showed a similar pattern of staining to that described here with
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antibody 6/1G i.e. specific staining o f the plasma membrane and cytoplasm in MDR- 
3 transgenic cells.
For additional characterisation a small number o f cell lines o f known MDR-3 status 
were probed with antibody 6/ 1G. As expected these cell lines showed MDR-3 Pgp 
reactivity patterns which reflected mRNA levels previously studied, indicating again 
the specificity o f antibody 6/ 1G for MDR-3 encoded Pgp. Negligible staining was 
observed on the ovarian carcinoma cell line, A2780; this cell line has previously 
been shown not to express the MDR-3 gene (Herweijer et al., 1990). The multi drug 
resistant non-small cell carcinoma cell line, DLKP-A and the sensitive DLKP cell 
line showed weak staining with antibody 6/1G on both immunocytochemical and 
Western blot analysis; DLKP-A and DLKP have previously been shown to have low 
level MDR-3 gene expression using RT-PCR (O’Driscoll, PhD thesis 1994).
As the liver is known to express high levels o f MDR-3 RNA and protein (section
1.18.2) archival formalin fixed paraffin wax embedded tissue was examined for 
reactivity with antibody 6/ 1G. An overall high level of reactivity was observed with 
antibody 6/1G in this tissue. No pre  treatment of tissue with antigen retrival methods 
was required, indicating that this antibody recognised a formalin resistant epitope 
and therefore would be useful for assessment of MDR-3 Pgp status o f archival 
material. Positive staining with antibody 6/1G was observed in hepatocytes, with 
specific staining observed on canalicular membranes. We have previously shown low 
level MDR-1 reactivity in liver (Moran et al., 1997). Low level reactivity with 
antibody JSB-1 (MDR-1 specific) and strong reactivity with MAb C219 (which 
recognises both the MDR-1 and MDR-3 encoded gene products) has also been 
observed in liver (Bittl el al., 1993). These results reflect the documented distribution 
patterns o f MDR-1/ MDR-3 (Chin et al., 1989, Smit et al., 1994).
In order to further define a role for MDR-3, it was decided to probe a panel o f human 
tumour cell lines with this MAb. MDR-3 Pgp reactivity was observed in a wide 
range of tumour cell lines o f differing histological origin including ovarian, lung, 
breast and nasal carcinoma cell lines. Expression was also detected in both sensitive 
and MDR variants in some of these cell lines. These results suggest that MDR-3 is 
more widely expressed than thought originally, although its specific role in these
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tumours requires further investigation. The fact that MDR-3 has now been proven to 
transport a range o f cytotoxic drugs albeit at a lower rate than MDR-1 (Smith et at.,
2000), suggests again that the role o f MDR-3 in malignancies warrants further study.
It was decided to purify antibody 6/1G before further studies were carried out on 
archival tissue. It was thought that purification might aid the interpretation of 
staining patterns as immunohistochemical analysis o f liver showed apparent “sticky” 
non -  specific staining. Since it is well documented that IgM antibodies are unstable 
and difficult to purify, conventional affinity chromatography methods cannot be 
utilised for purification o f IgM antibodies. A purification system was used which 
employed immobilized mannan binding Protein (MBP); such a system had 
previously been successfully used for the purification o f IgM from ascites fluid 
(Nevens el al., 1992). However this system did not result in detectable recovery o f 
IgM. It was decided to use an alternative approach, adaptation o f the 6/ 1G 
hybridoma to grow in protein free medium. Resulting supernatants were tested by 
Western blotting and immunocytochemistry on control cell lines as before. This 
measure proved very satisfactory and results indicated that antibody was being 
successfully produced by this means. As may have been expected RID analysis of 
the quantity o f antibody present in supernatants indicated that the amount o f IgM was 
less that that produced in static flasks with the standard DMEM medium used 
routinely in this laboratory for growing o f hybridomas. However it did appear, 
particularly on immunocytochemical analysis, that the protein free antibody 
supernatant resulted in more defined staining with antibody 6/ 1G.
A panel of invasive breast carcinomas was investigated with antibody 6/1G, in order 
to further elucidate the role o f MDR-3, if  any, outside the liver. MDR-3 Pgp was 
expressed to varying extents, in the majority of tumours studied. To our knowledge 
this is the first report of MDR-3 Pgp expression in invasive breast carcinomas. A 
small number o f post chemotherapy treated tumours were studied, MDR-3 levels did 
not appear to increase following chemotherapeutic treatment indicating that MDR-3 
expression was not associated with exposure to chemotherapeutic drugs. MDR-3 
expression did not appear to correlate with known patient or tumour characteristics. 
In addition MDR-3 expression did not appear to correlate with any o f the other MDR 
associated proteins studied in these patients. Taken together with results from cell
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lines, it would appear that MDR-3 Pgp is probably expressed in a wider range o f 
tumour types than that was thought originally. However although it may have 
widespread expression, its exact function in breast cancer and other solid 
malignancies needs to be addressed.
As the human MDR-3 gene is closely related to the murine mdr-2 gene, normal 
mouse kidney and liver together with a small number o f cell lines from different 
species available to us were examined with antibody 6/1G. Antibody 6/1G identified 
a 170kD band on preparations of the Buffalo rat liver cell line BRL-3A but showed 
very low level reactivity on the African green monkey kidney cell line, BSC-1. A 
170kD band was also identified on mouse liver and kidney preparations. These 
results reflected previously determined mdr-2 mRNA expression patterns for these 
particular tissues (Croop el al., 1989, Teeter et a l, 1990), and indicated that antibody 
6/1G cross-reacted with the mdr-2 gene and may therefore be useful for studies of 
cross-species MDR-3 encoded Pgp expression.
As previous reports of MDR-3 gene expression had been shown to be limited to 
leukaemias o f B cell origin it was attempted to obtain a small panel o f both B cell 
and T cell leukaemias in order to characterise antibody 6/1G further. Pro 
lymphocytic leukaemia is a variant o f chronic lymphocytic leukaemia (CLL) which 
is usually refactory to chemotherapy effective in CLL. High expression of MDR-3 
has been observed in cases o f B cell pro lymphocytic leukaemia (PLL) with no 
MDR-1 expression whereas t cell PLL cases have been shown to have no MDR-3 
expression but exhibit high levels o f MDR-1 (Nooter et a l, 1990, Herweijer el al., 
1990).
As it had been indicated that MDR-3 may be involved in drug resistance in certain 
B-CLL leukaemias, it was decided to look at expression of antibody 6/ 1G in a 
range o f B-cell leukaemias to address further any possible prognostic role for MDR- 
3 and whether it may be involved in chemotherapy resistance in these haematological 
malignancies (Nooter et al., 1990, Herweijer et a l, 1990). For comparison MDR-1 
Pgp levels were also examined using BRI MDR-1 MAb, 6/1C. MDR-1/ P170 is 
thought to be implicated as a cause o f clinical resistance in AML and Multiple 
Myeloma (MM) and possibly in late stages o f ALL and NHL. The significance of
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MDR-1 /P-170 expression in other haematological malignancies remains to be 
clarified.
Previous studies have shown that in general B-CLL leukaemias exhibit both MDR-1 
and MDR-3 gene expression (Herweijer el a l, 1990, Sonneveld el a l, 1992, Nooter 
and Sonneveld 1993, Ludescher et al., 1993). MDR-1 and MDR-3 Pgp expression 
were detected in two post-treatment samples o f B-CLL. MDR-1 positivity was 
observed in both malignant and normal cells whereas MDR-3 positivity was confined 
to malignant cells. It is not thought that MDR-1 plays a major role in CLL which is 
in agreement with our results. A differential pattern of MDR-3 positive staining was 
observed in both cases with intense MDR-3 positivity, possibly indicating a more 
malignant phenotype being associated with the larger more malignant cells. This was 
not observed with MDR-1 positive staining.
Prior treatment has been associated with higher MDR-3 gene expression levels (no 
influence on MDR-1 levels) in one study (Herweijer et al., 1990). Later work did not 
show such a correlation (Sonneveld et a l, 1992, Ludescher et a l, 1993). In patients 
with advanced B-CLL, MDR-3 mRNA expression (not MDR-1 expression) was 
significantly higher than in early stage disease (Sonneveld 1992). Ludscher et al., 
(1993) also found a tendency towards higher MDR-3 mRNA expression in patients 
with advanced stages o f CLL. These observations together with these studies suggest 
that MDR-3 overexpression (in our case as shown by intense MDR-3 positivity using 
antibody 6/1G) may represent a marker of a more malignant phenotype/ more 
aggressive disease in B-CLL.
As we also had access to a small panel o f acute myleoid leukaemia (AML) cases we 
also looked at expression of MDR-1 and MDR-3 Pgp in these malignancies. In our 
study two untreated cases of AML (FAB (see section 1.5.1.), MO and M l ) showed 
MDR-1 positivity and were both negative for MDR-3. A stage M5a patient showed 
weak MDR-1 positivity but showed intense MDR-3 positivity. The MDR-1 
expression observed is in agreement with previous studies where the MDR-1 gene 
has shown to be frequently expressed at diagnosis (i.e. prior to treatment) and at 
relapse. A review on AML by Marie et al. (1996) has reported a high correlation
228
between P-170 overexpression and clinical drug resistance. It is generally accepted 
that Pgp/ MDR-1 expression constitutes an unfavourable prognostic factor in AML.
Reports vary regarding the levels o f MDR-1 expression within the various FAB 
classes o f AML. One comprehensive study has reported that Pgp overexpression was 
detected more frequently in classes M4, M5A and M5B and less frequently in class 
M3 (Nussler el al., 1996). This M3 promyelocytic subtype is particularly sensitive to 
chemotherapy. As the number o f cases in our study was small Pgp expression cannot 
be associated with particular subclasses.
To date MDR-3 expression has not been reported in AML. In our study one AML 
M5A patient showed intense MDR-3 positivity in monoblasts. Initially it was 
thought that this AML case could be a conversion from ALL; such a transformation 
is commonly observed in childhood AML and is associated with treatment with 
Topoisomerase II a  inhibitors. This patient had not, however, received any prior 
treatment.
Another explanation considered, was that since AML stage M5a has an 
undifferentiated monoblastic lineage; the possibility existed that MDR-3 is not 
expressed in certain sub types: MO, M l, M2 and M3, all o f which have myeloblastic/ 
myelocytic morphology. Obviously MDR-3 reactivity in a wider range o f AML 
subtypes would need to be examined to investigate these observations further. 
Perhaps it is the case that MDR-3 expression is restricted to the M5a and M5b 
subtypes which have a monocytic morphology. It has already been suggested that 
MDR-3 expression may be restricted to certain B-cell developmental stages; no 
MDR- 3 expression has been found in MM which presents with end stage B-cells 
(Herweijer et al., 1990). MDR-3 expression appears to be restricted to those 
malignancies which represent intermediate and mature B-cell developmental stages; 
no MDR-3 was found in malignancies representing early B-cell development or in 
very mature B-cell tumours such as Waldenstrom and multiple myeloma (MM), in a 
study carried out by Nooter and Sonneveld (1993).
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Interestingly in one B-NHL we examined the malignant cells comprised o f 
lymphoplasmacytoid cells which are late stage B-cells; this sample was negative for 
both MDR-1 and MDR-3. Our preliminary results suggest that investigation o f 
MDR-3 Pgp in representative cases from AML patients with various sub classes o f 
the disease should be carried out in order to further define the association between 
MDR-3 and the B cell developmental stage.
Most previous work on MDR-1 encoded Pgp in NHL has been performed on frozen 
lymph node sections. In general more MDR-1/ Pgp expression is seen in treated than 
untreated patients. There appears to be no difference in Pgp expression between high 
and low grade lymphomas and between B and T sub types (Marie et ah, 1996). Adult 
T-cell lymphoma (ATL) has been shown to frequently express MDR-1/ Pgp at 
presentation (Kuwazuru et al„ 1990). As to whether MDR-1/ Pgp is an indicator o f 
better clinical response; three studies have shown a correlation (Pileri et ah, 1991, 
Cheng et al., 1993, Rodriguez et ah, 1993). A larger study did not show such a 
correlation (Niehans et ah, 1992). To date only one study has looked at MDR-3 
mRNA expression in B-NHL, where expression was observed in 9 out o f 21 B-NHL 
patients (Nooter and Sonneveld 1993). As we have already outlined in the results 
section, the B-NHL cases in our study (mantle cell, follicle centre and unclassified B- 
NHL) showed varying levels of MDR-1 and MDR-3 Pgp expression. A high level o f 
MDR-3 positivity appeared to develop following treatment in a case o f follicle centre 
lymphoma (atypical, CD5+ve). More work is obviously required to investigate 
whether MDR-3 expression is significantly related to treatment in B-NHL, and also 
to assess the significance o f the MDR-1/ MDR-3 expression levels observed in other 
subtypes o f this malignancy.
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A new method for the generation o f novel MAbs using dewaxed formalin fixed 
paraffin embedded archival tissue as an immunogen was successfully developed in 
this laboratory; antibodies directed against archival normal kidney have been 
generated and one of these, antibody 1/11C has been partially characterised (Moran 
et a l, 1998). As discussed in section 1.9. antibody epitopes are often masked or 
denatured during routine formalin fixation and processing of tissue; many antibodies 
therefore cannot be used for immunohistochemical analysis o f archival material. 
Immunising with formalin fixed routinely processed tissue, facilitates the generation 
o f MAbs against cellular antigens preserved during routine fixation and processing 
and which will therefore be useful in retrospective studies.
In an attempt to isolate possible novel breast cancer antigens, formalin fixed paraffin 
embedded breast tumour tissue was employed as an immunogen. An archival tumour 
was chosen from the group o f invasive breast cancer tumours being investigated for 
expression o f MDR associated protein expression (section 3.1). This tumour 
specimen, which was from a patient who relapsed with disease and died, was 
obtained at surgery, prior to the patient receiving CMF treatment. This pre  treatment 
tumour, on immunohistochemical analysis did not appear to show Pgp or MRP-1 
immunoreactivity to any great degree, suggesting that neither o f these transport 
pumps was responsible for the observed clinical resistance. Thus, it was hoped that 
MAbs recognising possible novel antigens associated with resistance in breast cancer 
would be generated.
Following the method of Moran et al., (1998), with minor modifications, antibodies 
to dewaxed formalin fixed paraffin embedded breast invasive ductal tumour tissue 
were successfully generated. The initial screening method i.e. immunohistochemical 
analysis o f 375 positive clones on control breast tumour tissue was very time 
consuming but proved very discriminating allowing for the isolation o f supernatants 
with very discrete staining patterns.
A possible problem with this system could o f been the introduction of potentially 
toxic/ dangerous substances into the host mouse via the dewaxing o f the immunogen 
and earlier formalin fixation/ tissue processing, but this was proved not to be the 
case. The excised spleen, on observation did not appear to have a healthy appearance
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as was normally observed following immunisation with various protein immunogens 
routinely employed in this laboratory. The spleen in this case was darker than normal 
suggesting it was haemorraghic, in addition it also had an atrophic appearance. This 
was also observed with the generation of the MAb directed to normal kidney; 
however again, despite this observation, it proved that high numbers o f viable spleen 
cells were indeed available for fusion (Moran et ah, 1998).
Following repeated immunohistochemical screening on control tissue sections 7 
hybridoma clones were expanded. As all o f these supernatants resulted in staining 
patterns which were very similar i.e. intense cytoplasmic reactivity (and membranous 
reactivity in some cells) o f tumour cells it appeared, that these 7 hybridomas were 
secreting antibodies which were probably recognising the same antigen or a very 
closely related antigen. Following further screening, supernatant 5C3 was chosen for 
further study.
Antibody 5C3 showed intense cytoplasmic reactivity in tumour cells in all 3 control 
tumour blocks, however some reactivity was also observed in endothelial cells and 
muscle/ stromal cells. When viewed at high power, antibody 5C3 appeared to show 
positivity which appeared to be radiating towards the plasma membrane in a manner 
somewhat similar to that of cytokeratins/ intermediate filaments, suggesting that the 
antigen being recognised may be an intracellular filament like component. This was 
only an observation, at this stage it was not possible to assume from antibody 
staining patterns that the antigen reactive with antibody 5C3 was associated with any 
specific cell type. Preliminary studies on live cells did not indicate that the antigen 
was expressed on the cell surface, which was the case with the MAb generated using 
similar methodology by Pancino et ah, (1990). Obviously detailed ultrastructural 
analysis (i.e. electron microscopy) would need to be carried out to ascertain the target 
localisation o f this antigen.
In one particular tumour control block however very intense staining was observed in 
individual tumour cells invading lymphatic channels (Figure 3.1.2.). A common 
feature o f malignant tumour cells is their ability to promote the growth of 
surrounding fibrous tissue; this process is known as desmoplasmia. The 
desmoplasmic stromal reaction observed in this tumour was confirmed by the
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histopathology report. Also, on a number of invasive tumours there appeared to be 
more intense 5C3 staining associated with infiltrating tumour cells compared to the 
non-invasive DCIS (comedo type) component, which often accompanies invasive 
ductal tumours (Figure 3.1.1.).These observations o f increased staining with antibody 
5C3 on infiltrating tumour cells suggested that the antigen recognised by 5C3 may 
possibly be associated with the invasion/ metastasis processes in breast cancer. 
However, this difference was not considered significant enough to confirm such as 
association with an infiltrating phenotype. Considerable variability in staining 
patterns was observed in this panel o f tumours, ranging from all o f tumour cells 
staining to individual tumour cells exhibiting intense immunoreactivity. Such 
heterogeneity of antigen expression has been reported previously in breast 
carcinomas, in different renal cell carcinomas and among tumour cell populations in 
any particular renal cell carcinoma with MAbs raised to breast carcinoma cells and 
renal carcinoma tissue (Stacker et al., 1985, Yoshida & Iman 1989). It has been 
reported that such heterogeneity in the expression o f cell surface antigens is cell 
cycle dependent (Schlom et al., 1985, Grenier et al., 1987). Perhaps the expression 
reactive 5C3 antigen was also cell cycle dependent, thus contributing to the 
heterogenous expression observed.
There did not appear to be any increase in 5C3 positivity associated with post 
treatment tumours, suggesting that chemotherapy treatment did not appear to have 
any effect in the expression of the 5C3 reactive antigen. In addition positive staining 
was not exclusively associated with tumour cells, normal breast ducts also showed 
reactivity with antibody 5C3. The expression of antibody 5C3 was also evaluated on 
a small panel o f non malignant breast tissues. Heterogenous expression o f antibody 
5C3 was observed in these benign breast tumours known as fibroadenomas.
A panel o f cell lines derived from various human breast cancers including a number 
o f ductal breast tumours were also studied. As expected strong reactivity was 
associated with all breast tumour cell lines examined, although there were some 
differences in the intensity o f the staining observed. As antibody 5C3 was apparently 
showing similar reactivity in ductal breast cells lines to that seen in tumour sections 
from the ductal tumour block which was used as immunogen, this suggested that this 
antibody was recognising an antigen directed against a conserved native epitope in
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vivo rather than to an artificial neo epitope generated during the fixation/ processing. 
The non tumourogenic breast cell line MCF-10A appeared to have a reduced level o f 
staining compared to breast tumour cell lines. However as this was the only non 
cancer breast cell line available, no definitive conclusion could be drawn from this 
observation. In agreement with the heterogenous staining patterns observed on 
archival breast tumours, considerable variations both in the intensity and in the 
numbers o f tumours cells staining were also observed with cell lines. Thus the 5C3 
reactive antigen appeared to be heterogenously expressed by all o f the breast tumour 
cell lines investigated irrespective of their histological subtype and in addition this 
expression did not appear to be confined to malignant breast phenotypes.
Obviously the best outcome in the generation of MAb against tumour tissue would 
be the recognition o f cellular antigen totally confined to malignant tissue with no 
expression associated with normal tissue. Although several MAbs have been 
generated against breast cancer associated antigens, very few o f these recognise 
antigenic determinants which are exclusively expressed in breast cancer and not in 
normal tissue (section 1.4.3. ) These preliminary results suggested that antibody 5C3 
was not recognising a specific breast tumour associated antigen, it was more likely 
that this antigen was an as yet unidentified breast antigen expressed in the normal 
breast which may become over expressed (or possibly underexpressed) during the 
malignant process.
A number o f archival ovarian tumours together with a panel o f tumour cell lines o f 
various histological origins including ovarian, lung and leukaemia showed varying 
degrees o f 5C3 reactivity, indicating that expression of the 5C3 reactive antigen was 
not confined to breast tumours, it appeared to have a wide spectrum of reactivity 
among different tumour types. These characterisation studies did reveal that the 
sensitive variant o f the non small cell lung tumour cell line, DLKP and the ovarian 
adenocarcinoma cell line, OAW42 appeared to show weaker reactivity with antibody 
5C3 than their MDR variants, again as this was only observed in 2 cell lines no 
conclusion could be made. Another observation was a melphalan drug selected 
variant o f the human nasal carcinoma cell line which failed to show any reactivity 
with antibody 5C3, however until 5C3 expression is studied in the parental RPMI 
nasal carcinoma cell line, the significance o f this observation cannot be addressed.
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In agreement with immunocytochemical analysis, results from Western blot analysis 
with antibody 5C3 indicated that the reactive antigen is heterogenously expressed in 
number o f breast carcinoma cells lines including a number o f ductal tumour cell lines 
and in a non tumourogenic cell line (section 3.3. ). Again results indicated that this 
antigen was not exclusively expressed by breast carcinoma cell lines; expression was 
also observed in lung, ovarian, and colon tumour cells lines. These Western blotting 
studies revealed a series o f bands reactive with antibody 5C3 at approx. 210kDa, 
160kD,a lOOkDa and 50kDa on crude cell lysates o f the ductal breast tumour cell 
lines, ZR-75-1, BT-20, MDA-MB-231 and MDA-MB-435S. However the relative 
expression of these bands appeared to vary among some cell lines and individual 
Western blot.. Interestingly a lot o f background was observed when membranes were 
blocked for longer them one hour with 5% dried milk powder (Blotto), the standard 
blocking system used in this laboratory. This observation suggested that the 5C3 
reactive antigen was possibly reacting with a component in human milk.
A very distinct band at higher than 210kDa was consistently identified on the ductal 
carcinoma cell line, ZR-75-1; this band appeared to be at a slightly lower molecular 
weight in all other cell lines probed with antibody 5C3. This band was consistently 
identified on all immunoblots regardless o f the relative expression of the lower 
bands, suggesting that this may be the major band. The ovarian and colon tumour 
cell lines which were probed with antibody 5C3 again revealed similar bands to those 
identified in breast cell lines, however the 210kD was not detected as strongly in 
these cell lines as was observed in some of the breast cell lines. One possible 
explanation for the observed heterogeneity o f the 5C3 reactive bands could be that o f 
different glycoslyated forms of this protein being expressed by different cell lines. 
Glycosylated proteins when analysed on SDS-PAGE generally show higher than 
expected molecular weights. It is possible that such altered glycosylation could result 
in different proteins with different antigenic profiles amongst various cell lines 
studied. Aberrant glycosylation is one of the many molecular changes that 
accompany malignant transformation. Such altered glycosylation o f mucins is 
thought to probably be responsible for many antigenic differences in mucin 
expression between carcinomas and adjacent normal epithelial tissues (reviewed by 
Devine & Me Kenzie, 1992).
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As a supply of normal mouse tissue was readily available, it was decided to probe a 
panel of partially purified normal murine tissues with antibody 5C3. The major band 
in these tissues was approx. 70kDa; a distinct band was observed in spleen and to a 
lesser degree in lung tissue. These results indicated that the antigen being recognised 
by antibody 5C3 was indeed expressed in murine tissues, suggesting that this antigen 
was probably conserved amongst species. A possible explanation for the differences 
in molecular weights o f observed bands with these tissues and those observed when 
crude cell lysates o f cell lines were separated, could possibly be attributed to the 
fact that they were differentially centrifuged and the resultant membrane fractions 
only (not the supernatants) were separated on SDS-PAGE. Thus the observed 5C3 
reactive bands from tissues represent the expression o f the antigen in the cell 
membrane fraction and not the cytosol/ cytoplasmic fraction. Crude cell lysates from 
cells would have included cytoplasmic as well as membrane material. In agreement 
with immunocytochemical results, this result suggests that the 5C3 reactive antigen 
is localised to the cell membrane as well as the cytoplasm of the cell. It was also 
possible that perhaps the distribution o f the antigen in question varies among 
malignant and normal cells types, reflected by the heterogenous expression observed 
on Western Blot analysis.
It was attempted to probe commercially supplied human tissue lysates with antibody 
5C3; however due to problems in the solublisation of the preparations no results were 
obtained therefore a direct comparison o f the expression o f the antigen in question 
between murine and human tissue was not possible.
It was decided to carry out immunoprécipitation studies; immunoprecipitated protein 
could then be separated on SDS-PAGE and then sequenced. In addition this method 
might also reveal the precise molecular weight of the 5C3 reactive antigen. As the 
ZR-75-1 cell line showed consistent reactivity with antibody 5C3 both on 
immunocytochemical analysis and Western blot analysis it was decided to use this 
cell line in an attempt to immunoprecipitate the reactive antigen. This cell line was 
derived from an infiltrating ductal carcinoma o f the breast (Engel et al., 1978).
Immunoprecipation was carried out by using a cocktail o f protein G and protein L, 
(the latter being a novel Ig binding bacterial cell wall protein (Bjorck 1988)) to pull
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out the 5C3 reactive antigen from crude cell lysates o f ZR-75-1 cells which were 
labelled directly with antibody 5C3. As results were obtained using this direct 
labelling system, a biotinylation step was not required. Following separation on 7.5% 
SDS PAGE, Western blot analysis of the ZR-75-1 immunoprecipitates revealed one 
band at approx. 175kDa when probed with antibody 5C3 (the predominant band 
detected by Western blotting of ZR-75-1 lysates was at approx. 210 kDa). No other 
bands were detected, however on some Western blots a very faint band could be 
observed at approx. 110 kDa. No band except that o f IgG was detected in 
immunoprecipitates o f mouse IgG.
The fact that the reactive band had an apparent molecular weight o f 175 kDa was an 
unexpected result, this band was not identified on Western blots. 
Immunoprécipitation was carried out by pulling out the antigen in its native state 
from ZR-75-1 cells (although immunoprecipitates were placed in reducing buffer 
prior to loading on SDS Page), which may explain the difference. Differences in 
molecular weights o f proteins in reducing/ non reducing conditions are well 
documented. Non-reduced immunoprecipitates were also separated on SDS-PAGE, 
however these samples did not resolve correctly and therefore no reactive bands 
could be identified. Another possibility to consider was that the immunoprécipitation 
procedure was pulling out the antigen in a different glycosylated form.
Supernatants which were retained following antibody incubation with antigen and 
prior to washing were also separated on SDS-PAGE. All o f the 5C3 reactive bands 
including the 175 kDa band could be observed on Western Blots, when supernatants 
(and 50:50 mixtures o f supernatant/ immunoprecipitate) were probed with antibody 
5C3. Although this immunoprécipitation method used here proved sensitive and 
consistent, it did appear that some of the antigen o f interest i.e. the 175 kDa band 
was not being pulled out. Use of smaller volumes o f ZR-75-1 lysate/ antibody 
/protein L/G and shortened incubation times did result in a stronger reactive band 
being detected on Western Blots. The final volume is considered crucial to successful 
immunoprécipitation; volumes used were within the range recommended by Harlow 
and Lane (1999). As the objective of these studies was to obtain enough protein for 
sequencing, on assessment o f Coomassie R-250 stained gels it was considered that 
there was enough o f the 175kDa band present to be excised and sequenced.
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In preparation for N-terminal sequencing further ZR-75-1 immunoprecipitates were 
transferred to Sequiblot ™ PVDF membrane and stained with Coomassie Blue R- 
250. The major band at approx. 175 kD when lined up, corresponded to that observed 
on Western blots o f immunoprecipitated cells. This band was excised from PVDF 
membranes blotted from 5 well SDS PAGE gels and processed for N terminal 
sequencing. However no sequencing data could be obtained which suggested that the 
protein was N terminally blocked. Further attempts to avoid N-terminal blockage by 
the addition of 0.1% thioglycollic acid to the running buffer did not prove successful, 
lysates appeared to diffuse throughout gel which did not resolve properly. As it was 
unlikely that N-terminal blockage could be avoided it was decided that the best 
option would be to attempt to carry out internal sequencing.
Again ZR-75-1 immunoprecipitates were separated on SDS PAGE, and the gel was 
then stained with Comassie Blue R-250. The band o f interest i.e. the 175 kDa band 
was excised from gel and sent to Eurosequence (The Netherlands) for internal 
sequencing analysis. Sequencing of HPLC fractions obtained from the 175kDa band 
revealed that the protein sample (i.e the 175 kDa band) contained a mixture o f two 
peptides, their sequence levels were approx. 1:2. Actual sequence analysis results are 
presented in Appendix IV.
Data base searching carried out by Eurosequence indicated that that these peptides 
corresponded to human cytokeratin 6B and human cytokeratin 9. Twice as much of 
the peptide corressponding to cytokeratin 9 was present compared to the peptide 
corressponding to cytokeratin 6. Searching of protein databases was also carried out 
here to confirm results from Eurosequence. The first polypeptide sequence showed 
100% homology with a 14 a.a.sequence o f human cytokeratin 9. However these 
searches indicated that this second polypeptide showed 100% homology with a 12
a.a. sequence that was present in cytokeratin 6D (highest score), 6B, 6C, 6E, 6F, 6A, 
cytokeratin 5 and cytokeratin 2 (lowest score). Our observation o f a better match for 
for this second peptide to cytokeratin 6D rather than 6B, may perhaps be explained 
by the fact that Cytokeratin 6D has a shorter a.a. sequence than the other isomers of 
the cytokeratin 6 family and therefore achieved the highest score. It also appeared 
that all cytokeratin 6 isomers achieved a higher score than cytokeratins 5 or 2. Taken
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together these results suggested that this protein represented a member o f the 
cytokeratin 6 family, however it is not possible to fully conclude which cytokeratin 6 
isoform this peptide represents. It is thought that there are at least six isoforms of 
human cytokeratin 6, the 6A being the most common isoform (Takahashi et al., 
1995).
Cytokeratins constitute a family of closely related, phylogenetically conserved 
distinct proteins that are biochemically and immunologically related (Osborn et al., 
1982). There are two types o f cytokeratins; the smaller (m.w. 40-56.5 kDa) type 1 
keratins (cytokeratins 9-20) which are relatively acidic and the larger (m.w. 53-67 
kDa) type II cytokeratins which are largely basic-neutral (cytokeratins 1-8) ( Moll et 
al., 1982). Cytokeratins possess a pronounced sequence diversity that is not found in 
other intermediate filament family proteins. The alpha helical regions of type I 
cytokeratins share 50-99% sequence identity, whereas type II cytokeratins display 
30% homology in these regions (Steinert et al., 1993). During filament formation, 
cytokeratin filaments form obligate heteropolymers made of type I and type II, 
usually in a 1:1 molar ratio. Sequence results suggested then the 5C3 reactive 175 
kDa band may represent a cytokeratin heteroploymer, composed o f the type I 
cytokeratin 9 and the type II cytokeratin 6. The respective molecular weights o f the 
individual proteins, cytokeratin 9 (63 kDa), cytokeratin 6D (42kDa) and cytokeratin 
6B (59 kDa), suggest the most likely partner for cytokeratin 9 would be cytokeratin 
6B. However as all o f the molecular weights were only estimated it was not possible 
to conclude fully which cytokeratin 6 isoform was most likely to be the partner 
involved.
As a follow up to these results it was decided to conduct a small number o f 
experiments to address these findings further. Following immunoprécipitation o f ZR- 
75-1 cells, samples were reduced, this normally would result in any complex if 
present, being disassociated. However in this case the proposed “complex” appeared 
to be intact even after reduction and boiling for 1 minute. It is known that during the 
differentiation process cytokeratin complexes form disulphide bonds to stabilise the 
complex, perhaps this was the case with the proposed complex detected in ZR-75-1 
immunoprecipitates. Therefore it was attempted to disassociate this “complex” by 
employing a prolonged boiling time o f 10 minutes.
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Following attempted disassociation these immunoprecipitates were separated on 
SDS-PAGE. A band at approx. 60kDa in addition to the 175kDa band was observed, 
indicating that the complex had disassociated to some degree. As the molecular 
weights o f both cytokeratin 9 and cytokeratin 6 are similar it could not be concluded 
which cytokeratin this approx. 60kDa band represented. When separated proteins 
were probed with antibody 5C3 however, only IgG bands were detected, no specific 
5C3 bands were detected. This result indicated that antibody 5C3 only recognised 
the hetropolymer, cytokeratin 6/9 when complexed. It still was not clear whether 
antibody 5C3 recognised a similar epitope on both cytokeratins or whether it only 
recognised an epitope on 1 cytokeratin but appeared to recognise both as they were 
complexed.
All intermediate filament proteins contain a central rod domain composed of 4 a  - 
helical segments o f conserved size that possess a repeating heptad sequence motif, 
interspersed with flexible linker sequences, and flanked on the amino and carboxy 
termini by head and tail domains. The helical rod domain, 2B contains the most 
highly conserved a.a. sequences amongst the various cytokeratins, the 12 a.a. 
sequence present in all cytokeratin 6 isomers and in cytokeratin 5 which showed 
100% homology with one of the peptides sequenced here was located near this 
region. A MAb, TSI, directed against cytokeratin 8 has been shown to have a high 
degree o f recognition o f all other type II cytokeratins (Johansson et al., 1999). The 
epitope recognised by MAb TSI has been shown to be contained within a.a. 343-357 
within the rod domain o f cytokeratin 8 (Johansson et al., 1999). To ascertain the 
exact epitope o f antibody 5C3, it would be necessary to screen peptides covering the 
entire molecules cytokeratin 6 and 9 and test for antibody binding. This would 
conclusively reveal if  this MAb was recognising just I cytokeratin or similar epitope 
on both cytokeratins. Such work was beyond the scope of this thesis.
When the immunoprecipitates which were boiled for 10 minutes were probed with a 
a cytokeratin 9 specific MAb (Research Diagnostics, US), a cytokeratin 9 reactive 
band at approx. 62 kDa was identified. Immunoprecipitates which were boiled 
previously for 1 minutes were also probed with the cytokeratin 9 specific MAb, only 
a very faint band could be identified. Immunoprecipitates were also probed with a
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cytokeratin 6 specific MAb (Neomarkers, UK). No cytokeratin 6 reactive bands 
could be detected on immunoprecipitates which were boiled for either 10 minutes or 
1 minute. These results suggested that antibody 5C3 was recognising an epitope on 
cytokeratin 9 and not on cytokeratin 6, however as these two cytokeratins were 
complexed it appeared that antibody 5C3 was recognising both cytokeratins.
However when crude cell lysates of ZR-75-1 cells were also probed with cytokeratin 
6 and 9 specific MAbs, results were unexpected. Cytokeratin 6 reactive bands were 
identified on separated crude cell lysates when probed with cytokeratin 6 MAb, on 
probing with cytokeratin 9 MAb no specific bands were detected. These results 
suggested that during the immunoprecipitation process the conformation o f the 
cytokeratin 9 protein is altered somewhat and antigenic sites may have been masked 
in the crude cell lysates. As there is twice as much of this cytokeratin in complex 
perhaps this cytokeratin may be masking antigenic sites on cytokeratin 6, and thus it 
is not detected in immunoprecipitated samples. Taken together it would appear that 
antibody 5C3 recognises this hetropolymer o f “complexed” cytokeratin 9 and 6.
It is well recognised that complex cytokeratin polypeptide patterns exist in human 
cancers (Moll et al., 1982). Expression o f the cytokeratin network has been shown to 
be altered during malignant transformation, distinctive cytokeratin distributions have 
been observed between breast cancers (Jarasch et al., 1988). The proposed complex 
presented in these results between this particular type I and type II cytokeratin has 
not been reported to date.
Cytokeratin 6 has been shown to be induced under hyperproliferative conditions such 
as benign or malignant tumours, psoriasis and wound healing. This cytokeratin in a 
complex with cytokeratin 5 has previously been detected both in invasive breast 
cancers and DCIS breast cancers (Otterbach et al., 2000). This cytokeratin has been 
shown to be expressed in a distinctive manner in the developing mammary gland 
(Smith et a l, 1990). It is also thought that cytokeratin 6 may be involved in the 
tumour progression of skin tumours (Bowden 1995).
Cytokeratin 9 expression has not been reported to our knowledge in human cancer, it 
has only been observed in plantar epidermis and has been shown to be a component
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in the perinuclear ring of the manchette o f rat spermatids (Mochida et al., 2000). The 
manchette is a transient tubulin containing structure which is developed during 
mammalian spermiogenesis, it is thought to have a role in nuclear shaping, however 
its precise function is not known. Mochida et al., (2000) in an attempt to see if  
cytokeratin 9 exists with a partner, found expression o f another rat keratin which 
shows homolgy with human keratin 5 associated with the microtubules o f the 
manchette (Mochida et al., manuscript in preparation). The fact that cytokeratin 5 
shows high homology with cytokeratin 6 suggests therefore that cytokeratin 9 does 
indeed form a partner with cytokeratin 6. It cannot be ruled out, that one sequenced 
peptide here is actually cytokeratin 5, as discussed previously. Interestingly also, 
epidermolytic palmoplantar keratosis (EPPK) co segregates with a cytokeratin 9 
mutation in breast and ovarian cancer (Torchard et al. 1994). The finding of 
cytokeratin 9 complexed with its type II partner cytokeratin 6 (or perhaps cytokeratin 
5) in human breast cancer is novel and warrants further investigation to see if 
expression of this complex has any prognostic significance in this disease.
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5. Conclusions and Future Work
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Conclusions
The expression of MRP-1 protein was studied in a series o f 204 invasive breast 
cancers; 46 o f these tumours were also studied for expression o f a range o f MDR1 
associated proteins. As expected multivariate analysis revealed that nodal status and 
tumour size were independent prognostic factors for relapse free survival in patients 
with invasive breast cancer; tumour (histological) grade was identified an an 
independent prognostic factor for overall survival.
Expression o f MRP-1 protein at diagnosis did not offer any prognostic value in 
those patients who did not receive chemotherapy. In patients who did receive 
chemotherapy however, a prognostic role for MRP-1 was shown. MRP-1 protein 
expression at diagnosis was shown to be an independent prognostic factor for overall 
survival in node positive breast cancer patients treated with CMF based 
chemotherapy, absence o f MRP-1 expression at diagnosis was significantly 
associated with increased overall survival. It can also be concluded that this 
prognostic role o f MRP-1 was greater in patients with high grade i.e. grade III 
tumours. A larger study would be required however to establish any possible 
predictive role for MRP-1 protein.
MRP-1 protein was significantly associated with higher histological grade in 
chemotherapy treated patients, suggesting that MRP-1 expression is possibly 
associated with a more aggressive tumour phenotype in these patients.
The expression of cerbB-2 protein was associated with a worse prognosis (shortened 
relapse free survival times and shortened overall survival times) in chemotherapy 
treated node positive patients. No conclusion could be drawn regarding any possible 
predictive role as cerbB-2 protein levels were not studied in any tumours from non 
chemotherapy treated patients.
Preliminary analysis did suggest that the co-expression o f MRP-1 and cerbB-2 may 
possibly have stronger prognostic value in node positive chemotherapy treated 
patients than expression of either individual marker. However as the numbers of
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patients analysed for both markers were small no statistical analysis could be carried 
out to address the significance o f this observation.
cerbB-2, MDR-1, Bcl-2 and survivin protein expression were not significantly 
associated with the age of patients at diagnosis, node status, tumour size or 
histological subtype or grade. Conclusions regarding a possible association between 
MDR-1, Bcl-2 and survivin expression and clinical outcome, cannot be drawn as the 
numbers studied were too small. Expression o f none o f the proteins studied was 
associated with chemotherapy treatment.
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A new monoclonal antibody which specifically recognises the MDR-3 encoded gene 
product was successfully generated and characterised during the course o f this thesis. 
As discussed, it has now been established that MDR-3 can in fact transport certain 
cytotoxic drugs. MDR-3 Pgp was present in a number o f human breast tumours and 
appears to be present in a range of human tumour cell lines o f various histogenic 
origins including breast and other solid tumour types. Taken together these results 
suggest that MDR-3 Pgp is present to some degree in a number o f human tumour 
types, but the significance o f its presence has yet to be eluciadated.
Studies on a small panel of B cell malignancies suggested that MDR-3 Pgp may 
possibly be associated with a more malignant phenotype in B-CLL. In addition 
preliminary results indicate that MDR-3 may be associated with certain 
developmental stages o f B cell development. Results from investigation o f B-NHL 
cases were inconclusive, although MDR-3 Pgp showed a significant increase in 
expression following treatment in one specific patient.
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In an attempt to identify a possible novel breast cancer resistance-associated antigen, 
MAb 5C3 was generated using a novel source o f immunogen i.e. paraffin wax 
embedded formalin fixed archival breast tumour tissue. The novel source o f antigen 
used to generate MAb 5C3, (although time consuming) proved successful and can 
therefore be applied to a large number o f prospective tumours which are clinically 
interesting to use as possible immunogens.
It appeared from characterisation studies that antibody 5C3 did not recognise any of 
the well established breast tumour associated antigens, but was recognising a breast 
antigen expressed in the normal breast which may become over expressed (or 
possibly underexpressed) during the malignant process.
Subsequent internal protein sequencing analysis revealed that MAb 5C3 recognises a 
complex o f cytokeratin 9 and cytokeratin 6. A comprehensive literature has shown 
that such a complex between this particular type I and type II cytokeratin has not 
been reported in breast cancer, or indeed any other malignancy to date.
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Future Work Suggested
1. Further work should include a study o f MDR associated proteins in a larger series 
o f invasive breast carcinoma patients. It is essential for any future studies that 
patient numbers are large enough to allow for statistical analysis.
2. A larger study would establish if  perhaps MRP-1 may hold predictive value in 
certain sub-groups of patients treated with CMF based chemotherapy (i.e. 
stratified by tumour size, tumour histology, tumour grade etc.). The numbers of 
patients studied here were too small to investigate the possible predictive role of 
MRP-1 (and indeed any further prognostic role) in such sub-types o f invasive 
breast carcinomas.
3. Currently for node negative breast cancer patients there are few reliable 
prognostic markers, so identification o f new prognostic markers (and indeed 
possible predictive markers) for these patients is important. A larger study may 
address this.
4. The associations between MDR-1 and survivin protein expression and clinical 
outcome (and the significance o f the nuclear staining of survivin) observed in this 
study needs to be addressed in a larger series o f patients. A larger study would 
also reveal if  survivin is actually associated with a better outcome in invasive 
breast cancer, which in itself, this would be an important observation. The 
observed correlation between survivin and MDR-1 expression patterns observed 
should also be addressed in a further study.
5. Also, the observation o f the co-expression o f MRP-1 and cerbB-2 offering 
stronger prognostic power than either o f the individual proteins as regards 
clinical outcome should also be addressed further, to see if this observation is 
significant.
6. It may also be useful to look at the expression o f the other members o f the cerbB- 
2 family in tumours from the patients investigated, such a study will further 
address the role o f these proteins in breast cancer.
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7. In addition as recently neo adjuvant chemotherapy is being used successfully in 
the breast cancer clinic, it is important to investigate the expression o f MDR 
associated proteins in pre and post chemotherapy treated tumours specimens 
from patients treated in this fashion.
8. When MAbs to other members of the MRP family (including BRCP) which work 
on archival material become available it may be interesting to look at expression 
o f these MRPs in breast cancer and address any possible prognostic/ predictive 
significance and investigate their contribution, if  any, to chemotherapy resistance 
in breast cancer.
9. As it has recently been shown that MDR-3 can transport certain cytostatic drugs, 
antibody 6/ 1G may be useful in further assessment o f MDR-3 Pgp status in 
malignant cells and tissues and establish if indeed MDR-3 is playing a role in 
drug resistance. As results presented here suggest that MDR-3 Pgp is present in a 
number o f invasive breast tumours, these preliminary observations should be 
confirmed by immunohistochemical analysis o f further breast tumours including 
other histological subtype o f tumours and non-invasive DCIS tumours.
10. Also immunohistochemical studies o f other tumour types are required to see if 
the expression of MDR-3 Pgp observed in the cell lines studied here is reflected 
in vivo; and to establish if  this observed MDR-3 Pgp expression in various 
malignancies is significant i.e. if  there any association with clinical resistance in 
individual patients. Therefore tumours treated with various chemotherapy 
regimes might be included in a follow up study in order to establish if  there is a 
role for MDR-3 Pgp in malignancies other than haematological ones.
11. As antibody 6/ 1G is the first MAb that specifically recognises the MDR-3 
encoded gene product, this antibody should prove useful in further defining the 
physiological role, if  any, o f the MDR-3 encoded gene product outside the liver. 
This antibody will also be useful in the diagnosis o f type III PFIC as well as other 
liver disorders such as Dubin-Johnson syndrome and ICP where mutations in the 
MDR-3 gene are thought to be involved (discussed in section 1.7.3).
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12. To confirm results presented here, regarding MDR-3 expression in B-CLL, AML 
and B-NHL, further studies with increased patient numbers need to be carried out 
to define the role of MDR-3 in these malignancies and other haematological 
malignancies such as MM which is incurable and also subgroups o f B-cell 
chronic lymphocytic disorders (B-CLPD). Such studies may reveal MDR-3 as 
having possible prognostic value in these patients. In addition the correlation of 
MDR-3 with the molecular abnormalities associated with these malignancies 
should be addressed in any future work.
13. Recent studies have suggested that B-CLL can be subdivided into two major 
subgroups on the basis of whether or not the IgVH genes are mutated, those 
patients with unmutated genes have a poor prognosis whereas those with 
mutated IgVH have a good prognosis. The possible prognostic contribution of 
MDR-3 (i.e. a possible reliable surrogate immunophenotypic marker) in the 
identification of B-CLL patients with unmutated or mutated IgVH genes might 
also be addressed.
14. Any further studies should also include investigation o f the expression o f MDR-1 
Pgp and LRP protein, which as discussed previously may be implicated in the 
chemoresistance o f some haematological malignancies.
15. Further work with specific antibodies should confirm which member o f the 
cytokeratin 6 family is actually involved in the proposed complex being 
recognised by MAb 5C3. By employing a MAb specific for cytokeratin 5 also, it 
will be possible to deduce if  this cytokeratin is involved in the proposed complex 
instead of cytokeratin 6. The possibility o f this being the case cannot be ruled out 
at present based on analysis o f database searching.
16. The expression of this proposed cytokeratin complex needs to be investigated in 
additional archival samples of normal breast tissues, invasive breast tumours, 
(representing all histological subtypes o f breast cancer), DCIS and other tumours 
o f varying histological origin to address any prognostic or predictive role for co­
expression of these two cytokeratins.
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17. Expression o f this antigen complex should also be investigated in metastatic 
breast carcinomas including lymphatic nodes completely replaced by metastatic 
disease o f known mammary origin, to see i f  the antigen is more highly expressed 
in these tissues compared to primary carcinoma tissue.
18. In order to identify an antigen which may be a possible marker o f 
chemoresistance, it may also be interesting to use post chemotherapy treatment 
archival tumour from the same patient (whose pre treatment archival tumour was 
used), as a possible immunogen. Thus it may be possible to identify further novel 
proteins, including tumour specific antigens which may have ultimate prognostic 
implications.
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Appendix I
ABBREVIATIONS
ABC/HRP Streptavidin/biotin-horseradish peroxidase conjugate
AI)CC antibody dependent cell mediated cytotoxicity
ACMF Adriamycin cyclophosamide methotrexate 5-fluorouracil
ADEPT antibody directed enzyme pro drug therapy
Adr Adriamycin
AI apoptotic index
ALL acute lymphocytic leukaemia
AML acute myeloid leukaemia
ANLL acute non lymphocytic leukaemia
APC antigen presenting cells
ATCC American Tissue Culture Collection
BCA Bicinchoninic acid
B-CLPD B-cell lymphocytic proliferative diseases
BRCA1 breast cancer susceptibility gene
BRCP breast cancer resistance protein
BSA Bovine serum albumin
CDR’s antigen binding complementarity determining regions
CEA carcinoembryonic antigen
CLL chronic lymphocytic leukaemia
CIY1I cyclophosamide methotrexate 5-fluorouracil
DAB Diaminobenzidine
DCIS ductal carcinoma in situ
dH20 Deionised water/glass distilled water
I)M IM Dulbeccos Modified Eagles Medium
DMSO Dimethyl sulfoximide
DNA Deoxyribonucleic acid
DOX Doxorubicin (Adriamycin)
EBV Epstein Barr virus
ECACC European Collection o f Animal Cell Culture
ECL Enhanced chemiluminescence
ECM extracapsular metastasis
EDTA Ethylene diamino tetra-acetic acid
ELISA Enzyme-linked immunoabsorbent assay
EPPK epidermolytic keratosis
ER estrogen receptor
FAB French American British
FCS Foetal calf serum
FISH fluoresence in situ  hybridisation
FITC Fluoroscein-isocyanate
GPx glutathione peroxidase
GST glutathione -s-transferase
11 AC A human anti chimeric antibody
HAMA human anti mouse antibody
HAT Hypoxanthine, aminopterin, thymidine
HCL hairy cell leukaemia
HCL Hydrochloric acid
HEPES 4-(2-hydroxethyl-)-piperazine ethane sulphonic acid
HGPRT hypoxanthine guanine phosphoribosyl transferase
HT Hypoxanthine, thymidine
ICP intrahepatic choleostasis o f pregnancy
IMS Industrial methylated spirits
kDa KiloDalton
LCIS lobular carcinoma in situ
LCM laser capture microscopy
LGL large cell granulomatous lymphoma
LRP Lung resistance related protein
MAb/s Monoclonal antibody/monoclonal antibodies
MBV mannon binding protein
MCL mantle cell leukaemia
MDR Multidrug resistance
MDR1 Multidrug resistance protein 1 gene (P-gp encoding gene)
MEM Minimum Essential Medium
MgCl2 Magnesium chloride
MM multiple myeloma
MMP matrix metalloproteinase
mRNA Messenger RNA
MRP1 Multidrug resistance-associated protein 1 (protein or gene)
Mw Molecular weight
NaCl Sodium chloride
NaHCOj Sodium bicarbonate
NaOH Sodium hydroxide
NCTCC The National Cell and Tissue Culture Centre
NEAA Non-essential amino acids
NHL non-Hodgkins lymphoma
NSCLC Non-small cell lung carcinoma
OD Optical density
PAGE Polyacrylamide gel electrophoresis
PBS Phosphate buffered saline
PEG Polyethylene glycol
P-gP P-glycoprotein or P-170 (MDR1 gene protein product)
Pgr/  PR progesterone receptor
PKC protein kinase C
PM SF Phenylmethyl sulfonyl fluoride
PNAG Phenyl-N-acetyl-a-D-galactosaminide
PNPP P-nitrophenyl phosphate
Pristane 2,6,10,14 tetramethylpentadecane
PSA prostate specific antigen
PVDF Polyvinyldifluoride (blotting membrane)
RID radioimmunodiffusion
RNA Ribonucleic acid
RT room temperature
SCID severely combined immune deficiency
SDS Sodium dodecyl sulphate
SEREX serological identification o f antigens by recombinant expression
cloning
SPF S - phase fraction
SSCP single strand confirmation polymorphism
TBS Tris buffered saline
TEMED N,N,N,N,-tetramethyl-ethylenediamine
tPA tissue type plasminogen activator
Tris Tris (hydroxymethyl) aminomethane
TV Trypsin/versene
UICC international union against cancer
uPA urokinase plasminogen activator
UV Ultra violet
VPNI Van Nuys prognostic index
vol/vol Volume to volume ratio
w/vol Weight to volume ratio
Appendix II 
LIST OF SUPPLIERS
•  Amersham International pic. Bucks HP7 9NA, UK.
•  Antec International Ltd. Sudbury, Suffolk CO 16 6XD , UK.
•  B D H  Laboratory Supplies, Poole, BDH 15 1TD, England.
•  Beckm an Instruments (UK) Ltd. High W ycombe, Bucks HP 12 4YH , UK.
•  Becton Dickinson UK Ltd, Betw een Towns Road, Crowley, Oxford 0 X 4  3LY, UK.
•  B io Rad laboratories Ltd. Herts HP2 7TD, UK.
•  Bioresearch Ireland, Forbairt, Glasnevin, Dublin 9, Ireland.
•  B iosyn  Ltd., 10 M alone Road, Belfast, BT9 5BN, Northern Ireland.
•  Roche Diagnostics GM BH, B ell Lane, Lew es, East Sussex B N 7 1LG, UK.
•  Clintech, Clacton-on-Sea, Essex, UK.
•  Costar Cambridge M A, USA.
•  Dako, 16 Manor Courtyard, Hughenden Avenue, H igh W ycom be, Bucks HP 13 
5RE, UK.
•  Gelman, United Kingdom Pall Gelman Sciences, Brackmills Business Park, Caswell 
Road, Northampton N N 4 7EZ, UK.
•  Gibco, Life Technologies Ltd, 3 Fountain Drive, Inchinnan Buisness Park, Paisley  
PA4 9RF, UK.
•  Greiner Labortechnik Gmbh, Maybachstabe 2, D -72636 Frickenhaussen.
•  Hoefer. Hoefer Scientific Instruments, San Fransisco, USA.
•  Immune System s Ltd., PO B ox  120, Paignton, TQ4 7X D , UK.
•  Lab V ision Corporation, 47790 W estinghouse Dr, Fremont CA, 94539 U SA .
•  Merck, M agna Park, Little-worth, Leicestershire, UK.
•  Novacastra Labs Ltd, Balliol, Business Park W est, Benton Lane, N ew castle Upon  
Tyne, N E 12 8EW, UK.
•  N U N C  A/S. Roskilde, Denmark.
•  Chemical Products, R. Borghgraef s.a. Belgium.
•  Nuaire, 2100 Fembrook Lane, Plymouth, M innesota 55447, USA.
•  Oxoid Ltd, Basingstoke, Hampshire, UK.
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• Pharmingen, BD Diagnostic Systems, Pottery Road, Kill O'The Grange, Dun 
Laoghaire, Co. Dublin, Ireland.
•  Pierce, Post Office Box 117, Rockford, Illinois 61105 USA.
• Research Diagnostics Ltd. Pleasant Hill Rd, Flanders, NJ 07836, US.
• Sigma Diagnostics, St. Louis, MO 63178 USA.
• Sigma, Sigma-Aldricli Company LTD. Fancy Road, Poole, Dorset, BH12 4QH, UK.
• Sterlin Ltd, Middlesex TW148QS, UK.
• The Binding Site Ltd., Birmingham, UK.
•  Vector Laboratories Ltd., 16 Wulfric Square, Bretton, Peterborough PE3 8RF, UK.
• Vector Laboratories, Inc. Burlingame, CA 94010 USA.
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Appendix III
1. Water for cell culture
Ultrapure water was used in the preparation of all media and solutions. This 
water was purified to a standard o f 12-18 Mm/cm resistance by a reverse 
osmosis system (Millipore Milli-RO 10 Plus and Maxima UF water system, 
ELGA). A digital display provided a visual indication o f water quality.
2. Media Preparation
The basal media used during routine cell culture consisted o f 10X media 
(DMEM (Sigma, D5648) and Hams-F12 (Gibco, H6760)) which were 
added to sterile ultra pure water, buffered with HEPES and NaHCC>3 and 
adjusted to a pH of 7.45-7.55 using sterile 1.5M HCL. The medium was 
then filtered through a sterile 0.22 (im bell filter (Gelman, G1423S) and 
stored at 4°C until required. Prior to use aliquots o f media were 
supplemented with 2 mM L-glutamine (Gibco, 043-0503) and 5-15% FCS. 
Hybridoma and SP2/0-A gl4 myeloma cells were grown in a basic basal 
medium of commercially available DMEM, DMEM with Glutamax I 
(Glutamax is L-Amyl-LGlutamine, high glucose concentration -  4.5 mg 
(Gibco, 61965-026) supplemented with 10 % heat inactivated FCS 
(Myoclone, Gibco, 10082-147). This was further supplemented for 
hybridoma growth and hybridoma cloning with 1% Penicillin streptomycin 
and 5% Briclone (Archport Ltd.). Briclone is a conditioned medium 
collected from a human cell line, for use in post fusion stages o f hybridoma 
production and cloning, replacing the function of feeder cells. Sterility 
checks (Tryptone soya broth, Tryptone soya agar and Thioglycollate) were 
routinely carried out on all media, media supplements and reagents used in 
cell culture.
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3. Mycoplasma analysis (indirect staining procedure)
Mycoplasma negative NRK cells (Normal Rat Kidney fibroblasts) were 
used as indicator cells for this analysis. The cells were cultured with 
supernatant (harvested from test cell lines after 2-3 days confluency) from 
test cell lines for 4-5 days, fixed and stained with Hoescht fluorescent stain 
which binds specifically to DNA. Thus the nucleus o f the cell and any 
Mycoplasma infection will be stained, this positive staining is seen as small 
fluorescent bodies in the cytoplasm of the NRK cells. Positive controls 
consisted o f NRK cells infected with Mycoplasma enriched supernatants. In 
the case o f hybridomas and SP2 cells, cells were passaged 3-4 times in 
antibiotic free medium prior to Mycoplasma testing.
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TABLE 1 Lysis buffer for immunoprécipitation studies
All materials in for this buffer were supplied in the cellular labelling and 
immunoprecipitation kit supplied by Roche Diagnostics GmbH (Mannheim, 
Germany, 1647652).
* Complete ™, 1697498, Roche Diagnostics GmbH, Mannheim, Germany.
STOCK SOLUTIONS VOLUMES
REQUIRED
Core buffer 4m 1
NaCl 1.8ml
25 X stock protease 0.5ml
cocktail *
Nonidet P-40 1.2ml
Sodium deoxtcholate 0.6ml
dH20 4.3ml
T A B L E  2 W ash  buffers fo r im m unoprec ip ita tion  studies
W ASH BUFFER W ASH  BUFFER W ASH  BUFFER
1 2 3
Final volume 24 ml (conc) 24 ml (conc) 24 ml (conc)
1 M Tris buffer 1.2 ml 1.2 ml 0.24 ml
(50mM) (50mM) (lOmM)
1 MNaCl 3.6 ml 12 ml -
(159mM) (500mM)
Nonidet P-40 0.24 ml 0.24 ml -
d.H20 19 ml 10.54 ml 23.8 ml
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Internal Sequencing Results from Eurosequence BY.
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EUROSEQUENCEbv
Analysis and Synthesis of Proteins and DNA
INTERPRETATION N-TERMINAL PROTEIN SEQUENCE ANALYSIS RESULTS
S ee  a l s o  'P r o d u c t  I n f o r m a t i o n  N - t e r m i n a l  P r o t e i n  S e q u e n c e  A n a l y s i s ' f o r  
e x p l a n a t i o n  o f  ' I n i t i a l  Y i e l d '  a n d  am ino a c i d s  i n  p a r e n t h e s e s .
Page 1 of 1
Our order number »  010716 
Product code »  01C318 Sample: 010716-B-T
Sample amount 
Date of analysis 
Performed
Date of interpretation report 
Investigator
10%
August 24, 2001 
6 cycles
September 28, 2001 
Dr. Wicher J. Weijer
MAIN SEQUENCE 
Position # 
Amino Acid
1 5
???-(Arg/Leu)- (Asp/Tyr)- (Gly/Gln//Gly)- (Met/Leu)
Initial Yield:
(Ile/Ser/Arg/Phe)
appr. 1-2 pmol
REMARKS
1. Your sample "06-07-01/175 kDa" was digested with trypsin and the resulting 
peptides were extracted from the gel [our sample name after digestion/ 
extraction: 010716-B-T].
2. A portion of 10% of the extract was analyzed.
3. This analysis was performed to check digestion/extraction.
4. All assignments are tentative because of the presence of a mixture of
peptides.
5. Signals are present at a sequence level of appr. 1-2 pmol; this means that
peptides in the digest may be present at a level of 2 x 10 x (1-2) = 20-40
pmol, assuming an Initial Yield of sequence analysis of 50%.
6. After this analysis, 90% of the digest was subjected to preparative HPLC (our 
product code: 01E177).
Signature : Signature :
('investigator') ('verifier')
Meditech Center L.J. Zielstraweg 1 NL 9713 GX Groningen The Netherlands Tel.: +31 50 3172424 Fax: +31 50 3172420 
E-mail: eurosequence@chem,rug.nl Internet: www.fwn.rug.nl/eurosequence 
Bank: ING Groningen nr. 670447447 Chamber of Commerce Groningen nr. 02043673 VAT nr. NL 0090.18.487.B 01
- 0 8 - 2 0 0 Ì  0 8 : 4 9  
01C318-010716-10%-B-T-II
01C318-010716-10%-B-T-II
3:Residue 1
3 ¡ R e s i d u e  1 ,  I n t e r p o l a t e d  b a s e l i n e
Peak  No 
2
4
5
6
7
8 
11 
13 
17 
19
27
28 
29  
32
34
35
36
37
38
39
RT 
4 .42
5 . 0 7  
5 . 3 5  
5 . 5 8  
5 . 8 5  
6 . 2 9
7 . 5 4
8 . 0 8
9 . 5 4  
1 0 . 1 8  
12 .37  
12 .92  
1 3 . 2 0  
1 4 . 2 7  
15 . 1 8  
1 5 . 4 5
15 . 7 8  
16..1.8
16 .3 8  
1 6 . 6 3
Peak ID 
N 
S 
Q 
T 
G 
E 
H 
A 
R
Y 
P 
M
V
dp t u  
w 
dpu  
F 
I  
K 
L
Type
c
c
c
c
c
c
c
c
c
c
c
c
c
r
c
c
c
c
c
H e i g h t
2 7 0 0 4
6 92 73
1 18 69
23143
83821
2 2 8 1 3
12 103
25794
3203
3 0 7 5 9
1 0 4 7 2
22 3 5
1 4 5 5 0
2 1 7 1 9 8
628
2 5 4 4 8
7 7 2 6
81 7 4
89 9 6
9673
Pmol Ht  
1 1 . 2 6  
44 . 5 5  
5 . 9 4  
1 3 . 5 7
5 1 . 5 9  
1 0 . 4 8
6 . 2 9
1 6 . 4 0
2 . 5 7
1 9 . 5 9  
6 . 7 0  
1.  81
10.12 
1 6 6 . 6 5  
0 . 3 5  
3 0 . 6 3  
5 . 0 1  
7 . 0 5  
4 . 6 0  
6 . 2 0
Applied Biosystems Procise PROCISE
-08-2001 08:49 01C318-010716-10%-B-T-II
01C318-01071 6-10%-B-T-II 5 ¡Residue 3
5 ¡ R e s i d u e  3 ,  I n t e r p o l a t e d  b a s e l i n e
Peak No 
1 
3 
6
7
8 
9
10
13
14 
16 
18 
25
27
28 
31
34
35
36
37
38
RT
.95  
.43 
, 08 
.36
5 . 58 
5 .  86 
6 . 2 9
7 . 5 3  
8 .09
9 . 5 4
1 0 . 1 7  
1 2 . 3 4  
1 2 . 9 2  
13 . 2 0  
1 4 . 2 7  
1 5 . 4 4  
1 5 . 7 7
1 6 . 1 7  
1 6 . 3 6  
1 6 . 6 2
P e a k  ID 
D 
N 
S 
Q
T
G
E
H
A
R
Y 
P 
M
V
d p t u
dpu
P
I
K
L
Type
c
c
c
c
c
c
c
c
c
c
c
c
c
c
r
c
c
c
c
H e i g h t
1 9 3 2 1
10220
2 1 0 3 2
8807
5540
4 2 2 2 2
1 6 3 8 3
3572
8085
4407
1 3 8 0 0
4 6 2 8
1608
8307
13 6 2 0 5
3412
3358
3467
3 3 8 0
1 0 7 2 8
Pmol Ht  
8 . 6 5  
4 . 2 6  
13 . 53 
4 . 4 1  
3 . 25 
2 5 . 9 9
7 . 5 3  
1 . 86 
5 . 1 4
3 . 5 4  
8 . 7 9  
2 . 9 6  
1 . 3 0  
5 . 7 8
1 0 4 . 5 1  
4.
2 .
2 .
.11
.18
.99
1 . 7 3  
6.  87
Applied Biosystems Procise - PROCISE
-08-2001 08:49 01C318-010716-10%-B-T-II
01C318-01071 6-10%-B-T-II 7¡Residue 5
7 : R e s i d u e  5,  I n t e r p o l a t e d  b a s e l i n e
No RT P e a k  ID Type H e i g h t Pmol Ht
1 3 . 9 5 D c 1 6 1 6 8 7 . 2 4
3 4 . 4 4 N c 7107 2 . 9 6
6 5 . 0 8 S c 1 1 217 7 . 2 1
7 5 . 3 6 Q c 8952 4 . 4 8
8 5 . 5 9 T c 3156 1 . 8 5
9 5 .  86 G e 4 8 194 2 9 . 6 6
10 6 . 3 0 E c 1 2 5 6 5 5 . 7 7
13 7 . 5 5 H c 1499 0 . 7 8
14 8 . 0 9 A c 8250 5 . 2 5
18 9 . 5 4 R c 4260 3 . 4 2
19 1 0 . 1 7 y c 5792 3 . 6 9
27 12 . 3 4 p c 3343 2 . 1 4
28 1 2 . 9 1 M c 2003 1 .  62
29 13 . 1 9 V c 3983 2 . 7 7
33 1 4 . 2 6 d p t u r 10 5 6 1 6 8 1 . 0 4
35 1 5 . 1 8 W c 84 0 . 0 5
36 15 .43 dpu 1672 2 . 0 1
37 1 5 . 7 6 F c 2273 1 . 4 7
38 1 6 . 1 6 I c 3532 3 . 0 4
39 1 6 . 3 6 K c 2109 1 . 0 8
40 1 6 . 6 2 h c 9326 5 . 9 7
Applied Biosystems Procise - PROCISE
eurqseQ u e n c e -
Analysis and Synthesis of Proteins and DNA
INTERPRETATION N-TERMINAL PROTEIN SEQUENCE ANALYSIS RESULTS
S ee  a l s o  'P r o d u c t  I n f o r m a t i o n  N - t e r m i n a l  P r o t e i n  S e q u e n c e  A n a l y s i s '  f o r  
e x p l a n a t i o n  o f  ' I n i t i a l  Y i e l d ’ a nd  am ino a c i d s  i n  p a r e n t h e s e s .
Page 1 of 1
Our order number »  0 1 0 7 1 6  
Product code »  01C335 Sample: 0 1 0 7 1 6 - B - T - f r . 33
Sample amount 
Date of analysis 
Performed
Date of interpretation report 
Investigator
100%
S e p t e m b e r  1 2 ,  20 0 1  
14 c y c l e s
S e p t e m b e r  2 7 ,  2 0 0 1  
Dr.  W i c h e r  J .  W e i j e r
MAIN SEQUENCE 
Position # 
Amino Acid
Initial Yield:
1 5
( G l y ? / A s n / S e r ? ) - (Len/Phe)- ( A s p / G l y ) - ( L e u / G l y ) - ( A s p / A l a ) -
10
( S e r ) - ( I l e / G l y ) - ( I l e / G l y ) - ( A l a / G l y ) - ( G l u / T y r ) - ( V a l / S e r ) -
14
( L y s / S e r )  -  ( S e r )  -  (Gly)  
a p p r .  2 - 4  pm ol
REMARKS
1. Fraction 33 of HPLC 01E17 7 was analyzed.
2. No unambiguous sequence can be determined because of the presence of a
mixture of two peptides; slight differences in the height of PTH-signa.ts of 
amino acids allowed the discrimination of signals from each of the two
peptides as well as the protein database searches as indicated under remarks
3 and 4.
3. One of the signals at positions 1-14, viz.: (Gly?)- (Phe)- (Gly)- (Gly)- (Ala)- 
(Ser)- (Gly)- (Gly)- (Gly)- (Tyr)- (Ser)- (Ser)- (Ser)- (Gly), is 100% identical with 
a sequence from Cytokeratin 9 (e.g. from human; see Appendix III).
4. One of the signals at positions 1-12, viz.: (Asn)- (Leu)- (Asp)- (Leu)- (Asp)- 
(Ser)- (lie)- (lie)- (Ala)- (Glu)- (Val)- (Lys), is 100% identical with a sequence 
from Cytokeratin 6B (e.g. from human; see Appendix IV).
Signature :
( 'verifier')
Signature :
('investigator ' )
Meditech Center L.J. Zielstraweg 1 NL9713G X Groningen The Netherlands T e l.:+31 50 3172424 F ax:+31 50 3172420 
E-mail: eurosequence@chem.rug.nl Internet: www.fwn.rug.nl/eurosequence 
Bank: ING Groningen nr. 670447447 Chamber of Commerce Groningen nr 02043673 VAT nr. NL 0090 18 487.B.01
01C335-010716-100%-B-T-fr33 3 : Res i du e  1
-09-2001 10:54 0lC335-010716-100%-B-T-fr33
0.00
-1.00
- 2 . 0 0
3 ¡ R e s i d u e  1,  I n t e r p o l a t e d  b a s e l i n e
No RT P e a k  ID Type H e i g h t Pmol Ht
2 4 . 3 4 N c 41 7 7 1 . 7 9
5 4 . 9 7 S c 603 5 4 . 0 4
6 5 . 1 8 Q c 1899 0 . 9 9
8 5 . 4 6 T c 11 5 5 0 . 8 7
9 5 . 7 4 G c 694 5 4 . 3 9
10 6 . 1 8 E c 1228 0 . 6 2
14 7 . 6 6 H c 1438 0 . 7 5
16 7 . 9 4 A c 1584 1 . 0 5
19 9 . 1 8 S' 794 5 . 7 2
20 9 .42 R c 200 0 . 2 9
21 1 0 . 0 2 Y c 1064 0 . 7 2
25 1 2 . 2 0 P c 406 0 . 2 8
26 1 2 . 7 4 M c 146 0 . 1 1
28 1 3 . 0 3 V c 528 0 . 3 8
30 1 4 . 1 2 dp t u r 7 9 8 8 2 6 2 . 6 7
32 1 5 . 0 1 W c 257 0 . 1 5
33 1 5 . 2 9 dpu 2372 2 . 9 5
34 1 5 . 6 4 F c 463 0 . 3 2
36 1 6 . 0 2 I c 502 0 . 4 4
37 1 6 . 2 2 K c 824 0 . 3 9
38 1 6 . 4 9 h c 902 0 .  60
Applied Biosystems Procise - PROCISE
-09-2001 10:54 01C33 5-010716-100%-B-T-fr33
01C335-010716-100%-B~T-fr33 5 ¡R e s id u e  3
0.00
-1.00
2 . (.10
5 ¡ R e s i d u e  3 ,  I n t e r p o l a t e d  b a s e l i n e
No RT P e a k  lD Type H e i g h t Pmol Ht
1 3 .94 D C 9874 5 . 1 7
2 4 . 3 8 N c .2148 0.  92
4 5 . 0 1 S c 1183 0 . 7 9
5 5 . 2 9 Q c 622 0 . 3 2
6 5 . 5 3 T c 3 94 0 . 3 0
7 5 . 7 9 G c 57 3 0 3 . 6 2
8 6 . 2 4 E c 108 1 0 . 5 5
11 7 . 4 7 H c 123 0 . 0 6
12 8 . 0 0 A c 639 0 . 4 2
15 9 . 4 7 R c 21 5 0 . 3 1
16 10 . 0 6 Y c 368 0 . 2 5
21 1 2 . 2 3 P c 221 0 . 1 5
23 13 . 0 9 V c 849 0 . 6 1
27 15 .3 3 dpu 10 35 1 . 2 9
28 1 5 . 6 8 F c 424 0 . 2 9
30 1 6 . 5 1 L c 2 1 7 4 1 . 4 4
Applied Biosystems Procise - PROCISE
13-09-2001 10:54 01C335-010716-100%-B-T-fr33
01C335~01071G-100%-B-T-fr33 7:Residue 5
7 : R e s i d u e  5 ,  I n t e r p o l a t e d  b a s e l i n e
Ho RT Peak ID Type H e i g h t Pmol Ht
1 3 . 9 5 D e 70 4 3 3 . 69
2 4 . 3 7 N c 73 9 0 . 3 2
4 5 . 0 1 S c 812 0 .  54
5 5 . 2 8 Q c 641 0 . 3 3
6 5 . 7 9 G c 3 0 3 3 1 . 9 2
7 6 . 2 4 E c 1013 0 . 5 1
10 7 .43 H c 2 2 1 0 . 1 1
11 8 . 0 0 A c 3 5 7 7 2 . 3 6
13 9 . 1 5 S ’ 202 1 . 4 6
14 9 .48 R c 144 0 . 2 1
15 1 0 . 0 7 y c 384 0 . 2 6
17 1 2 . 2 5 p c 356 0 . 2 5
18 1 2 . 8 0 M c 339 0 . 2 5
19 1 3 . 1 0 V c 363 0 . 2 6
21 1 4 . 1 7 d p t u r 5 7 3 6 9 4 5 . 0 1
23 1 5 . 0 7 w c 86 0 . 0 5
24 1 5 . 3 3 dpu 680 0 . 8 4
25 1 5 . 6 8 F c 116 0 . 0 8
26 1 5 . 9 7 I c 302 0 . 2 7
28 1 6 . 2 7 K c 87 0 . 04
29 1 6 . 5 1 L c 23 1 1 1 . 5 3
Applied Biosystems Procise - PROCISE
-09-2001 10:54 0lC335-010716-100%-B-T-fr33
4.0 6.0 8.0 10.0 12.0 14.0 16.0 18.0
9: Residue 7, Interpolated baseline
No RT Peak  ID Type H e i g h t Pmol Ht
2 4 . 3 8 N c 781 0 . 3 3
5 5 . 0 3 S c 1492 1 . 0 0
6 5 .3 0 Q c 780 0 . 4 1
7 5 . 5 3 T c 192 0 . 1 4
8 5 . 8 0 G c 47 4 8 3 . 0 0
9 6 .24 E c 122 5 0 . 6 2
13 8 . 0 0 A c 758 0 . 5 0
15 1 0 . 0 8 Y c 646 0 . 4 4
18 12 . 2 5 P c 495 0 . 3 4
20 13 . 1 2 V c 713 0 . 5 1
25 1 5 . 3  5 dpu 742 0 . 9 2
26 1 5 . 6 8 F c 367 0 . 2 5
27 1 6 . 0 7 I c 2619 2 . 3 2
28 1 6 . 5 4 L c 1152 0 . 7 6
Applied Biosystems Procise - PROCISE
13-09-2001 10:54 0lC335-010716-100%-B-T-fr33
1 1 : R e s i d u e  9 ,  I n t e r p o l a t e d  b a s e l i n e
No RT P eak ID Type H e i g h t Pmol Ht
2 4 . 3 8 N c 666 0 . 2 8
4 5 .  00 S c 841 0 . 5 6
5 5 . 2 9 Q c 558 0 . 2 9
6 5 . 5 1 T c 411 0 . 3 1
7 5 . 7 9 G c 523 5 3 . 3 1
8 6 . 2 4 E c 1028 0 . 5 2
11 7 . 1 5 H c 103 0 . 0 5
12 8 . 0 0 A c 2923 1 . 9 3
14 9 . 1 8 S ’ 239 1 . 7 2
16 1 0 . 0 7 Y c 560 0 . 3 8
20 1 2 . 2 5 P c 505 0 .3 5
21 13 .1 0 V c 553 0 . 4 0
25 1 5 . 3 5 dpu 669 0 . 8 3
26 1 5 . 6 7 F c 411 0 . 2 8
27 1 6 . 0 6 I c 1683 1 . 4 9
28 1 6 . 5 1 L c 790 0 . 5 2
Applied Biosystems Procise - PROCISE
13-09-2001 10:55 0lC335-010716-100%-B-T-fr33
1 3 : R e s i d u e  1 1 ,  I n t e r p o l a t e d  b a s e l i n e
No RT Peak ID Ty pe H e i g h t Pmol Ht
2 4 . 3 8 N c 731 0 . 3 1
5 5 . 0 1 S c 137 8 0 . 9 2
6 5 . 2 9 Q c 112 6 0 . 5 9
7 5 . 5 2 T c 344 0 . 2 6
8 5 . 7 9 G c 34 5 1 2 .1 8
9 6 . 2 4 E c 2 3 6 8 1 . 2 0
12 7 . 4 5 H c 21 0 0 . 1 1
14 7 .9 9 A c 1150 0 . 7 6
16 9 . 2 0 S' 203 1 . 4 6
17 9 . 4 3 R c 137 0 . 2 0
18 1 0 . 0 7 Y c 888 0 . 6 0
22 1 2 . 2 0 P c 283 0 . 2 0
23 13 .09 V c 20 3 8 1 .  47
25 14 . 1 6 d p t u r 6 0 4 7 6 4 7 . 4 4
27 1 5 .  00 W c 144 0 . 0 8
28 1 5 . 3 2 dpu 570 0 . 7 1
29 1 5 . 6 6 F c 41 0 0 . 2 8
30 1 6 . 0 3 I c 607 0 . 54
31 1 6 . 2 5 K c 214 0 . 1 0
32 1 6 . 5 2 L c 1034 0 . 6 8
Applied Biosystems Procise - PROCISE
13-09-2001 10:55 01C335-010716-100%-B-T-fr33
1 5 : R e s i d u e  1 3 ,  I n t e r p o l a t e d  b a s e l i n e
No RT P e a k  ID Type H e i g h t Pmol  Ht
2 4 . 3 8 N c 906 0 . 3 9
5 5 . 0 2 S c 15 7 0 1 . 0 5
6 5 . 2 9 Q c 1040 0 . 5 4
7 5 . 5 0 T c 332 0 . 2 5
8 5 . 7 9 G c 31 47 1 . 9 9
9 6 . 2 4 E c 13 09 0 .  66
12 7 .47 H c 177 0 . 0 9
13 8 . 0 0 A c 847 0 . 5 6
14 9 . 4 5 R c 74 0 . 1 1
15 1 0 . 0 8 Y c 536 0 . 3 6
16 1 2 . 2 4 P c 339 0 . 2 3
17 1 2 . 6 0 M G 138 0 . 1 0
18 1 3 . 0 8 V c 849 0 . 6 1
23 1 5 . 3 4 dpu 608 0 . 7 6
24 1 5 . 6 6 F c 276 0 . 1 9
26 1 6 . 2 7 K c 695 0 . 3 3
27 1 6 . 5 2 L c 982 0 . 65
Applied Biosystems Procise - PROCISE
istrument 1 9/3/2001 5:05:41 PM Page 1 of 1
p a g i u a  i  V e in  h
< ">  N C B 1
I >• ' ;: ■.’■ .‘ v . .' ■;)
» • • • • •  ®e t í ,
■ •' ■» • '  ? r  • ••• •> -J> r p i
ein Genome
: *  ) © * » « Ö£' ■'•' ¿tffíari9 M€ • ■ J .
0 9  • • • • • •  . •
• •  ..'vf’® . *  P r n f p i n;> :.•■ '$ ÿ •; W  • • ^ V C  11 I
Structure Pop-Set Taxonomy
DetPreview/Index History Clipboard
f fo g  i ; ; Add to Clipboard |
1 : P35527. KERATIN TYPE I C... BLink, Related Sequences, OMIM, PubMed, Taxonomy,
[gi:547748] " ’ Link0ut
LOCUS
DEFINITION
ACCESSION
PID
VERSION
DBSOURCE
622 aa
I CYTOSKELETAL
PRI
9 (CYTOKERATIN 9)
20-AUG-2001 
(K9) (CK 9).
accession P35527;
4 53155, gi: gi:
545257 , gi: gi:
HSSP P02876, MIM 144200, InterPro 
Pfam PF00038, PRINTS PR01248,
435475,
107639
gi: gi:
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
MEDLINE
REMARK
REFERENCE
AUTHORS
TITLE
JOURNAL
MEDLINE
REMARK
REFERENCE
AUTHORS
TITLE
JOURNAL
MEDLINE
REMARK
REFERENCE
AUTHORS
TITLE
JOURNAL
MEDLINE
REMARK
REFERENCE
AUTHORS
Craniata; Vertebrata; Euteleostomi; 
Catarrhini; Hominidae; Homo.
K1CI HUMAN 
KERATIN, TYPE 
P35527 
g5477 48
P35527 GI:547748 
swissprot: locus K1CI_HUMAN, 
class: standard.
extra accessions:Q14665,created: Jun 1, 1994. 
sequence updated: Jun 1, 1994. 
annotation updated: Aug 20, 2001. 
xrefs: gi: gi: 453154, gi: gi:
435476, gi: gi: 54525 6, gi: gi 
xrefs (non-sequence databases)
IPR001664, InterPro IPR002957,
PROSITE PS00226
Intermediate filament; Coiled coil; Keratin; Disease mutation, 
human.
Homo sapiens
Eukaryota; Metazoa; Chordata;
Mammalia; Eutheria; Primates;
1 (residues 1 to 622)
Langbein,L., Heid,H.W., Moll,I. and Franke,W.W.
Molecular characterization of the body site-specific human 
epidermal cytokeratin 9: cDNA cloning, amino acid sequence, and 
tissue specificity of gene expression 
Differentiation 55 (1), 57-71 (1993)
94131202
SEQUENCE FROM N.A., AND PARTIAL SEQUENCE.
TISSUE=Foot sole tissue
2 (residues 1 to 622)
Rosen,E.M., Meromsky,L., Romero,R., Setter,E. and Goldberg,I.
Human placenta contains an epithelial scatter protein 
Biochem. Biophys. Res. Commun. 168 (3), 1082-1088 (1990)
90267446
SEQUENCE OF 4 4 9-4 65.
3 (residues 1 to 622)
Hennies,H .C ., Zehender,D., Kunze,J., Kuster,W. and Reis,A.
Keratin 9 gene mutational heterogeneity in patients with 
epidermolytic palmoplantar keratoderma 
Hum. Genet. 93 (6), 649-654 (1994)
94274199
VARIANTS EPPK VAL-15 6 AND PRO-171.
4 (residues 1 to 622)
Bonifas,J .M ., Matsumura,K. , Chen,M.A., Berth-Jones,J.,
Hutchison,P.E ., Zloczower,M ., Fritsch,P.O. and Epstein,E.H. Jr. 
Mutations of keratin 9 in two families with palmoplantar 
epidermolytic hyperkeratosis 
J. Invest. Dermatol. 103 (4), 474-477 (1994)
95015968
VARIANT EPPK SER-160.
5 (residues 1 to 622)
Torchard,D., Blanchet-Bardon,C., Serova,O., Langbein,L., Narod,S., 
Janin,N., Goguel,A.F., Bernheim, A. , Franke,W.W., Lenoir,G.M. and
http://www.nc.../query.fcgi?cmd=Retrieve&db=proiein&list_uids=547748&dopt=GenPep 14/09/01
p t i g i  11CI _ ) V C U I H
Region
Region
Region
Region
Region
Region
Region
Region
Region
Region
Region
Region
Region
Region
Region
Region
Region
Region
Region
Protein
ORIGIN
/product="KERATIN, TYPE 
12
/region_name="Conflict" 
/note="T -> SR (IN REF. 
14 . .20
/region_name="Domain"
/note="POLY-GLY."
152..187
/region_name="Domain" 
/note="C0IL 1A."
152..460
/region_name="Domain" 
/note="ROD."
156
/region_name="Variant"
/note="M -> V (IN EPPK). 
156
/region_name="Variant" 
/note="M -> T (IN EPPK) .
159
/region_name="Variant" 
/note="L -> V (IN EPPK).
160
/region_name="Variant" 
/note="N -> S (IN EPPK). 
160
/region_name="Variant"
/note="N -> K (IN EPPK). 
160
/region_name="Variant" 
/note="N -> Y (IN EPPK) . 
162
/region_name="Variant" 
/note="R -> W (IN EPPK). 
162
/ region__name="Variant" 
/note="R -> Q (IN EPPK). 
167
/region_name="Variant" 
/note="L -> S (IN EPPK). 
171
/region_name="Variant"
/note="Q -> P (IN EPPK).
188..206
/region_name="Domain" 
/note="LINKER 1."
207..298
/region_name="Domain" 
/note="COIL IB."
299..321
/ region__name=" Domain"
/note="LINKER 12."
322..460
/region_name="Domain" 
/note="COIL 2."
461..622
/region name="Domain" 
/note="TAIL."
1..622
I CYTOSKELETAL 9"
1; CAA82315)."
/FTId=VAR 010500."
/FTId=VAR 0104 99."
/FTId=VAR 010501."
/FTId=VAR 010502."
/FTId=VAR 003822."
/FTId=VAR 010503."
/FTId=VAR 003824."
/FTId=VAR 003823."
/FTId=VAR 003825."
/FTId=VAR 010504."
1 mscrqfsssy 
61 grggggsfgy 
121 gfgggygsgf 
181 enkiqdwydk 
241 kfemeqnlrq 
301 qnsgdvnvei 
361 evqssakevt 
421 qitdvrqeie 
481 ggsygrgsrg
c
ltsggggggg
sygggsgggf
gglggfggga
kgpaaiqkny
gvdadinglr
nvapgkdltk
qlrhgvqele
cqnqeyslll
gsggsygggg
lgsggsirss 
sasslgggfg 
gggdggilta 
spyyntiddl 
qvldnltmek 
tlndmrqeye 
ielqsqlskk 
sikmrlekei 
sgggygggsg
ysrfsssggr 
ggsrgfggas
nekstmqeln
kdqivdltvg
sdlemqyetl
qliaknrkdi
aaleksledt
etyhnllegg
srggsggsyg
ggggrfssss 
gggysssqgf
srlasyldkv 
nnktlldidn 
qeelmalkkn 
enqyetgitq 
knrycgqlqm 
qedfessgag 
ggsgsgggsg
gygggssrvc 
gggfgggsgg 
qaleeanndl 
trmtlddfri 
hkeemsqltg 
iehevsssgq 
iqeqisnlea 
kiglggrggs 
ggygggsggg
http://www.nc.. ./query.fcgi?cmd=Retrieve&db=protem&list_uids=547748&dopt=GenPep 14/09/01
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LOCUS
DEFINITION
ACCESSION
PID
VERSION
DBSOURCE
PRI
(CYTOKERATIN 6B)
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
MEDLINE
REMARK
REFERENCE
AUTHORS
TITLE
JOURNAL
MEDLINE
REMARK
REFERENCE
AUTHORS
TITLE
JOURNAL
MEDLINE
REMARK
COMMENT
K2CB_HUMAN 5 64 aa 
KERATIN, TYPE II CYTOSKELETAL 6B 
KERATIN).
P04259 
gl34 6345
P04259 GI: 134 634 5
swissprot: locus K2CB_HUMAN, accession P04259; 
class: standard, 
created: Mar 20, 1987. 
sequence updated: Feb 1, 1996. 
annotation updated: Aug 20, 2001. 
x r e f s :  g i : g i :  9 0 8 7 8 8 , g i :  g i : 9 0 8 7 9 0 , g i :
: gi: 908782, gi
20-AUG-2001 
(CK 6B) (K6B
g i :
gi
g i
g i
g i
9 0 8 7 8 0 , g i : g i :  
9 0 8 7 8 4 . g i : g i  
3 8 6 8 4 9 ,
1 8 6 7 0 9 .
1 8 6 7 1 3 ,
g i :  g i :  
g i :  g i :
g i :  g i :
9 0 8 7 8 1 . gi: 9 0 8 7 8 2 , : gi : 9 0 8 7 8 3 , gi
9 0 8 7 8 5 . gi: gi: 9 0 8 7 8 6 , gi: gi: 1 8 6 7 1 4. gi
1 8 6 7 0 6 , gi : gi : 1 8 6 7 0 7 , gi; gi: 1867Q8, gi
1 8 6 7 1 0 , gi: gi: 1 8 6 7 1 1 , gi: gi: 1 8 6 7 1 2 , gi
7428711
xrefs (non-sequence databases): Aarhus/Ghent-2DPAGE 1418, MIM 
148042, InterPro IPR001664, InterPro IPR003054, Pfam PF00038, 
PRINTS PRO127 6, PROSITE PS00226
Intermediate filament; Coiled coil; Keratin; Multigene family; 
Phosphorylation. 
human.
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; 
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (residues 1 to 564)
Takahashi,K., Paladini,R.D. and Coulombe,P.A.
Cloning and characterization of multiple human genes and cDNAs 
encoding highly related type II keratin 6 isoforms 
J. Biol. Chem. 270 (31), 18581-18592 (1995)
95355491
SEQUENCE FROM N.A.
TISSUE=Skin
2 (residues 1 to 564)
Tyner,A.L., Eichman,M.J. and Fuchs,E.
The sequence of a type II keratin gene expressed in human skin: 
conservation of structure among all intermediate filament genes 
Proc. Natl. Acad. Sci. U.S.A. 82 (14), 4683-4687 (1985)
85270392
SEQUENCE FROM N .A.
3 (residues 1 to 564)
Rasmussen,H.H ., van Damme,J., Puype,M., Gesser,B., Celis,J.E. and 
Vandekerckhove,J.
Microsequences of 145 proteins recorded in the two-dimensional gel 
protein database of normal human epidermal keratinocytes 
Electrophoresis 13 (12), 960-969 (1992)
93162043
SEQUENCE OF 194-202 AND 349-355.
TISSUE=Keratinocytes
On Jun 1, 1996 this sequence version replaced gi:125107.
This SWISS-PROT entry is copyright. It is produced through a
http://www.ri.. ./query.fcgi?cmd=Retrieve&db=protein&list_uids=l 346345 &dopt=GenPep 14/09/01
o c 4 U c i k ;c  v i c w c i p a g in a  j  v an  j
/ n o t e = " T A I L . "
ORIGIN
/ /
1 m a s t s t t i r s  
61 l y g l g g s k r i  
121 g f g g p g f p v c  
181 v r f l e q q n k v  
241 n m q d l v e d l k  
301 l y d a e l s q m q  
361 e e l q v t a g r h  
421 k d a k n k l e g l  
481 v g q v n i s v v q  
541  s v g g g s s t i k
h s s s r r g f s a
s i g g g s c a i s
p p g g i q e v t v
l d t k w t l l q e
n k y e d e i n k r
t h i s d t s v v l
g d d l r n t k q e
e d a l q k a k q d
s t v s s g y g g a
y t t t s s s s r k
s s a r l p g v s r
g g y g s r a g g s
n q s l l t p l n l
q g t k t v r q n l
t a a e n e f v t l
s m d n n r n l d l
l a e i n r m i q r
l a r l l k e y q e
s g v g s g l g l g
s y k h
s g f s s i s v s r  
y g f g g a g s g f  
q i d p a i q r v r  
e p l f e q y i n n  
kkdvdaaymn  
d s i i a e v k a q  
I r s e i d h v k k  
l m n v k l a l d v  
g g s s y s y g s g
s r g s g g l g g a
g f g g g a g i g f
a e e r e q i k t l
l r r q l d s i v g
k v e l q a k a d t
y e e i a q r s r a
q c a n l q a a i a
e i a t y r k l l e
l g v g g g f s s s
c g g a g f g s r s  
g l g g g a g l a g  
n n k f a s f i d k  
e r g r l d s e l r  
l t d e i n f l r a  
e a e s w y q t k y  
d a e q x g e m a l  
g e e c r l n g e g  
s g r a t g g g l s
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